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PREFACE 
 
"The next day was a miracle.  The young man had been on the brink of 
death only 24 hours previously.  Yet, the morning following surgery he 
looked at me with bright eyes, and he felt hungry for the first time in 
months… 
The transplanted kidney functioned immediately, with a dramatic 
improvement in the patient’s renal and cardiopulmonary status.  This 
spectacular success was a clear demonstration that organ 
transplantation could be life-saving.” 
 
Joseph Murray, winner of the Nobel Prize in Physiology or Medicine, 
recalls the first successful kidney transplant, performed at Peter Bent 
Brigham Hospital, Boston, Massachusetts, 1954. 
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ABSTRACT The	incidence	of	end-stage	renal	disease	is	increasing	in	Western	Society.		Renal	transplantation	is	known	to	be	the	optimal	treatment	for	ESRD,	being	associated	with	significant	reduction	in	morbidity,	mortality	for	patients	and	cost	for	wider	society	when	compared	to	remaining	on	dialysis.		Unfortunately,	the	growing	number	of	patients	listed	for	renal	transplantation	has	occurred	without	a	matched	supply	in	the	number	of	suitable	organs.		This	has	led	to	longer	average	waiting	times	for	increased	numbers	of	patients,	who	consequently	suffer	adverse	outcomes	at	considerable	cost	to	the	National	Health	Service	as	a	result	of	organ	shortage.			One	strategy	employed	by	clinicians	to	meet	demand	for	organs	has	been	to	transplant	‘suboptimal’	kidneys’	historically	rejected	as	unsuitable	for	transplantation,	which	are	usually	retrieved	from	older	and	less	fit	donors.		Sometimes	referred	to	as	‘extended	criteria’	or	‘marginal	kidneys’,	such	allografts	are	more	prone	to	damage	in	the	peri-transplantation	period,	with	the	major	pathological	process	recognised	to	be	ischemia-reperfusion	injury	(IRI).		Although	functioning	‘marginal’	allografts	have	been	shown	to	confer	benefit	to	recipients,	early	transplant	failure	is	associated	with	negative	outcomes.		Consequently,	there	is	a	real	need	to	develop	treatments	to	mitigate	renal	IRI,	especially	since	the	use	of	‘marginal’	kidneys	is	likely	to	increase.			Stem	cell	therapy	has	been	shown	to	protect	solid	organs	from	IRI	in	a	number	of	different	animal	models.		Consequently,	there	is	great	interest	in	researching	the	ability	of	stem	cell-based	therapies	to	ameliorate	solid	organ	damage	and	perhaps	to	encourage	organ	regeneration.		However,	debate	exists	regarding	the	exact	mechanism	by	which	stem	cells	produce	their	effects.		Some	researchers	suggest	that	stem	cells	directly	differentiate	to	replace	specialised	cell	types	in	damage	organs.		Other	investigators	conclude	that	stem	cells	produce	their	effects	in	a	paracrine	fashion	via	the	release	of	extracellular	vesicles	with	the	horizontal	transfer	of	genetic	material	between	cells.			Unfortunately,	no	therapies	are	currently	in	widespread	use	to	reduce	damage	to	allografts	in	the	peri-transplant	period.		In	part,	this	reflects	the	lack	of	robust	
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small	animal	models	for	screening	potential	renal	IRI	therapies	before	testing	in	large	animal	models.		Furthermore,	clinical	application	has	been	limited	by	safety	concerns,	and	particularly	by	the	risk	of	stem	cells	undergoing	malignant	transformation	and	subsequent	tumour	formation	in	recipients.		However,	investigators	hypothesise	that	the	use	of	stem	cell-derived,	extracellular	vesicles	may	confer	similar	beneficial	therapeutic	efficacy,	but	lack	many	of	the	side	effects	associated	with	stem	cells	themselves.		This	thesis	describes	experiments	in	which	stem	cell-based	therapies	are	tested	in	conventional	and	novel	animal	models	of	renal	IRI	and	renal	transplantation.	In	Chapter	3,	initial	experiments	unexpectedly	demonstrated	the	potential	of	ex	
vivo	expanded	stem	cells	to	undergo	malignant	change	and	induce	tumour	formation	in	recipient	animals.		Therefore,	the	subsequent	research	investigated	the	effects	of	freshly	isolated	stem	cells	or	those	of	novel	extracellular	vesicle	preparations.		In	Chapter	4,	experiments	unexpectedly	demonstrated	the	shortcomings	of	a	conventional	rat	model	of	renal	IRI.		Therefore,	Chapter	5	describes	the	development	of	a	novel	rat	of	model	of	renal	IRI,	in	which	stem	cell-based	therapies	may	be	tested.	Using	this	animal	model,	Chapters	6	and	Chapter	7	describe	the	investigation	of	novel	stem	cell-based	therapies	and	their	effects	on	renal	IRI.		Some	of	these	treatments	were	found	to	protect	kidneys	from	IRI	damage	with	preservation	of	renal	function	and	structure	in	the	medium	to	long-term.		Chapter	8	describes	a	rat	model	of	renal	transplantation,	in	which	therapies	were	investigated	after	being	screened	for	efficacy	in	the	novel	rat	IRI	model.		Although	no	functional	difference	was	demonstrated,	renal	histology	was	preserved	by	treatment,	although	the	mechanisms	by	which	this	effect	occurred	remain	unclear.		These	findings	suggest	that	stem	cells	and	their	extracellular	vesicles	have	the	potential	to	reduce	peri-transplantation	renal	IRI	and	hence	improve	long-term	outcomes	of	‘marginal’	allografts.		However,	clinical	translation	requires	the	long-term	efficacy	and	safety	of	these	novel	therapies	to	be	investigated	in	large	animal	models	of	renal	transplantation,	before	further	testing	in	pilot	studies.		
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CHAPTER 1 
 
A REVIEW OF RENAL DISEASE AND KIDNEY 
TRANSPLANTATION AND THE POTENTIAL OF STEM 
CELL TREATMENTS TO AMELORIATE ACUTE 
KIDNEY INJURY 
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INTRODUCTION 
1.1 END-STAGE RENAL DISEASE AND TRENDS IN RENAL 
TRANSPLANTATION  
The rapidly increasing incidence of end-stage renal disease (ESRD) in the developed 
world is a direct consequence of an ageing population who are more frequently 
suffering from lifestyle-related conditions such as type II diabetes and obesity.  
Predictions of global population demographics suggest that the number of people with 
ESRD will continue to rise, as will the proportion of the population who are elderly. 
 
The kidneys' principle role is the elimination of toxic waste products, and the 
regulation of both circulating volume and the composition of body fluids.  
Furthermore, the kidney produces hormones including erythropoietin and renin and 
plays a crucial role in the metabolism of vitamin D.  These functions are lost with the 
development of renal failure, and those patients with ESRD require renal replacement 
therapy (RRT) in order to survive.  The term RRT encompasses the different 
modalities of dialysis (both peritoneal and haemodialysis) and kidney transplantation. 
 
In patients undergoing dialysis, waste products are removed from the blood by 
diffusion across a semi-permeable membrane.  Such patients are subjected to dietary 
and fluid intake restrictions, in addition to regular medication in an attempt to 
compensate for the loss of normal renal function.  Inevitably, patients receiving 
dialysis have negative outcomes regarding length and quality of life when compared 
to healthy individuals (Collins et al., 2008, Zelmer, 2007, Wight et al., 1998).  
Furthermore, survival of dialysis patients has not changed appreciably in the last two 
decades, with an annual mortality of approximately 20% (Galliford and Game, 2009) 
and only 35% of dialysis patients alive after five years (Collins et al., 2008).  This 
means that dialysis patients on average have only 20 – 25% the life expectancy of 
healthy age-matched controls (Collins et al., 2008).  Data from the UK renal registry 
shows that since 2000 there has been an average 5% annual increase in the prevalence 
of RRT requirement, with 56,940 individuals receiving RRT in the UK at the 
beginning of 2014 (Pruthi et al., 2013).  Of these, 49% of patients were undergoing a 
form of dialysis.  At an annual cost of £35,000 per individual on haemodialysis, and 
£17,500 on peritoneal dialysis, dialysis provision amounts to 3% of the National 
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Health Service budget (Pruthi et al., 2013).  ESRD patients receiving dialysis 
therefore create a huge national health and economic burden with sufferers 
experiencing poorer than average health status and quality of life (van Manen et al., 
2002, Wight et al., 1998). 
 
A cursory examination of the long-term outcomes of the current dialysis patient 
population reveals a minor reduction in morbidity and mortality associated with 
modern treatment regimes. However, it is clear that more elderly patients are now 
routinely offered dialysis than was the case two decades ago (Collins et al., 2012, 
Jager et al., 2003). Comparison of age-matched populations highlights the improved 
outcomes associated with dialysis in modern practice (Pippias et al., 2015, Marshall et 
al., 2015).  
 
Nevertheless, kidney transplantation has long been associated with survival and 
quality of life benefits for recipients when compared with patients receiving other 
modalities of RRT (Laupacis et al., 1996, Wolfe et al., 1999, Port et al., 1993, 
Schnuelle et al., 1998, Simmons et al., 1990, Gokal, 1993, Kontodimopoulos and 
Niakas, 2008, Zelmer, 2007, Whiting et al., 1999, Meier-Kriesche et al., 2005).  Life 
expectancy of patients who receive a deceased donor transplant is ultimately twice 
that of those remaining on dialysis (Wolfe et al., 1999).  The recognised benefits of 
transplantation, coupled with improved safety in recent years has led to increased 
numbers of patients on UK transplant waiting lists in the last decade.  (See figure 1.1)  
Older recipients now comprise the highest proportional increase of those patients 
added to national waiting lists, with almost half of patients awaiting renal transplant 
being aged > 50 years (Wolfe et al., 2010).  High volume studies have shown reduced 
mortality rates for elderly patients undergoing successful renal transplantation 
compared with similar patients remaining on waiting lists and receiving dialysis.   
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Figure 1.1: shows the trend in the number of patients on the kidney transplant list at 31 March each 
year between 2007 and 2016.  The slight fall in the number of patients actively waiting for a transplant 
largely reflects the increasing use of ‘marginal’ kidneys (Transplant, 2016).  
 
 
Unfortunately, the length of time on dialysis is recognised as an independent predictor 
of poor transplant survival as ESRD patients are subjected to considerable 
physiological deterioration due to the systemic nature of their disease (Meier-
Kriesche and Kaplan, 2002).   
With health economics playing an increasingly important role in modern healthcare 
provision, it is notable that within 2 years renal transplantation becomes cost 
effective, saving the NHS an annual of £25,800 per patient transplanted (Pruthi et al., 
2013).  Renal transplantation is therefore an excellent example of a healthcare 
technology that provides a reduction in morbidity and mortality, and is at least 
theoretically, cost saving and cost effective when compared to dialysis.  The 
promotion of renal transplantation to expand the available number of kidneys has 
additional appeal especially considering evidence that ESRD patients transplanted 
earlier experience better outcomes (Meier-Kriesche and Kaplan, 2002).  Consequently 
the number of renal transplants performed in the UK has tended to increase annually 
(see figure 1.2), although there is still a shortfall in the supply of kidneys due to a lack 
of suitable donors.  
2016 
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Figure 1.2 shows the total number of kidney transplants performed in the last ten years.  The number 
of transplants steadily increased each year from 2130 in 2006/07 to 3,265 in 2015/16 (Transplant, 
2016). 
 
1.11 TRENDS IN KIDNEY DONATION 
Unfortunately, the growing demand for transplantable kidneys has occurred without a 
matched increase in kidney supply, resulting in progressively increasing waiting list 
times (Matas et al., 2014).  This disparity has been a problem since renal 
transplantation became part of accepted clinical practice.  However, with increasing 
numbers of patients with ESRD listed for transplantation, the shortage of 
transplantable kidneys has never been so apparent.  This shortfall is the result of a 
number of factors, the most important of which is increased demand due to the 
success of modern transplantation itself.  Coupled with the falling number of kidneys 
from young, deceased donors, there is a persistent kidney shortage that is the primary 
factor limiting the wider use of transplantation.  This inevitably results in increased 
morbidity, mortality and cost as ESRD patients remain on dialysis. 
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1.12 CLASSIFICATION OF RENAL ALLOGRAFTS 
To analyse the disturbing current donation trends that lead to thousands of patients 
languishing on UK waiting lists, one must first understand the types of kidney donor 
and subsequent classifications of allograft that arise as a result of the donation 
process. 
 
In essence, kidney donors may be divided into three categories:  
Living donors  
It is accepted that outcomes from living donors are superior to those from age-
matched deceased donors – fully HLA-mismatched live donor kidneys have improved 
outcomes when compared to fully matched deceased donor grafts (Meier-Kriesche 
and Kaplan, 2002, Mange et al., 2001).  The previous two decades have seen a 3-fold 
increase in live donation, although in recent years the trend for living donation has 
plateaued while the total demand for organs has continued to rise.  (See figure 1.3) 
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Figure 1.3: shows the total number of adult kidney-only transplants performed in the last ten years, by 
type of donor.  The number of adult transplants from donors after circulatory death (DCD) steadily 
increased from 272 in 2006/2007 to 851 in 2015/2016.  The number of adult transplants from donors 
after brain death (DBD) has increased in the last four years to 1,134 in 2014/2015 after remaining 
relatively constant between 2007/2008 and 2011/2012.  The recent increase in DBD transplantation is 
due to the increased used of extended criteria kidneys.  The number of adult living kidney transplants 
performed was steadily increasing over time before plateauing, and subsequently decreasing by 8% to 
~ 960 in the two financial years.  (Transplant, 2016) 
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Deceased Donors 
Kidneys for transplantation are recovered from deceased donors who: 
 (1) Donate after brain stem death (DBD)  
(2) Donate after circulatory-confirmed death (DCD) 
Formerly referred to as ‘heart-beating' (DBD) and ‘non-heart-beating’ (DCD) the 
current terminology more accurately reflects the absence of peripheral pulses and 
blood pressure over asystole to declare death.  
Outcomes from deceased donor kidneys are inferior to those obtained with allografts 
from living donors.  Partly this is probably due to hormonal and cardiorespiratory 
disturbances that occur in the donor during the retrieval process.  Kidneys in patients 
suffering brain stem death (DBD) are exposed to variations in catecholamine levels 
and a ‘cytokine storm’ (Chiari et al., 2000, Gramm et al., 1992, Pratschke et al., 
2001).  The hypoperfusion that results from this inflammatory milieu may explain the 
adverse allograft outcomes observed in DBD kidneys when compared to those from 
living donors.  It is unclear if this process is substantially different in the setting of 
severe, irreversible head injury without herniation that is present in the majority of 
DCD donors (Brook et al., 2003). However, compared to DBD kidneys, those 
allografts that result from DCD are subjected to greater periods of hypoxia and 
hypotension during the progression to circulatory arrest (so-called “agonal phase”) 
and the mandatory 5-minute period of warm pulseless ischemia prior to retrieval 
(Perera, 2012).   
 
Traditionally, the use of DBD kidneys predominated in most transplant centres.  
However, due to falling numbers of suitable DBD donors, coupled with increased 
demand for transplantable kidneys, the use of DCD kidneys has grown in the past 
decade as a further means of expanding the pool of donor kidneys.  (See figure 1.3)  
DCD kidneys show higher rates of primary non-function and delayed graft function 
(Neyrinck et al., 2013, Renkens et al., 2005, Singh et al., 2011), but after the 
immediate postoperative period have been shown to have comparable outcomes when 
compared to DBD kidneys (Huynh et al., 2015, Weber et al., 2002), provided cold 
ischemic times are kept below 24 hours (Summers et al., 2010, Summers et al., 2013).  
Furthermore, DCD transplantation demonstrates a survival benefit to recipients over 
waiting for a DBD kidney to become available (Snoeijs et al., 2010a, Snoeijs et al., 
2010b). 
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Traditionally, kidneys for transplantation were retrieved from deceased individuals 
meeting the criteria for ‘ideal donors’ (Port et al., 2002).  These criteria include:  
(i) Age between 10 – 39 years.  
(ii) No history of hypertension 
(iii) Did not die from a cerebrovascular accident 
(iv) Pre-donation creatinine < 150µg/dL.  
 
Such ‘ideal' kidneys typically came from individuals who had been in excellent health 
but had suffered an isolated traumatic event.  However, during the last 15 years, there 
has been a steady decline in the numbers of ‘ideal’ deceased donor kidneys offered 
for transplantation (Johnson et al., 2010).  The cause for the falling numbers of ‘ideal 
donors’ is not entirely understood.  Reasons cited often include a reduction in high-
energy traumatic accidents, reduced intracranial haemorrhage due to improved 
radiological intervention, and increased reluctance of intensive care doctors to 
ventilate patients with head injuries whose radiology reveals a poor prognosis (Briggs 
et al., 1997, Bederson et al., 2009). 
 
1.13 NOVEL STRATEGIES TO EXPAND SUPPLY OF RENAL 
ALLOGRAFTS 
The falling number of kidneys from ‘ideal donors’, coupled with increased demand 
for transplantation, has led to persistent kidney shortages resulting in morbidity and 
mortality for dialysis patients who wait for a transplant to become available.  In an 
attempt to fill this void, clinicians have adopted a number of strategies, involving the 
use of kidneys that previously would have been deemed un-transplantable.   
One such strategy has been the use of kidneys from ‘extended criteria donors' (ECD).  
The criteria for ECD kidneys are based on national registry analysis from the United 
States for kidneys transplanted between 1995 and 2000.  Age and a combination of 
medical risk factors were found to be associated with a relative risk for graft failure of 
greater than 1.7 when compared to the ideal donor reference group (Port et al., 2002). 
Donor elements utilised to define ECDs include:(Port et al., 2002, Metzger et al., 
2003) 
(i) Donor age greater than 60 
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(ii) Or donor age between 50 -59 with 2 of the following features 
- Cerebrovascular accident as cause of death 
- Hypertension 
- Preexisting donor renal dysfunction with serum creatinine > 150mg/dL.  
 
Growing demand has necessitated the routine use of DCD and ECD kidneys.  Despite 
controversies regarding allograft survival rates, both DCD and ECD kidney 
transplants have gained acceptance, although clinicians now acknowledge a higher 
risk of poor outcome when compared to those allografts that come from ‘ideal' donors 
(Port, 2003, Nathan et al., 2003).  However, the risk of a poor outcome needs to be 
balanced against the benefits provided by a functioning transplant, compared to 
remaining on dialysis (Merion, 2005).  Short-term allograft survival rates have 
improved continuously in recent years, and most recent studies have reported 
acceptable medium-term DCD and ECD allograft survival rates.  However, less 
impressive improvements are reported for long-term outcomes (Lamb et al., 2011), 
and transplanting ECD kidneys with increased donor age is known to result in higher 
rates of graft failure (Veroux et al., 2012).  Inevitably, recipient survival is reduced 
when a sub-optimal graft fails (Meier-Kriesche et al., 2001). 
Nevertheless, many DCD and ECD kidneys perform extremely well, and there 
appears to be substantial survival, lifestyle and financial benefit in receiving an ECD 
kidney when compared to remaining on dialysis (Merion, 2005, Meier-Kriesche et al., 
2001, Ojo et al., 2001, Martin Navarro et al., 2009, Rao et al., 2007). 
 
As the evidence for the use of kidneys from DCD and ECD sources accumulates, 
transplantation of such kidneys is progressively increasing in many centres.  (See 
Figure 1.4).  Recently > 50% of kidneys transplanted in Europe or North America are 
from donors aged > 50 years, with many recipients of these often being elderly in an 
‘old for old' allocation scheme (Wolfe et al., 2010, Moers et al., 2009).  Here, older 
kidneys are considered a solution for more elderly patients, as lower patient life 
expectancy compensates for the lower expected survival rate of the aged kidney (Foss 
et al., 2009, Chavalitdhamrong et al., 2008, Giessing et al., 2009).  
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Figure 1.4: shows the use of ‘Extended Criteria’ DBD kidneys has almost double in the last decade 
(Transplant, 2016).  
 
 
The trend of transplanting kidneys that would previously have been deemed 
unsuitable is likely to continue as clinicians ‘push the boundaries’ in an attempt to 
meet demand for transplantation.  Transplanting ECD kidneys present unique 
challenges, and innovative approaches are required to achieve satisfactory results.  
The future challenges are therefore to predict better which organs are likely to benefit 
recipients by functioning well, and how best to counter the early, non-specific 
inflammatory insults to which they have been exposed in the transplantation process. 
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1.2 MECHANISM OF RENAL REGENERATION IN RESPONSE TO INJURY 
From donor to recipient, kidney transplantation entails a series of steps, during all of 
which allograft damage may result.  Long-term function and outcome of kidney 
transplants are determined by cumulative peri-transplantation injury, arising from 
such factors as hypoperfusion during organ retrieval, prolonged cold ischemia, warm 
ischemia, ischemia reperfusion injury, episodes of acute rejection and calcineurin 
toxicity (Forsythe, 2009).  Injury to the allograft in the initial stages is recognised to 
have a significant influence on long-term allograft function, by predisposing to 
chronic interstitial fibrosis and tubular atrophy (Pascual et al., 2012, Campistol et al., 
2009).  Over time this ultimately leads to a reduction in functional nephron mass 
(Mueller et al., 2011).  These changes, often referred to ‘chronic allograft 
nephropathy’ have clear implications for transplant survival and hence patient 
longevity (Nankivell and Kuypers, 2011, Moreso and Hernandez, 2013).  
 
As described, current trends in organ donation have forced clinicians to utilise 
kidneys from older and less fit donors (ECD kidneys), in addition to kidneys from 
DCD patients.  Such allografts are more prone to peri-transplantation injury (Bagul et 
al., 2013, Wolfe et al., 1999, Mollura et al., 2003, Meier-Kriesche and Kaplan, 2002, 
Pomfret et al., 2008, Singh et al., 2011, Renkens et al., 2005), and as a result are more 
susceptible to acute complications including delayed graft function (defined as the 
need for dialysis in the first post-transplant week, except for reasons of hyperkalaemia 
or volume overload (Cantaluppi et al., 2013)) acute rejection or primary non-function 
(2010, Singh et al., 2011, Renkens et al., 2005, Pomfret et al., 2008).  Peri-
transplantation injury that results in a long-term reduction in functional capacity of 
allografts that contained fewer nephrons to begin with is likely to be associated with 
negative outcomes.  Therefore, the minimization of allograft injury in the peri-
transplant period and/or strategies to promote the healthy repair of transplant damage 
seems likely to represent a new field, aiming to optimise transplant function and 
patient health following graft implantation (Powell et al., 2013, Furuichi et al., 2012).  
However, the development of new therapeutic strategies necessitates an 
understanding of both the mechanisms by which renal injury occurs and the process 
of endogenous kidney regeneration (Wise and Ricardo, 2012). 
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1.21 RENAL REGENERATION 
Different solid organs have a varying capacity for regeneration, and also the rate of 
cell turnover varies between tissues.  Consequently the time it takes different organs 
to recover after acute injury is variable.  For example, the epithelial tissues of the skin 
and intestine have a high cell turnover and may completely self-renew within days 
(Blanpain et al., 2007, Blanpain et al., 2004). 
 
In contrast to the skin and intestines, the mammalian kidney is particularly 
morphologically complicated, containing approximately 26 terminally differentiated 
cell types that are organised into a highly ordered structure (Miner, 1999). 
Furthermore, the kidney has a high metabolic rate and is constantly exposed to waste 
products and toxins.  Consequently, the kidney has a relatively low cell turnover rate, 
and the rate of repair and regeneration after injury is dependent on the specialised cell 
type involved (Bussolati et al., 2008, Humphreys and Bonventre, 2008).  As a result, 
the mammalian kidney is particularly prone to acute injury.  Despite this, the 
mammalian kidney does have some capacity for self-regeneration and repair, and the 
ability to recover from severe damage.   
 
The capacity for renal regeneration is variable between different species.  For 
example, adult cartilaginous fish display the capacity to form new nephrons in 
response to a significant renal insult (Elger et al., 2003, Roufosse and Cook, 2008).  
In contrast, mammalian kidneys exhibit very limited regenerative ability.  Neo-
nephrogenesis has been reported in prenatal sheep after unilateral nephrectomy, with 
the remaining kidney demonstrating up to a 45% increase in nephron number 
(Douglas-Denton et al., 2002).  Initial studies in post natal rabbits illustrated an 
increase in the total number of glomeruli with the capacity to differentiate following 
unilateral nephrectomy (Sidorova, 1978), but subsequently these results have not been 
reproduced.  The general consensus therefore is that mammalian kidneys cease the 
formation of new nephrons after birth, and merely demonstrate compensatory 
hypertrophy of the remaining nephrons after injury (Sidorova, 1978).  However, the 
mammalian kidney does undergo limited regeneration and remodeling after injury and 
has the capacity to restore deficits in both structure and function.   
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1.22 ACUTE KIDNEY INJURY 
Native acute kidney injury (AKI) is a syndrome characterised by a rapid decline in 
glomerular filtration rate, reflected by a rise in serum creatinine and/or a fall in urine 
output (Khwaja, 2012).  The loss of excretory function leads to the rapid 
accumulation of products of nitrogen metabolism, increased potassium and phosphate 
and a metabolic acidosis.  This is a significant clinical problem, occurring in 5 – 10% 
of all acute hospital admissions, and accounting for up to 20% of admissions to 
intensive care units (Erpicum et al., 2014).  Overall mortality rates for inpatients 
suffering AKI is reported to be 35 – 40%, rising to around 75% for patients with 
multifactorial, sepsis associated renal failure (Nash et al., 2002).  A significant 
proportion of patients with AKI require dialysis, at least on a temporary basis 
(Lameire et al., 1998).  The mortality rate of patients requiring dialysis for AKI (50 -
60%) is nearly twice that of patients without AKI (Ricci et al., 2008, Bellomo et al., 
1995).  
 
Aetiology of AKI is often multifactorial.  Hypovolemia, sepsis, nephrotoxic injury, 
autoimmune damage and physical obstruction to urine flow are all well recognised 
causes of AKI affecting native kidneys. 
 
 
Figure 1.5: Various pathophysiological states and medications can contribute to a reduction of RBF, 
causing generalised or localised ischemia to the kidney leading to AKI.  This figure represents a partial 
list and points to ischemia as being a common pathway in a variety of clinical states affecting the 
kidney (Bonventre and Yang, 2011). 
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Transplanted kidneys are susceptible to all forms of AKI that are seen in native 
organs, especially in the peri-transplant period when the allograft is ‘bedding in'.  
However, the ischemia that occurs during allograft retrieval and cold storage, coupled 
with the warm ischemia and reperfusion injury that occurs during implantation makes 
IRI an especially important insult affecting renal allografts (Koffman and Gambaro, 
2003, Sanchez-Fructuoso et al., 2003, Pascual et al., 2008, Ojo, 2005).   
 
Unfortunately IRI is an unavoidable event in kidney transplantation, as it is 
technically impossible to move a transplant from donor to recipient without temporary 
cessation of renal blood flow.  IRI is therefore a necessary injury that negatively 
impacts on short and long-term outcomes by causing direct inflammatory tissue 
damage and predisposes to enhanced allograft immunogenicity, and hence to episodes 
of acute cell-mediated rejection (Eltzschig and Eckle, 2011). 
 
1.23 CELLULAR AND MOLECULAR MECHANISMS OF KIDNEY 
DAMAGE DURING ISCHEMIA REPERFUSION INJURY 
The cellular and molecular mechanisms that culminate in ischemic tissue damage 
after kidney IRI have been extensively studied and well described (Sutton et al., 2002, 
Bonventre and Yang, 2011, Kosieradzki and Rowinski, 2008).  A sustained 
interruption of renal blood flow is associated with a rapid drop in oxygen partial 
pressure and nutrient concentration.  Anaerobic respiration via glycolysis is necessary 
to maintain a meager supply of adenosine triphosphate (ATP), but as a by-product of 
this process, lactate accumulates in the cell cytosol, lowering pH levels such that 
mitochondrial function is impaired.  Interestingly, a recent paper has identified the 
accumulation of succinate during ischemia as a pivotal step in the generation of 
mitochondrial ROS during reperfusion (Chouchani et al., 2014)  
In this "initiation phase" of IRI, proximal tubular epithelial cells are the primary site 
of damage.  They quickly display a loss of cellular polarity, cytoskeleton disruption, 
and loss of brush border integrity in response to hypoxia (Ashworth and Molitoris, 
1999). Tubular obstruction from sloughed cells and protein aggregation occurs as a 
result of cellular ATP depletion (Kellerman, 1993, Ashworth and Molitoris, 1999).  
Proteases and phospholipases become activated and cause extensive cellular injury 
(Goligorsky, 2005).  This eventually leads to functional impairment of tubules, which 
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are not able to preserve distinct fluid filled compartments with precise electrolyte 
concentrations (Sheridan and Bonventre, 2000). 
 
Endothelial dysfunction and swelling results in microvascular occlusion increased 
resistance to blood flow and renal hypoperfusion.  This pathological process 
exacerbates and extends the initial renal injury and is consequently known as the 
"extension phase"(Sutton et al., 2002).  At this stage, sustained hypoxia causes tubular 
cells and/or glomerular podocytes to undergo necrosis or apoptosis while surrounding 
cells shift their metabolism from aerobic to anaerobic pathways.  The resulting further 
accumulation of lactate and oxygen free radicals leads to an increase in pro-
inflammatory cytokines and the activation of innate immunity (Linfert et al., 2009).  
Expression of adhesion molecules leads to the infiltration and activation of 
macrophages and other leukocytes, augmenting an aggressive inflammatory response 
(Akcay et al., 2009).  Subsequently trans-epithelial and trans-endothelial leaks appear 
at the cortico-medullary junction, an area where high oxygen demand and low oxygen 
tension at steady state predispose to acute tubular necrosis (Evans et al., 2008).  
 
Paradoxically, the final stage of the ischemic injury occurs during the reperfusion 
period.  This is characterized by re-oxygenation, production of ATP by oxidative 
phosphorylation and generation of high concentrations of reactive oxygen species that 
result in hyper-oxidation of proteins, lipids and membranes of both epithelial and 
endothelial cells.  Concurrently, the synthesis of inflammatory cytokines, including 
tumour necrosis factor alpha (TNF-α), interleukins 6 and 8 and surface adhesion 
molecules further encourage the non-specific recruitment of inflammatory cells.  
Leukocyte adherence and lymphocyte activation perpetuate inflammatory cell 
recruitment to the allograft, leading to tissue damage, apoptosis and inflammation.  In 
addition, up-regulation of major histocompatibility complex (MHC) class II antigen 
expression increases organ alloreactivity, increasing the probability of acute cell-
mediated rejection.  Ultimately, the processes of ischemia and reperfusion lead to 
renal tubular cell dysfunction, the release of donor MHC antigens into the host 
circulation, increased allograft immunogenicity, tissue injury and apoptotic cell death.  
These processes contribute to short and long-term allograft dysfunction. 
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Figure 1.6: Endothelial injury in ischemia/reperfusion AKI.  (A) Normal epithelium and endothelium 
separated by a small interstitial compartment.  (B) Ischemia/reperfusion causes swelling of endothelial 
cells; disruptions of the endothelial monolayer; and upregulation of adhesion molecules such as 
ICAMs, VCAMs, and selectins, resulting in enhanced leukocyte-endothelium interactions.  There is 
formation of microthrombi, and some leukocytes migrate through the endothelial cells into the 
interstitial compartment.  The interstitial compartment is expanded with enhanced numbers of 
inflammatory cells and interstitial oedema forms.  
(C) Transmission electron microscopy of normal human peritubular capillary (Cap).   
(D–F)  Acute tubular necrosis.  The peritubular capillaries (PT) show vacuolar degeneration of the 
endothelial cell (arrow in D), thickening and multilayer basement membrane formation (arrows in E), 
and attachment and penetration of monocyte-like cells (arrows in F) in the interstitial region.  Scale 
bars: 2 µm (C and F); 1 µm (D and E).  From Bonventre and Yang (Bonventre and Yang, 2011). 
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1.24 RENAL REPAIR 
Initial renal repair occurs in the “maintenance phase”, via cellular replacement of the 
injured tubular epithelium.  Under normal conditions, proximal tubular epithelial cells 
divide at a low rate, which under normal circumstances is enough to balance the 
routine loss of other epithelial cells (Nadasdy et al., 1994, Prescott, 1966).  However, 
after IRI there is a marked increase in cell turnover, with increased numbers of new 
epithelial cells needed to replenish those lost by necrosis or apoptosis.  
There has been debate regarding the origin of the new renal epithelial cells.  Potential 
sources from which epithelial cells may originate include: 
(1) Intra-renal progenitor cells.  
(2) Circulating stem cells that localise to the site of injury and differentiate into 
functional epithelium. 
(3) Surviving epithelial cells that divide into new epithelial cells.  
 
Recent evidence suggests mammalian kidneys contain resident stem cells, with 
progenitor cell populations initially described in embryonic kidneys reportedly 
identified within the urinary pole of the glomerular parietal epithelium of Bowman's 
capsule (Ronconi et al., 2009, Appel et al., 2009, Sagrinati et al., 2006).  Furthermore, 
another population of resident stem cell has been localised in papillary 
"niches"(Oliver et al., 2009), although these have not yet been confirmed to 
participate in kidney repair (Song et al., 2011).  Either of these may represent stem or 
progenitor cell populations that localise to the urinary pole of the parietal epithelium 
and could be responsible for podocytes replacement after injury (Ronconi et al., 2009, 
Appel et al., 2009).  Despite these observations, the role of resident stem or progenitor 
cells within both healthy and injured mammalian kidneys has not been well defined.  
Given the of presence of stem cells within the embryonic kidney, and the 
demonstration of neo-nephrogenesis during prenatal life, it is possible that stem cells 
play a role in the response of adult mammalian kidneys to both minor and severe 
injury (Reule and Gupta, 2011).  However, studies using genetic fate-mapping 
techniques in transgenic mice have demonstrated surviving tubular cells proliferate to 
replenish lost tubular cells and are unlikely to come from either resident or circulating 
renal stem or progenitor cells (Humphreys et al., 2008).  
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Renal cellular loss leads to the infiltration of bone marrow-derived inflammatory cells 
that contribute to both tissue destruction or repair depending on the extent of an injury 
(Ricardo et al., 2008).  Circulating stem and progenitor cells, including mesenchymal 
stem cells and hematopoietic stem cells, are also known to migrate to damaged 
organs, and may also contribute to renal repair (Patschan et al., 2006, Togel et al., 
2004).  Early studies suggested that replacement of lost epithelial cells was directly by 
circulating stem cells of a bone marrow origin (Bonventre, 2003, Witzgall et al., 
1994).  However, later analysis failed to replicate these findings and demonstrated 
that bone marrow derived stem cells do not directly replace lost epithelium, but exert 
paracrine effects that facilitate repair by reducing inflammation (Duffield et al., 2005, 
Humphreys and Bonventre, 2008).  
 
The formation of new tubular epithelium in response to injury is most likely mediated 
by surviving epithelial cells near the site of damage (Humphreys et al., 2008, 
Romagnani, 2009, Duffield et al., 2005).  Neighbouring cells are thought to de-
differentiate, re-express developmental programs and migrate to areas of denuded 
basal membrane, where damaged cells have undergone apoptosis, necrosis or 
detachment.  (See figure 1.7)  Subsequently proliferation, engraftment and re-
differentiation into functional tubular epithelial cells occurs, resulting in tubular cells 
that exhibit normal polarity and physiological transport mechanisms (Duffield et al., 
2005, Bussolati et al., 2008, Bonventre and Yang, 2011, Humphreys et al., 2008, 
Romagnani, 2009).  
 
	 46	
 
 
 
Figure 1.7: Normal tubular cell repair after ischemic AKI.  With IRI, the typically highly polar 
epithelial cell loses its polarity and brush border with proteins mislocated on the cell membrane.  With 
increasing time/severity of ischemia, there is cell death by either necrosis or apoptosis.  Some of the 
necrotic debris is released into the lumen.  Viable epithelial cells migrate and cover denuded areas of 
the basement membrane.  These cells undergo division and replace lost cells.  Ultimately, the cells go 
on to differentiate and reestablish the multivesicular polarity of the epithelium (Bonventre and Yang, 
2011) 
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This is associated with the exit of inflammatory cells, downregulation of 
inflammatory pathways and re-establishment of normal renal blood flow.  Apoptotic 
pathways initiate the removal of damaged and "surplus cells", with subsequent return 
of physiologic tubular and vascular integrity and function.  Unfortunately, severe 
glomerular injury is irreversible, and progressive glomerular loss leads to expansion 
of the renal interstitium and the formation of fibrosis (Liu and Brakeman, 2008, 
Abbate and Remuzzi, 1996). 
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1.3 RATIONALE FOR THE USE OF STEM CELL-BASED THERAPIES IN 
THE TREATMENT OF RENAL ISCHEMIA-REPERFUSION INJURY 
Regenerative medicine is broadly defined as the study of the repair, regeneration and 
restoration of diseased or damaged cells, tissues and organs (Mironov et al., 2004).  
As a field it still very much in its infancy with clinical applications being limited.   
There are no therapies that reduce injury to native or transplanted kidneys, or 
treatments that promote the renewal of specific kidney cell types in widespread 
clinical use.  Modern management strategies focus instead on supporting failing 
organs until recovery, during which time exposure to further systemic or iatrogenic 
insults may injure a kidney further (Mongardon et al., 2009).  ECD and DCD organs 
are particularly vulnerable to peri-transplantation injury (Koffman and Gambaro, 
2003, Metcalfe et al., 2001a, Metcalfe et al., 2001b), and the trend towards increasing 
use of marginal allografts has highlighted the lack of progress in the regenerative 
area.  Innovative approaches to developing protective and restorative treatments are 
needed, and reports of stem cell-based therapies mitigating renal IRI in animal models 
has led investigators to actively pursue novel therapies for AKI that are based on 
cellular mechanisms of repair and regeneration.  
 
Stem cells are prime candidates for regenerative therapies because they can 
theoretically replace damaged cells when administered either centrally or 
peripherally.  In addition, stem cells secrete a broad range of trophic growth factors, 
cytokines and chemokines and release extracellular vesicles that facilitate the lateral 
transfer of organ-protective messages into target cells.  Furthermore, stem cells 
possess powerful immunomodulatory and anti-inflammatory functions and may 
enhance the proliferation of endogenous stem or progenitor cells in the repair of 
damaged organs and tissues (Togel and Westenfelder, 2012).  The rationale for stem 
cell use in clinical renal transplantation is therefore to reduce the severity of IRI, 
prevention of acute cell-mediated rejection, with the long-term aim of lessening 
immunosuppression requirement (Franquesa et al., 2012a), encouraging cellular 
regeneration and reducing chronic allograft nephropathy (Bank et al., 2015). 
 
The potentially beneficial effects of using stem cells in tissue regeneration were first 
reported by Till and MuCulloch more than 50 years ago (Becker et al., 1963, Till and 
Mc, 1961).  The subsequent enthusiasm for the potential of this novel therapy led to a 
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variety of different stem cell types being investigated for use in regeneration 
medicine, with varying degrees of success.  The first successful uses of a cell-based 
therapy for tissue regeneration described the use of bone marrow-derived stem cells to 
repair damaged muscle fibres in immunodeficient mice (Ferrari et al., 1998).  
Subsequently, numerous studies have reported beneficial effects of various stem cell-
based therapies for mitigation of acute injury and/or restoration of healthy tissue 
(Monsel et al., 2014).  
 
1.31 DEFINITIONS AND CLASSIFICATION OF STEM CELLS 
Stem cells are found in all multicellular organisms and have two characteristic 
properties by which they are defined (Potten and Loeffler, 1990): 
(1) Self-renewal – the ability to undergo cycles of cell division and remain in an 
undifferentiated state:  
(2) Potency – the ability to differentiate into both non-renewing progenitor cells or 
terminally differentiated, functioning specialised cell types.  
 
Stem cells may be classified according to their developmental potential:  
• Totipotent Stem Cells: Produced by the fusion of an egg and sperm cell, these cells 
are able to give rise to all embryonic and extra-embryonic cell types and therefore can 
create a complete and viable organism.  In mammals only the zygote and the first 
cleavage blastomeres are totipotent (Donovan and Gearhart, 2001).  
 
• Pluripotent Stem Cells are able to differentiate into any of the three germ cell 
layers: - Endoderm: gives rise to tissues of respiratory and digestive tracts. - Mesoderm gives rise to muscle, bone, cartilage, blood and fat. - Ectoderm gives rise to epidermal cells and cells of nervous system (Donovan 
and Gearhart, 2001, Lovell-Badge, 2001, Spradling et al., 2001, Surani, 2001). 
 
• Multipotent Stem Cells: Able to give to a subset of cell lineages, and therefore are 
limited in their ability to differentiate.(Eckfeldt et al., 2005) For example 
haemopoietic stem cells are able to give rise to different subtypes of terminally 
differentiated blood cells, but would unable to give rise to cells of neural origin.  
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• Unipotent Stem Cells: Able to differentiate into only one mature cell type.  
 
The term progenitor cell is also often used in the stem cell literature. Unlike stem 
cells, progenitor cells lack the capacity for repeated self-renewal, and their progeny 
only gives rise to specific mature cell types (Reule and Gupta, 2011).  Progenitor 
cells’ ability to give rise to a few cell types sometimes leads them to be classed as 
oligopotent.  
Stem cells from 2 sources are commonly used in biological research:  
• Embryonic stem cells (ESCs) are pluripotent stem cells harvested from the inner 
cell mass of the blastocyst, around five days after fertilization (Donovan and 
Gearhart, 2001). This process results in the destruction of the embryo.  Research 
involving ESCs has therefore been subject to considerable ethical debate (Green, 
2007).  
 
• Adult stem cells (ASCs) are undifferentiated cells found throughout the body 
amongst the differentiated cells of tissues and organs (Spradling et al., 2001).  They 
are best considered multipotent.  ASCs appear able to differentiate and replenish 
damaged cells, thereby repairing the tissue or organ in which they are found.  For 
example, in adult bone marrow there are hematopoietic stem cells (HSC) and 
mesenchymal stem cells (MSCs).  HSC can give rise to all types of blood cell, while 
MSCs have the ability to differentiate into cells of chondrocyte, osteocyte and adipose 
lineage.  
 
Unlike ESC based research, isolating ASC lines does not involve the destruction of a 
fertilized human embryo and is therefore considered less controversial (Green, 2007).  
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1.32 INDUCED PLURIPOTENT STEM CELLS 
The ideal solution to current organ shortages may lie in the development of 
techniques that allow the growth of organs ex vivo, thereby eliminating the need for 
organ donors per se.  This panacea might involve the directed differentiation of 
pluripotent stem cells into a viable organ, ideally of an identical immunological 
profile to the intended recipient.  This would eliminate the requirement for life-long 
immunosuppression and the side effects that are associated with this.  However, it is 
unclear how best to stimulate stem cells to differentiate into mature and fully 
functioning organs, partly because experiments investigating the utility of embryonic 
stem cells or stem cells derived from human fetal tissue have been the subject of 
vigorous ethical debate.  Furthermore, as yet human fetal stem cells are unproven with 
regard to their ability to generate the diverse population of differentiated cell types 
required to produce a viable organ.  
 
However, in 2006 work by Takahashi et al. described techniques that have the 
potential to circumnavigate both of these barriers (Takahashi and Yamanaka, 2006). 
The overexpression of four critical transcription factors (Oct 3/4, Sox 2, Klf 14 and c-
myc) was demonstrated to potentially return any somatic cell to a pluripotent state.  
Stem cells that result from this method are referred to as induced pluripotent stem 
cells (iPSCs) and are thought to have the same potency as ESC lines.  Theoretically, 
iPSCs may be induced from an individual’s somatic cells and stimulated to grow into 
a transplantable organ that has the same immunological profile as the somatic cell 
donor.  Furthermore, this approach is not subject to the same ethical debate as 
experiments utilising ESCs or cells from human fetal tissue.  
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After Takahashi’s seminal work, studies using iPSCs have described experimental 
protocols that have allowed the ex vivo development of precursor kidneys in a 3D 
matrix (Takasato et al., 2016a, Takasato et al., 2016b).  
Termed kidney “organoids”, these precursors are essentially a miniature, self-
organizing multicellular structure, which due to tissue structure and function may be 
regarded as a simplified kidney (Schutgens et al., 2016).  However, while the ethical 
issues surrounding the use of ESCs may be removed by the use of iPSCs, the use of 
iPSCs for the generation of kidney organoids have several potential disadvantages.  
Firstly, iPSCs are genetically unstable, as reprogramming factors introduced by 
lentiviral vectors may incorporate into the cell genome.  This poses the risk of later 
tumour formation (Briggs et al., 2013, Rao and Malik, 2012).  Secondly, organs 
derived from iPSCs may contain cell types that are not fully differentiated, and it is a 
concern that these may give rise to teratoma formation after transplantation 
(Gutierrez-Aranda et al., 2010).  Finally, organoids derived from iPSCs have been 
reported to be less efficient that organoids that are derived from ESCs (Freedman et 
al., 2015).  
 
Nevertheless, while many technical steps require clarification before the successful 
growth of transplantable kidneys, it is apparent that organoids themselves may have 
some useful clinical applications (Little, 2016).  Firstly, organoids could be utilised to 
screen drugs for toxicity, and secondly, organoids may prove useful models in which 
to study genetic aspects of kidney disease.  Furthermore, organoids may prove useful 
sources from which to gather stem cells for use in regenerative therapies (Little and 
Kairath, 2016). 
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Several studies have reported the considerable efficacy of cells derived from iPSCs 
for the treatment of an acute renal injury. However, there are conflicting reports 
regarding the possible mechanism by which this effect is achieved. Imberti et al. 
reported that iPSC kidney cell types reduced renal damage by direct kidney 
integration and differentiation into specialised cell types (Imberti et al., 2015), while 
another study concluded that this effect was mediated via paracrine factors (Toyohara 
et al., 2015).   
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1.33 MESENCHYMAL STEM CELLS  
Mesenchymal stem cells (MSCs) were originally identified in bone marrow stroma by 
Friedenstein et al (Friedenstein et al., 1974, Friedenstein et al., 1968).  They are a 
heterogeneous adult population of multipotent stromal cells that can differentiate into 
cells of the mesodermal lineage.  The presence of MSCs has been detected in the 
tissues of several organs, including peripheral blood, connective tissue, the umbilical 
cord, amniotic fluid, adipose fat and the kidney (Bruno et al., 2009a, Crisan et al., 
2008, Edwards and Hollands, 2007, Flynn et al., 2007).  Similarly, the isolation and in 
vitro expansion of MSCs has been described from bone marrow, adipose tissue, the 
umbilical cord, muscle, fetal liver and lung.  Most often isolated from bone marrow, 
bone marrow derived mesenchymal stem cells (BD-MSCs) constitute only 0.01 – 
0.001% of the total bone marrow cell population (Uccelli et al., 2006). 
 
The Mesenchymal and Tissue Stem Cell Committee of the International Society of 
Cellular Therapy have outlined a combination of phenotypical, morphological and 
functional characteristics that are required to define MSCs (Dominici et al., 2006).  
These are primarily based on three criteria:  (1) MSCs must adhere to plastic under standard tissue culture conditions, 
exhibit fibroblast-like morphology, while displaying the ability to 
proliferate (Le Blanc, 2006, Tse et al., 2003). (2) MSCs must express certain cell surface markers such as CD73, CD90 and 
CD 105, but must not express CD45, CD34, CD14 or CD11b, CD79  
CD19 and major histocompatibility complex II (Dominici et al., 2006). (3) Must have the capacity to differentiate into mesenchymal lineages 
including osteoblast, adipocytes and chondroblasts when exposed to the 
appropriate inductive media in vitro.  
Numerous reports have described the beneficial regenerative effects of MSCs.  The 
majority of these published studies describe the use of MSCs to mitigate injury to 
solid organs - a reflection of the potential efficacy of MSCs in regenerative medicine.  
In addition, MSCs possess several advantageous properties that facilitate their use in 
clinical research (Wise and Ricardo, 2012).  (1) MSC are easily identifiable by their cell surface markers.  (2) They adhere to plastic and are capable of substantial proliferation and 
expansion in culture ex vivo.  
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(3) They are capable of differentiation into multiple cell lineages.  (4) MSC can be cryopreserved with no loss of phenotype or differentiation 
potential. (5) They can be sourced from adult tissue, hence they are free from the ethical 
issues surrounding ESCs.  
 
1.34 MALIGNANT POTENTIAL OF MESENCHYMAL STEM CELLS 
Extensive expansion of MSCs in culture may lead to changes in cell phenotype and 
function, and it remains unclear if in vitro cultured MSCs differ in their properties 
from populations that have been obtained in vivo (Mohseny and Hogendoorn, 2011).  
The production of sufficient MSCs for clinical use may require consistent in vitro 
expansion, which could lead to spontaneous malignant transformation (Rubio et al., 
2008, Casiraghi et al., 2013b).  This remains the primary concern regarding stem cell 
therapy in clinical application.  Initially MSCs were reported not to form teratomas 
following transplantation in rodents (Kuroda et al., 2010), unlike ESCs and induced 
pluripotent stem cells, which are known to have malignant potential (Blum and 
Benvenisty, 2008, Baker et al., 2007, Barrilleaux et al., 2006, Kuroda et al., 2013).  
However, studies have reported the ability of BD-MSCs to stimulate the growth of 
existing cancers (Studeny et al., 2002) and promote metastases in mice (Karnoub et 
al., 2007).  In vitro cultures of mesenchymal stem cells derived from adipose tissue 
have shown spontaneous malignant transformation after being passaged multiple 
times over 20 weeks (Froelich et al., 2013, Rubio et al., 2005).  This phenomenon was 
not observed when BD-MSCs were passaged 25 times over 44 weeks (Bernardo et al., 
2007), suggesting that the potential for malignant transformation could vary according 
to source and/or the culture conditions (Mannello and Tonti, 2007).  However, whilst 
some studies have reported malignant transformation of BD-MSCs in culture 
(Rosland et al., 2009, Rubio et al., 2005), these have subsequently been retracted as 
the cultures investigated were contaminated with tumor cell lines (Torsvik et al., 
2010).  
 
Nevertheless, MSCs therapy applied to clinical practice ought to use cells produced 
over a short period of time with low passage numbers, and such use would require 
cautious application and rigorous surveillance (Bartmann et al., 2007).  
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1.35 BENEFICIAL PROPERTIES OF MESENCHYMAL STEM CELLS 
MSC Homing Capacity 
In non-injured states, MSCs given intravenously tend to migrate to bone marrow (Gao 
et al., 2001).  However, in vivo studies have demonstrated that after systemic 
administration, MSCs not trapped in the lung have a tendency to localise in sites of 
inflammation in damaged tissues (Horwitz et al., 2002, Mahmood et al., 2003).  
Specific and preferential migration to kidneys after renal injury is also reported 
(Ittrich et al., 2007, Herrera et al., 2004, Morigi et al., 2004).  
 
As MSCs express a variety of adhesion molecules and chemokine receptors(Fox et 
al., 2007), it is likely that chemokines are regulators of this preferential migration to 
sites of inflammation and damage.  Up-regulated in ischemic or hypoxic conditions, 
chemokine ligand 12 receptor 4 (CXC-R4)(Togel et al., 2005b, Wynn et al., 2004, 
Herrera et al., 2007) and platelet–derived growth factor (PDGF)(Burton et al., 1999) 
have been implicated in MSC migration to acutely injured kidneys.  The expression of 
CD44 also appears to be involved in the localisation of MSCs to injured renal tissue 
(Herrera et al., 2007).  This is based on the observation that MSCs, engineered to lack 
CD44 expression, are unable to preferentially migrate to an acutely injured kidney, 
and subsequently, do not aid renal repair (Herrera et al., 2007).   
 
Additionally, matrix metalloproteinase 2 and vascular-cell-adhesion-protein-1 have 
been shown to be essential in MSC rolling and adherence to endothelial cells and 
hence MSC engraftment both in vitro and in vivo (Ruster et al., 2006).  Furthermore, 
expression of these homing-related molecules is up-regulated by inflammatory 
cytokines, including TNF-α and IL-1 (Ren et al., 2010, Shi et al., 2007).  Therefore 
different tissue inflammatory states, as expressed by different levels of inflammatory 
cytokines may be pertinent to MSC engraftment and therapeutic efficacy of MSC 
preparations (Wei et al., 2013). 
 
Immunomodulatory Properties 
Administration of MSCs has been found to exert protective effects in response to IRI 
in a wide range of solid organ animal models.  Such models include acute lung injury 
(Ortiz et al., 2003), AKI (Franquesa et al., 2012b), acute brain injury (Mahmood et 
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al., 2003) and acute myocardial infarction (Gnecchi et al., 2006).  There is general 
consensus amongst researchers that the benefits of MSC therapy in a wide range of 
diseases indicate that MSCs produce their effects in different organs by the 
modulation of common pathways.  MSCs are known to dampen inflammation in 
response to injury, thereby limiting initial tissue damage and subsequently promoting 
tissue repair (Uccelli et al., 2008, Han et al., 2012).   
The immunomodulatory potential of MSCs has been extensively studied (Aggarwal 
and Pittenger, 2005, Krampera et al., 2003).  MSCs poorly present antigen to other 
cells, lacking the expression of MHC class II proteins or co-stimulatory molecules 
(Dominici et al., 2006).  Consequently, MSCs do not stimulate T-cell proliferation in 
mixed lymphocyte culture but are known to down-regulate alloreactive T-cell 
responses in vitro via several mechanisms (Di Nicola et al., 2002).  Furthermore via a 
paracrine effect, infiltrating MSCs have been shown to alter both proliferation and 
cytokine secretion profiles from T helper cells (Krampera et al., 2003, Glennie et al., 
2005, Nauta et al., 2006a).  Additionally, in vitro experiments, demonstrate MSC 
paracrine action dampens IL-2 and IL-15 driven Natural Killer cell proliferation 
(Aggarwal and Pittenger, 2005, Spaggiari et al., 2006), and furthermore production of 
dendritic cells from peripheral blood monocytes (Nauta et al., 2006a, Jiang et al., 
2005, Zhang et al., 2004).  Data on the role of MSCs on B cell function is less clear 
(Tabera et al., 2008, Franquesa et al., 2012b).  It is postulated that MSCs may reduce 
B cell proliferation both indirectly via T cell immunomodulation, and directly by up-
regulating IL–10 production (Franquesa et al., 2015).  
MSC administration has been reported to reduce cell-mediated rejection in rodent 
transplant models (De Martino et al., 2010).  The increasingly used ECD and DCD 
renal allografts are known to suffer from more severe IRI injury (Bagul et al., 2013) 
and are consequently more prone to short-term complications including DGF and 
acute cell-mediated rejection (Pomfret et al., 2008, Renkens et al., 2005, Singh et al., 
2011).  The immunomodulatory ability of MSCs to reduce inflammatory response to 
local injury and increase tolerance (Casiraghi et al., 2013a) makes such therapies an 
attractive option for the treatment of renal IRI (Vanikar et al., 2014). (See figure 1.8)  
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Figure 1.8: MSC origin and function, paracrine function and immunomodulatory properties (Asanuma 
et al., 2010). Since this publication, it has become apparent that MSCs progeny are limited to bone, 
cartilage and adipose cell types.  MSCs are not able to give rise to neurons, hepatocytes or muscle cells 
as originally thought.  
 
 
1.36 MESENCHYMAL STEM CELLS AND CLINICAL TRIALS 
 Given this potential, a small number of clinical studies been conducted, 
administering MSCs to patients undergoing kidney transplantation.  The timing of 
MSC preparation administration has tended to be during induction, and most studies 
have focused on safety and feasibility endpoints (Perico et al., 2011, Mudrabettu et 
al., 2015).  Initial reports suggest a reduction in acute rejection associated with MSC 
induction therapy in comparison to a more conventional induction regime utilising 
antibodies directed against IL-2 receptors (Tan et al., 2012).  Correspondingly, renal 
function at one year was reported to be better in the MSC-treated group (Tan et al., 
2012).  A further randomised study concluded that donor ADRC therapy, when co-
infused with hematopoietic stem cells peri-transplant, was safe and associated with 
fewer episodes of acute rejection (Vanikar et al., 2014).  However, another study 
reported that timing of MSC therapy is critical, with administration prior to 
transplantation yielding better results (Pileggi et al., 2013).  
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1.37 PATHFINDER CELLS 
There is interest in testing the efficacy of novel stem cells types, that are distinct from 
conventional MSCs.  For example, pancreatic ductal epithelial cells are reported to 
have the ability to de-differentiate into progenitor cells capable of forming new 
pancreatic islets and acini (Bonner-Weir et al., 2004).  As ductal cells replicate, they 
transiently express PDX-1, an embryonic transcription factor necessary for pancreatic 
development and the maturation of β-cells.  Cells expressing PDX-1 are reputed to 
display multi-potency (Bonner-Weir et al., 2004). 
 
The isolation and characterization of a novel population of pancreatic ductal 
progenitor cells has subsequently been described (Stevenson et al., 2009).  These 
cells, termed ‘pathfinder cells’ were originally obtained from adult rat pancreatic 
ducts, and have also been demonstrated to express PDX-1.  Two populations of 
pathfinders, either positive or negative for the MSC surface marker CD90 have been 
characterized (Stevenson et al., 2009).  Pathfinders positive for CD90 have been 
shown to form islet like structures when appropriately stimulated in vitro, in addition 
to the transcriptional expression of insulin.  CD90 negative cells do not form islets but 
are able to display insulin gene transcription (Stevenson et al., 2009).  
 
Pathfinder cells have been reported to aid organ regeneration in response to injury in a 
number of animal models.  In streptozotocin-induced diabetic mice, administration of 
intravenous human pathfinders was associated with normalised blood glucose and 
insulin that was murine in origin (Stevenson et al., 2011).  The authors concluded that 
Pathfinders were able to stimulate native β-cell regeneration, probably via a paracrine 
mechanism.  This conclusion was later supported by additional work by the same 
group, using extracellular secretory vesicles isolated from pathfinder cells in the same 
animal model with similar results (McGuinness et al., 2016).  Another study, 
administering intravenous infusion of Pathfinder cells to mice, reported mitigation of 
renal IRI, again thought to be via a paracrine mechanism (McGlynn et al., 2013).   
 
1.38 EVIDENCE FOR THE MECHANISM OF ACTION OF STEM CELLS  
Considerable evidence exists demonstrating the regenerative effects of stem cells as a 
therapy for the repair of damaged solid organs.  However, the precise mechanism by 
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which the beneficial action of stem cells is conferred is not well understood, and no 
single mechanism has gained universal acceptance. 
 
1.381 DIFFERENTIATION-DEPENDENT HYPOTHESIS 
The initial theory, often termed the “Differentiation-Dependent Hypothesis” stated 
that the administration of exogenous stem cells resulted in stem cell localisation 
within the tissues of an injured solid organ.  According to this theory, after 
administration stem cells would migrate to the site of injury, become engrafted into 
the organ and differentiate into healthy, functional specialized cells and their 
supporting types (Orlic et al., 2001, Terada et al., 2002, Ferrari et al., 1998).  
 
The main evidence for the Differentiation –Dependent mechanism was provided by 
the following studies: 
 
•  In murine glycerol and cisplatin AKI models, intravenous MSC therapy was 
reported to promote structural and functional repair of injured kidneys, via MSC 
engraftment and differentiation into functional tubular epithelial cell (Herrera et al., 
2004, Morigi et al., 2004).  Up to 22% of injected MSCs were found engrafted within 
damaged kidneys (Herrera et al., 2004).  This indicated MSC tropism for the injured 
kidney and a potential contribution of the stem cells to aid tubular regeneration and 
subsequently protect long-term kidney function (Herrera et al., 2004, Morigi et al., 
2004).  
 •  In both porcine and rodent animal models of acute myocardial infarction, initial 
experiments demonstrated restoration of cardiac function after intra-cardiac MSC 
administration.  This led some groups to conclude that MSC differentiation into 
cardiomyocytes and other cell types was the likely mechanism by which MSCs act 
(Shake et al., 2002, Tomita et al., 2002, Davani et al., 2003). 
 
Subsequently, evidence from multiple studies utilising different organ injury models 
emerged to challenge the theory of stem cell differentiation as the possible 
mechanism by which stem cells act to cause organ regeneration in response to injury.  
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In summary:  
• Using a rat model of acute myocardial infarction Mangi et al reported improved 
heart function only 72 hours after intra-cardiac MSC administration (Mangi et al., 
2003).  Due to the short timeframe between exposure and response to MSC therapy, 
the authors, concluded myocardial regeneration could not be attributed to MSC 
engraftment and differentiation.   
 
• Herrera et al demonstrated limited replacement of damaged renal tissue by 
differentiated MSCs, with only 2.0 – 2.5% of injected cells showing engraftment 
(Herrera et al., 2007).  Other studies also reported a negligible percentage (<5%) of 
administered cells became engrafted in the injured kidney (Imberti et al., 2007, 
Morigi et al., 2008).  These studies also reported administered MSCs did not persist in 
the kidney in the long-term.  This was a direct contradiction to previous reports 
(Herrera et al., 2004, Morigi et al., 2004) although there was consensus that MSC 
therapy protected against AKI, reducing tubular cell apoptosis and stimulating 
proliferation.  
 
• The work by Herrera et al (Herrera et al., 2007) was later substantiated in rat renal 
IRI models, whereby MSCs were only found to become engrafted transiently.  
Nevertheless improved renal function, likely as a result of reduced tubular damage by 
production of anti-apoptotic, pro-mitogenic and vasculotropic factors was observed 
within 48 hours (Lange et al., 2005).  Furthermore, MSC therapy was associated with 
up-regulation of anti-inflammatory cytokines and growth factors (Togel et al., 2005a, 
Lange et al., 2005, Togel et al., 2007). 
 
• MSC therapy in animal models had typically been delivered intravenously, due to 
the minimally invasive nature of this route and the easy of access.  However, the 
majority of intravenously administered MSCs remain in the circulation for less than 
60 minutes, before accumulating within filtering organs such as the lung, liver and 
spleen (Barbash et al., 2003, Kraitchman et al., 2005, Sackstein et al., 2008, Bieback 
and Brinkmann, 2010).   
 
• Although a limited number of transplanted exogenous cells were seen within the 
injured tissues, endogenous stem/progenitor cells were reported to become the 
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majority of the stem cell population that contribute to tissue repair after injury (Usas 
et al., 2011). 
 
 
1.382 DIFFERENTIATION-INDEPENDENT (PARACRINE ACTION) 
HYPOTHESIS 
As evidence emerged to challenge the differentiation-dependent hypothesis, 
complementary studies introduced the concept that stem cells, via a beneficial 
paracrine action, may mediate their effects via the release of biologically active 
factors.  
 
Paracrine signalling may be defined as a form of communication between two 
different cells, where one cell releases chemical mediators to its immediate 
environment, which results in a change in the behaviour of a cell in the adjacent 
environment.  
 
Supported by a wealth of convincing evidence, the idea that stem cells work via a 
paracrine mechanism gained widespread acceptance. 
 
• It was reported that intra-myocardial injection of cell-free culture medium 
conditioned by MSCs, protected cardiomyocytes from ischemic injury to the same 
extent as medium containing MSCs (Gnecchi et al., 2006).  MSC conditioned media 
improved cardiac function within 72 hours, but no improvement was observed with 
the use of medium that had never been exposed to MSCs (Gnecchi et al., 2006).  This 
experiment was later replicated in a porcine model of myocardial infarction, 
concluding that MSC conditioned medium protected cardiomyocytes from ischemic 
injury (Timmers et al., 2007).   
 
• Lee et al. reported that despite the majority of intravenously administered MSCs 
becoming trapped in the lungs of treated mice, MSC therapy was associated with 
significant myocardial injury reduction.  They concluded that lung engrafted MSCs 
were acting in a paracrine fashion by secreting the anti-inflammatory protein TSG-6 
(Lee et al., 2009). 
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• In a rat renal IRI model, Togel et al reported MSC therapy to be associated better 
outcomes than vehicle only treatment.  MSCs were found to up regulate anti-
inflammatory growth factors such as IGF-1 and IL-10, whilst causing the down-
regulation of pro-inflammatory mediators such as TNF-alpha and inducible nitric 
oxide synthase (i-NOS) (Togel et al., 2005a).  The same group would later 
demonstrate that MSC-conditioned media increased the survival and proliferation of 
endothelial cells in vitro, postulating that paracrine factors were responsible for their 
observations (Togel et al., 2007). 
 
These findings provided strong evidence that stem cells produce their beneficial 
effects in solid organs by the release of biologically active paracrine mediators.  
Despite this, some research groups argue that the differentiation-dependent hypothesis 
is the more likely to be correct, and cite a recent study concluded that stem cell 
conditioned medium did not protect against AKI in a murine cisplatin-induced AKI 
model (Gheisari et al., 2011). 
 
Nevertheless, in recent years the differentiation-independent mechanism has gained 
more supporters.  Interestingly, recent studies argue the differentiation-dependent and 
differentiation-independent mechanisms both play a role in limitation of initial injury 
and long-term kidney regeneration (Zhao et al., 2014).  Whilst acknowledging that the 
differentiation-dependent mechanism may exist in the organ repair process, the 
limited cell engraftment and differentiation reported by most studies would make it 
more likely that stem cells exert the majority of their regenerative effects in a 
paracrine fashion.  
 
1.39 EVIDENCE FOR A PARACRINE MECHANISM IN MITIGTION OF 
ACUTE RENAL INJURY 
Several studies using different models of acute renal injury have demonstrated the 
protective effects of exogenous stem cells.  In these studies, the use of MSCs has 
predominated.  Although MSCs, when administered systemically, were shown to 
migrate to the site of injury, the extent of tissue repair did not correlate with the 
degree of exogenous MSC engraftment.  This suggested that MSCs produced their 
effects in an indirect fashion, leading many of these studies to conclude that stem cells 
produced their beneficial effects via a paracrine mechanism.  
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Consequently, the ‘differentiation-dependent hypothesis' began to lose favour.  
Researchers suspected that the transfer of biologically active factors carried in 
membrane bound extracellular cellular vesicles (ECVs) between stem and recipient 
cells could be responsible for the observed results.  This realisation, together with the 
knowledge that cell-free therapy may have a number of benefits over cellular therapy 
led investigators to isolate preparations of ECVs and utilise them in experiments, in 
an attempt to demonstrate ECV efficacy.  
 
With respect to the kidney, an initial study reported the effects of cell media, 
conditioned by MSCs, injected into the peritoneal cavity of mice with cisplatin-
induced renal failure (Bi et al., 2007).  Media administration was found to be 
associated with reduced tubular cell apoptosis and increase tubular cell survival, 
replicating findings that had previously been observed with MSC therapy itself.  As 
with previous experiments utilizing conditioned cell media, the authors suspected 
there were active agents residing in the media, released by MSCs during culture.  
 
The first ever study to demonstrate the therapeutic effect of MSC-derived ECVs 
focused on kidney injury.  Here, after centrifugation of MSC conditioned cell media, 
Bruno et al demonstrated the protective effects of ECVs in a glycerol-induced murine 
model of AKI (Bruno et al., 2009b).  They concluded the ECVs were able to shuttle a 
subset of micro-RNA (miRNA) that was characteristic of MSC phenotype, thereby 
influencing cell proliferation, transcription and immune-regulation (Bruno et al., 
2009b, Bruno and Bussolati, 2013).  
 
Subsequently, a number of studies, using ECVs purified from conditioned cell media 
have demonstrated protective effects of ECVs given by an intravenous route. 
 
Gatti et al. reported that rats subjected to renal IRI, were protected by a single dose of 
ECVs obtained BD-MSC, given immediately after injury (Gatti et al., 2011).  ECV 
use was associated with improved renal function and histology, with reduction in 
tubular cell apoptosis.  Interestingly, ECVs obtained from fibroblasts conferred no 
benefit to damaged kidneys.  These findings were corroborated in a study by Zou et al 
(Zou et al., 2014).  Here, in rat renal IRI model, the use of intravenously administered 
ECVs isolated from MSCs that originated in umbilical cord tissue, was associated 
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with improved renal function and histology.  The authors concluded that the likely 
mechanism of ECV action was via a reduction in infiltrating macrophages, due to 
reduced expression of the chemo-attractant protein CX3CL1 (Zou et al., 2014).   
 
Cantaluppi et al reported that in a rat renal model of IRI, ECVs derived from 
endothelial progenitor cells, accumulated in peri-tubular capillaries and tubular cells 
after intravenous injection (Cantaluppi et al., 2012).  The use of ECVs was found to 
accelerate tubular proliferation while reducing apoptosis and leucocyte infiltration.  
Significantly, improved renal function was associated with ECV administration.  The 
use of RNAase on ECVs prior to administration negated their effects (Cantaluppi et 
al., 2012).  Furthermore this experiment analysed the effect of ECVs harvested from 
Dicer knockdown endothelial progenitor cells.  Dicer is an intracellular enzyme 
essential for the production of miRNA.  ECVs from Dicer silenced endothelial 
progenitors were not found to be capable of conferring protection against renal IRI.  
 
Taken together with the effect of RNAase treatment on ECV efficacy, these findings 
clearly implicate the horizontal transfer of miRNA as a key step in the action of ECVs 
on other cells (Cantaluppi et al., 2012).  These results were supported by subsequent 
studies (Bruno et al., 2012, Milwid et al., 2012), which reported amelioration of 
neighbouring AKI in SCID mice by repeated intravenous injections of ECVs obtained 
from BD-MSCs.  Again, RNAase treatment negated any protection conferred by ECV 
administration (Bruno et al., 2012).  In addition to these results, He et al. described 
the reno-protective effects of BD-MSC ECVs, given intravenously to mice 
undergoing a 5/6 nephrectomy (He et al., 2012).  
 
However, the ECVs obtained in each the above studies were isolated using uniform 
centrifuge speeds of 100,000g (Bruno et al., 2009b, Cantaluppi et al., 2012, Gatti et 
al., 2011, Bruno et al., 2012, He et al., 2012, Milwid et al., 2012, Zou et al., 2014).  
As discussed below, ECVs released from stem cells are far from uniform, differing in 
size, membrane surface proteins and biological content.  Centrifugation at 100,000g is 
likely to result in the isolation of at least two active vesicle populations that are 
present in the ECV fraction.  Correct identification of the responsible vesicle type is 
necessary to allow the characterization the active biological factors through which 
tissue repair and regeneration might be achieved (Han et al., 2016).  
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1.4 WHAT IS THE EXACT NATURE OF THE PARACRINE MEDIATORS 
BY WHICH STEM CELLS ACT?  
The exchange of information between cells may involve soluble factors or direct cell-
to-cell contact.  A weight of evidence suggested that stem cells produce their 
beneficial effects via paracrine factors, and subsequently, researchers have 
investigated as to what the identity and nature these factors might be.  
 
Extracellular secretory vesicles (ECVs) have emerged as the leading candidates by 
which stem cells might achieve paracrine signaling.  Correctly applied, ECV is term 
that encompasses the entire spectrum of membranous vesicle derived from cells 
(Anthony and Shiels, 2013).  ECVs are also broadly referred to in the literature using 
several terms including micro-secretory vesicles, micro-particles and (incorrectly) 
microvesicles and exosomes.  Indeed, a recognised standard needs to be reached with 
regard to the nomenclature in this area (Pilzer et al., 2005).  Too often different 
studies use different criteria to define ECVs, and due to inconsistent terminology 
comparison between studies becomes difficult (Anthony and Shiels, 2013, Gould and 
Raposo, 2013).  
 
ECVs were initially identified from a large number of cell types, both in vitro and in 
vivo.  They are membrane bound, spherical, submicron factors that are released from 
the cell membrane.  For a long time, ECVs were considered to be inert cellular debris 
lacking any specific biological purpose (Siekevitz, 1972).  Using electron microscopy, 
ECVs observed in vitro were thought to be the result of cell preparatory methods and 
dismissed as irrelevant artifacts.  Similarly, ECVs obtained from biofluids while in 
vivo were regarded as the result of cell damage or routine cell membrane turnover and 
dismissed as inconsequential (Siekevitz, 1972).  
Subsequently, it was demonstrated that circular plasma membrane fragments released 
from human cells were the result of a specific export process, with ‘membrane 
fragments’ carrying enzymes in the same ratio as the cells from which they originated 
(De Broe et al., 1977).  More recent evidence has questioned the validity of initial 
assumptions, and it is now widely recognized that ECVs influence and participate in 
numerous biological processes (Cocucci et al., 2009).  Recent experiments have 
identified specific functions of ECVs released from various cell types, with the 
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recognition that ECVs should now be considered carriers of genetic information that 
is exchanged in cell-to-cell communication (Raposo and Stoorvogel, 2013).   
Apoptotic vesicles have been demonstrated as being released from both healthy and 
diseased cells undergoing apoptosis.  They range in size from 1 – 5µm (Raposo and 
Stoorvogel, 2013) and  do not appear to have a major role in cell-to-cell signaling 
(Akers et al., 2013). 
 
 However, two broadly distinct types of ECV been reported as participating in the cell 
signalling process – microvesicles and exosomes (Gyorgy et al., 2011, Raposo and 
Stoorvogel, 2013, Thery et al., 2009).  Despite continuing confusion regarding the 
nomenclature used to describe these, there is growing acceptance that microvesicles 
and exosomes are structurally and morphologically distinct.  Furthermore, 
microvesicles and exosomes are thought to contain different biologically active 
factors, and this has clear potential implications for their effects on target cells 
(Raposo and Stoorvogel, 2013, Lai et al., 2012).  
 
Microvesicles are sometimes loosely referred to as “shedding vesicles” (Cocucci et 
al., 2009). They originate by direct budding of small cytoplasmic protrusions of the 
cell plasma membrane in a process that is dependent on calcium influx.  With regard 
to size, microvesicles are a heterogeneous population that range between 100nm – 
1µm (Cocucci et al., 2009, Dragovic et al., 2011).  (See Figure 1.9) 
 
On the other hand, exosomes are derived from the endosomal membrane 
compartment, and after fusion with the plasma membrane undergo exocytosis from 
activated cells (Hugel et al., 2005, Johnstone et al., 1987).  Exosome content entered 
the cell of origin by endocytosis, before being biologically altered and stored as 
intraluminal vesicles within multivesicular bodies of the late endosome.  They are 
released when these multivesicular bodies fuse with the cell membrane in a 
mechanism dependent on cytoskeleton activation.  They are a more homogenous 
population with a size ranging from 30 – 100nm (Heijnen et al., 1999, Rozmyslowicz 
et al., 2003, Dragovic et al., 2011, Hugel et al., 2005, Raposo and Stoorvogel, 2013).  
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Figure 1.9: Release of microvesicles and exosomes.  Microvesicles bud directly from the plasma 
membrane, whereas exosomes are represented by smaller vesicles that are more regular in size and 
shape.  Exosomes originate from inward budding of the cell membrane and the formation of 
multivesicular bodies (MVBs).  When MVBs fuse with the plasma membrane, exosomes are released.  
The point of divergence between these types microvesicles and exosomes is drawn at early endosomes, 
but the existence of distinct early endosomes feeding into these two pathways cannot be excluded.  
Other intracellular vesicles fuse with lysosomes and are degraded (Anthony and Shiels, 2013). 
Interestingly, the release of ECVs from cultured stem cell lines is known to be 
dependent on conditions in which the cells are maintained.  A number of triggers for 
increased ECV production have been identified, including hypoxia, shear stress, 
oxidative stress and the presence of inflammatory cytokines, including TNF-alpha and 
IL-6.  Studies report a 15-fold increase in ECV production when cultured stem cells 
are stimulated with either hypoxia or sheer stress (Bian et al., 2012, Diamant et al., 
2004, VanWijk et al., 2003, Ratajczak et al., 2006b).  
 
ECVs have been shown to contain cell surface receptors and cytoplasmic 
components, including proteins and lipids, which originate from their cell of origin 
(Ratajczak et al., 2006a, Collino et al., 2010, Deregibus et al., 2007, Yuan et al., 
2009).  The presence of cell-specific surface receptors suggests that ECVs are an 
important mechanism by which cells communicate.  Furthermore, this is an indication 
that ECVs target specific cells in the immediate environment and do not communicate 
with other cells in a random fashion.  Analysis has revealed that both microvesicles 
and exosomes contain biologically active nucleic acids in the form of DNA, 
messenger RNA (mRNA), and microRNAs.  The biologically active content of ECVs 
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implies that functional modulation and re-programming of recipient cells may occur 
in response to ECV stimulation.  The membrane structure of ECVs suggests that this 
process is carefully regulated, and consequently is dependent upon the interaction 
between cell-specific surface protein receptors (Collino et al., 2010, Deregibus et al., 
2007, Ratajczak et al., 2006a, Yuan et al., 2009). 
 
Ratajczak et al (Ratajczak et al., 2006a) were the first to show that stem cell derived 
ECVs are able to reprogram cells resident in neighbouring tissue.  In this study, 
haemopoietic progenitor cells were induced to transcribe proteins in response to 
ECVs stimulation.  Since RNAase treatment ablated this process, the authors 
concluded that RNA contained in ECVs was critical in this signaling process.  
 
Subsequent reports described the activation of angiogenic pathways in quiescent 
endothelial cells using ECVs derived from endothelial progenitor cells (Deregibus et 
al., 2007).  Again ECV treatment with RNAase negated this effect.  Later, the same 
group would report that such ECVs contained the pro-angiogenic miRNAs, including 
miR-126 and miR-296 and hypothesized that delivery of these by ECVs into recipient 
cells could explain their observations (Cantaluppi et al., 2012).  
 
These studies suggest that stem cells exert at least some of their beneficial effects in 
damaged solid organs via transfer of genetic information within ECVs (Camussi et 
al., 2010). The resultant alteration of gene expression may result in the up-regulation 
of anti-inflammatory cytokines and anti-apoptotic genes, whilst down regulating 
inflammatory and pro-apoptotic factor expression (Johnstone et al., 1987, Camussi et 
al., 2010). 
 
Tissue resident cells, rather than circulating stem or progenitors cells, seem to provide 
the major contribution to regeneration with solid organs.  Within the kidney, repair 
following ischemia is attributed to tubule re-population from resident tubule cells.  
These are likely to de-differentiate, migrate to the site of injury and differentiate again 
into mature tubular cells.  ECVs released from resident stem cells possibly modulate 
this chain of events, by re-programming remaining tubular cells to enter the healing 
process.  However, these processes may be overwhelmed in the face of severe injury, 
especially if the organ is biologically old.  Administration of either exogenous stem 
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cells, or their ECVs, that results in high localized renal ECV concentration may 
provide a boost to the healing process by both down-regulation of the inflammatory 
process, and direct stimulation of tissue regeneration.  (See Figure 1.11) 
 
 
Figure 1.11: Potential mechanism by which stem cells and their ESVs can induce renal regeneration.  
(Cantaluppi et al., 2013) 
 
1.41 WHICH TYPE OF EXTRACELLUALAR VESICLE IS RESPONSIBLE 
FOR ORGAN REGENERATION 
It has been reported that the microvesicles will sediment at centrifugation speeds 
lower than 100,000g (Muralidharan-Chari et al., 2010).  Due to their smaller size, the 
exosomal fraction requires speeds of around or higher 100,000g to sediment.  Hence it 
is possible to broadly separate the ECV constituents by the use of differential 
centrifugation speeds.  
 
Unfortunately, most studies typically report the use of a single centrifugation speed of 
around 100,000g when preparing their ECV samples.  Hence, the many ECV 
preparations reported to have regenerative effects when applied to injured solid 
organs, are likely to contain both microvesicles and exosomes.  Consequently, any 
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biological effects associated with the use of such mixed preparations are difficult to 
attribute to a particular ECV fraction and their specific nucleic acid and protein 
content (Muralidharan-Chari et al., 2010). 
 
 
1.5 ADVANTAGES OF CELL-FREE vs. STEM CELL THERAPY 
Understanding the identity of the active paracrine factors and how they may influence 
solid organ repair and regeneration is clearly important in the development of future 
regenerative therapies.  As noted previously, therapeutic administration of stem cells 
is known to carry the risk of mal-differentiation into malignant cell lines.  This is of 
particular concern in patients undergoing solid organ transplantation as such 
procedures carry the necessity of life-long immunosuppression to prevent rejection by 
the adaptive immune system.  Immunosuppression is well recognised to increase the 
risk of malignancy.  It is generally accepted that a recent donor or recipient history of 
a malignant process should be an absolute contraindication to solid organ 
transplantation.  Transplant clinicians recognise the potential risk of using cultured 
stem cell lines as a therapy to reduce peri-transplantation injury and consequently 
there is reluctance to expose transplanted, immunosuppressed patients to novel 
cellular therapies. 
 
ECVs have been shown to be more stable in storage than aliquots containing stem 
cells.  It is also easier to prepare frozen ECVs for delivery than cellular preparations, 
making ECVs more suitable for everyday use (Vlassov et al., 2012).  Moreover, cell-
free preparations are thought to carry a much-reduced risk of causing malignancy 
when compared to preparations containing potent stem cells (Vishnubhatla, 2014) 
(Han et al., 2016).  Identification of the active paracrine factors that mediate 
protection in the short term and/or tissue regeneration in the long-term may allow 
these factors to be manufactured synthetically (Vishnubhatla, 2014), reducing the 
potential for harm to a minimum (Rani et al., 2015).  Furthermore, in clinical 
transplantation, the likely route of administration of any therapy would be into the 
artery supplying the allograft just prior to transplantation.  This would minimise the 
drug dose needed, and would probably dramatically reduce the systemic distribution 
when compared to the intravenous route.  One potential drawback of intra-arterial 
therapy is the increased likelihood of microvascular occlusion, a process originally 
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termed “passive-entrapment” (Walczak et al., 2008).  Supra-therapeutic dose of stem 
cells, administered intra-arterially have since been reported to cause passive 
entrapment, resulting in renal hypoperfusion and dysfunction (Shih et al., 2013, Lee et 
al., 2012, Cai et al., 2014).  In contrast, a therapeutic dose of smaller, soluble and 
highly concentrated biologically paracrine factors would be most unlikely to cause 
such a problem (Rani et al., 2015).   
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
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The materials and methods presented in this chapter describe general methodology 
relevant to all ‘results’ chapters.  Where appropriate, additional materials and methods 
specific to individual experiments presented within a particular results chapter are 
addressed within that chapter.  
 
2.1 RODENT HUSBANDRY, ANASTHESIA, SURGERY AND 
POST SURGICAL CARE 
2.11 RODENT DIET AND HOUSING 
Albino Swiss rats, their mutant rat substrain (AS-AGU), and Fischer 344 rat strain 
were used in different experiments reported throughout this thesis.  Albino Swiss and 
AS-AGU rats were bred in the Joint Research Facility, University of Glasgow.  Male 
Fisher 344 rats were bought from Harlan UK Ltd, and housed for at least two weeks 
before surgery to allow the animals to equilibrate with their new environment. 
All animals were housed in the Joint Research Facility under standardised conditions 
in plastic metal cages, light-dark cycle 12/12 hours, temperature 22oC +/- 2oC, 
humidity 55 +/- 5%. 
Animals were fed a standard diet of rodent chow and had access to tap water ad 
libitum both pre and post procedures. 
 
2.12 RODENT ANASETHSIA 
All animals were weighed prior surgery.  Anaesthetic induction was achieved by 
placing the rat in an anaesthetic chamber, and ventilating with 5% isoflurane.  Once 
anaesthetized, the animal was shaved as appropriate.  
Unless otherwise stated, anaesthesia was maintained throughout surgery with an 
inhaled mix of 5% isoflurane and 1 litre/ minute of oxygen given via facemask.  The 
required amount of anaesthestic agent was adjusted by an assistant according to the 
animal’s respiratory rate and pain withdrawal reflexes. 
 
2.13 POSITION AND TEMPERATURE CONTROL DURING RODENT 
SURGERY  
The animal was placed supine under a sterile drape on a corkboard, containing a far-
infrared heating mat.  A mobile board is useful for microsurgery, as it allows the 
animals position relative to the surgeon to be easily manipulated during theprocedure.  
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The animal’s core temperature was measured regularly with an infrared thermometer 
and maintained in the range of 36.9oC  - 37.3oC by adjusting the far infrared heating 
mat.  
 
2.14 SURGICAL STERILITY 
The methods used to ensure sterility are recommended by the Home Office and were 
observed and approved by the Home Office veterinary surgeon.  Great care was made 
to ensure sterility at all times including liberal use of sterile drapes and gloves, 
autoclaved instruments (30 minutes at 134oC) and sterile surgical technique.  After 
shaving, the animals were cleaned with 2% chlorhexidine solution before being 
covered with a sterile drape.  
 
2.15 MICROSURGICAL SET-UP AND EQUIPMENT - Wild Heerbrugg Ltd operating microscope – zoom 10 – 30x with 60mm LED 
light ring (Microscope Systems Scotland).  - Far infrared heating pad and infrared thermometer.  (Kent Scientific: DCT-15) - Operating Cork Board (30 x 30 cm). (See Figure 2.1) Covered with disposable 
plastic sheeting, held in place with adhesive tape.  Ordinary paper clips, after 
being autoclaved, were attached to elastic bands and used as tissue retractors, 
held in place with sterile 16G needles.   
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Figure 2.1: Typical microsurgical setup, showing the relationship of operating microscope, cork board 
and the attached far infrared heating mat.   
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The following microsurgical instruments were obtained from S&T® - Microsurgical vessel dilators with 0.1mm tips.  (D-5a.1) - Microsurgical vessel dilators with 0.2mm tips.  (D-5a.2) - Microsurgical vessel dilators with 0.3mm tips.  (D-5a.3) - Angulated forceps with 0.3mm tips.  (JFA-5b) - Dissecting microsurgical scissors with curved tips (SDC-15) - Adventia microsurgical scissors with sharp tips (SAS-15) - Microsurgical needle holder without a lock, curved tips 0.4mm.  (B-15-8) - Tubing introducing forceps, tips 0.35mm.  (TIF02) - Clamp applying forceps.  (CAF-4) - Atraumatic vascular clamps.  (B1-V and B2-V)) - Aceland Frame Clamp.  (ABB-1V) - Silicon strip visibility background material – essential to place behind vessels 
during anastomosis, both to protect surrounding structures and to aid 
visualisation.  (VB2 and VB4) - 0.6mm rubber sloop  
Additional equipment used during microsurgery included:  - Electric hair clippers (Oster-A5-00) - 15G Scalpel.  (Ethicon Ltd) - Sterile Dressing packs (Nu-Care Products) - Sterile Cautery  (John Weiss International Eye Cautery 0111122)  - 30G Rycroft Cannula (0108003)  - Sterile cotton tip applicators (Nu-care Products) - 10/0 nylon sutures.  (Schuco Ltd, ZX-AK-0105, DR4 needle) - 4/0 polyglactin 910 (vicryl®) sutures (Ethicon Ltd) 
 
2.16 POST-SURGICAL CARE 
Post-operatively, all animals were injected with 2.5ml of subcutaneous 0.9% saline  
(Baxter Healthcare, Thetford UK).  Buprenorphine analgesia was injected 
subcutaneously at 0.0045% per 100g of body weight.  This was repeated every 12 
hours for a maximum duration of 48 hours post surgery.  The animal was placed in a 
warming box at 38oC for 60 minutes after surgery and then returned to its cage.  
Animals were allowed free access to rodent chow and water and were weighted daily. 
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2.17 RODENT VENESECTION 
Measurement of serum creatinine is a commonly used to assess kidney function in 
humans and laboratory animals.  
Creatinine is a byproduct of muscle metabolism, formed during the breakdown of 
phosphocreatine by creatine kinase.  For an individual animal, the rate of production 
of serum creatinine is relatively constant, although this varies between animals 
according to muscle mass.  Creatinine is mainly filtered from the blood in the 
glomerulus, although it is also secreted by the proximal tubules.  When glomerular 
filtration is impaired, the blood level of creatinine rises.  
 
~ 200µL of blood for creatinine levels was obtained from rat-tail veins by puncture 
with a 23G needle after anaesthesia was induced as described in Section 2.12.  
The blood was spun for 6 minutes at 6000rpm, and the serum stored on ice before 
being transported to the Diagnostic Veterinary Diagnostic Services Laboratory, 
University of Glasgow at Garscube. Serum creatinine was measured via a kinetic 
modification of the Jaffe procedure, using an automated Olympus AU5400 analyzer.  
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2.2 DETERMINATION OF GLOMERULAR FILTRATION RATE 
VIA CONTINUOUS INFUSION CLEARANCE WITH 
FLUORESCENT INULIN 
 
2.21 BACKGROUND 
The formation of urine begins in the glomerulus with the generation of plasma 
ultrafiltrate.  The rate of ultrafiltrate formation, known as ‘Glomerular Filtration Rate’ 
(GFR) is regarded as the ‘gold standard' for determining renal function in both 
animals and humans (Schock-Kusch et al., 2012, Meneton et al., 2000). 
 
However, the use of the term ‘gold standard' implies there are widely employed 
correct procedures with optimised protocols to measure GFR (Schock-Kusch et al., 
2012).  In fact, GFR as determined by the administration of an exogenous tracer, may 
be measured by using two standard approaches:   
 
(1)  Two compartment clearance models - determination of a tracer’s elimination 
kinetics from plasma after a single bolus injection, requiring timed blood 
collection (Qi et al., 2004, Sturgeon et al., 1998, Fischer et al., 2000). 
 
(2) Constant Infusion Clearance (CIC) models - a tracer is infused at a constant 
rate until a steady-state tracer concentration is reached in the distribution 
volume.  This allows determination of a tracer’s urinary excretion rate via 
timed urinary and blood collection.  To achieve steady state as quickly as 
possible, a loading dose of tracer is administered in most protocols before 
constant infusion of tracer begins (Schock-Kusch et al., 2012, Fleck, 1999, 
Fleck and Braunlich, 1984, Jobin and Bonjour, 1985). 
 
An ideal exogenous tracer for determining GFR should be biologically inert, freely 
filtered across Bowman’s capsule and neither reabsorbed, manufactured nor secreted 
by the renal tubule (Sturgeon et al., 1998). 
 
Inulin is a biologically inert, uncharged fructan-type polysaccharide molecule.  It is 
unbound by plasma proteins and is not manufactured nor metabolised in vivo. 
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Furthermore, it is freely filtered by glomeruli, and unlike creatinine is neither secreted 
nor reabsorbed by tubular epithelial cells (Wang et al., 2010).  Consequently, inulin is 
widely regarded as an excellent reporter of GFR, with inulin clearance techniques 
employed to measure GFR in numerous studies.  Recently, the use of fluorescently 
conjugated inulin has emerged as a reliable technique for GFR characterization, with 
the use of fluorescent reporter simplifying reporter quantification in the collected 
biofluids (Fleck, 1999, Fleck and Braunlich, 1984, Qi et al., 2004, Sturgeon et al., 
1998). 
 
Throughout this thesis, Glomerular Filtration Rate (GFR) was calculated via a 
constant infusion clearance (CIC) technique, utilising fluorescently conjugated inulin, 
in a protocol adapted from Barber et al (Barber and Bourne, 1971). 
 
2.22 PREPARATION OF FITC-INULIN SOLUTION  
 0.2% Fluorescein Isothiocyanate Inulin (FITC-Inulin, Sigma-Aldrich) solution was 
made by dissolving 40mg of FITC Inulin in 20mls of 0.9% saline solution.  1% FITC-
Inulin was made by dissolving 10mg FITC-Inulin per ml of 0.9% Physiological Saline 
Solution (Baxter Pharmaceuticals).  To facilitate dissolution of inulin into solution, 
0.9% saline was warmed in a water bath to 40oC before use. 
 
 The solutions were dialysed for 24 hours through a GeBAflex-tube with a 1Kda 
semipermeable membrane (Gene Bio-Applications) in 0.9% Physiological Saline 
Solution, to remove unbound fluorescein.  The solution was then sterilised by passing 
it through a 0.22µm syringe filter.  At all possible times, inulin solutions were 
protected from light to prevent dissociation prior to infusion.  Furthermore, inulin 
solutions were universally made and utilised within 24 hours to avoid degradation of 
inulin solution. 
 
2.23 ANESTHESIA DURING INULIN CLEARNACE STUDIES 
Anesthetic induction was with isoflurane as described in Section 2.12.  During inulin 
studies, anaesthesia was then maintained with an initial intraperitoneal injection of 
thiobutabarbitol sodium (Inactin®) using 12mg per 100g of body weight.  Further 
maintenance doses of 2.4mg per 100g of body weight were given as required.  This 
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dosing protocol has previously been shown to provide stable cardiovascular 
parameters (Brammer et al., 1993).  
 
 
2.24 SURGICAL PROCEDURE TO DETERMINE GLOMERULAR 
FILTRATION RATE 
 
POSITIONING AND TEMPERATURE CONTROL 
 As described in Section 2.13 
 
FEMORAL VESSEL DISSECTION AND CANNULATION - (Figure 2.2i – 
2.2xii) 
The left groin was shaved and an incision made inferior and parallel to the inguinal 
ligament.  Dissection was carried out to retract the groin fat pad proximally, thereby 
exposing the femoral vessels.  The femoral artery and vein were fully dissected.  (See 
Figure 2.2)  After clamping the femoral vein proximally and ligating distally, 
microsurgical polyethylene tubing (Smiths Medical), 0.96mm external diameter (ED), 
was used to cannulate the vein.  The tubing was secured using 5/0 ligatures.  A 0.5ml 
bolus of 1% inulin solution was given before starting a constant infusion of 0.2% 
FITC inulin using a syringe pump (World Precision Instruments, NE300) at a rate of 
3ml per hour. 
A microsurgical catheter (0.8mm ED) was then placed in the femoral artery.  This 
was used to take blood samples during the experiment.  Between sampling, the line 
was locked with heparin-saline solution. 
 
URETERIC CANNULATION - (Figure 2.2 xii – xvi) 
The abdomen was re-opened along the line of the previous midline incision.  The 
bowel was wrapped in damp swabs, the ureters dissected and cannulated using a 7cm 
length of microsurgical tubing (0.61mm ED) Ligatures were applied to secure the 
catheters’ position. 
 
Via these cannulas, urine was collected into separate tubes during each 30-minute 
interval.  In the middle of each 30-minute collection period, an 80ul blood sample was 
taken via the arterial line. 
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Urinary volume for each 30-minute period was measured using a Gilson's pipette after 
a gentle spin at 2000 rpm for 15 seconds to remove sediment.  Once volume was 
measured, urine was transferred to a fresh Eppendorf tube for subsequently 
fluorescent measurement.  Similarly, immediately after collection, blood was spun 
down at 6000rpm for 6 minutes, and serum transferred into a fresh Eppendorf tube for 
later analysis. 
 
The experiment was terminated after six timed urinary/blood samples had been 
collected.  The animal was killed, liver, spleen, heart, lungs and both kidneys were 
taken and stored in 10% formation, liquid nitrogen and RNA later.   
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Figure 2.2: Dissection of Femoral Vessels 
(i) Dissection of the rodent left groin to expose the femoral anatomy.  The left common femoral artery 
(L-CFA), left common femoral vein (L-CFV), left femoral nerve (L-FN), left superficial circumflex 
iliac vessels (L-SCIV) and left external pudendal vessels (L-EPV) are clearly seen.     (ii) The L-SCIV 
and L-EPV are ligated.  (iii) The femoral sheath is opened, and dissection carried out to separate the 
femoral artery and vein.  The left profunda femoral artery (L-PFA) and vein (L-PFV) are exposed, 
allowing identification of the left common femoral artery (L-CFA) and vein (L-CFV), and also the left 
superficial femoral artery (L-SFA) and vein (L-SFV).  (iv) The L-PFVs are ligated and divided.  
(i)	 (ii)	
(iii)	 (iv)	
L-CFA	
L-CFV	
L-FN	
L-EPV	 L-SCIV	
L-FA	
L-FN	
L-FV	
L-SCIV	
L-EPV	
L-SFA	
L-SFV	
L-PFV	
L-PFA	
L-CFA	
L-CFV	 L-CFV	
L-CFA	
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Figure 2.2: Dissection and cannulation of femoral vessels. 
(v) The L-PFA is dissected before being divided with cautery.  Both femoral artery and vein have now 
been dissected, and their side branches ligated.  (vi) The L-SFV is ligated distally (DL).  A vascular 
clamp (VC) is applied to the L-CFV proximally.  Ligatures (L) are loosely placed in preparation for 
cannulation.  (vii) A venotomy (V) is made in the distal part of the L- SFV.  (viii) The vessel is 
cannulated, and the ligatures tightened before being cut to size.  The vascular clamp is re-positioned 
onto the cannula to provide extra security against slippage.  A bolus is inulin is given at this point, and 
the FITC-inulin infusion (II) is started.  
(v)	 (vi)	
(viii)	
L-CFA	
L-PFA	
L-SFA	
VC	
L	
L-SFV	
DL	
VC	
II	
L	V	
(vii)	
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Figure 2.2: Cannulation of Femoral Artery. 
(ix) The L-CFA has a vascular clamp (VC) applied proximally and ligature applied distally (DL).  
Loose ligatures are applied in preparation for cannulation.  An arteriotomy (Ar) is then made distally.  
(x) An arterial line prepped with heparinized saline, the vessel cannulated and ligatures tightened to 
secure the line in place.  The vascular clamp is released and blood flows into the arterial line allowing a 
sample to be taken.  The inulin infusion (II) is continuously running.  (xi) The smooth cannula tip 
achieved by cutting with a scalpel (top) versus the ragged edge made with sharp scissors (bottom).  
(xii) Overview of rat position with left groin dissection during inulin clearance.  
(ix)	
(xi)	 (xii)	
VC	
L	
Ar	
DL	
II	
AL	
II	
(xii)	
IL	
II	
AL	
(x)	
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Figure 2.2: Ureteric cannulation.  
(xiii) After a midline incision, retroperitoneal dissection is carried out to expose the right ureter (R-U).  
This involves mobilising the small bowel (SB) by incision of it posterior attachments.  The ureter, 
containing fluorescent urine, is easily identified by its characteristic vermiculation.  Cannulation is 
easiest at the point the ureter runs over the right common iliac vein (R-CIV).  The inferior vena cava 
(IVC) and left common iliac vein (L-CIV) are easily visible.  (xiv) Dissection is carried out to expose 
the left ureter (L-U), again easily identified by the fluorescent urine.  The IVC and aorta (A) are easily 
seen.  The left kidney (LK) and, spleen (S) are also visible.  (xv) The left ureter is cannulated and urine 
is seen to freely flow into the cannula.  (xvi) The position of the rat after ureteric cannulation.  The 
urine in collected into Eppendorf tubes (UB), placed to catch under ureteric cannulas as it flows.  Note 
the inulin infusion line (II).   
  
(xiii)	
(xv)	
(xiv)	
(xvi)	
IVC	
R-U	
R-CIV	
L-CIV	
SB	
C	
L-K	
S	
SB	
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A	
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L-K	
L-U	
L	
L-UC	
R-UB	
L-UB	
R-UC	
L-UC	
II	
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2.25 MEASUREMENT OF BIOFLUID FLUORESCENCE 
Plasma and urine fluorescence were measured by pipetting a10µL sample of biofluid 
onto with a Fluorescent Plate (Thermo-Scientific F96 Microwell plate).  To this, 40µL 
of HEPES 500mM buffer solution (dissolved 59.6g of HEPES buffer in 500ml of 
water, adjusted to pH 7.4 by adding Sodium Hydroxide solution) was added to give a 
total volume in each well of 50µL.  The addition of buffer is necessary, as 
fluorescence of biofluids has been shown to vary according to pH (Lorenz and 
Gruenstein, 1999).  Each sample was assayed in triplicate to identify pipetting error. 
 
Serum and urinary fluorescence were measured using a fluorescence microplate 
spectrometer (BIO-TEK flx-800) measuring emission and absorbance wavelengths of 
495nm and 430nm respectively.  
 
 From triplicate assays, mean fluorescence values were obtained and mean fluorescent 
values calculated.  
 
Steady state was reached in the plasma when the amount of inulin infused was equal 
to the amount filtrated by the kidneys.  This is defined as a <5% change in inulin 
plasma concentration over a 30-minute period (Sturgeon et al., 1998).  Data indicated 
that steady state is typically reached 60 - 90 minutes after the inulin infusion had 
commenced.  
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2.26 CALCULATION OF GLOMERULAR FILTRATION RATE 
At steady state, the amount of inulin removed per minute from the plasma is equal to 
the urinary inulin concentration (Ui) multiplied by the urinary volume per minute 
(Uv).  As inulin is freely filtered at the glomerulus, measuring the plasma inulin 
concentration at steady state (Pi) allows the volume of plasma filtered per minute 
(GFR) to be calculated according to the formula: 
 
GFR = Ui x Uv / Pi 
 
Where Ui  = Urinary fluorescence: Uv = Urine volume per minute: Pi = Plasma 
fluorescence. 
 
2.27 KEY FACTORS IN ACHIEVING RELIABLE GFR RESULTS 
Avoiding unnecessary blood loss is key to ensuring accurate GFR results.  To achieve 
this, it is advisable to ligate all branches of the femoral vessels and to provide 
proximal and distal control of vessels before making an incision for cannulation.  
Bleeding points on the re-opened abdominal wall should be cauterised or over-sewn 
immediately.  Cauterisation of small retroperitoneal vessels encountered during 
dissection of the ureter is advised, as these may bleed profusely over the time course 
of the study if left uncontrolled.  
 
2.28 TIPS FOR SUCCESSFUL MICROSURGICAL CANNULATION 
Cannulation is easier if a precise hole is made in the front wall of the structure to be 
cannulated.  A horizontal cut with a pair of pointed microsurgical scissors is most 
effective.  This manoeuvre allows the structure to remain under tension, while the 
created defect gapes open, allowing easy access for the passage of the cannula.  (See 
Figure 2.2 (xii) and (ix))  Fully dividing a structure causes proximal retraction, 
whereby cannulation becomes extremely problematic.  
 
It is useful to have ligatures to secure a catheter loosely applied prior to cannula 
insertion.  This allows simple tightening of the ligature as soon as the cannula is 
inserted, reducing the chance of the cannula inadvertently slipping out.  (Figures 2.2 
(xi) and (ix)) 
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When the microsurgical tubing is cut to size, the use of a scalpel blade allows a 
smooth, angled but non-pointed end of the tube to be fashioned.  (Figure 2.2 (xi))  The 
use of scissors leads to a ragged pointed tube that is difficult to insert and will tear 
holes in vessel walls when advanced.   
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2.3 RODENT RENAL TISSUE ANALYSIS 
2.31 PROTOCOL FOR EMBEDDING FORMALIN-FIXED KIDNEYS IN 
PARAFFIN 
Kidneys, fixed in 10% formalin, were halved prior to embedding in paraffin.  The 
remaining half of the kidney was returned to formalin.  
In order to dehydrate the tissue: 
(1) Kidneys were placed in 80% ethanol for 30 minutes 
(2) Kidneys were placed in 95%% ethanol for 30 minutes 
(3) Kidneys were placed in 95% ethanol for 45 minutes 
(4) Kidneys were placed in 100% ethanol for 40 minutes 
(5) Kidneys were placed in 100% ethanol for 40 minutes 
(6) Kidneys were placed in 100% ethanol for 40 minutes 
(7) Kidneys were placed in xylene for 40 minutes 
(8) Kidneys were placed in xylene for 40 minutes 
(9) Kidneys were placed in hot paraffin for 60 minutes 
(10) Kidneys were then finally placed into hot paraffin for 30 minutes 
before being allowed to cool on a ‘cold plate', and blocks turned out. 
 
Using a hand-operated microtome, blocks were then cut into 5µm sections, and 
floated in a warm water bath, before being placed on poly-L-lysine coated glass 
slides.  
 
To fix paraffin sections to the sides, slides were then placed in a drying oven for 90 
minutes at 60oC, before being stored at 4oC in a cold room.  
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2.32 PROTOCOL FOR STAINING RENAL SECTIONS WITH 
HAEMATOXYLIN AND EOSIN  
Haematoxylin and Eosin (H & E) staining are the most commonly used histological 
stains.  Cell nuclei are stained blue, and cell cytoplasm is stained pink. 
 
METHOD 
2% Eosin was made up by dissolving 20g of Eosin in 1000ml of distilled water, using 
magnetic stirring.  A 20ml scoop of Calcium chloride was added to the mixture.  This 
helps eosin fix to the tissue sections.  
 
Paraffin-fixed tissue was cut to 5µm and mounted on poly-L-lysine coated glass slides 
as previously described in Section 2.31. 
In order to remove paraffin from the sections: 
(1) Slides were placed in xylene for 5 minutes 
(2) Slides were then replaced in a fresh xylene for a further 5 minutes 
In order to re-hydrate tissue sections: 
(3) Slides were then placed in 100% ethanol for 3 minutes 
(4) Slides were placed in 100% ethanol for a further 3 minutes 
(5) Slides were placed in 90% ethanol for 2 minutes 
(6) Slides were placed in 70% ethanol of 2 minutes 
(7) Slides were placed in running water for 2 minutes 
(8) Slides were then stained Harris haematoxylin for 8 minutes 
(9) Slides were then rinsed in running tap water for 2 minutes 
(10) Slides were then placed in ‘Scott’s’ tap water for 45 seconds until blue 
(11) Slides were then rinsed in running tap water for 2 minutes 
(12) Slides were then placed in 2% Eosin stain for 10 minutes.  
(13) Slides were then rinsed in running tap water for 2 minutes 
(14) Slides were quickly dipped in 90% ethanol 
(15) Slides were quickly dipped in 100% ethanol 
(16) Slides were quickly dipped in 100% ethanol 
(17) Slides were placed in xylene for 1 minute 
(18) Slides were placed in xylene for 1 minute 
(19) Slides were mounted with coverslips and fixed using DPX.  
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2.33 RENAL HISTOLOGY ASSESSMENT 
 IRI-related changes in renal histology are most severe in the S3 segment of the 
proximal renal tubule, located at the outer stripe of outer medulla.  Such changes 
typically include denudation of tubular basement membrane, loss of brush border, and 
sloughed debris in the tubular lumen that results in hyaline cast formation.   
 
To assess renal histology and quantify ischemic related damage, 5µm kidney sections 
were routinely stained with hematoxylin and eosin as described in Section 2.32. 
Histology scoring was a method described in a previous study (Melnikov et al., 2002) 
and subsequently modified in later reports.(Wang et al., 2012, Gatti et al., 2011, 
Allam et al., 2012) Using a 200x objective [high-power field (HPF)] 10 non-
overlapping fields were randomly selected by a single blinded observer.  Within each 
field, the following were counted in a 60 second period:  
(i) Number of hyaline casts  
(ii) Number of epithelial breaks (denudation of tubular basement membrane) 
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2.4 IMMUNOHISTOCHEMISTRY PROTOCOL 
Immunohistochemistry (IHC) was carried out in a standardised fashion for the 
proteins of interest listed below.  Primary antibody type and dilution are 
expressed in brackets.   
 
Kidneys sectioned to 5µm and fixed to poly-L-lysine coated glass slides as described 
in Section 2.31, were removed from storage at 4oC, placed in a plastic slide rake, and 
baked for 30 minutes at 56oC.  
 
2.41 DE-WAXING AND REHYDRATION OF PARAFFIN FIXED TISSUES 
(1) Slides were placed in xylene for 2 minutes. 
(2) Slides were placed in xylene for 2 minutes. 
(3) Slides were placed in 100% ethanol for 2 minutes. 
(4) Slides were placed in 100% ethanol for 2 minutes. 
(5) Slides were placed in 90% ethanol for 2 minutes. 
(6) Slides were placed in 70% ethanol for 2 minutes. 
(7) Slides were placed in running tap water for 2 minutes. 
 
During this process, solution for antigen retrieval was prepared.  
 
2.42 ANTIGEN RETRIEVAL 
(1) 1000ml of distilled water was placed in a plastic pressure cooker 
(2) 0.37g of EDTA (Sigma E-5134) and 0.55g Tizma Base (Sigma T-1503) were 
added to the water 
(3) Using a pH probe, the pH of the solution was adjusted to 8.0.  This usually 
necessitated the addition of a few drops of hydrochloric acid via a Pasteur 
pipette. 
(4) This solution was then heated for 13.5 minutes in the microwave at high 
power 
(5) Slides were then placed in the hot solution, and the lid locked onto the 
pressure cooker to provide a tight seal.  
(6) The slides were then heated in the microwave at high temperature, and under 
pressure for 5 minutes.  
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(7) Slides were left in antigen retrieval solution to cool for 20 minutes at room 
temperature, before being rinsed in distilled water.  
 
2.43 SLIDE STAINING 
A 3% solution of hydrogen peroxide (H2O2) solution was made by mixing 360ml of 
distilled water with 40ml of 30% H2O2.  
 
(1) Slides were placed in 3% H2O2 solution for 10 minutes, the solution being 
gently agitated with a magnetic stirrer. 
(2) Slides were washed in running tap water for 2 minutes. 
(3) Slides were then ‘ringed’ with a DAKO marker to create a hydrophobic 
barrier. 
(4) 200µl of a 1x casein solution made up at a 1 in 10 dilution in TBS was then 
applied to each section.  This was incubated for 60 minutes at 25oC in a 
humidified chamber.  
(5) Casein solution was then blotted from sections.  
(6) Primary antibody for the protein of interest was made then up to the stated 
dilution in 5% casein. 
(7) 200µl of primary antibody solution was applied to each slide, which were then 
incubated overnight at 4oC. 
(8) Slides were washed in TBS for 2 x 5 minutes 
(9) Secondary anti-Rabbit Envision antibody was made up to 1:200 dilution in 1x 
casein in TBS. 200µL was applied to each slide. 
(10) Slides were incubated at 25oC for 30 minutes in a humidified chamber.  
(11) Slides were washed in TBS for 2 x 5 minutes 
(12) DAB substrate (Vector SK4100) was made by mixing two drops of 
stock buffer with 5ml of distilled water, four drops of DAB substrate and two 
drops of hydrogen peroxide. 
(13) Sections were incubated at room temperature until colour developed.  
Typically this took around 7 minutes.  
(14) Slides were then washed in water for 10 minutes.  
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2.44 COUNTER-STAINING OF SLIDES 
(15) Slides were stained for 45 seconds in Harris Haematoxylin. 
(16) Slides were then rinsed in running water. 
(17) Slides were de-stained in acid alcohol for 30 seconds. 
(18) Slides were then rinsed in running water. 
(19) Slides were then stained in Scot’s tap water substitute for 1 minute.  
(20) Slides were then rinsed in running water. 
 
2.45 SLIDE DEHYDRATION AND MOUNTING 
(21) 1 minute in 70% ethanol 
(22) 1 minute in 90% ethanol 
(23) 1 minute in 100% ethanol 
(24) 1 minute in 100% ethanol 
(25) 1 minute in xylene 
(26) 1 minute in xylene 
(27) DPX and coverslips were added. 
 
2.46 P-16 IMMUNOHISTOCHEMISTRY PROTOCOL WITH VECTOR LAB 
IMPRESS PEROXIDASE POLYMER KIT MOUSE-ANTI-MOUSE (MP2400) 
The protocol used for p16 IHC differed slightly from the standardised IHC technique 
in that a specific, pre-prepared reagent kit (MP2400) was utilised for the primary and 
secondary antibody applications steps.  De-waxing, antigen retrieval, counterstaining 
and mounting of slides were as described in Sections 2.41, 2.42, 2.43 and 2.44.  
 
2.461 SLIDE ANTIBODY STAINING 
A 3% solution of hydrogen peroxide (H2O2) solution was made by mixing 360ml 
of distilled water with 40ml of 30% H2O2.  
(1) Slides were placed in 3% H2O2 solution for 10 minutes, the solution being 
gently agitated with a magnetic stirrer. 
(2) Slides were washed in running tap water for 2 minutes. 
(3) Slides were then ‘ringed’ with a DAKO marker to create a hydrophobic 
barrier. 
	 96	
(4) Three drops of Protein blocking solution (Reagent 1) was added to each slide 
to completely cover the tissue section.  This was incubated for 30 minutes at 
25oC in a humidified chamber.  
(5) Protein blocking solution was then blotted from sections.  
(6) MaxHomo TM blocking reagent (Reagent 2) was then added to completely 
cover tissue sections.  This was incubated for 60 minutes at 25oC in a 
humidified chamber.  
(7) Slides were washed in TBS for 5 minutes 
(8) Slides were washed again in TBS for 5 minutes 
(9) Primary antibody (Mouse anti-mouse p16 (F12) Santa Cruz sc-1661) was 
made up to a 1:150 dilution in DAKO diluent.  200µl of primary antibody 
solution was applied to each slide to cover tissue sections. 
(10)  Sections then incubated overnight at 4oC in a humidified tray. 
(11) In the morning, slides were washed in TBS for 5 minutes. 
(12) Slides were washed again in TBS for 5 minutes. 
(13) Mouse Antibody Amplifier (Reagent 3) was added to cover tissue 
sections.  Slides were then incubated for 30 minutes at 25oC in a humidified 
chamber.  
(14) Slides were washed in TBS for 5 minutes 
(15) Slides were washed again in TBS for 5 minutes 
(16) Ready to use Polymer HRP Secondary antibody (Reagent 4) was 
added to slides to cover tissue completely.  Slides were then incubated for 30 
minutes at 25oC in a humidified chamber. 
(17) Slides were washed in TBS for 5 minutes 
(18) Slides were washed again in TBS for 5 minutes 
(19) DAB substrate (Vector SK4100) was made by mixing two drops of 
stock buffer with 5ml of distilled water, four drops of DAB substrate and two 
drops of hydrogen peroxide. 
(20) Sections were incubated at room temperature until colour developed.  
Typically this took around 7 minutes.  
(21) Slides were then washed in water for 10 minutes, counterstained and 
mounted as described in Sections 2.44 and 2.45.  
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2.47 CALCULATING HISTOSCORES 
Histoscores from each immunohistochemistry slide were calculated in standard 
fashion as previously described (Hirsch et al., 2003).  Using a semi-quantitative 
approach, immunohistochemistry slides were assigned a histoscore by two blinded 
observers.  This was achieved by evaluating both nuclear and cytoplasmic staining 
intensity.  This is graded as follows:  
Grade 0 = non staining; Grade 1 = weak staining; Grade 2 = medium staining; Grade 
3 = strong staining. 
The percentage of each staining intensity level is estimated and a histoscore assigned 
using the following formula: 
 
[1 x (%cells @ Grade 3) + 2 x (%cells @ Grade 2) + 3 x (% cells @ Grade 3)] 
 
The final score for each tissue section may range from 0 to 300. 
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2.5 ISOLATION, PURIFICATION AND QUANTIFICATION OF 
NUCLEIC ACIDS 
2.51 RNA EXTRACTION FROM TISSUE USING TRIZOL®  
Unless otherwise stated, reagents used during RNA extraction, manufacture of cDNA 
and q-PCR were obtained from Invitrogen Ltd (Paisley, UK) 
 
Workspace and tools were cleaned with RNAase away spray prior to starting RNA 
extraction. 
(1) 50 – 100mg of tissue, previously stored at -20oC in RNAse later, was added to 
a sterile tube containing 0.5ml of Trizol.  
(2) This was homogenised with a sterile fashion, using an electric homogenizer. 
(3) A further 0.5ml of Trizol was added and the solution vortexed for 20 seconds. 
(4) Samples were incubated at room temperature for 10 minutes. 
(5) 0.2ml of ice-cold chloroform was added, and the tube vortexed for 20 seconds, 
and incubated for 5 minutes at room temperature.  
(6) Tubes then underwent centrifugation for 10 minutes (14,000rpm at 6oC). 
(7) The colourless upper phase was then transferred to a new tube, and 1x volume 
of phenol/chloroform/ isoamyl alcohol at pH 6.6 was added. 
(8) This was vortexed for 20 seconds, incubated for 5 minutes at room 
temperature, before further centrifugation for 10 minutes (14,000rpm at 6oC). 
(9) The colourless upper phase was then transferred to a new tube, and 1x volume 
of ice-cold isopropanol added.  Tubes were inverted a few times to mix the 
solutions. 
(10) RNA was precipitated at – 80oC for 30 minutes.  
(11) Tubes were centrifuged for 30 minutes (14,000 rpm at 6oC). 
(12) RNA pellets were obtained, and supernatant removed without 
disturbing the pellet. 
(13) The pellet was washed with 1ml of 95% ice-cold ethanol.  
(14) The sample underwent centrifugation for 10 minutes.  (14,000 rpm at 
6oC).  
(15) The supernatant was removed. 
(16) The pellet was washed with 75% ice-cold ethanol. 
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(17) The sample underwent centrifugation for 10 minutes.  (14,000 rpm at 
6oC).  
(18) The supernatant was removed. 
(19) Samples were left to air-dry for 5 minutes. 
(20) Pellets were dissolved in 40ul of 0.1% diethylpyrocarbonate-treated 
(DEPC) water (ThermoFisher Scientific). 
 
Nanodrop® spectrophotometry analysis was then carried out, to measure RNA 
concentration and purity.  
(1) The machine is ‘zeroed’ using a 1.5ul sample of DEPC water 
(2) A 1.5ul RNA sample is placed on the pedestal.  The machine 
automatically adjusts to create a column of fluid, forming the optimum 
path length, through which the absorbance of the sample is measured. 
(3) Nucleotides, including RNA, single-stranded DNA and double-stranded 
DNA absorb at 260nm and contribute to the total absorbance of the 
sample.  The ratio of absorbance at 260nm and 280nm is used to assess the 
purity of RNA.  A ratio of ∼2.0 is accepted as pure for RNA. If the ratio is 
lower, it may indicate the presence of protein or phenol, which strongly 
absorb at 280nm. 
(4)  Samples were stored in – 80oC freezer.  
 
2.52 DNAase TREATMENT 
(Promega RQ1-RNase Free DNase®) 
Before the conversion of mRNA to cDNA, it is necessary to perform DNAase 
treatment to remove all genomic DNA.  This was achieved in the following standard 
fashion. 
(1) Samples were retrieved from the – 80oC freezer and thawed at room 
temperature.  
(2) The volume of RNA solution required to give 2µg was calculated for each 
sample, and this was added to fresh 200µl Eppendorf tube. 
(3) The total volume in each tube was then made up to 15µl by adding the 
requisite volume of DEPC water.  
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(4) DNAase ‘master-mix’ was made, containing 40% 10x DNAase buffer, 40% 
RNAase Out and 20% RQ DNase by volume.  
(5) 5µl DNAase ‘master-mix’ was added to each Eppendorf tube, so that each 
tube held exactly 20µl containing: - 2µg of RNA - 2µl 10x DNAase buffer - 2µl RNase OUT - 1µl RQ DNase 
(6) Samples were then incubated at 37oC for 30 minutes 
(7) 1µl of STOP solution was added  
(8) Samples were incubated at 65oC for 10 minutes to inactivate DNAase.  
(9) Samples were kept on ice, and Nanodrop measurement repeated to assess 
RNA concentration without genomic DNA contamination.  
 
2.53 cDNA SYNTHESIS 
(Roche Transcriptor Reverse Transcription).  
After purification of RNA, conversion to cDNA is necessary to proceed to q-PCR.  It 
is crucial to have equal concentrations of cDNA for q-PCR, and to do this the RNA 
concentration during reverse transcription must be kept constant.  This was achieved 
via the following standardised protocol: 
(1) After establishing RNA concentration with Nanodrop, exactly 1µg of RNA 
from each sample was added to a separate 200µl Eppendorf tube. 
(2) DEPC water was added to make the total volume of RNA and water to 20µl.  
(3) 2µl of random hexamer solution was added.  
(4) 2µl of dNTP solution was added 
(5) The solution was then incubated for at 65oC for 10 minutes before being 
placed on ice.  
(6) RT ‘master-mix’ containing, by volume 50% 5x Buffer, 25% 0.1M DDT, 
12.5% RNAase, and 12.5% reverse transcriptase was made.  
(7) 16µl of RT ‘master-mix' was then added to each sample so that each 
Eppendorf contained 40µl solution made up of:  - 1µg RNA - 2µl random hexamer solution 
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- 2µl dNTP solution - 8µl 5x RT buffer - 4µl 0.1M DTT solution - 2µl RNase Out  - 2µl Reverse Transcriptor  
(8) Samples were mixed and then incubated for at 25oC for 12 minutes, 42oC for 
50 minutes and 70oC for 15 minutes.  
(9) Samples were then stored at -20oC until q-PCR.  
 
 
2.54 TAQMAN REAL-TIME POLYMERASE CHAIN REACTION 
Polymerase Chain Reaction (PCR) is a method that allows exponential amplification 
of short DNA sequences (usually 100 – 600 bases) within a longer double-stranded 
DNA molecule.  PCR entails the use of a primers pairs that are complementary to a 
defined sequence on each of the two strands of DNA and specific to the gene of 
interest.  During PCR cycling, these primers are extended by a DNA polymerase, so 
that a copy is made of the designated gene sequence. Repeating the process leads to 
logarithmic amplification.  During each cycle, the strands of DNA are separated by 
heat denaturation, during which the primers become annealed to their complementary 
sequence.  The use of heat-stable polymerases (Taq-polymerase) eliminates the need 
to added fresh polymerase after each cycle.  
 
TaqMan probes are oligonucleotides that have fluorescent reporter dye attached to the 
5’ end and a quencher to the 3’ end.  When the probe is intact, the reporter dye 
emission is quenched due to the physical proximity of the reporter and quencher 
fluorescent dyes.  During the extension phase of the PCR cycle, the 5’ nuclease 
activity of the Taq-polymerase cleaves the hybridization probe and releases the 
reporter dye from the probe.  With each cycle of PCR amplification, there is an 
increase in fluorescence emission that is monitored in real-time (RT –PCR) using the 
ABI 7700 sequence detector.  
TaqMan RT-PCR was done using a Roche Lightcycler.  Using a standardised RT-
PCR ‘master-mix’, so that each sample was measured in triplicate, using specific 
	 102	
probe and primers for the genes of interest.  Each PCR plate well contained the 
following:  
(1) 1µl cDNA 
(2) 5µl 2x Taqman Universal Master Mix 
(3) 3.5µl DEPC water 
(4) 0.5µl of probe/primer mix 
 
Quantification of RT-PCR was via the comparative CT method (∆∆CT).  A threshold 
was set at a point where the amplification appeared linear for both the gene of interest 
and the housekeeping gene HPRT.  The resultant cycle number (CT) for both of these 
genes was recorded for each sample and also for a control tissue sample.  The CT 
values of both the sample of interest and control are then normalised to the 
housekeeping gene HPRT and quantified according to the following equation:  
 
∆∆CT = ∆CTsample - ∆CT reference 
 
Where ∆CTsample is the CT value for any sample normalised to the endogenous 
housekeeping gene (∆CTsample – CT housekeeping gene), and ∆CT reference is the CT value for 
the control also normalised to the endogenous housekeeping gene (∆CTreference – CT 
housekeeping gene) 
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2.6 ISOLATION OF PANCREATIC DERIVED PATHFINDER 
CELLS 
Laboratory staff, using methods described in a previous report, conducted pathfinder 
isolation and colony maintenance (Stevenson et al., 2011, Stevenson et al., 2009).  
The author did not perform this task, but was provided with cell preparations, used for 
the experiments described in Chapter 3.  
 
Briefly, minced pancreatic tissue was obtained from 12-month-old Albino Swiss rats.  
Seeding into CMRL medium (Invitrogen, Paisley UK) produced a confluent 
monolayer containing Pathfinder cells after ~ 5 weeks, which was then harvested and 
washed in phosphate buffered saline.  Cells were maintained in CMRL-1066 medium, 
supplemented with 10% fetal bovine serum ((FBS), Sigma, Poole UK).  Cells were 
characterised as described in previous reports.  Pathfinder cells were comprised of a 
mixed CD90 cytotype, positive for expression of c-met, CD147, CD44, CD49f and 
CD71.  Cells were negative for CD31, CD34, CD45, CD105, CD73 and c-kit 
expression.   
 
2.61 PREPARATION OF PATHFINDER DERIVED 
MICROVESICLES 
The microvesicles used throughout this thesis were isolated by Dr Diane Anthony. 
 
The methods employed have been previously described in detail (McGuinness et al., 
2016).  
Briefly, pathfinder cells, grown as described above in T50 flasks, CMRL-1066 
medium and FBS, and were centrifuged for 2.5 hours at 120,000 x g and then 
supernatant was carefully removed.  Pathfinders were then cultured without medium 
change until 80% confluent and the supernatant harvested. 
Under aseptic conditions, the supernatant was centrifuged at 1000 x g for 10 minutes 
to remove cell debris.  The supernatant removed and centrifuged at 16,000 x g for 2.5 
hours at 4oC.  The cell pellet was removed, re-suspended in sterile PBS and 
centrifuged for 2.5 hours at 16,000 x g at 4oC.  The yield was a cell free fraction, 
made up predominantly of microvesicles.  These were kept at -80oC until required for 
use.  
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2.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using Graphpad Prism 6.0.  
The specific parametric and non-parametric statistical tests used to analyse each 
experiment are detailed within each results chapter.  Data are presented as means ± 
Standard Deviation (SD) with the level of significance set at p<0.05.  
Error bars on graphs represent SD unless otherwise stated.  
 
2.71 DETERMINATION OF ANIMAL NUMBERS IN 
EXPERIMENTAL GROUPS 
Most previous rodent renal IRI studies have utilized a group size of 6 – 8 animals. 
However, these experiments have exclusively used serum creatinine / BUN to 
measure kidney functional status, with these being recognized as less sensitive 
indicators than GFR. Furthermore, there appears to be a complete absence of reported 
data describing the effect of stem cells and / or ECVs on GFR in renal IRI 
experiments.  
 
A recent paper, outlining a similar model to the novel renal IRI model described in 
Chapter 5, used a power calculation to determine a sample size requirement of 6 
animals per group (Le Clef et al., 2016).  Furthermore, studies using ADRCs (Chen et 
al., 2011, Shih et al., 2013, Wang et al., 2013b, Iwai et al., 2014) or ECVs (Gatti et 
al., 2011, Cantaluppi et al., 2012) have employed 6 or 8 animals per group to 
demonstrate significant findings.   
 
The experiments presented throughout the course of this thesis were novel. As such, it 
was not thought feasible to perform formal power calculations to determine group 
numbers, as effect size of therapeutic agents and standard deviation were unknown 
due to a lack of previous pilot data. Therefore, based on the findings / methods of the 
previous studies noted above, it was decided to employ 6 animals per group, but to 
review this requirement based on experimental findings.  
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CHAPTER 3 
 
TESTING THE RENAL REGENERATIVE EFFICACY 
OF PATHFINDER CELLS IN A RODENT MODEL OF 
CHRONIC RENAL FAILURE AND PREMATURE 
AGING  
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3.1 INTRODUCTION 
The increase in ESRD seen in the Western world is mainly related to chronic disease 
processes that are a consequence of lifestyle in individuals with a genetic 
predisposition to cardiovascular disease and diabetes.  While there has been much 
interest in developing cell-based therapies to mitigate acute events affecting native 
and transplanted kidneys, there has been less interest in the potential of stem cells to 
combat disease processes that culminate in patients with chronic renal failure 
progressing to end-stage disease. 
 
In part, this is due to a lack of suitable animals models that display chronic renal 
failure in association with increased cellular senescence.  However, within Glasgow 
University exists the mutant rat substrain (AS/AGU), which arose spontaneously in a 
colony of Albino Swiss rats (Clarke and Payne, 1994).  As a result of a mutation in 
the gene encoding the protein kinase PKCϒ, the AS/AGU rat is predisposed to 
excessive levels of oxidative stress, manifested by increased levels of cellular 
senescence and hence premature ageing (Craig et al., 2001).  This is most obliviously 
apparent in a Parkinsonian type movement disorder that is the result of the 
progressive loss of dopaminergic neurones (Payne et al., 2000).  However, the 
AS/AGU strain has been shown to develop chronic renal failure, with associated renal 
senescence in an age-dependent fashion (Gingell-Littlejohn, 2014).  It is therefore 
feasible to hypothesise that the AS/AGU rat provides a good model in which to study 
the ability of multiple doses of stem cell-based therapy to halt the progression of 
chronic renal disease in the long-term.   
 
A previous study reported that intravenous therapy with Pathfinder cells reduces 
senescence in acutely injured kidneys (McGlynn et al., 2013).  Furthermore, in mice 
subjected to streptozotocin-induced diabetes, intravenous Pathfinder therapy is 
reported to initiate native islet regeneration, with subsequent long-term 
normoglycemia observed in treated animals (Stevenson et al., 2011). 
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3.2 HYPOTHESIS 
(1) AS/AGU rats treated with multiple doses of intravenous Pathfinder cells may 
show improved renal function and reduced molecular marker of renal ageing 
12 months after treatment is initiated.   
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3.3 METHODS 
3.31 ANIMAL HOUSING AND HUSBANDRY 
Animals were housed and fed as described in Section 2.1.  Animals were weighed 
weekly and assessed on a daily basis for signs of distress or illness.  
 
3.32 GROUP SELECTION 
16 AS/AGU rats (eight male and eight female) aged from 4 -12 months, were 
randomly assigned to treatment and control groups so that each group contained four 
male and four females rats of similar ages. 
 
All animals were weighed at baseline and bled for baseline serum creatinine levels 
one week before the first injection. 
 
3.33 STEM CELL TREATMENT 
Animals randomised to treatment received 3 x 106 rat pathfinder cells in 0.9ml 
phosphate buffered saline (PBS) via tail vein injection.  Animals randomised to the 
control group received 0.9ml PBS vehicle via tail vein injection. 
Injections were repeated every two weeks. 
 
3.34 RENAL FUNCTION ASSESSMENT 
Rats underwent tail vein bleeding (Section 2.17) every two weeks.  Bleeding and tail 
vein injection weeks were alternated, so that no rat was both injected and bled in the 
same week.  
Animals were culled in terminal GFR studies (Section 2.2) 
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3.4 RESULTS 
3.41 ANIMAL WEIGHTS 
No significant weight difference was noted between Pathfinder treated and control 
animals at any point.  (See Figure 3.1)  However, a trend of weight loss in the 
Pathfinder treated group was observed prior to the experiment being halted. 
 
 
3.42 ANIMAL HEALTH 
35 days after the experiment began, a Pathfinder treated male rat was found dead in 
its cage.  For the previous five days, this animal had displayed weight loss, and signs 
of illness (marked piloerection, increased respiratory rate, reduced movement and 
food intake).  A post-mortem examination was carried out, with the finding of 
multiple pulmonary nodules, highly suspicious of disseminated malignancy.  (See 
Figure 3.2 (i)) 
 
By this time, other animals in the Pathfinder treatment group were displaying similar 
signs of weight loss, illness and distress.  Accordingly, both the University Veterinary 
Officer and the Home Office inspector were asked for an opinion.  It was deemed that 
all treated animals were distressed and consequently an order was made to 
immediately cull the animals.  It was permitted to do this in terminal GFR 
experiments.  A post-mortem examination was performed on each Pathfinder-treated 
animal, with the universal finding of multiple pulmonary lesions.  In addition five 
animals displayed macroscopic evidence of cardiac, renal or splenic involvement.  
(See Figure 3.2).  Formal pathology reports, produced by the Veterinary Diagnostic 
Services, University of Glasgow identified the macroscopic lesions as highly 
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infiltrating neoplastic tumours, and these were present in the lungs of all examined 
animals, in addition to the heart, spleen and kidneys of specific individuals.  These 
tumours were highly anaplastic, displaying signs of bone formation although the cells 
of origin could not be determined.  (See report attached: Appendix 1) 
These features are most frequently observed in teratoma or osteosarcomas.  
 
No sign of illness or distress was observed in the control group animals, which were 
also culled in terminal GFR experiments.  Post mortem examination revealed no 
evidence of pulmonary or abdominal malignancy in any animal treated with PBS 
vehicle.  
 
 
 
(i)	 (ii)	
Figure	3.2:	(i)	Le#	lung	and	heart	of	AS/AGU	rat	found	dead	35	days	a#er	Pathﬁnder	injec>on.	
(ii)	Right	lung	of	AS/AGU	rat	44	days	a#er	Pathﬁnder	injec>on.		
Both	lungs	display	evidence	of	disseminated	malignancy	in	the	form	of	mul>ple	pulmonary	
nodules.		
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3.43 SERUM CREATININE 
No difference in serum creatinine was noted between groups at any point, although a 
trend was noted towards increased serum creatinine in Pathfinder treated animals by 
Week 5.  (See Figure 3.3). 
 
 
Figure 3.3: No difference was noted at any point in serum creatinine levels between Pathfinder treated 
and control animals. However, blood tests at the end of Week 5 did show a trend towards elevated 
serum creatinine in the Pathfinder treated group (p=0.089) 
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3.44 GLOMERULAR FILTRATION RATE 
Only 6 Pathfinder treated animals underwent GFR studies, as one animal had been 
found deceased and another suffered a cardiac arrest under anaesthesia before steady 
state was reached.  Furthermore, 2 Pathfinder treated animals were clearly unwell 
during GFR study and failed to pass urine, resulting in a GFR of zero.  As a result, 
Pathfinder-treated animals were found to have a significantly lower GFR compared to 
control animals (p=0.0015).  (See Figure 3.4) 
 
 
Figure 3.4: Pathfinder treated animals surviving to undergo GFR studies (n=6) had a significantly 
lower GFR compared to control animals (n=8). p =0.0015 
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3.5 DISCUSSION 
In the field of regenerative medicine, the development of stem cell-based therapies are 
eagerly anticipated as promising tools to treat patients with a range of diseases. Such 
optimism is based on the ability of pluripotent and multipotent stem cells to 
differentiate into numerous cell lineages, with the potential to either replace damaged 
tissues directly by differentiation or to affect solid organ repair via a paracrine 
mechanism of action.  
 
Due to the ethical issues surrounding the use of ESCs, research has tended to focus on 
the use of MSCs.  These may be obtained from a number of different tissue types, 
although the use of BD-MSCs has predominated in most laboratories.  However, to 
obtain sufficient numbers of cells to achieve efficacy in clinical protocols, extensive 
ex vivo expansion is required (Rosland et al., 2009).  Unfortunately, accumulation of 
DNA damage through genomic instability, loss of cell cycle regulation and 
deregulation of epigenetic signature is more likely to arise during long-term, repeated 
culture under standard in vitro conditions (Maitra et al., 2005, Narva et al., 2010).  
This may eventually result in expanded stem-cell populations displaying 
tumorigenicity – defined as ‘the capacity of a cell population inoculated into an 
animal model to produce a tumor by proliferation at the site of inoculation and /or at a 
distant site by metastasis (Organization., 2013).  Therefore, the potential ability of 
stem-cell lines to undergo malignant transformation during repeated passage 
necessitates a stringent quality and assessment procedure in order to minimise the risk 
of negative, malignancy related outcomes to recipients (Yasuda and Sato, 2015). 
 
Any normal cell in the body has the potential to undergo malignant transformation. 
Such cells usually exhibit changes in their morphology, growth kinetics, cell surface 
markers, genetic composition and tumorigenicity (Lye et al., 2016). 
 
Pluripotent and multipotent stem cells, of both human and rodent origin, have been 
reported to undergo oncogenic transformation with the potential to cause 
disseminated malignancy as a result of their use in animal models.  Passaged MSCs 
obtained from rodents have been reported to display abnormal morphology, high 
proliferation rates and aneuploidy (Miura et al., 2006, Furlani et al., 2009a).  Evidence 
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of tumorigenicity has also been observed in rodent MSCs after only 3 passages, with 
MSCs undergoing malignant transformation and producing malignant tumors when 
injected into rats, rabbits and mice (Furlani et al., 2009a, Ahmadbeigi et al., 2011, 
Zhou et al., 2006). 
  
The longer telomere lengths in rodents (30 – 100kb) versus humans (5 – 10kb) 
theoretically reduces the risk of spontaneous transformation in expanded cell lines of 
human origin (He et al., 2012, Smogorzewska and de Lange, 2002, Oeseburg et al., 
2010).  Nevertheless, malignant transformation during passage has been reported in 
human MSC cell lines (Rubio et al., 2005, Rosland et al., 2009).  Subsequently, 
however, these findings were retracted as it was suspected that expanded human 
MSCs had been contaminated with tumour cell lines (Torsvik et al., 2010, de la 
Fuente et al., 2010).  While some reports have stated categorically that cultured 
human MSCs do not undergo spontaneous transformation in vitro (Bernardo et al., 
2007, Augello et al., 2010, Choumerianou et al., 2008), other researchers have 
recently indicated that such change does occur, while excluding the possibility of cell 
line contamination in their experiments (Pan et al., 2014, Wang et al., 2013a).  
Consequently, there is uncertainty regarding the ability of human MSC cell lines to 
display tumorigenicity after ex vivo expansion, although a reasonable body of 
evidence exists to suggest this phenomenon is at least a possibility (Lye et al., 2016, 
Yasuda and Sato, 2015).  
 
While there are no previous reports of ex vivo cultured Pathfinder cells displaying 
tumorigenicity, there is little doubt that Pathfinder treated animals in this experiment 
developed malignant tumours as a result of their therapy. Furthermore, both the 
distribution of disease and the timing of onset of symptoms of tumour burden reported 
here mimic the results of a previous study where intravenous MSC therapy resulted in 
multiple pulmonary metastatic lesions (Rosland et al., 2009).  It seems logical to 
conclude that the observed reduction in GFR results from dehydration and general 
illness that results from widespread metastatic disease that was universally seen in 
Pathfinder treated animals.  
 
This finding serves to highlight the dangers associated with the use of passaged stem 
cell preparations.  Patients undergoing renal transplantation are universally treated 
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with powerful immunosuppression medication in order to reduce the incidence of 
acute and chronic rejection episodes.  However, immunosuppressed patients are 
known to be at increased risk of long-term malignancy as a consequence of this 
therapy.  In addition, several studies in rodents have confirmed increasing teratoma 
formation rates with increasing levels of immune deficiency (Drukker et al., 2006, 
Dressel et al., 2008, Hentze et al., 2009). 
 
Theoretically, it is possible that treatment with stem cell preparations in an attempt to 
improve long-term allograft function increases patient risk of adverse outcomes as a 
result of malignant stem cell transformation.  That controversy exists regarding the 
ability of ex vivo expanded human MSC lines to display tumorigenicity is perhaps a 
moot point, as the potential for cell line contamination or spontaneous malignant 
transformation during passage will always exist – hence the clinical application of 
passaged cell preparations predisposes patients to unnecessary risk.  When 
considering this fact, it is pertinent to recall the salient principle of clinical medicine 
“Primum non nocere” – “First do no harm”.  
 
It follows that to facilitate the implementation of novel stem cell-based therapies, the 
adoption of strategies that exclude ex vivo stem cell expansion are of paramount 
importance.  Failing that, it would be highly desirable to implement stringent quality 
assurance procedures to exclude tumourogenesis, such as was observed here in 
immunocompetent animals.  Two strategies with the potential to reduce the risk of 
malignant complications have been reported in the literature: 
 
(1) The use of cell-free preparations, usually containing a biologically active 
fraction consisting of Extracellular secretory vesicles. (ECVs) 
(2) The use of stem cell preparations requiring little or no ex vivo expansion. This 
may comprise cells freshly isolated and used immediately, or cells that are 
isolated and immediately cryopreserved, being stored for later ‘off the shelf’ 
use.  
 
The negative findings of this chapter provided a persuasive argument to restrict the 
study of ex vivo expanded stem cell populations in animal models of renal failure. 
Indeed, the unexpected results reported above breeched the terms of the Project 
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Licence under which this experiment was conducted.  The Home Office inspector 
stipulated that no further work should be undertaken with pathfinder cells which had 
been expanded ex vivo without prior discussion with the Home Office.   
 
Consequently, due to the reduced potential for tumourogenesis, it was decided to 
focus investigation on the reno-protective abilities of both cell-free preparations and 
non-expanded stem cell preparations for the remainder of this thesis. 
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CHAPTER 4 
INVESTIGATING THE EFFECTS OF PATHFINDER 
CELL-DERIVED MICROVESICLES IN AN 
IMMUNOCOMPETENT RAT MODEL OF RENAL 
ISCHEMIA/REPERFUSION
	 118	
4.1 INTRODUCTION 
Currently no therapies are in widespread clinical use for the treatment or prevention 
of acute injury to either native kidneys or renal allografts.  This partly reflects the 
imperfect nature of the animal models in which novel treatments for renal injury are 
tested (Singh et al., 2012, Lieberthal and Nigam, 2000).  In vitro models including 
renal cell cultures, isolated renal tubules and isolated perfused kidneys have been 
gainfully employed to research the pathophysiological mechanisms by which renal 
injury occurs at the cellular and molecular level (Ortiz et al., 2015).  However, such 
models lack the physiological complexity to properly investigate the systemic effects 
of renal disease and the kidney’s subsequent response to novel therapies (Lieberthal 
and Nigam, 2000).  To draw meaningful conclusions regarding the efficacy and safety 
of cell-based treatments, in vivo models must be employed – a point highlighted by 
the findings of Chapter 3.  
 
In vivo models of renal failure have been commonly described and utilized, with 
approximately 50% of experiments conducted in rats (Wei and Dong, 2012).  For 
preliminary experiments, both rats and mice are considered favourable species as in 
vivo models for the investigation of renal disease.  Rodents are widely available and 
inexpensive when compared to research using large animals species, although large 
animals exhibit the closest similarity with humans and are considered the ‘gold 
standard’ for testing novel therapies (Giraud et al., 2011).  Nevertheless, rodents bear 
physiological and anatomical similarity with higher order mammals, and novel 
therapies may be screened using rodents before treatments are investigated further in 
large animal models.  
 
 
Rodent models commonly utilized to investigate the pathological pathways that lead 
to renal damage include:  
(1) Renal mass reduction by 5/6 nephrectomy 
(2) Renal ischemia-reperfusion injury (IRI) 
(3) Administration of nephrotoxic drugs to induce renal damage.  
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The 5/6 nephrectomy model is commonly used to create impaired renal function by 
ablation of renal mass.  This produces proteinuria but does not mimic the pathological 
mechanisms seen in acute transplant-associated injury or the processes involved in the 
presentation of native renal disease (Perez-Ruiz et al., 2006). 
 
Alternatively, prolonged warm renal IRI in rodents has been shown to cause 
significant tubular injury and an influx of inflammatory cells, leading to long-term 
renal fibrosis (Basile et al., 2001).  Warm renal IRI is considered to be the main 
pathological process affecting renal allografts, and models using warm IRI are 
probably the best mimics of the clinically observed acute transplant injury (Lameire, 
2005, Lameire et al., 2005).  In addition, warm renal IRI may also negatively impact 
upon the function of native kidneys, and is often seen in patients subjected to cardiac 
and vascular surgery, trauma, and burns (Lameire and Vanholder, 2004).  IRI is 
therefore a common and important pathology in which to study renal disease in an 
animal model. 
 
Therefore, rodent IRI models are of clinical relevance and furthermore such models 
are useful for assessing the efficacy of potential treatments before testing in a more 
technically complex rodent transplant model.  Here, a period of transplant cold 
storage is added to closely emulate the processes of involved during clinical 
transplantation (Wang et al., 2013b).   
 
Established in vivo models of renal IRI may broadly be divided into two types: 
bilateral  (B-IRI) or unilateral renal injury (U-IRI).  (See figure 4.1)  
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Figure 4.1: Commonly used rodent IRI models. 
 
U-IRI may be further divided into models with or without a contralateral nephrectomy 
(Le Clef et al., 2016, Wei and Dong, 2012).  Models using B-IRI or U-IRI with 
contralateral nephrectomy are the most commonly studied, probably because blood 
analysis may demonstrate trends in renal function throughout the experimental time 
course (Skrypnyk et al., 2013).  
 
However, the metabolic and electrolyte disturbances resulting from a severe and 
prolonged acute kidney injury may lead to unacceptable numbers of postoperative 
animal deaths (Wang et al., 2012) (Jang et al., 2009) usually within 48 hours of 
surgery (Skrypnyk et al., 2013).  As post-reperfusion renal function is known to be 
closely related to warm ischemic time, it is important to strike the correct balance 
between an acceptable number of post-procedure animal deaths and an ischemic 
period long enough to cause a permanent renal injury (Zager et al., 2011, Zager et al., 
2013).  Such a deficit in kidney function is necessary to demonstrate the long-term 
effects of novel therapies on renal recovery.  
 
(U–IRI-N) (U–IRI+N) 
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Most studies examining the use of renal IRI in rats report ischemic times of between 
30 – 60 minutes (Le Clef et al., 2016, Wang et al., 2012, Singh et al., 2012, Jo et al., 
2001, Jablonski et al., 1983, Nemoto et al., 2001, Ysebaert et al., 2000).  
Unfortunately, the majority of these experiments are concluded within a week of 
surgery and only a few studies applied to renal IRI report the long-term sequelae of an 
acute renal insult (Delbridge et al., 2007, Gueler et al., 2004, Kim and Padanilam, 
2015).  This may reflect the difficulty encountered when attempting to inflict a 
permanent renal injury using IRI without suffering unacceptable numbers of post 
surgical deaths from acute renal failure.  For example, serum creatinine levels after 60 
minutes of bilateral renal ischemia have been reported to return to sham levels after 7 
days recovery and remain stable for 40 weeks subsequently (Basile et al., 2001).  This 
duration of bilateral ischemia has been reported subsequently to result in ~ 50% 
mortality within 30 days post surgery (Wang et al., 2012). 
 
Most IRI experiments are preformed using healthy young rodents.  Clearly this does 
not mimic the clinical situation where organs from older donors are increasing used.  
The AS/AGU rat substrain displays premature renal dysfunction (Gingell-Littlejohn, 
2014) and consequently may be a useful model in which to perform renal IRI 
experiments.  Unfortunately, the available colony of AS/AGU rats was not large 
enough to power the planned IRI experiments, and so the Albino-Swiss strain was 
chosen for use in this experiment.   
 
After review of the literature, it was decided to investigate the effects of a 30-minute 
period of unilateral warm ischemia in Albino-Swiss rats undergoing a simultaneous 
contralateral nephrectomy.  The pathological course of unilateral ischemia with 
simultaneous contralateral nephrectomy model is expected to be quite similar to 
bilateral ischemia in that both models leave the animal with injured renal tissue only 
(Le Clef et al., 2016).  This allowed the use of serum creatinine to monitor gross renal 
function over the course of the experiment.  However, in view of the potential 
insensitivity of serum creatinine as a marker of rodent renal function, terminal inulin 
studies were performed after 14 days to characterize GFR in the most accurate way 
possible.  
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Furthermore, after the negative findings associated with the use of stem cell therapy 
described in Chapter 3, it was decided to investigate the use extracellular vesicles 
harvested from Pathfinder cells, as ESVs are thought to have a reduced malignant 
potential (Han et al., 2016, Vishnubhatla, 2014, Rani et al., 2015).  
 
4.2 HYPOTHESIS 
 
(1) 14 days after undergoing 30 minutes of warm renal IRI, changes in renal 
function, histology and molecular markers of damage will be evident versus 
controls not undergoing renal IRI.  
(2) Pathfinder-derived microvesicles, given intravenously, will mitigate the 
effects of renal IRI, resulting in improved renal function and histology, while 
reducing molecular markers of damage. 
(3) Microvesicles lack the ability to induce teratoma formation after intravenous 
administration.  
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4.3 METHODS 
4.31 EXPERIMENTAL GROUPS 
24 AS rats aged between 10 - 12 months were randomly assigned to 3 different 
groups. There were four males and four females, for a total of 8 rats in each group.  
• Group 1 – Right nephrectomy + saline vehicle via tail vein injection. 
• Group 2 – Right nephrectomy + left renal ischemia + saline vehicle via tail vein 
injection. 
• Group 3 – Right nephrectomy + left renal ischemia + pathfinder derived 
microvesicle therapy via tail vein injection.  
 
Group Nephrectomy Ischemia MV Therapy 
1 √ x x 
2 √ √ x 
3 √ √ √ 
 
Table 4.1: Summary of experimental groups. Randomly assigned to each group were four male and 
four female Albino Swiss Rats. 
 
Rodent husbandry, anaesthesia, positioning during surgery and post-surgical care, 
including venesection were conducted in standard fashion, as previously described in 
Sections 2.11 – 2.17.  
 
Microvesicles were harvested from Pathfinder cells as outlined in section 2.61. Using 
data from studies where intravenous Pathfinder microvesicles had achieved 
normoglycemia in diabetic mice, microvesicle dose was calculated per gram of rodent 
body weight and adjusted for rats.  
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4.32 SURGICAL PROCEDURE: RIGHT NEPHRECTOMY +/- LEFT RENAL 
ISCHEMIA 
A midline incision was made through the skin and subcutaneous fat using a 15 bladed 
scalpel, to expose the abdominal wall musculature. The linea alba was then incised 
with scissors from the xiphisternum and approximately 4cm inferiorly to provide 
excellent access to both kidneys. (See Figure 4.2)  To expose the left renal pedicle, 
the small and large bowel were packed away as necessary using sterile gauze swabs 
soaked in warm saline.  In all Groups, the left renal pedicle was dissected from the 
renal hilum proximal to the origin of the supra-adrenal vein, using a combination of 
sharp and blunt dissection.  The renal artery, which lies supero-posteriorly to the renal 
vein on the left, was not dissected free of the vein.  Once dissection had been 
achieved, the renal pedicle was clamped en mass using an atraumatic vascular clamp 
(B2-V) in animals belonging to Groups 2 and 3.  The pedicle was not clamped in 
Group 1 animals.  Visual inspection of the kidney at this point was undertaken, with 
the universal finding of a colour change, confirming correct application of the clamp. 
 
A right nephrectomy was then carried out.  The small and large bowel were repacked 
to provide exposure of the right kidney.  A folded swab was also placed to retract the 
right lobe of the liver, which was carefully detached from the vena cava using sharp 
dissection.  The right kidney was then mobilised from the renal bed, and the right 
ureter ligated using 8/0 nylon before being divided.  Attention was then directed 
towards the right renal pedicle, which was dissected, double ligated en mass with 6/0 
prolene and then divided.  The right kidney was then removed, and hemostasis noted. 
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Figure 4.2: (i) Exposure of the left kidney (LK) via retraction of the rectus muscle (R). The left renal 
vein (LRV), left renal artery (LRA) and left ureter (U) are clearly visible.  (ii) Extensive dissection of 
the left renal pedicle, to display relationship of relevant local anatomy.  The inferior vena cava (IVC), 
aorta (A), left colon (C) are easily seen, as are the LRV and LRA.  The vascular clamp (not pictured) 
was universally applied at the level of the double black line, just distal to the origin of the left gonadal 
vein.  (iii) Retraction of the right rectus (R) to expose the right kidney (RK).  The IVC and right renal 
vein (RRV) are seen.  The right renal artery runs posterior to the RRV and is not visible.  (iv) The right 
renal bed (RRB) after right nephrectomy.  The doubly ligated right renal pedicle (L-RRP) is clearly 
seen.  
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In groups undergoing ischemia, the clamp was removed from the left renal pedicle, to 
provide exactly 30 minutes of warm ischemia.  
 
The abdomen was closed en mass using a continuous 4/0 vicryl suture, with a 
subcuticular 4/0 un-dyed suture for the skin edges.  
 
Groups 1 and two were given 800µl of 0.9% saline vehicle, intravenously via tail vein 
injection using a 30G insulin syringe.  Group 3 animals received 800µl intravenous 
MV therapy via tail vein injection.  Tail vein injection was given after abdominal 
closure, typically 20 minutes after unclamping of the renal pedicle.  
 
Blood was taken from each animal for creatinine levels at days 2, 4, 7 and 10.  
 
At day 14, the animals underwent terminal inulin clearance studies in order to 
accurately characterise the GFR of the remaining kidney, according to the standard 
protocol described in Section 2.2. After the animal was sacrificed, left kidneys were 
stored in 10% formalin and RNA later solution for later analysis.  
 
Formalin preserved kidneys were paraffin embedded and sectioned as described in 
Section 2.3.  Histological analysis and immunohistochemistry for P16, P21 and Ki 67 
were carried out as described in Sections 2.3 and 2.4 
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4.4 RESULTS 
4.41 GROUP WEIGHT LOSS COMPARED TO BASELINE WEIGHT 
As shown in Figure 4.3 all animals suffered significant weight loss in response to the 
trauma of surgery.  By day 14 animals undergoing nephrectomy alone (Group 1) had 
regained their baseline weight.  In contrast, animals subjected to nephrectomy and 
ischemia (Groups 2 and 3), remained significantly below their baseline weight by Day 
14. 
 
 
 
 
Fig 4.3: Compared to baseline, animals in Groups 1, 2 and 3 exhibited significant weight loss on Day 2 
(p =0.0004, 0.0003 and <0.0001 for Group 1, 2 and 3 respectively) There remained significant weight 
loss for all Groups on Day 4 (p =0.0006, 0.0005, and <0.0001 respectively), Day 7 (p=0.0011, 
<0.0001, and <0.0001) and day 10 ( p=0.0006, 0.0039 and <0.0001) 
By day 14, animals undergoing nephrectomy alone (Group 1) had regained baseline weight (p = 
0.6980).  In contrast, animals subjected to nephrectomy and ischemia (Groups 2 and 3) failed regained 
their baseline weight by day 14 (p = 0.0358 and <0.0001 respectively).  
Statistical analysis by unpaired Students t test.  
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4.42 COMPARISION OF PERCENTAGE WEIGHT LOSS FROM BASELINE 
BETWEEN GROUPS 
Animals undergoing nephrectomy alone (Group 1) regained weight more quickly than 
animals subjected to nephrectomy and ischemia (Groups 2 and 3).  No significant 
difference was observed at any point in weight loss compared to baseline, between 
Group 2 and Group 3.  (Figures 4.4) 
 
 
 
Figure 4.4(i) Group 1 animals were found to have lost significantly less of their baseline body weight 
at day 7 (p =0.0259), day 10 (p =, 0.0253) and day 14 (p= 0.0378) when compared to Group 2 animals.  
(ii) Group 1 animals lost significantly less of their baseline body weight compared to Group 3 animals 
at day 4 (p=0.0149), Day 7 (p=0.0015), Day 10 (p=0.0004) and Day 14 (p=0.0002) (iii) There was not 
significant difference in baseline body weight lost at any time point when comparing Groups 2 and 3.   
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test 
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4.43 SERUM CREATININE LEVELS COMPARED TO BASELINE VALUES 
After surgery, all groups displayed significantly elevated serum creatinine levels 
when compared to baseline for the duration of the experiment. (Figure 4.5).  
 
Figure 4.5: All groups displayed significantly elevated serum creatinine from baseline (p<0.0001), at 
all the experimental time points of Day 2, Day 4, Day 7 and Day 10. 
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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4.44 COMPARISION OF SERUM CREATININE LEVELS BETWEEN 
GROUPS 
 
No significant difference in serum creatinine level was observed between any groups 
at any time point. (Figure 4.6). 
 
 
Figure 4.6: At all time points, Group 1 was found to have no significant difference in serum creatinine 
when compared to Group 2 (p = 0.9350, 0.9270, 0.8110 and 0.6478 at days 2, 4, 7 and 10 respectively) 
or Group 3 (p = 0.2093, 0.4583, 0.3365 and 0.3863 at days 2, 4, 7 and 10 respectively). 
No significant difference in serum creatinine level between Group 2 and Group 3 was observed at any 
time point (p= 0.3359, 0.6815, 0.6912 and 0.8955 at days 2, 4, 7 and ten respectively). Statistical 
analysis by one-way ANOVA with Tukey multiple comparisons test.   
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4.45 GLOMERULAR FILTRATION RATE 
All rats were culled on day 14 after undergoing terminal GFR experiments via 
continuous inulin infusion as described in Section 2.2.  
No significant difference in GFR was observed between any of the groups.  (See 
Figure 4.7) 
 
 
Figure 4.7: No significant differences were observed in GFRs between group 1 and 2 (p=0.9697), 
groups 2 and 3 (p=0.2976) and groups 1 and 3 (p=0.4143).  
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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4.46 RENAL HISTOLOGY SCORING 
Histological examination of kidney tissue revealed no significant difference between 
Groups in either the number of epithelial breaks or hyaline casts per high-powered 
field. (Figure 4.8)   
 
Figure 4.8: (i) No difference was observed in the number of epithelial breaks between Groups 1 and 2 
(p =0.7353 ) or Groups 1 and 3 (p=0.8782).  No difference in epithelial break formation was observed 
between Groups 2 and 3. (p=0.9619) (ii) No difference in hyaline cast formation was observed between 
Groups 1 and 2 (p=0.7663) or Groups 1 and 3 (p=0.9945).  No difference in hyaline cast formation was 
found between Group 2 and 3 (p=0.8218)  
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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4.47 IMMUNOHISTOCHEMISTRY DATA 
Histoscores for p16, p21 and Ki 67 were calculated by 2-blinded observers as 
described in Section 2.47.  
No significant difference between groups was found for p16, p21 or Ki 67 (Figure 
4.9).  
 
Figure 4.9: (i) No significant difference in cortical nuclear p16 expression was found between Group 1 
and 2 (p=0.9644) or Groups 1 and 3 (p=0.9882).  No difference was found between Groups 2 and 3 
(p=0.9146). (ii) No significant difference in cortical nuclear p21 expression was found between Group 
1 and 2 (p=0.8139) or Groups 1 and 3 (p=0.8060). No difference was found between Groups 2 and 3 
(p=0.9999). (iii) No significant difference in cortical nuclear Ki67 expression was found between 
Group 1 and 2 (p=0.8313) or Groups 1 and 3 (p=0.4160. No difference was found between Groups 2 
and 3 (p=0.7611).  
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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4.5 DISCUSSION 
Home Office Legislation in the UK regarding animal work requires intra-experiment 
animal pain and post-procedural animal mortality to be kept to a minimum.  Using 
conventional animal models, long periods of renal ischemia are therefore effectively 
prohibited as severe acute renal dysfunction is likely to cause severe metabolic and 
electrolyte disturbances that result in excessive numbers of post-procedural animal 
deaths (Skrypnyk et al., 2013, Wang et al., 2012). 
 
The unilateral renal ischemia with contralateral nephrectomy rodent model has been 
utilised in a number of studies, although ischemic times applied to the remaining 
kidney have varied from study to study.  Results from these studies indicate 
acceptable animal mortality rates with shorter periods of ischemia, but with increased 
mortality as ischemic times lengthen (Wang et al., 2012, Le Clef et al., 2016).  
Furthermore, the magnitude and duration of renal injury are clearly related to the 
length of the ischemic period (Grigoryev et al., 2008) with healthy rodents exhibiting 
considerable renal regeneration after ischemic renal injury (Ysebaert et al., 2000, 
Forbes et al., 2000).  However, 30 - 60 minutes of ischemia has previously been 
reported in some studies to result in a long-standing functional renal deficit in rats, 
with associated changes in renal histology and increased molecular markers of injury 
(Gatti et al., 2011, Cantaluppi et al., 2012, Shih et al., 2013, Feng et al., 2010b, Cai et 
al., 2014, Chen et al., 2011). 
 
30 minutes of ischemia was chosen for this experiment in the belief that this would 
produce a long-standing deficit in renal function with concomitant changes in renal 
histology and molecular markers of damage that would be detectable 14 days after 
injury occurring.  By establishing a long-term renal injury in animals subjected to 
nephrectomy and ischemia, it was intended to investigate the protective and 
regenerative effects of stem cell derived ESV therapy.  Also, it was hoped that animal 
mortality would be kept within the confines of the Home Office Project License. 
 
Unfortunately, it is clear from this study in Albino Swiss rats undergoing a 
contralateral nephrectomy, 30 minutes of warm ischemia to the remaining kidney is 
not enough to produce a renal injury that is evident after 14 days recovery.  While 
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body weight in animals undergoing nephrectomy alone (Group 1) recovered to 
baseline more quickly than those animals subjected to nephrectomy and ischemia 
(Groups 2 and 3), no markers of renal injury were significantly different between 
Group 1 and Group 2 after 14 days recovery and the GFR between groups was not 
statistically different.  
 
Serum creatinine levels did not vary significantly between the Groups at any time.  It 
may be that 30 minutes of warm unilateral ischemia in the Albino Swiss strain is not 
enough to produce an acute kidney injury resulting in renal dysfunction.  However, 
another explanation is that serum creatinine lacks the sensitivity to accurately 
characterise renal function in rodents, especially when dysfunction is kept to a 
minimum (Finco and Duncan, 1976, Harvey and Malvin, 1965, Katayama et al., 2010, 
Meyer et al., 1985).  This would explain the apparent lack of difference in serum 
creatine between Groups 1 and 2 during the initial post-operative period.  
 
By day 14 the lack of significant difference between Groups in any of the functional, 
histological or molecular markers of damage, is an indication that 30 minutes of 
ischemia is not enough to cause a permanent renal injury in the Albino Swiss rat 
strain.  The lack of injury negates the ability of such a model to detect any protective 
or regenerative effects of cellular therapy on the renal system, as these results suggest 
a healthy Albino Swiss rat has the ability to recover from a 30-minute period of 
ischemia within 14 days of ischemia occurring.  
 
Consequently, it seemed impossible to continue to use this or similar models to 
investigate the long-term effects of stem cell-based therapies at mitigating renal 
ischemia.  It was felt that longer periods of renal ischemia were necessary to produce 
a permanent renal injury, but that this would not be possible in conventional models 
without breaching the terms of the Home Office Project License.  The natural 
conclusion was that in order to better test the medium and long-term effects of stem 
cell based therapies in rodents, a novel model was required. 
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CHAPTER 5 
 
DEVELOPMENT OF A NOVEL RAT MODEL OF 
SEVERE RENAL ISCHEMIA-REPERFUSION INJURY 
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5.1 INTRODUCTION 
Despite considerable research efforts to develop novel anti-ischemic compounds to 
combat renal IRI, there are no protective or regenerative agents in clinical use and 
supportive therapy remains the mainstay of treatment (Chatterjee, 2007, Chatterjee 
and Thiemermann, 2003).   
 
The dearth of novel therapies in part reflects the lack of suitable animal models in 
which new medicines can be tested.  The salient finding of Chapter 4 was the 
difficulty encountered when subjecting rats to an ischemic insult that causes a 
measurable permanent reduction in renal function without unacceptable numbers of 
animals dying first from acute kidney failure.  Establishing a state of chronic renal 
failure is a necessary first step in order to investigate the long-term efficacy of 
emerging treatments (Lieberthal and Nigam, 2000).   
 
The majority of renal IRI experiments have been conducted in rodents, which are 
considered favourable to larger animals due to their relatively low cost and wide 
availability (Ortiz et al., 2015).  The most commonly studied rodent models utilise 
either bilateral renal ischemia (B-IRI), or unilateral ischemia (U-IRI) after performing 
a contralateral nephrectomy (U-IRI+N) (Wei and Dong, 2012).  Serum creatinine and 
BUN are almost universally used in such models to monitor renal function (Wei and 
Dong, 2012).  In both of these model types, ischemic times of 30 – 60 minutes have 
been shown to cause acute renal dysfunction (Jo et al., 2001, Nemoto et al., 2001, 
Ysebaert et al., 2000, Jablonski et al., 1983) although studies indicate this usually 
resolves within a week of surgery (Forbes et al., 2000, Ysebaert et al., 2000, Jablonski 
et al., 1983).  Longer periods of warm ischemia are associated with unacceptable 
numbers of post-procedure animal deaths, often within 48 hours as a result of acute 
renal failure (Zager, 1987, Zager, 1991).    
The majority of studies investigating the effects of novel therapies on renal IRI only 
report outcomes during the first few post-operative days, by which time rodent serum 
creatinine typically approaches baseline.  Although a few longer-term studies have 
been published, most reports indicate that injured control kidneys return to a state of 
normal morphology within two weeks of injury.  Serum creatinine and BUN levels 
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normalise by two weeks post procedure, remaining stable 40 weeks later indicating no 
long-term functional decay (Basile et al., 2001, Horbelt et al., 2007).   
 
 This highlights the shortcomings of conventional rodent models of renal IRI – 
namely the paradox of inflicting a severe enough injury to cause permanent renal 
damage while avoiding unacceptable numbers of post procedure animal deaths 
(Skrypnyk et al., 2013).  Using conventional rodent models, it therefore appears 
difficult to inflict a longstanding renal injury, as rodent kidneys seem to regenerate to 
function normally after non-fatal periods of renal ischemia.  The benefit of testing the 
long-term effects of novel therapies in conventional rodent models is therefore 
questionable (Wang et al., 2012). 
 
U-IRI without contralateral nephrectomy (U-IRI-N) leaves animals with a healthy 
functioning kidney that serve as protection against acute renal failure and death 
(Zager et al., 2011).  Consequently, such models allow the study of prolonged 
ischemic times well beyond the typical first few days of acute renal injury (Lech et 
al., 2009), with animals subjected to prolonged ischemia eventually developing 
chronic renal failure (Ascon et al., 2009).  Ischemic times of up to in 60 minutes in 
mice (Adachi et al., 2013) and 190 minutes in rats (Craddock, 1976) have been 
reported.  Such severe injury more closely resembles the nephropathology observed in 
the clinical setting (Salahudeen, 2004).  However, U-IRI-N models do not allow 
functional elements of the ischemic injury to be studied using serial blood analysis, as 
renal function markers in such models are affected by the filtration of the uninjured 
kidney (Skrypnyk et al., 2013).  
 
Nevertheless, while serial blood analysis may be useful to map renal function trends 
during the experimental time course, in rodents the accuracy of serum creatinine and 
BUN in assessing renal function is of dubious significance (Finco and Duncan, 1976, 
Harvey and Malvin, 1965, Katayama et al., 2010, Meyer et al., 1985, Namnum et al., 
1983).  With blood analysis unable to accurately determine both short and long-term 
rodent renal function in IRI experiments, any conclusion regarding the quantified 
efficacy of therapies based on blood analysis must be questionable, and more accurate 
methods of demonstrating renal function should be employed.  
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5.11 QUANTIFICATION OF RENAL FUNCTION 
As described in Section 2.2, GFR as determined by inulin clearance is widely 
regarded as the most reliable and accurate method of quantifying renal function.  
Using inulin clearance, split renal function has been measured in dogs (Tsuji et al., 
1993), pigs (Downey et al., 2001) and rats (Malis et al., 1983, Kassab et al., 2001) by 
separate cannulation of each ureter and accurate urine collection.  Unfortunately, the 
size constraints when using a murine model make ureteric cannulation impractical.  
However, in rat models of U-IRI-N, inulin clearance with ureteric cannulation offers 
the most accurate method of quantifying split renal response to injury +/- 
intervention.    
 
5.12 ROUTE OF DRUG DELIVERY 
The optimum route of administration for stem cell therapy has yet to be clarified.  
Novel stem cell therapies have typically been delivered systemically during animal 
experiments investigating the mitigation of renal IRI.  The most common route of 
systemic administration has been by intravenous injection, although other studies 
have given intra-aortic treatment via carotid cannulation (Feng et al., 2010b).  
However, while systemic delivery methods have been shown to mitigate renal 
ischemia, this requires larger numbers of cells to produce efficacy than with local 
administration (Shih et al., 2013).  Moreover, systemic distribution results in the 
majority of administered cells being filtered by the pulmonary circulation (Fischer et 
al., 2009, Burst et al., 2010).  This has been shown to produce undesirable effects 
such as pulmonary damage (Anjos-Afonso et al., 2004) and pulmonary vascular 
occlusion (Shih et al., 2013). 
 
Direct renal intra-parenchymal injection of stem cells has been demonstrated to be an 
efficient route (Chen et al., 2011) and furthermore may increase the retention and 
survival of administered cells.  However, a direct intra-parenchymal injection may 
result in local storage of stem cells and ultimately lead to renal damage (Mias et al., 
2008).  
 
Administration of therapy into the renal artery is the likely route of drug 
administration in clinical transplantation, where the availability of the renal artery 
allows easy ex vivo delivery prior to implantation.  Intra-renal artery therapy injection 
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theoretically allows high local concentration of treatment without the potential side 
effects of systemic distribution.  One study in an allogeneic rat renal transplant model 
has reported that intra-renal artery infusion of MSCs was superior to MSC treatment 
by intravenous injection for the prevention of acute rejection (Zonta et al., 2010). 
 
However, in rodents, this is a technically demanding procedure requiring 
fluoroscopically guided renal artery catheterization in animal models where the renal 
artery has not been opened, or a direct arterial injection with subsequent vascular 
repair to prevent catastrophic haemorrhage if the artery is available.  Nevertheless, to 
mimic the transplantation process as closely as possible, novel rodent models utilising 
intra-renal artery infusion of stem cell therapies are potentially of relevance.   
 
 
5.2 HYPOTHESIS 
(1) Rats subjected to 120 minutes of unilateral warm renal ischemia will exhibit 
long-term functional deficit in function of the damaged kidney, together with 
abnormal renal histology and elevated molecular markers of injury. 
(2) The presence of a healthy contralateral kidney will reduce to an acceptable 
level the post procedure animal deaths that result from metabolic derangement 
as a result of acute renal dysfunction.  
(3) Direct intra-renal artery injection of therapy is the route most likely employed 
during clinical transplantation.  Animal models developed to investigate novel 
therapies should utilise this route. 
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5.3 METHODS 
5.31 ANIMAL HOUSING AND HUSBANDRY  
Male Fisher 344 rats, aged 12 - 14 weeks and weighing 225 – 250g were sourced 
from Harlan UK Ltd. Animals were housed in the JRF, University of Glasgow for at 
least two weeks prior to surgery to allow the animals to equilibrate with their new 
environment.  Animals were housed and fed as described in Section 2.1.  During 
equilibration prior to surgery, animals put on weight such that on the day of surgery, 
rats weighing 250 – 320g were used.  
 
Post surgery, animals were weighed weekly and assessed on a daily basis for signs of 
distress or illness.  
 
5.32 GROUP SELECTION 
Animals were randomly assigned to sham operation (Group 1), 120 minutes of left 
renal IRI with two weeks recovery (Group 2), or 120 minutes of left renal IRI with six 
weeks recovery (Group 3).  (See Table 5.1) 
 
Group 120 minutes left 
renal ischemia 
Recovery prior to 
Inulin Clearance 
Intra-renal artery 
flush 
1 X 2 weeks None 
2 √ 2 weeks Normal saline 
3 √ 6 weeks Normal saline 
Table 5.1: Summary of experimental groups.  Six rats were randomly assigned to each group. 
 
  
	 142	
5.33 SURGICAL PROCEDURE 
Rodent anaesthesia, positioning during surgery and post-surgical care, were 
conducted in standard fashion, as previously described in Sections 2.12 – 2.16.  
 
Surgical Procedure: A high midline incision was made.  The small bowel was 
wrapped in damp swabs, and retractors placed to enable access to the left renal 
pedicle.  (Fig 5.1a)  Mobilisation of the left colon was achieved by incising the lateral 
peritoneal attachments, thereby exposing the renal vasculature.  The renal artery was 
separated from the renal vein using blunt dissection with cotton tips and/or forceps, to 
fully expose the length of the renal artery from its origin on the aorta to the renal 
hilum.  (Fig 5.1b)  This necessitated tying of the suprarenal vein.  Once exposed, an 
atraumatic vascular clamp was placed on the on the artery, close to its junction on the 
aorta, signifying the start of the ischaemic period.  A colour change in the kidney was 
quickly visible, confirming correct placement of the clamp. 
 
Group 1 (sham operated animals) underwent dissection of the renal pedicle, but no 
clamping of the renal artery. 
 
After 90 minutes of ischemia, an arteriotomy was made, and the kidney flushed with a 
0.8ml intra-arterial injection of normal saline given via a 30G Ryecroft cannula.  To 
facilitate this, a thin rubber sloop was placed around the cannula at the point of 
insertion and tension applied to prevent back-leak while an assistant gently injected 
the contents of the syringe.  A colour change in the cortex of the kidney was 
universally observed, confirming infiltration of the kidney parenchyma with saline 
vehicle.  (Fig 5.1d) 
The artery was fully transected, then re-anastomosed in a standardised triangulated 
fashion, using 12 interrupted 10/0 nylon sutures.  (Fig 5.1f-j)  A frame clamp was 
used to secure the arterial ends during anastomosis, and background material placed 
to prevent damage to posterior structures.  (See fig 5.1e)  The arterial clamps were 
removed after exactly 120 minutes and reperfusion of the kidney confirmed visually.  
Wound Closure: The abdominal musculature was closed en mass using a continuous 
4/0 vicryl suture, with a subcuticular 4/0 suture applied to close skin edges.  Using 
this closure, there were no wound infections or dehiscence, and only a single episode 
of an animal gnawing its skin sutures.  
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Figure 5.1: (a) View of the left renal pedicle before mobilisation of the left colon.  (b) View after 
mobilising the left colon and dissection of the renal artery to its origin on the aorta.  
(c) Preparation of renal artery for intra-arterial injection.  Background material has been inserted to 
protect posterior structures.  (d) View during intra-arterial injection.  Note colour change of renal 
cortex during perfusion.  (e) Transected artery in frame clamp, ready for anastomosis.  (f) Insertion of 
stay suture into the renal artery. 
LC = left colon: LK = left kidney: LRV = left renal vein: RA = renal artery: IVC = inferior vena cava: 
A = aorta: LLL = left lobe of liver: S = rubber sloop: C = 30G cannula.   
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Figure 5.1(g) Completion of front arterial wall anastomosis.  (h) The sixth suture inserted into the 
middle of the back wall.  (i) Completed anastomosis prior to clamp removal.  (j) Finished anastomosis 
post clamp removal.  Note renal perfusion and bulging artery downstream of anastomosis indicating 
technical success. 
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5.34 POST-SURGICAL CARE 
This was carried out in standard fashion as described in Section 2.16.  
 
5.35 QUANTIFICATION OF RENAL FUNCTION AND RENAL INJURY 
At day 14, Group 1 and Group 2 animals underwent inulin clearance studies to 
accurately characterise the function of the left kidney, according to the standard 
protocol described in Section 2.2.  Group 3 animals underwent inulin clearance 
studies six weeks after ischemia, again according to standard protocol. 
Left kidneys and right kidneys were weighed, before being stored in 10% formalin 
and RNA later solution for later analysis. 
 
Formalin preserved kidneys were paraffin embedded and sectioned as described in 
Section 2.3 Histological analysis was carried out as described in Sections 2.3 and 2.4 
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5.4 RESULTS 
5.41 POST-PROCEDURE MORTALITY RATES AND TECHNICAL 
COMPLICATIONS 
In the 18 rats subjected to 120 minutes of unilateral warm renal ischemia, (and 
subsequently in more than 60 animals used to test stem cell-based therapies) there was 
only one post-procedure death.  
 
Furthermore, there was one failed attempt to successfully anastomose the renal artery, 
indicating that for a trained microsurgeon, successful anastomosis of vessels ~ 0.6mm 
is technically feasible. 
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5.42 GROUP WEIGHT LOSS COMPARED TO BASELINE WEIGHT 
 
Fig 5.2: Compared to baseline, animals in Groups 1, 2 and 3 exhibited significant weight loss on Day 2 
(p <0.0001, 0.0011 and 0.0033 for Group 1, 2 and 3 respectively) There remained significant weight 
loss for all Groups on Day 4 (p <0.0001, <0.0001, and 0.0002 respectively), Day 7 (p=0.0003, 0.0027, 
and 0.0001) and day 10 (p=0.0311, 0.0157 and 0.0033).  By day 12 animals weights in all groups had 
returned to baseline (p=0.4394, 0.9734 and 0.2189 respectively).  
By day 14, animals in all groups had put on weight in comparison to baseline (p =0.0002, 0.0006 and 
0.0066 respectively).  
Statistical analysis by unpaired Student’s t test.  
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5.43 COMPARISION OF PERCENTAGE WEIGHT LOSS FROM BASELINE 
BETWEEN GROUPS
 
Figure 5.3(i) At no time point were Group 1 animals were found to have a significant weight 
difference as % of baseline weight, when compared to Group 2 animals.  (ii) At no time point were 
Group 1 animals were found to have a significant weight difference as % of baseline weight when 
compared to Group 3 animals.  (iii) At no time point were Group 2 animals were found to have a 
significant weight difference as % of baseline weight when compared to Group 3 animals.   
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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5.44 GLOMERULAR FILTRATION RATE 
120 minutes of renal ischemia was found to produce a permanent, severe and 
reproducible injury that resulted in a long-term GFR deficit.  (See figure 5.4).  
 
 
Figure 5.4: Left sided renal function in Group 1 (sham-operated), Group 2 (120 minutes IRI with two 
weeks recovery) and Group 3 (120 minutes IRI with six weeks recovery).  Group 2 animals experience 
a severe reduction in GFR (~ 50%) compared to sham operated animals (p=0.0022).  GFR is typically 
~ 65% of sham values after six weeks recovery (p=0.0013). 
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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5.45 RENAL HISTOLOGY SCORING 
Histological examination of kidney tissues as described above reveals significant 
disruption in renal architecture in those animals subjected to 120 minutes of warm 
ischemia.  (See figure 5.5) 
 
 Figure 5.5: (a) Renal histology shows that Group 2 animals exhibit significantly more epithelial 
breaks than Group 1 animals (p<0.0001). Similarly, more epithelial cell breaks are observed in Group 3 
animals than Group 1 (p<0.0001). Group 2 animals had more epithelial breaks than Group 3 animals 
(p<0.0001).  
(b) More hyaline casts are observed in both Group 2 (p<0.0001) and Group 3 (p=0.0285) when 
compared Group 1.  More hyaline casts are found in Group 2 animals compared to Group 3 animals 
(p=0.0001).  
Statistical analysis by one-way ANOVA with Tukey multiple comparisons test. 
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5.5 DISCUSSION 
Cell-based therapy has emerged as a potential treatment for acute renal injury 
affecting either native or transplanted kidneys.  IRI is a particular problem in the field 
of transplantation where changing trends in organ donation have led clinicians to meet 
demand by utilising ‘marginal’ organs from the DCD category, or from older and less 
fit DBD donors (Schold et al., 2005, Tuttle-Newhall et al., 2009).  Such kidneys, may 
be subjected to longer periods of warm ischemia during retrieval, and consequently 
are more susceptible to IRI during implantation (Port et al., 2002, Koffman and 
Gambaro, 2003, Metcalfe et al., 2001a, Metcalfe et al., 2001b).  Developing 
strategies, including pharmacological interventions to improve the outcomes of these 
‘extended criteria' allografts is of the utmost importance.   
 
The absence of interventions for the treatment of renal IRI reflects the lack of relevant 
animal models in which novel therapies may be easily studied. Many standard rodent 
models used to induce renal dysfunction do not rely on warm ischaemia as a 
mechanism of injury.  These include models that utilise reduction of renal mass (5/6 
nephrectomy), administration of nephrotoxins,  or renal  
injury caused by ureteric obstruction.  However, warm renal ischemia and the injury 
that follows reperfusion are the most common causes of renal transplant dysfunction 
encountered in clinical practice (Giraud et al., 2011, Jang et al., 2009).  Establishing 
authentic animal models that mimic the pathological process of renal IRI is of vital 
importance in evaluating the feasibility and efficacy of novel therapeutic 
interventions.  Unfortunately, commonly used rodent models of renal IRI lack the 
capacity to inflict a severe, long-standing renal injury without excessive post-
operative animal deaths.  To address this, Wang et al. investigated the use of 
prolonged warm ischemic times to create a severe and sustained renal injury model 
(Wang et al., 2012).  They observed warm ischemic times of up to 90 minutes were 
associated with long-term disruption of renal architecture, increased levels of 
apoptosis and renal fibrosis.  However, they reported prolonged ischemia resulted in 
almost 80% animal deaths at four weeks, although renal function as determined by 
serum creatinine, had normalised by this time in surviving animals.   
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Rodent kidneys subjected to prolonged periods of warm ischemia have been reported 
to display abnormal histology after several days recovery, while the serum 
creatinine/blood urea nitrogen (BUN) were found to be normal (Basile et al., 2001, 
Forbes et al., 2000, Wang et al., 2012, Chen et al., 2011, Jablonski et al., 1983, 
Marshall V, 1982).  This paradox may be explained by the relative insensitivity 
creatinine and BUN at quantifying renal function in rodents (Finco and Duncan, 1976, 
Harvey and Malvin, 1965, Katayama et al., 2010, Meyer et al., 1985).  While 
convenient, these surrogate markers of glomerular filtration do not become 
significantly elevated until 50 – 75% of kidney function is lost (Finco and Duncan, 
1976).  Also, creatinine secretion varies in acute renal failure.  Creatinine clearance 
studies are reported to be more accurate than serum analysis alone, but necessitate the 
timed collection of urine in conjunction with serum analysis.  This makes creatinine 
clearance an impractical tool for estimating renal function in postoperative rodents 
(Sturgeon et al., 1998).  Furthermore, such studies have been shown to overestimate 
GFR by as much as 10% (Harvey and Malvin, 1965, Namnum et al., 1983).  
 
With blood analysis unable to accurately determine both short and long-term renal 
function in IRI experiments, any conclusion regarding the efficacy of therapies based 
on such markers is questionable.  To accurately quantify the effect of novel 
treatments, other methods of assessing renal function should be employed.  
 
The model described here goes some way to addressing the problems encountered by 
Wang et al (Wang et al., 2012), and additionally has several advantages over 
commonly used in vivo models.  This model can inflict a reproducible and severe 
renal IRI without excessive post-operative mortality.  Cannulation of both ureters in a 
terminal procedure allows the accurate calculation the GFR of each kidney by inulin 
clearance.  This is the most sensitive method of characterising the injury that results 
from a given ischemic time and also of assessing the renoprotective effect of any 
therapeutic intervention.   
 
Given the severity of the ischemic insult inflicted, a major advantage of our model is 
the small number of post -operative animal deaths observed.  This probably reflects 
the relative lack of metabolic disturbance that results from the filtration of the 
uninjured right kidney.  It may be argued that this produces an artificial setting, 
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leaving an injured kidney to recover in a non-uraemic environment.  However, a non-
uraemic state after renal IRI has been reported to increase fibrosis in injured kidneys 
(Jablonski et al., 1985), hindering long-term renal recovery by arresting tubular 
epithelial cells in G2/M phase of the cell cycle (Yang et al., 2010).  Indeed, one recent 
report hypothesised that U-IRI-N rodent models might offer greater reliability by 
allowing the assessment of the natural course of post-ischemic renal damage, without 
the anti-inflammatory effects of ischemia (Le Clef et al., 2016).  There do not appear 
to be any studies that show U-IRI-N models to be unreliable.  
 
Furthermore, this is one of the first descriptions of therapy given directly into the 
renal artery in an in vivo IRI animal model.  Intra-renal artery infusion is a more 
technically challenging procedure than either intravenous injection or aortic injection 
via carotid cannulation, but with practice, it is possible to achieve arterial anastomotic 
patency rates approaching 100%.  By using this route, the systemic drug distribution 
and the negative effects of pulmonary entrapment are minimised, while a high local 
concentration of therapy to the damaged kidney is provided.  Importantly this method 
mimics the therapeutic route likely to be employed in clinical transplantation, where 
the renal artery is readily available for drug administration prior to implantation.  This 
route could easily be utilised in a rodent transplant model.  However, results obtained 
using our model are less variable as there is no need for venous and ureteric 
anastomosis.  Hence, we can screen potential therapies’ efficacy prior to their use in a 
more technically complex transplant model.  This reduces animal numbers needed to 
test potential drugs for clinical transplantation and allows refinement of dosing 
schedules.  
 
Finally, a recent paper using mice has described a U-IRI-N model similar to the rat 
model described here (Le Clef et al., 2016).  That another group has identified many 
of the shortcomings of commonly used animal models partly validates the logic 
behind the development of this novel rat model. In recognition of this, findings of this 
Chapter were recently published (Whalen et al., 2016). 
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CHAPTER 6 
INVESTIGATING THE RENO-PROTECTIVE 
EFFICACY OF SYNGENEIC CRYOPRESERVED 
ADIPOSE-DERIVED REGENERATIVE STEM CELLS IN 
A NOVEL RAT MODEL OF SEVERE RENAL 
ISCHEMIA-REPERFUSION INJURY 
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6.1 INTRODUCTION 
As discussed previously, renal transplantation is established as the optimal treatment 
for ESRF with recognized benefits including reduced mortality, morbidity and cost 
when compared to remaining on dialysis (Laupacis et al., 1996, Wolfe et al., 1999, 
Zelmer, 2007).  However, the increased demand for organs has not been matched by a 
concomitant rise in donation (Matas et al., 2013, Port, 2003) and clinicians have 
attempted to meet demand by utilizing organs from ‘extended criteria donors’ (ECD) 
or individuals who donate after circulatory death (DCD)(Port, 2003, Nathan et al., 
2003).  Ischemia-reperfusion injury (IRI) is magnified in these ‘marginal’ organs, 
resulting in worse short and long-term outcomes when compared to other categories 
of age-matched kidneys (Bagul et al., 2013, Neyrinck et al., 2013, Wadei et al., 2013). 
 
IRI is an inevitable event during transplantation, characterized by an inflammatory 
reaction associated with the infiltration of monocytes and the production of reactive 
oxygen species (Bonventre and Yang, 2011, Eltzschig and Eckle, 2011).  
Furthermore, IRI is thought to be responsible for approximately 30% of delayed graft 
function (Kosieradzki and Rowinski, 2008). Such events, by increasing 
immunogenicity, predispose to acute rejection and early graft dysfunction (Bouma et 
al., 2009).  Both of these are well recognized to be predictors of poor long-term 
outcomes (Joosten et al., 2004, Matas et al., 1994, Troppmann et al., 1995). 
 
Therefore, the current trend towards increasing use of ECD and DCD kidneys 
necessitates the development of protective and regenerative novel therapies to 
mitigate IRI.  Unfortunately, no such treatments are in widespread clinical use and 
current post-transplant management strategies remain largely supportive.  
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6.11 BONE DERIVED MSCs VERSUS ADIPOSE REGENERATIVE CELLS 
FOR THE TREATMENT OF RENAL ISCHEMIA REPERFUSION INJURY 
Stem cell therapy has emerged as a potential approach to combat the early graft 
dysfunction and enhanced immunogenicity that follow IRI as a result of the 
transplantation process.  Beneficial effects associated with the administration of 
mesenchymal stem cells (MSCs) have been reported in various rodent renal IRI 
models, where MSCs have been shown to act via anti-inflammatory and 
immunomodulatory mechanisms. 
 
MSCs may be obtained from a variety of sources including bone marrow, umbilical 
cord blood and adipose tissue.  Most studies investigating the effects of protective 
MSCs on organ ischemia have utilised bone marrow-derived mesenchymal stem cells 
(BD-MSCs).  Whilst these are a convenient cell line in a laboratory setting, a number 
of potential problems exist with the application of BD-MSCs to the clinical 
environment.  
 
Firstly, allogeneic MSCs have been demonstrated to be immunogenic (Nauta et al., 
2006b) and the use of autologous or syngeneic MSCs is considered preferable in the 
transplant setting (Roemeling-van Rhijn et al., 2012).  Unfortunately, extracting 
autologous BD-MSC preparations is invasive, and furthermore requires ex vivo 
cellular expansion.  Achieving this within the time constraints associated with 
deceased kidney donation is likely to prove problematic.  Moreover, the malignant 
potential of cells expanded ex vivo has raised safety concerns, especially when applied 
to immunosuppressed patients in the transplantation setting (Roemeling-van Rhijn et 
al., 2012, Lee et al., 2009, Mantovani, 2012, Ren et al., 2012).  
 
Fortunately, there are other tissues sources from which to isolate stem cells for 
therapeutic application.  Adipose tissue is abundant and in contrast to bone marrow 
can be obtained in a minimally invasive fashion.  Large numbers of adipose-derived 
regenerative cells (ADRCs) can quickly be obtained from adipose tissue. It is 
important to note that the ADRC population is heterogeneous, containing 
mesenchymal stem cells, endothelial cells, endothelial progenitor cells and vascular 
smooth muscle cells (Lin et al., 2008). 
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No ethical concerns exist regarding the use of adipose tissue as a source of 
regenerative cells, and it is therefore an attractive option from which cells may be 
isolated for immediate use.  
 
The yield of MSCs from adipose tissue is reported to be 40 times greater than from 
bone marrow (Kern et al., 2006). Hence, ADRCs can be isolated in large quantities by 
minimally invasive liposuction, and require no ex vivo expansion prior to storage or 
use. Therefore, ADRCs are an easily accessible and abundant source of autologous 
cells, which may be isolated and administered immediately, or cryogenically 
preserved for later use.   
 
If the safety and efficacy of ADRCs can be demonstrated, it is feasible to envisage a 
scenario involving recipient liposuction at the same procedure as kidney 
transplantation.  Cell isolation would yield an autologous ADRC preparation that 
could be delivered directly into the renal artery ex vivo, thereby providing a high local 
cell concentration, whilst minimizing systemic distribution.  A study confirming that 
ADRC function and phenotype is not affected by the uremic conditions suffered by 
ESRF patients has important implications for autologous ADRCs use in transplant 
recipients (Roemeling-van Rhijn et al., 2012). 
 
However, for logistical reasons, ADRC isolation may not be possible at the time of 
transplantation.  Here, it is feasible that ADRCs could be harvested from a patient 
soon after they were placed on a transplant waiting list.  Cryogenic freezing of the 
ADRCs at the transplant center would allow cells to be ready for use in the event of 
that individual being offered a kidney, although the efficacy of cryogenic ADRCs 
would need to be demonstrated in studies beforehand.   
 
6.12 ROUTE OF DELIVERY 
Several studies have reported the safety and efficacy of ADRCs in the treatment of 
renal IRI rat models.  Initial studies, using fresh and cryogenically frozen cells (either 
syngeneic or autologous), used carotid artery cannulation (Feng et al., 2010b) and 
intra-venous (Chen et al., 2011) delivery methods that resulted in systemic ADRC 
distribution.  Whilst systemic delivery methods have been shown to mitigate renal 
ischemia, this requires larger numbers of cells to produce efficacy than with local 
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administration (Shih et al., 2013).  Moreover systemic distribution results in the 
majority of MSCs remaining in the lungs, where the large size of MSCs (15 -19µm) 
results in MSC entrapment by pulmonary filtration (Fischer et al., 2009, Burst et al., 
2010, Schrepfer et al., 2007).  This has been shown to produce undesirable effects 
such as pulmonary infarction (Anjos-Afonso et al., 2004) and pulmonary vascular 
occlusion (Shih et al., 2013).  Local administration of therapy into the renal artery is 
therefore preferable, and has been shown to be a more effective route at ameliorating 
IRI in rodents treated with MSCs, undergoing renal transplantation (Zonta et al., 
2010, Iwai et al., 2014).  Furthermore, it is the likely route of drug administration in 
clinical transplantation, where the availability of the renal artery allows easy ex vivo 
delivery prior to implantation. 
 
 
6.13 CHOICE OF ANIMAL MODEL FOR TESTING ADRCs 
Current studies in rat renal IRI models have not convincingly demonstrated a long-
standing benefit of MSCs on renal function (Wang et al., 2012).  In part, this is due to 
shortcomings in conventional models that usually subject animals to 30 - 60 minutes 
of warm ischemia (Jo et al., 2001, Ysebaert et al., 2000, Nemoto et al., 2001, 
Jablonski et al., 1983).  This typically only results in impaired renal function for the 
first postoperative week (Forbes et al., 2000, Ysebaert et al., 2000, Jablonski et al., 
1983, Marshall V, 1982).  
 
The recognized shortcomings of commonly used rodent models led to the 
development of the novel model described in Chapter 5.  In this chapter, the effects of 
uncultured, cryopreserved syngeneic ADRCs in renal IRI in the novel rodent model 
are investigated, utilizing an intra-renal artery infusion.  Renal function was examined 
after a 2-week recovery period.   
 
6.14 RATIONALE FOR DOSES OF ADRC  
In order to reduce experimental time and animal numbers, the authors of a study 
(Feng et al., 2010b) reporting the effects of intra-arterial ADRCs on renal IRI were 
contacted for advice regarding initial dosing protocols.  A starting dose of 1 x 106 
ADRCs was recommended.  After 6 animals were treated with 1 x 106 ADRCs, it was 
decided to increase the dose to 1.3 x 106 to investigate if this affected efficacy.  As it 
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was quickly apparent that 1.3 x 106 ADRCs had a negative effect on renal perfusion, a 
group of 6 animals were treated with 7 x 105 ADRCs.  
	 160	
6.2 HYPOTHESIS 
(1) Syngeneic, cryopreserved ADRCs may protect long-term renal function 
from severe renal ischemia-reperfusion injury 
(2)  The effects of ADRCs may occur in a dose-dependent fashion.  
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6.3 METHODS 
6.31 ANIMAL HOUSING AND HUSBANDRY  
This was conducted in standard fashion, as previously described in section 5.31. 
Briefly, male Fisher 344 rats, aged 12 - 14 weeks and weighing 225 – 250g were 
allowed to equilibrate for at least 2 weeks prior to surgery.  Animals were housed and 
fed as described in Section 2.1.  During equilibration prior to surgery, animals put on 
weight such that on the day of surgery, rats weighing 250 – 320g were used.  
 
Post surgery, animals were weighed weekly and assessed on a daily basis for signs of 
distress or illness.  
 
6.32 GROUP SELECTION 
Control Groups 
Animals were randomly assigned to sham operation (Group 1, n=6) or 120 minutes of 
left renal IRI and renal artery injection with normal saline vehicle (Group 2, n=6).  
Animals were then recovered for 2 weeks.  
 
Adipose Derived Mesenchymal Stem Cell Groups 
Group 3 animals (n=6) were treated with 1 x 106 cryopreserved ADRC, given via the 
renal artery and recovered for 2 weeks.  Group 4 animals (n=4) were treated with 1.3 
x 106 ADRC and recovered for 2 weeks.  Group 5 animals (n=6) were treated with 7 x 
105 ADRC and recovered for 2 weeks.  
(See Table 6.1) 
 
Group 120 minutes left 
renal ischemia 
Recovery prior to 
Inulin Clearance 
Intra-renal artery 
Injection (0.9ml) 
1 X 2 weeks None 
2 √ 2 weeks Normal saline 
3 √ 2 weeks 1 x 106 ADRC 
4 √ 2 weeks 1.3 x 106 ADRC 
5 √ 2 weeks 7 x 105 ADRC 
 
Table 6.1: Summary of experimental groups.  6 rats were randomly assigned to each group.  
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6.33 SURGICAL PROCEDURE 
Rodent anesthesia, positioning during surgery and post-surgical care, including were 
conducted in standard fashion, as previously described in Sections 2.12 – 2.16.  
 
Surgery was carried out was described in Section 5.33.  Treatment groups received 
intra-renal artery therapy as outlined in Table 6.1.  All intra-renal artery infusions 
were made up to a total volume of 0.9ml in normal saline immediately prior to use.  
 
6.34 POST-SURGICAL CARE 
This was carried out in standard fashion as described in Section 2.16.  
 
6.35 QUANTIFICATION OF RENAL FUNCTION AND RENAL INJURY 
At day 14, animals underwent inulin clearance studies in order to accurately 
characterize the function of the both kidneys, according to the standard protocol 
described in Section 2.2.  
Left kidneys and right kidneys were weighed, before being stored in 10% formalin 
and RNA later® solution for later analysis. 
 
Formalin preserved kidneys were paraffin embedded and sectioned as described in 
Section 2.3 Histological analysis and immunohistochemistry for P16, P21 and Ki 67 
were carried out as described in Sections 2.3 and 2.4 
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6.36 DISECTION OF RAT INGUINAL FAT PAD 
(1) A male Fisher 344 rat, weighing 250 – 320g was euthanized by placing in a 
pre-filled CO2 chamber until motionless. 
(2) 1 minute was allowed to pass from the animal’s last movement until the 
animal was removed from the chamber. 
(3) The abdomen and groins of the rat were shaved, and the animal pegged out on 
a cork board, cleaned with 2% chlorhexidine and covered with a surgical 
drape. 
(4) Horizontal incisions in both groin creases were made to allow exposure of the 
groin adipose fat pads, which lies between the skin and muscles of the femoral 
triangle. 
(5) Lymph nodes in both fat pads were excised and discarded.  Likewise, any 
visible vessels were excised. 
(6) The fat pads were dissected free and weighted.  Typically ~ 4g of fat was 
obtained from each rat.  
(7) Fat was placed in sterile Hartmann’s solution ((Baxter Healthcare, Thetford 
UK) 
(8) At this point, fat was transferred to the British Heart Foundation Building, 
University of Glasgow for ADRC isolation to begin.  
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6.37 ADRC ISOLATION FROM INGUINAL FAT PAD 
ADRCs were isolated from the inguinal fat pad of freshly culled Fisher 344 rats (200 
– 320g) as previously described (Feng et al., 2010b, Schenke-Layland et al., 2009), 
but with minor modifications.  ADRC isolation work was done solely by Dr Diane 
Hardie Ph.D.  
 
(1) 5ml of Hartmann’s solution was added to a vial containing 35mg of Celase (a type 
of collagenase) reagent.  (Cytori Therapeutics, San Diego, CA, USA)  This 
produced a concentration of ~ 30 units/ml.  
(2) Homogenization of adipose tissue was achieved using large, and then small sterile 
scissors in a sterile, dry Petri dish.  Homogenization was judged complete when 
pieces were <4mm in diameter. 
(3) Homogenized adipose tissue was placed in a 50ml conical tube with 5x volume of 
collagenase solution.  
(4) The conical tube was agitated for 30 minutes, whilst being incubated at 37oC.  
(5) The tube was shaken violently to break up the largest remaining tissue pieces and 
agitated for a further 15 minutes at 37oC.  
(6) The ADRC fraction was separated by centrifugation at 600 g for 5 min.  
(7) The resulting pellet was washed in sterile PBS, centrifuged at 400g for 5 mins and 
repeated.  
(8) Incubation with Intravase™ (Cytori Therapeutics, San Diego, CA, USA) for 10 
min was followed by more PBS washing.  
(9) The cells were then passed through 100- and 40-µm Falcon™ cell strainers (BD 
Biosciences, San Jose, CA, USA), sequentially.  
(10) ADRCs were counted and prepared for cryopreservation. 
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6.38 ADRC CRYOPRESERVATION 
Cryopreservation of ADRCs was as described in a previous study (Feng et al., 
2010b). 
Briefly, ADRCs were isolated and frozen in 10% serum from Fisher 344 rats and 10% 
dimethyl sulphoxide in lactated Ringer's solution at a concentration of 3 x 106 
cells/ml. Cells were stored in liquid nitrogen until required. 
Prior to infusion, cells were thawed rapidly and re-suspended in 10× volume of PBS.  
The cells were centrifuged at 400 g for 10 min, washed in PBS and re-suspended in a 
minimum volume.  Counting of viable cells was carried out to ensure that the desired 
number of viable cells was obtained.  Immediately prior to injection, cells were 
diluted with normal saline to give a total volume of 0.9ml.  
 
6.39 CHARACTERISTICS OF CELLULAR PREPARATION OBTAINED 
FROM ADIPOSE TISSUE 
Flow cytometric studies were not performed on adipose tissue-derived cell 
preparations, isolated as part of these experiments.  However, previous studies 
utilizing the same protocols for ADRC extraction have performed flow cytometric 
analysis of fresh and cryopreserved cell extracts obtained from rat adipose tissue 
(Feng et al., 2010b).  
 
This revealed that ~ 44% of cells were CD45+, most of which were monocytes, 
neutrophils and tissue macrophages.  The majority of CD45- cells were found to be 
CD73+ and CD90+ and considered to be of mesenchymal origin.  
Hence ~ 50% of cells obtained using this protocol were considered MSCs, with the 
remainder thought to be blood and tissue derived leucocytes (~ 44%) and endothelial 
cells (~3.4%).  
Epitope expression was retained following cryopreservation, with a slight reduction in 
the frequency of CD45+/CD11b+ cells, and an increase in CD45-/CD31+ cells.  This 
probably represents a fall in neutrophil presence in the samples, which is consistent 
with the known sensitivity of neutrophils to freezing and thawing (Feng et al., 2010b). 
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6.4 RESULTS 
6.41 GROUP WEIGHT LOSS COMPARED TO BASELINE WEIGHT 
 
Fig 6.1: Compared to baseline, sham-operated animals, those treated with saline vehicle, those treated 
with 1 x 106 ADRC and those treated with 1.3 x 106 ADRC exhibited significant weight loss on Day 2 
(p <0.0001, 0.0011, 0.0001 and p <0.0001 respectively).  There remained significant weight loss for 
these Groups on Day 4 (p <0.0001, <0.0001, 0.0012 and 0.0019 respectively), Day 7 (p=0.0003, 
0.0027, 0.0004 and 0.0490).  By day 10, sham-operated animals, saline treated animals and those given 
1 x 106 ADRC were still below their baseline weight (p=0.0311, 0.0157 and 0.0740), whilst animals 
treated with 1.3 x 106 ADRC weights were not significantly below baseline (p=0.6106).  
By day 12, animals in the aforementioned groups had regained baseline weight (p=0.4394, 0.9734, 
0.4232 and 0.2038 respectively).  
By day 14, animals the aforementioned groups had put on weight in comparison to baseline (p 
=0.0002, 0.0006 and 0.0064 and 0.0573 respectively).  
Animals treated with 7 x 105 ADRC lost weight on day 2 (p=0.0005), day 4 (p=0.0002) and day 7 
(p=0.0278).  By day 10, the weight of animals treated with 7 x 105 ADRC had risen above baseline 
(p=0.0005) and remained so at day 12 (p<0.0001) and at day 14 (p=0.0001).  
Statistical analysis by unpaired Students t test.  
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6.42 COMPARISION OF PERCENTAGE WEIGHT LOSS FROM BASELINE 
BETWEEN GROUPS 
 
Figure 6.2: (i) There was no difference in weight trends between sham-operated animals and animals 
treated with 7 x 105 ADRC up to day 7.  By day 10, the 7 x 105 ADRC group were observed to have 
gained weight faster than sham-operated animals (p=0.0011).  This trend continued at day 12 
(p=0.0038) and day 14 (p=0.0028).  (ii) There was no difference in weight trends between animals 
treated with saline vehicle and those treated with 7 x 105 ADRC up to day 7.  By day 10, the 7 x 105 
ADRC group were observed to have gained weight faster than the saline group (p=0.0009).  This trend 
continued at day 12 (p=0.0013) and day 14 (p=0.0012).  
(iii) There was no difference in weight trends between animals treated with 7 x 105 ADRC and those 
treated with 1 x 107 ADRC up to day 7.  By day 10, the 7 x 105 ADRC group were observed to have 
gained weight faster than the 1 x 107 ADRC group (p=0.0034).  This trend continued at day 12 
(p=0.0034) and day 14 (p=0.0165).  (iv) There was no difference in weight trends between animals 
treated with 7 x 105 ADRC and those treated with 1.3 x 106 ADRC up to day 12.  By day 14, the 7 x 
105 ADRC group were observed to have gained weight faster than the 1.3 x 106 ADRC group  
(p=0.0009).  
No significant difference was observed between the % baseline weights of sham-operated animals, 
saline-treated animals, 1 x 106 ADRC or 1.3 x 106 ADRC, at any time point.  
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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6.43 GLOMERULAR FILTRATION RATE 
Effect on GFR after ADRC Infusion 
ADRCs were found to protect GFR in a dose-dependent manner. 
 
 
 
 
 Figure 6.3: Compared to saline vehicle alone, a dose of 7 x 105 ADRCs was found to significantly 
protect GFR versus saline treated animals (p= 0.0014).  Indeed, the GFR of sham-operated animals and 
animals treated with 7 x 105 ADRCs were not significantly different (p= 0.9992).  
7 x 105 treated animals were observed to have significantly higher GFR versus animals treated with 1 x 
106 ADRC (p=0.0457) and those treated with 1.3 x 106 ADRC (p=0.0015).  A larger dose of 1 x 106 
ADRCs was not found to improve GFR versus saline treated animals (p=0.5793). 
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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6.44 RENAL HISTOLOGY SCORING 
Epithelial Breaks 
 
 
Figure 6.4: Sham-operated animals were found to have significantly fewer epithelial breaks compared 
to animals treated with saline (p<0.0001), 1 x 106 ADRC (p<0.0001), and 1.3 x 106 ADRC (p<0.0001).  
Similarly, sham operated animals were found to have fewer epithelial breaks than animals treated with 
7 x 105 ADRC (p=0.0003). 
Animals treated with 7 x 105 ADRC were found to have fewer epithelial breaks compared to animals 
treated with saline (p<0.0001), and animals treated with 1.3 x 106 ADRC (p<0.0001).  
Animals treated with 1 x 106 ADRC had fewer breaks compared to animals treated with saline 
(p<0.0001), and those treated with 1.3 x 106 ADRC (p=0.0216).  
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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Hyaline Cast Formation 
 
 
Figure 6.5: Sham-operated animals were found to have fewer hyaline casts than saline treated animals 
(p<0.0001) and those treated with 1.3 x 106 ADRC  (p<0.0001). 
Animals treated with 7 x 105 ADRC were found to have fewer hyaline casts than those treated with 
saline (p=0.0004) and those treated with 1.3 x 106 ADRC (p<0.0001). 
Fewer casts were found in animals treated with 1 x 106 vs 1.3 x 106 ADRC (p=0.0091). 
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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Furthermore, 1.3 x 106 ADRCs were universally observed to result in renal artery 
‘clogging' post clamp removal, resulting in renal hypoperfusion post clamp removal 
(see figure 6.7). Experiments with 1.3 x 106 ADRCs were therefore halted after 
recovering 4 animals, with a further 2 animals culled intra-operatively. 
 
 
 
Figure 6.6: (a) Haematoxylin and eosin stained kidney sections from rats 2 weeks post surgery.  
Kidneys from saline treated animals show marked tubular dilation (green asterisks) and epithelial 
breaks (black arrowheads).  Hyaline casts are also present (black dots).  Dilation of Bowman’s space is 
also present (blue arrows).  (b) These changes are less marked in animals treated with 7 x 105 ADRC, 
which display healthy glomeruli (large black arrows).  (c) Animals treated with 1 x 106 ADRC have 
fewer markers of damage compared to saline treated animals. (d) Animals treated with 1.3 x 106 
ADRC have grossly abnormal renal histology, similar to those animals treated with saline alone.    
(A)	Saline	Vehicle	 (B)	7	x	105	ADRC	
(D)	1.3	x	106	ADRC	(C)	1	x	106	ADRC	
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6.5 DISCUSSION 
The current trend towards transplanting ‘marginal’ kidneys necessitates the 
development of novel therapies to combat peri-transplantation injury and IRI in 
particular.  Stem cell therapy has great potential in this regard, with investigators 
actively testing the efficacy of cellular preparations to reduce injury affecting both 
native and transplanted kidneys.  
 
Various stem cells have been investigated for the treatment of renal IRI, including 
BD-MSCs, ADRCs and hematopoietic stem cells.  The ideal characteristics of a stem 
cell source include widespread availability with minimally invasive harvesting, 
thereby allowing isolation of fresh or cryopreserved preparations, without the need for 
ex vivo cellular expansion. 
 
Here, ADRCs were selected for further investigation as ADRCs fulfill many 
requirements that are necessary to apply a stem cell source to the clinical 
environment.  Also, the paracrine mechanisms of ADRCs have been shown to be 
different from those of BD-MSCs, showing more potent anti-inflammatory and 
immunomodulatory function (Banas et al., 2008). 
 
One weakness of this experiment is the lack of molecular data to support the 
mechanisms by which ADRCs may produce their effects.  However, it is known that 
the renal tubular epithelium releases pro-inflammatory mediators including TNF- α, 
IL-6 and IL-8 and transforming growth factor β in response to IRI.  Numerous studies 
examining the effects of ADRCs in renal ischemia have demonstrated that ADRC 
administration is associated with down-regulation of the inflammatory response.  
Chen et al demonstrated that ADRC therapy protected renal function by suppressing 
oxidative stress and the inflammatory response by reducing both cytokine production 
and expression of cell surface adhesion molecules (Chen et al., 2011).  Feng et al 
observed ADRC therapy to be associated with reduced macrophage infiltration as a 
result of reduced CXCL2 and IL-6 expression.  The authors concluded the increased 
tubular epithelial cell proliferation they observed was the result of a dampened 
inflammatory response that helped to restore renal architecture and preserve renal 
function (Feng et al., 2010b).  In a mouse model of renal IRI, Furuichi et al observed 
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treatment with ADRCs caused the suppression of IL-1β and TNF-α, leading to anti-
inflammatory activity and alleviation of tubular necrosis (Furuichi et al., 2012).  More 
recent studies, examining the effects of local ADRC administration on rat renal IRI 
have also reported a reduced inflammatory response after ADRC therapy (Shih et al., 
2013, Wang et al., 2013b).  It is possible that molecular data from this study would be 
in agreement with the above findings.  
 
Here, one possible route of administration in clinic transplantation was mimicked in 
order assess the feasibility of intra- renal artery administration.  Furthermore, intra-
renal artery administration avoids the potentially detrimental effects of systemic stem 
cell delivery that have been reported with administration via the intravenous route.  
Other studies report local arterial administration of cell therapy is superior to other 
administration methods (Iwai et al., 2014, Zonta et al., 2010).  However, at the outset 
of this experiment, there were apparently no published studies using ADRCs via the 
renal artery route in renal IRI models.  Therefore the authors of a previous study 
administering ADRCs via carotid cannulation were contacted for advice regarding 
ADRC dose (Feng et al., 2010b).  Following discussion, a starting dose of 1 x 106 
ADRCs was decided upon. 
 
Utilizing the intra-renal artery route in our rate model, a dose-dependent 
renoprotective effect of ADRCs was observed.  The lowest dose 7 x 105 ADRCs were 
found to significantly protect GFR and renal histology from severe IRI, whilst a 
higher dose of 1 x 106 ADRC preserved renal histology but did not protect GFR.  
 
The highest dose of 1.3 x 106 ADRCs was associated negative outcomes when 
compared to controls.  This finding may be explained by the universal intra-operative 
observation of macroscopic occlusion of the terminal branches of the renal artery 
when injecting 1.3 x 106 ADRCs (see figure 6.7).  Despite relieving this by 
downstream massage of the occluding cell ‘plug’, the kidney failed re-perfuse 
normally.  As ADRCs have a larger diameter than tissue capillaries (Furlani et al., 
2009b, Vulliet et al., 2004), it is likely that higher doses of cells cause occlusion of 
the macro and/or microscopic renal circulation.  The subsequent hypoperfusion is 
likely to result in negative effects on long-term kidney structure and function.  
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Figure 6.7: (i) Dissected renal pedicle after attempted reperfusion of left kidney post administration of 
1.3 million ADSC.  Despite the patent anastomosis, and a clear pulse distal to this (blue arrow), the 
kidney is poorly perfused (white arrows).  The renal artery bifurcation is also patent (green arrows).  
However, there is obvious renal artery occlusion due to viscous ADRC preparation causing arterial 
plugging (black arrows).  (ii) Further dissection of the hilar branches of the renal artery reveals the 
majority of the distal branches are occluded (black arrows).  (iii) After clearing the renal artery of cell 
preparation by gentle downstream ‘milking' with forceps, the kidney still perfused poorly (white 
arrows).  A pulse remains in the artery distal to the anastomosis and is now present in the hilar 
branches (blue arrows).  (iv) The kidney perfuses poorly and becomes discolored, indicating ongoing 
ischemia.  (white arrows)  
 
  
(i)	 (ii)	
(iii)	 (iv)	
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Prior to this experiment, studies investigating organ ischemia, utilizing both systemic 
and local administration of BD-MSCs had reported the dose-dependent phenomenon 
we observe (Furlani et al., 2009b, Freyman et al., 2006).  Freyman et al used 5 x 107 
BD-MSCs and reported adverse effects of intracoronary infusion of MSCs in a 
porcine model of myocardial infarction (Freyman et al., 2006).  They concluded that 
the reduced myocardial blood flow might have been due to occlusion of the cardiac 
microcirculation (Freyman et al., 2006).  
 
Subsequent to the conclusion of this experiment, studies observing dose dependence 
in rat models of renal IRI, utilizing renal artery administration of both BD-MSCs and 
ADRCs were published (Cai et al., 2014, Shih et al., 2013, Lee et al., 2012).  The 
findings of these studies are in agreement with the observation here that excessive 
doses of locally administered MSCs may produce negative effects via blockage of the 
tissue microcirculation.  
 
In rat models of renal IRI, laser Doppler has demonstrated reduced renal blood flow 
after administration of 5 x 107of ADRCs (Lee et al., 2012) or 1 x 106 BD-MSCs (Cai 
et al., 2014) directly into the renal artery.  Subsequently, using quantum dot-labeled 
ADRCs, renal vessel occlusion by ADRCs was reported after 1 x 107 and 5 x 107 
doses of cells were given via the renal artery (Shih et al., 2013).  These reports are in 
keeping with the findings here that local administration of 1.3 x106 ADRCs was 
associated with negative long-term outcomes, and that a lower dose of 1 x 106 ADRC 
did not improve GFR in comparison with saline vehicle controls.  
 
Nevertheless, here a dose of 7 x 105 ADRCs is associated with significant reno-
protection, when compared to saline vehicle controls.  The optimal dose of locally 
administered ADRCs here is broadly in keeping with the findings of previous studies, 
as is the observation that ADRCs can protect long-term renal histology from IRI 
damage (Shih et al., 2013, Lee et al., 2012, Feng et al., 2010b, Villanueva et al., 
2013).  However, in contrast to the other studies, here it is reported that ischemia 
causing long-term reduction in renal function is significantly mitigated by intra-renal 
artery ADRCs therapy at the correct dose.  
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The post-operative weight recovery of the animals treated with 7 x 105 ADRC was 
significantly better than the other experimental groups, including sham animals.  This 
observation may reflect more ‘healthy’ animals in the 7 x 105 ADRC group when 
compared to other animals subjected to ischemia.  However, the superior weight of 7 
x 105 ADRC treated animals versus the sham group is difficult to interpret.  
Theoretically, sham animals ought to regain their weight faster postoperatively than 
animals subjected to ischemia, and this finding may simply reflect a slower than 
expected weight gain in the sham group.  As the age and starting weights of animals 
in all groups was not significantly different, the reason for the apparent slow weight 
gain in the sham group, or the faster weight gain of the 7 x 105 group, is unclear.    
 
Translation of ADRCs therapy into routine clinical practice requires further 
investigation, with emphasis on clarifying the initial safe doses of ADRCs and the 
long-term effects in immunosuppressed transplant patients.  Establishing a rodent 
transplant model, utilizing both cold and warm ischemia whilst administering 
immunosuppression post-operative closely mimics the clinical transplant process.  
Such a model, again subjecting the injured kidney to prolonged ischemia might enable 
the effects of intra-renal artery ADRCs to be studied in a safe environment. 
After this, ex vivo models of porcine kidney reperfusion circuits could also be used to 
test initial ADRCs dosing schedules prior to efficacy testing in porcine renal 
transplant models.  
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CHAPTER 7 
 
THE MEDIUM AND LONG-TERM EFFICACY OF 
PATHFINDER DERIVED MICROVESICLES IN A 
NOVEL RAT MODEL OF SEVERE RENAL ISCHEMIA-
REPERFUSION INJURY 
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7.1 INTRODUCTION 
Stem-cell therapy has been reported to ameliorate both acute and chronic dysfunction 
of cardiac, respiratory, and renal systems in numerous animal models.  As described 
in Section 1.37 – 1.38, debate continues regarding the likely mechanism by which 
stem cells act.  However, general consensus accepts that the reported beneficial 
effects of stem cell therapy are likely to occur via a paracrine mechanism (Abreu et 
al., 2016), and this especially appears to be the case in the kidney (Wise and Ricardo, 
2012). 
 
It is clear that cell-to-cell communication plays a vital role in the regulation of tissue 
and organ function in multicellular organisms.  Extracellular vesicles (ECVs) have 
been implicated as important mediators of intercellular communication, appearing to 
act via ancestral mechanisms amongst cells and tissues (Valadi et al., 2007). 
 
The content of ECVs consists primarily of proteins, lipids and genetic material 
including messenger-RNA (mRNA) and micro-RNA (miRNA) (Bruno et al., 2016, 
Raposo and Stoorvogel, 2013, Witwer et al., 2013).  In general, the content of ECVs 
reflects the content of the parent cell (Quesenberry et al., 2014).  Recent data suggest 
that ECVs released from stem cells mediate paracrine effect by shuttling their content 
into target cells (Lai et al., 2011, Yeo et al., 2013, Lai et al., 2013).  The transfer of 
miRNA by ECVs is thought to be particularly important in regulating cell processes, 
as miRNAs have been shown to modify recipient cell gene expression and hence 
protein production (Raposo and Stoorvogel, 2013, Ratajczak et al., 2006b, Anthony 
and Shiels, 2013).  The transfer of genetic material and consequent cell stimulation 
may therefore modify target cells and reprogram their biological processes, resulting 
in long-lasting changes to cell phenotype, function and fate (Biancone et al., 2012, 
Bruno and Camussi, 2013, Deregibus et al., 2007, Ratajczak et al., 2006a, Valadi et 
al., 2007).  
The ability of ECVs to produce epigenetic changes in their recipients depends on 
upon the phenotype of the parent cell (Katsuda et al., 2013).  Experimental studies 
have shown that ECVs derived from MSCs emulate the effect of their parent cells in 
various experimental models of visceral injury, notably stimulating cell proliferation 
and enhancing tissue repair (Bruno et al., 2012, Herrera et al., 2010, Bruno et al., 
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2009b).  Data indicate such ‘cell-free’ therapies may have similar therapeutic efficacy 
compared to cell-based therapy, but are postulated to hold a number of advantages 
over the use of stem cells themselves.   
As a result, there is active research in the development of ECVs as novel treatments 
of organ damage.  
 
Potential advantages of cell-free therapies include:  
(1) Cell-free therapy is thought to carry significantly less risk of cell 
maldifferentiation and malignancy (Bruno et al., 2016, Kunter et al., 2007).  
The risk of this occurring was highlighted by the findings of Chapter 3.  
 
(2) The biologically active factors in cell-free therapy are smaller and more 
soluble than stem cells.  Theoretically, therapeutic doses of cell-free ECV 
therapy carried reduced risk of arterial or capillary occlusion (Rani et al., 
2015).  The risk of occlusion was a significant finding in experiments using 
ADRCs, described in Chapter 6.  
 
(3) Identification of the factors responsible for producing beneficial effects may 
subsequently allow synthetic manufacture packaged in vesicle form.  This 
would ensure quality control of biologically active contents (Vishnubhatla, 
2014, Taylor and Shah, 2015). 
 
(4) Cell-free preparations are easier to store, transport and use in clinical settings 
(Vishnubhatla, 2014, Kordelas et al., 2014, Yeo et al., 2013).   
 
 
7.11 PROBLEMS IDENTIFYING THE BENEFICIAL BIOLOGICAL 
FACTORS IN THE STEM CELL SECRETOME 
ECVs are a heterogeneous population of small, spherical, membrane-bound particles 
that originate from different sites in parent cells.  Consequently, ECVs differ in cell 
surface markers and crucially in size.  As highlighted in Section 1.4, this research 
field is still in its infancy and as yet no ECV classification system has been applied 
universally.  However, classification based on size and origin is now gaining 
widespread acceptance.  In part, this is due to the recognition that it is vital to identify 
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the specific beneficial ECV subtypes, thereby allowing the biologically active content 
to be characterized prior to manufacture for therapeutic application. 
 
ECVs may be considered to consist of 3 separate subtypes or ‘fractions’ (Anthony and 
Shiels, 2013): 
 
(1) Exosomes: 40 – 100nm in diameter, and of endosomal origin.  Exosomes are 
stored prior to their release, which occurs after fusion with multivesicular 
bodies.  (See figure 1.5) 
 
(2) Microvesicles: 100nm - 1µm in diameter, are formed after budding directly 
from the plasma membrane in an energy-dependent process, reliant on calcium 
influx and cytoskeleton reorganization (Cocucci et al., 2009). (See figure 1.5) 
 
(3) Apoptotic bodies (also termed ‘Shedding vesicles’) – 1 - 5µm sized particles 
released upon fragmentation of the plasma membrane that occurs during 
apoptosis.  
 
Each ECV subtype is normally present within the in vitro cultured cell medium and 
body fluids from which ECVs are typically obtained prior to experimental use.  
Isolation of a specific ECV fraction may be achieved either by differential 
ultracentrifugation, ultrafiltration and/or immunoprecipitation with the use of 
antibody loaded magnetic cell beads (Fierabracci et al., 2015).  Failure to adhere to a 
strict ECV isolation protocol will lead to preparations contaminated with different 
ECV types prior to use. 
 
This is important as the proteins, lipids and genetic material contained within each of 
the ECV fractions has been shown to differ in type and quantity (Quesenberry et al., 
2014, Keerthikumar et al., 2016).  Additionally, the content of ECVs from any 
particular cell type may be influenced by physical or chemical stressors, such as 
hypoxia, oxidative stress and inflammation (Robbins and Morelli, 2014).  
Consequently, each ECV fraction from the same parent cell may modulate protein and 
gene expression to a different extent in recipient cells.  Logically, therefore, 
identifying the ECV fraction which produces beneficial cellular effects is a crucial 
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step in characterizing protective/regenerative factors contained within that fraction, 
prior to manufacture of a synthetic drug.  
 
Unfortunately, the inconsistent use of terms in a number of reports has resulted in 
misleading titles and conclusions regarding the efficacious ECV subtype.  
For example, early and extensive work by Camussi et al used ‘microvesicles’ as a 
universal term to include each of the 3 separate ECV types (Gatti et al., 2011, 
Cantaluppi et al., 2012, Bruno and Camussi, 2013, Camussi et al., 2013, Camussi et 
al., 2011).  The group concluded that ‘microvesicles’ conferred beneficial effects after 
renal injury, although ECVs were harvested by using undifferentiated 100,000g 
centrifugation forces, probably resulting in a preparation containing exosomes, 
microvesicles and apoptotic bodies (Gatti et al., 2011, Cantaluppi et al., 2012, Bruno 
et al., 2009b).  Indeed, using analysis of therapeutic ECV preparation by transmission 
electron microscopy and Nanosight analysis in one study reported 90% of 
administered ECVs to range in size from 60 – 160nm (ie seemed to contain both 
exosomes and microvesicles) (Cantaluppi et al., 2012).  A more recent paper (Bruno 
et al., 2016) by the same authors replaced the term ‘microvesicles’ with ‘extracellular 
vesicles’ - perhaps after recommendation by the International Society for 
Extracellular Vesicles that ECV should be used as an umbrella term  for each of the 3 
ECV types (Katsuda et al., 2013).  Whilst it now appears the classification system 
used in this thesis (Section 1.4) is gaining acceptance, it remains necessary to examine 
the centrifugal spin protocols to determine the identity of the vesicles administered in 
any particular study.  
 
7.12 PATHFINDER DERIVED EXTRACELLULAR VESICLES 
Pathfinder cell administration has been shown to restore normoglycaemia with the 
recovery of normal tissue function in a murine model of streptozotocin-induced 
diabetes (Stevenson et al., 2011).  Furthermore, Pathfinder cells have been shown to 
restore normal renal function and architecture in a murine model of renal IRI, whilst 
also significantly reducing P16 levels in treated animals (McGlynn et al., 2013).  In 
both studies, Pathfinder cells were only faintly detected in damaged organs, with the 
majority of tissue restoration occurring with host cells.  This implies Pathfinder cells 
also act via a paracrine mechanism.  
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A recent study by the same group has demonstrated that ECVs derived from 
Pathfinder cells were able to replicate the findings of previous experiments in the 
streptozotocin-induced diabetic murine model (McGuinness et al., 2016).  
Importantly, by using differential centrifugation spin rates, exosomes enriched 
fractions were obtained and found to be ineffectual at repairing streptozotocin-
induced damage. The microvesicle enriched fraction however had equivalent efficacy 
at repairing damage when compared to Pathfinder cells (McGuinness et al., 2016).  
 
This finding implies that the microvesicles may be the paracrine entity by which 
Pathfinder cells produce their beneficial effects and consequently may have the ability 
to mitigate renal IRI.  This finding is contrary to previous reports, which have 
concluded that exosomes are more physiologically relevant and powerful components 
of stem cell secretome (Kordelas et al., 2014).  However, whilst it is possible MSCs 
produce their effects via exosomes, this does not appear to be the case with ECVs 
derived from pathfinder cells.  Therefore, we decided to investigate the effects of 
pathfinder-derived microvesicles in our novel model of rodent renal ischemia.  
 
 
7.2 HYPOTHESIS 
(1) Pathfinder-derived microvesicles may protect kidney function and architecture in 
both the medium and long-term in a novel rodent model of severe renal IRI. 
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7.3 METHODS 
7.31 ANIMAL HOUSING AND HUSBANDRY  
This was conducted in standard fashion, as previously described in section 2.1  
Post surgery, animals were weighed weekly and assessed on a daily basis for signs of 
distress or illness.  
 
7.32 GROUP SELECTION 
Control Groups 
Animals were randomly assigned each group.  Sham operation animals (Group 1, 
n=6), underwent laparotomy and dissection of the left renal pedicle only.  
After 120 minutes of left renal IRI, Group 2 animals (n=6) were treated with 0.9ml of 
intra-renal artery normal saline and 2 weeks recovery.  Group 3 animals (n=6) were 
likewise treated with 0.9ml saline vehicle after 120 minutes of left renal IRI, but with 
6 weeks recovery. 
 
Pathfinder Derived Microvesicle Treatment Group 
400ng of Pathfinder-derived microvesicles (PF-MV) were thawed and dissolved in 
0.9ml of normal saline immediately prior to use.  After 120 minutes of left sided renal 
IRI, Group 4 animals (n=6) were treated with 0.9ml of intra-renal artery PF-MVs, 
before being allowed to recovery for 2 weeks.  Group 5 animals (n=6) were likewise 
treated with 0.9ml of intra-renal artery PF-MVs after 120 minutes of IRI but were 
recovered for 6 weeks.  
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Group 
(n=6) 
120 minutes left 
renal ischemia 
Recovery prior to 
Inulin Clearance 
Intra-renal artery 
Injection (0.9ml) 
1 X 2 weeks None 
2 √ 2 weeks Normal saline 
3 √ 6 weeks Normal saline 
4 √ 2 weeks 400ng PF-MV 
5 √ 6 weeks 400ng PF-MV 
 
Table 7.1: Summary of experimental groups.  6 rats were randomly assigned to each group.  
 
7.33 SURGICAL PROCEDURE 
Rodent anesthesia and positioning during surgery were conducted in standard fashion, 
as previously described in Sections 2.12 – 2.16.  
Surgery was carried out as described in Section 5.33.  Treatment groups received 
intra-renal artery therapy as outlined in Table 7.1.  All intra-renal artery infusions 
were made up to a total volume of 0.9ml immediately prior to use.  
 
7.34 POST-SURGICAL CARE  
This was carried out in standard fashion as described in Section 2.16.  
 
7.35 QUANTIFICATION OF RENAL FUNCTION AND RENAL INJURY 
At day 14, animals in Groups 1, 2, and 4 underwent inulin clearance studies in order 
accurately to characterize the function of the remaining kidney, according to the 
standard protocol described in Section 2.2.  Group 3 and Group 5 animals underwent 
inulin clearance studies 6 weeks after ischemia, again according to standard protocol. 
Left kidneys and right kidneys were weighed, before being stored in 10% formalin 
and RNA later solution for later analysis. 
 
Formalin preserved kidneys were paraffin embedded and sectioned as described in 
Section 2.3 Histological analysis and immunohistochemistry for P16, P21 and Ki 67 
were carried out as described in Sections 2.3 and 2.4 
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7.36 PATHFINDER DERIVED MICROVESICLE ISOLATION 
This was achieved in a standard fashion as described in Section 2.6, to give an aliquot 
prepared in a minimal volume containing ~ 400ng of microvesicles.  This sample was 
made up to 0.9ml in normal saline immediately prior to intra-renal artery infusion. 
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7.4 RESULTS 
7.41 ANIMAL DATA AFTER 2 WEEKS RECOVERY POST SURGERY 
GROUP WEIGHT LOSS COMPARED TO BASELINE WEIGHT 
 
  
Figure 7.1: There were no significant differences in % baseline body weight loss between sham-
operated, saline treated or PF-MV treated animals at any time point postoperatively.  
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test 
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7.42 GLOMERULAR FILTRATION RATE 
Effect on GFR after PF-MV Administration after 2 weeks recovery 
 
 
 
Figure 7.2: Sham-operated animals had a higher GFR than animals subjected to 120 minutes of 
ischemia and treated with saline (p=0.0022).  A trend towards higher GFR in sham-operated animals vs 
PF-MV was observed, although this was not statistically significant (p=0.0623). 
Treatment with PF-MVs protected GFR from ischemia when compared to treatment with saline alone 
(p=0.0201). 
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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7.43 RENAL HISTOLOGY 
7.431 Epithelial Breaks after 2 weeks recovery 
 
 
Figure 7.3: After 2 weeks recovery, sham-operated animals had significantly fewer epithelial breaks 
than animals subjected to 120 minutes of ischemia and treated with saline (p<0.0001) or PF-MV 
(p<0.0001). 
Animals treated with PF-MV had fewer epithelial breaks than animals treated with saline alone (p = 
0.0012). 
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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7.432 Hyaline Cast Formation after 2 weeks recovery 
 
 
 
Figure7.4: Sham-operated animals had fewer hyaline casts vs animals treated with saline (p<0.0001).  
Although a trend towards fewer casts in sham-operated animals vs PF-MV treated animals was 
observed, this was not statistically significant (p=0.0860).   
PF-MV treated animals had fewer hyaline casts than those treated with saline alone (p=0.0061). 
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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7.44 ANIMAL DATA AFTER 6 WEEKS RECOVERY POST SURGERY 
GROUP WEIGHT LOSS COMPARED TO BASELINE WEIGHT 
 
 
 
Figure 7.5: Both saline and PF-MV treated animals lost significant weight from baseline in the first 
week following surgery.  Whilst saline treated animals remained below baseline weight at Day 7 
(p<0.0001) and Day 10 (p=0.033), PF-MV treated animals had regained baseline weight by Day 7 
(p=0.0935).  Saline-treated animals regained baseline weight by Day 12 and thereafter both groups 
continued to gain weight until the experiment was terminated. 
Statistical analysis by unpaired Students t test.  
 
 
7.45 COMPARISION OF PERCENTAGE WEIGHT LOSS FROM BASELINE 
BETWEEN GROUPS 
There was no significant difference between the weights of saline and PF-MV treated 
animals at any time point during the experiment (see figure 7.5). 
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7.46 GLOMERULAR FILTRATION RATE 
Effect on GFR after PF-MV after 6 weeks recovery 
 
 
 
Figure 7.6: Sham-operated animals were found to have a higher left sided GFR than those animals 
subjected to 120 minutes of ischemia and treated with saline. (p=0.0041)  There was no difference in 
the GFR of sham animals, and those treated with PF-MVs, after 6 weeks recovery (p=0.2541). 
6 weeks post surgery, PF-MV treated animals had a significantly higher GFR compared to saline 
treated animals (p=0.0093).  
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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7.47 RENAL HISTOLOGY SCORING 
7.471 Epithelial Breaks after 6 weeks recovery
 
 
Figure 7.7: Sham-operated animals had few epithelial breaks compared to animals treated with saline 
(p<0.0001) and PF-MV (p<0.0001), 6 weeks after surgery.   
PF-MV animals had fewer epithelial breaks than those animals treated with saline (p=0.0217).  
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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7.472 Hyaline Cast Formation after 6 weeks recovery 
 
 
 
Figure 7.8: 6 weeks post surgery, sham-operated animals had fewer hyaline casts than animals treated 
with saline (p=0.0285).  A trend was observed towards fewer casts in sham animals than those treated 
with PF-MV, although this was not statistically significant (p=0.0788).  
6 weeks post surgery, there was no difference in hyaline cast number between animals treated with 
saline and those treated with PF-MV (p=0.8452). 
Statistical analysis by 1 way ANOVA with Tukey multiple comparisons test. 
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Figure 7.9:  (a) Histology from a saline-treated rat subjected to 120 minutes of warm ischemia, 2 
weeks post surgery.  There is marked tubular dilation (green asterisk), with epithelial thinning and 
breaks (black arrowheads).  A glomerulus with an increase in Bowman’s space is marked with a blue 
arrow.  Hyaline casts are marked with black dots. (b) Tissue from a PF-MV treated rat 2 weeks after 
ischemia.  There is less disruption to renal histology compared to saline treated animals.  (c) Tissue 
from a rat subjected to 120 minutes of warm ischemia, 6 weeks post surgery.  Tubular dilation and 
epithelial breaks are less pronounced than 2 weeks post surgery, and there are fewer hyaline casts 
present.  (d) Tissue from a rat treated with PF-MV, 6 weeks post surgery.  Compared to saline treated 
animals, tubular dilation and epithelial breaks are less marked.  
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7.5 DISCUSSION 
7.51 Stem Cell versus Cell-free therapy 
Stem cell therapy, whilst potentially conferring a considerable benefit as a novel 
treatment for the protection and rejuvenation of damaged organs, remains associated 
with a number of serious possible side effects.  In this thesis, the findings of Chapter 
3, where disseminated malignancy as a result of cellular therapy, and Chapter 6 where 
supra-therapeutic doses of cells produced arterial occlusion, highlight some of the 
concerns raised previously regarding stem cells as a novel treatment.  Cell-free 
therapy theoretically has a reduced risk of inducing malignancy in recipients, and due 
to the small size of ECVs, microcirculation occlusion in organs treated with local 
arterial infusion is thought to be extremely unlikely (Rani et al., 2015).  Furthermore, 
if the active and beneficial components contained within ECVs can be identified, 
manufacture of a synthetic and pure drug may be possible.  However, in order to 
achieve this, it is necessary to demonstrate convincingly that ECV therapy produces 
long-term benefit, whilst identifying the biologically active components of the ECV 
fraction that are responsible for this.  
 
The experiment described here demonstrates that cell-free therapy has the potential to 
ameliorate severe renal IRI, with the preservation of renal morphology ultimately 
associated with improved long-term renal function as determined by GFR.  While the 
results of ECV therapy in renal IRI have been described by previous studies, this is 
the first account describing the effect of Pathfinder-derived ECVs on renal IRI.  
Furthermore, for the treatment of renal IRI, this appears to be the first application of a 
preparation containing a truly ‘purified’ microvesicle fraction, obtained from any 
particular stem cell source. 
 
 ECVs derived from BD-MSCs were the first cell-free preparations to be tested in 
models of acute kidney injury.  Bruno et al showed a single intravenous injection of 
BD-MSC derived ECVs were able to accelerate structural and functional recovery in 
a murine model of glycerol-induced AKI (Bruno et al., 2009b).  Importantly, the 
effects observed were comparable to those obtained with the cells of origin, indicating 
that ECVs might replicate the beneficial effects reported with MSC therapy.  Gatti et 
al would later report that a single intravenous dose of ECVs, again derived from BD-
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MSC, protected the renal function and morphology of rats subjected to contralateral 
nephrectomy and 45 minutes of unilateral ischemia (Gatti et al., 2011).  Molecular 
data presented suggests that shortly after injury, treated animals renal histology 
exhibit reduced leucocyte infiltration, a down-regulated inflammatory response 
leading to less tubular epithelial cell apoptosis and proliferation in response to injury.  
Long-term structural changes in renal morphology, such as glomerulosclerosis and 
tubulointerstitial were consequently reduced with the protection of long-term renal 
function.  They also demonstrated that treatment of ECVs with RNAase prior to 
injection abolished ECV efficacy, implying that the RNA cargo played a vital role in 
conferring the beneficial effects seen with ECVs. 
 
In a similar rat model of renal IRI, after administering ECVs derived from endothelial 
progenitor cells, Cantaluppi et al observed preserved renal function and histology as a 
result of ECV therapy, with progression to chronic renal failure prevented in treated 
animals (Cantaluppi et al., 2012).  The observed effects were again abolished by 
RNAase treatment.  
 
The lack of efficacy reported with ECVs subjected to RNAase treatment suggests a 
crucial role of RNA in the mechanism by which ECV convey renoprotection.  When 
compared to the parent cell RNA content, MSC-derived ECVs have been shown to be 
enriched in small non-coding RNAs, but also contain 239 mRNAs that are involved in 
cell differentiation, transcription, cell proliferation and immune regulation (Eirin et 
al., 2014, Bruno et al., 2009b). 
 
 Furthermore, ECVs contain concentrated levels of microRNAs (miRNAs).  miRNAs 
are non-coding RNA molecules that typically consist of 22 nucleotides.  They are 
highly conserved, negative regulators of gene expression that act on the post-
transcriptional level by binding to complementary sequences of mRNA in recipient 
cells.  This inhibits the translation of mRNA and promotes mRNA degradation 
(Bartel, 2004).  It is postulated that by silencing mRNA translation, the horizontal 
transfer of miRNA by ECVs may down-regulate recipient cell injury response, and in 
particular the inflammatory cascade.  
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The importance of miRNA in the renoprotective effect of ECVs was demonstrated by 
Cantaluppi et al (Cantaluppi et al., 2012), and this finding was later replicated by 
Collina et al (Collino et al., 2015).  Dicer and Drosha are miRNA processing enzymes 
that play a crucial role in the maturation of miRNAs (Kuehbacher et al., 2007).  
Application of either Dicer (Cantaluppi et al., 2012) or Dosha (Collino et al., 2015) 
knock-down in progenitor cells from which ECVs were harvested, resulted in the 
abolition of the renoprotection previously observed with ECVs from normal 
progenitor cells.  In addition, depletion of specific miRNAs from ECVs characterized 
the importance of the proangiogenic miRNA-296 and miRNA-126 (Cantaluppi et al., 
2012).  These results support the assertion that via horizontal transfer within ECVs, 
miRNAs play a crucial role in reprogramming damaged resident renal cells to a 
regenerative state.  
 
7.52 Which Extracellular Vesicle Type protects the Kidney - Exosomes or 
Microvesicles? 
The results of this study corroborate the findings of McGuiness et al, who reported 
that within the ECV population derived from Pathfinder cells, it is the MV fraction 
that contains the biologically active cargo responsible for the protective/regenerative 
effects on injured cells (McGuinness et al., 2016).  Prior to this experiment, the 
finding of McGuiness et al appears to be the only study that demonstrated therapeutic 
efficacy of a properly characterized population of microvesicles, whilst reporting the 
separated exosome fraction lacked biological effect (McGuinness et al., 2016).  It is 
worth re-iterating that as described in Section 7.11, a number of previous studies have 
reported the protective effects of administering stem cell-derived ‘microvesicles’ to 
injured organs (Cantaluppi et al., 2012, Bruno et al., 2009b, Bruno et al., 2012, Gatti 
et al., 2011, Bonventre, 2009).  However the protocols used in those studies is likely 
to have resulted in a mixed exosomes/microvesicle preparation according to the now 
widely accepted definition of ECVs used in this thesis, and it is impossible to 
conclude that the content of microvesicles alone was responsible for the observed 
protective effects. 
 
 The result of the current experiment – namely that ‘true’ microvesicles alone may 
ameliorate acute organ injury – disagrees with the previous reports in published 
literature.  The general consensus is that exosomes are likely to contain the factors by 
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which stem cells produce their paracrine effects.  The majority of reports have 
investigated ECVs obtained from MSCs that are of either a bone marrow or adipose 
origin (Han et al., 2016).  Those studies that have attempted to differentiate between 
the effects of individual ECV fractions have concluded that MSC-derived exosomes 
are able to promote angiogenesis in ischemic tissue and ameliorate tissue damage 
after ischemic injury (Arslan et al., 2013, Bian et al., 2014, Xin et al., 2013, Hu et al., 
2015, Lin et al., 2016).   
 
Work investigating the effects of ECVs from other stem cell classes also report the 
exosome fraction conveys the observed beneficial effects of parent stem cells.  Berger 
et al reported that exosomes derived from endothelial colony forming cells protected 
against renal IRI in a murine model (Burger et al., 2015).  Furthermore, the same 
group recently reported that this effect appears to be mediated by the horizontal 
transfer of miRNA -486-5p, which they observe to be selectively enriched within the 
exosomes fraction (Vinas et al., 2016).   
 
The apparent discrepancy regarding the efficacy of exosomes versus microvesicles 
may be explained by the parent stem cells source.  It is well recognized that the 
content of ECVs is dependent upon the type of stem cell from which they originate, 
and the conditions in which those stem cells were kept prior to ECV harvest.  For 
example, ECVs derived from fibroblasts contain little biologically active genetic 
material, and confer no organ protection compared to saline control in animals models 
of renal IRI (Quesenberry et al., 2014).  Logically, it seems possible that pathfinder 
cells may produce their effects via the transfer of genetic material contained within 
microvesicles, but that other stem cell types produce their therapeutic effects 
predominantly via exosomes.  Whilst studies have characterized a least some of the 
active miRNA classes within ECV fraction (Cantaluppi et al., 2012, Vinas et al., 
2016), work is on-going to identify the responsible factors within the PF-MV 
preparation (McGuinness et al., 2016). 
 
One clear weakness in this study is a lack of molecular data, which may have 
provided some insight into the mechanisms by which PF-MVs act. 
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Nevertheless, other studies using Pathfinder cells or PF-MVs have published 
molecular data that indicate the mechanisms by which the beneficial biological effects 
are obtained.  McGlynn et al reported the reduced renal expression of p16ink4a in mice 
treated with Pathfinder cells 2 weeks after IRI to be associated with improved renal 
function and morphology (McGlynn et al., 2013).  No difference in apoptosis, as 
measured by TUNEL staining was observed between treated and untreated animals, 
probably because the apoptotic process would have been completed 14 days post 
injury.  Furthermore, Pathfinder cells, as demonstrated by FISH, were notable by their 
absence in treated kidneys.  The authors concluded that via a paracrine mechanism, 
Pathfinder cells reduced cellular senescence in response to injury (McGlynn et al., 
2013).  This finding was in keeping with previous studies using Pathfinder cells, 
where reduced cellular senescence in damaged organs was been noted in Pathfinder 
treated animals, in the absence of Pathfinder engraftment (Stevenson et al., 2011).  
The authors concluded that Pathfinder cells, probably via material contained within 
microvesicles encourage organ repair through cell regeneration.  In the kidney, this 
may be via up-regulated mechanisms including the de-differentiation of surviving 
tubular epithelial cells followed by proliferation to repopulate damaged tubules, as 
suggested by Bonventre et al (Bonventre, 2003).  
Several different sources of ECVs have been reported to have similar efficacy at 
mitigating acute renal injury, culminating in the ability to reduce kidney fibrosis as a 
long-term outcome.  However, this effect cannot yet be assigned to a particular 
molecular mechanism.  This is perhaps unsurprising when considering the content of 
ECVs reflects the phenotype of the parent cell and consequently, the cargo within 
ECVs of different origin is may be markedly different (Quesenberry et al., 2014).  
There is no evidence to suggest that Pathfinder mediated protection is produced by an 
anti-inflammatory action.  This is in stark contrast to the postulated action of MSCs, 
where there is now a wealth of evidence to support the anti-inflammatory and 
immune-modulatory properties of MSCs, which appear to be mediated by ECVs in a 
paracrine fashion.  
 
Therefore, it is possible that MSCs and Pathfinder cells aid long-term recovery of 
organs after acute injury via different mechanisms.  There is clear evidence that 
Pathfinder cells do this by the transfer of material in microvesicles, and that this 
reprograms cells to enter regenerative pathways and avoid a senescent state.  In 
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contrast, MSCs appear to provide initial protection against injury by dampening local 
inflammatory responses and that this effect is primarily achieved via the horizontal 
transfer of genetic material contained within exosomes.  However, a recent study 
observed that a combination of ADRCs and ADRC derived exosomes provided 
additional protection against renal IRI when compared to either therapy alone (Lin et 
al., 2016).  This suggests that ADRC derived microvesicles act synergistically with 
ADRC derived exosomes to confer additional protection.  
In conclusion, these experiments strongly suggest that ECV treatment has the 
potential to mitigate the unavoidable renal IRI that occurs during the transplantation 
process.  Characterization of PF-MV content and obtaining molecular data to gain 
insight into the mechanisms by which PF-MV content produces effects are important 
next steps.  Furthermore, experiments to investigate any possible synergistic effect of 
PF-MVs and ECVs derived from MSCs are warranted.  
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CHAPTER 8 
THE EFFECT OF PATHFINDER DERIVED 
MICROVESICLES ON PROLONGED COLD AND 
WARM ISCHEMIC TIMES IN A NOVEL RAT MODEL 
OF RENAL TRANSPLANTATION  
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8.1 INTRODUCTION 
There are few, if any, animal models that accurately reproduce the insults a renal 
allograft encounters during the journey from donor to recipient.  Although animal 
models are a valuable tool for understanding the pathophysiological processes 
involved during renal IRI, the clinical translation of experimental results have several 
limitations, usually due to the anatomical and physiological differences between 
species.  Nevertheless, animal models have accentuated our understanding of the 
insults transplanted kidneys encounter, and may yet a play a significant role in the 
search for therapeutic intervention (Becker and Hewitson, 2013).  
 
Animal research requires investigators to continually refine experimental protocols so 
that the likelihood of gaining the knowledge sought is maximised, while animal 
suffering and a total number of laboratory animals used are reduced (Kobayashi et al., 
2012, 2011b).  Some of the shortcomings of commonly used animal models have 
been highlighted in this thesis – indeed these failings led to the development of a 
novel rat model of renal IRI described in Chapter 5.  However, while IRI remains the 
leading cause of injury to transplanted kidneys and is accentuated in the increasingly 
used ECD and DCD kidneys, other acute insults combine to negatively influence 
long-term transplant outcomes (Jang et al., 2009).  Such processes include hypoxia 
during cold storage, acute rejection, and calcineurin toxicity in the short and long-
term (De Rosa et al., 2016).  
 
Most preclinical renal IRI animal models use ischemia caused by occlusion of the 
renal artery to produce an acute kidney injury.  While this does not exactly replicate 
the clinical situation, several pathways are up-regulated that are important participants 
in acute allograft injury.  These include activation of the coagulation system (Thuillier 
et al., 2010), leukocyte infiltration (Versteilen et al., 2011), endothelium (Kwon et al., 
2009) with overexpression of adhesion molecules (Kato et al., 2009), cytokine 
release, intrarenal vasoconstriction pathway and apoptosis (Saikumar and 
Venkatachalam, 2003).  Nevertheless, these ‘traditional’ models of ischemia-
reperfusion do not expose animals to immunological or pharmacological insults, nor 
do they subject injured kidneys to cold storage.  In order to mimic this process and to 
investigate the ability of stem cell-based therapies to ameliorate renal injury that 
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results from such insults, animal models of kidney transplantation need to be 
employed (Becker and Hewitson, 2013, Lieberthal and Nigam, 2000, Saat et al., 2016, 
Masoud et al., 2012).  However, renal transplantation is a technically more 
demanding exercise than warm renal IRI, introducing more variables into both control 
and experimental groups.  It therefore seems reasonable to screen novel therapies for 
efficacy in IRI models, before progressing to experiments in models of 
transplantation.  
 
8.11 WARM VERSUS COLD RENAL ISCHEMIA 
Static cold storage is traditionally used to preserve kidneys ex vivo during the 
transplantation process.  Throughout cold storage, the kidney is placed in a 
hypothermic solution designed to cool the kidney and by reducing cellular 
metabolism, the effect of on-going ischemia is minimised.  Organs are usually cooled 
to 4oC, as it has been shown that each 10oC drop in temperature results in a 2-fold 
reduction in cellular metabolism (Lee and Mangino, 2009).  
 
The decrease in free radicle formation encountered as a result of reduced cellular 
metabolism during static cold storage reduces cell depolarization and membrane 
destabilisation.  However, while static cold perfusion lessens the degree of cell injury 
caused by ischemia, cold storage does not completely prevent it (Ponticelli, 2015).  
Reduced ATP production leads to dysfunction of the Na/K ATPase pump and calcium 
influx that eventually results in cell swelling and cell cycle arrest (Ponticelli, 2015).  
Also, ECD and DCD allografts tolerate cold anoxia poorly, with the detrimental 
impact of hypothermia demonstrated in several studies (Hamed et al., 2015, Kayler et 
al., 2011, Summers et al., 2013).  Furthermore, the abrupt temperature shift from 
hypothermia to normothermia that occurs during reperfusion has been shown to result 
in mitochondrial dysfunction and up-regulate pro-apoptotic signal transduction 
(Minor et al., 2013). 
 
Warm and cold ischemia are thought to produce structural injury in different areas of 
the kidney by distinct pathological processes.  Warm ischemic injury, characterised 
by an interruption in renal blood flow, produces tissue hypoxia as a principle insult.  
The resulting alteration in the medullary microcirculation causes endothelial 
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dysfunction and proximal tubular injury, principally in the cortico-medually junction 
(also referred to as the outer stripe of the medulla) (Heyman SN, 2010). 
 
The recognised mechanism of cold ischemic injury is also related to the disturbance in 
osmoregulation, energetics, and aerobic metabolism.  Dysfunction of the Na/K 
ATPase pump results in higher intracellular sodium concentrations and cell swelling.  
Ongoing anaerobic respiration results in lactic acid production and intracellular 
acidosis (Salahudeen, 2004).  However, cold ischemia has been shown to produce 
preservation of the proximal tubules, although distal nephron injury is more 
prominent upon reperfusion.  This produces an injury that is principally located in the 
inner medullary stripe, although damage to the outer medually stripe is observed if the 
period of cold ischemia is prolonged (Heyman SN, 2010).  For this reason, cold-
storage induced injury is a pivotal contributing factor to early graft dysfunction in 
renal transplant recipients, predisposing to DGF and the subsequent adverse outcomes 
that are associated with its occurrence (De Rosa et al., 2016).  
 
Wang et al. examined the effect of ADRC administration in a rat model of cold renal 
IRI (Wang et al., 2013b).  Using intra-renal and intravenous autologous ADRC 
injections after a 30-minute period of cold ischemia, protection of renal function and 
morphology was reported to be associated with a down-regulated inflammatory 
response in ADRC treated animals after 24 hours recovery (Wang et al., 2013b). 
 
Interestingly, telomere-independent cellular senescence, as shown by elevated p16 
expression has been associated with poor long-term renal allograft outcomes in 
humans and rodents (McGlynn et al., 2009, Koppelstaetter et al., 2008, Melk et al., 
2005, Serrano et al., 1996).  Braun et al reported that murine kidney transplants from 
donors lacking the p16INKK4a locus had reduced interstitial fibrosis and tubular atrophy 
compared to transplanted kidneys from wild-type controls (Braun et al., 2012).  This 
suggests that cellular senescence as a result of IRI/immunological rejection leads to 
premature chronic allograft nephropathy and ultimately allograft failure, implying that 
therapy that reduces senescence may benefit transplant outcomes.  McGlynn et al 
have previously demonstrated Pathfinder cell therapy to be associated with a 
reduction in p16 expression and serum creatinine levels in a murine model of renal 
IRI (McGlynn et al., 2013). 
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The results of experiments in the novel rat model of renal IRI suggest that PF-MVs 
and ADRCs protect renal function and structure against prolonged warm ischemia.  In 
order to mimic the process of clinical transplantation, it was decided to investigate the 
ability of stem cell-based therapies to protect against both cold and warm ischemia by 
developing an animal model of transplantation.  
 
8.12 CHOICE OF SPECIES IN ANIMAL MODELS OF RENAL 
TRANSPLANTATION 
The first major decision during the development of an animal model is the selection 
of species involved.  Essentially, smaller animal species, such as rodents, are easier to 
house and handle than larger animals but are anatomically distinct from humans, 
processing unilobular and unipapillary kidneys (Simmons et al., 2008). Unfortunately, 
the different vascular properties of the renal medulla contribute to variability in the 
pathophysiology of ischemic AKI between species.  When novel therapies are applied 
to large animal models, replicating the findings from rodent experiments may 
consequently be difficult.  This hampers clinical translation of new treatments.  
Rodent models of renal transplantation are therefore limited in the relevant 
information they provide by physiological and anatomical differences.  Furthermore, 
the size constraints associated with rodent renal transplantation requires a skilled and 
experienced surgeon to provide consistent results and avoid multiple surgical failings 
(Khalifeh et al., 2015). Nevertheless, the relatively low-cost and ease of licensing 
compared to large animals makes rodent transplant models more practical.  However, 
rodent IRI renal models remain more popular still, probably because conventional IRI 
models lack the requirement for vascular or ureteric anastomosis, and hence require 
less surgical expertise.  
 
 Larger animals more closely resemble human anatomy and physiology but are more 
expensive, labour intensive, and their use in experimental research is limited by 
ethical debate.  Nevertheless, three large animal models have been used extensively in 
models of renal transplantation: dogs, pigs, and non-human primates.  Of these, the 
pig has the significant advantage in that the public has little resentment for porcine 
research, leading to fewer ethical and legal restrictions on porcine studies (Dehoux 
and Gianello, 2007).  Furthermore, pigs are reasonably similar to humans in size, 
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metabolism, immunology and renal anatomy (Kirk, 2003, Giraud et al., 2011, 
Rothkotter, 2009).  While housing and husbandry of standard pigs are expensive and 
time-consuming, the advent of genetically modifiable mini-swine may change this 
situation (Lunney, 2007). Finally, pigs are easily bred, quickly bled and it is possible 
to repeatedly obtain biopsies during the experimental time course.  This establishes 
the pig as the ‘gold-standard' in renal transplantation research (Lunney, 2007).  
However, due to the expense, strict legislation and relative logistical difficulty of 
working with pigs, the numbers of reported studies using porcine models of renal 
transplantation are scarce when compared to those using rodents. 
 
While large animal studies are essential before moving to clinical trials, this was not 
feasible with the research facilities available.  With a view to the reducing the total 
number of animals experimented upon, it was decided to test novel therapies in a 
rodent transplant model after therapeutic effectiveness had been demonstrated in the 
novel rodent IRI model.  It was hypothesised this might provide efficacy data, prior 
testing in porcine models with a view to clinical translation in pilot studies.   
 
8.13 RODENT MODELS OF RENAL TRANSPLANTATION 
With the purpose of investigating the ability of stem cell-based therapies to combat 
both cold and warm renal ischemia, we decided to develop a rat model of renal 
transplantation.  Previous models of rodent transplantation have tended to use 
allografts from young healthy donors, exposed to only minimal cold and warm 
ischemic times.  This is clearly not representative of the human population 
undergoing kidney transplantation.  Furthermore, as described in Section 5.1, rat 
kidneys have the ability to recover long-term function from near fatal levels of 
ischemic injury.  In order to investigate the long-term effects of novel treatments on 
severely injured kidneys, it was decided to subject the transplanted kidneys to 
prolonged periods of cold and warm ischemia prior to reperfusion.  This has not been 
investigated previously, probably because prolonged transplant ischemic times are 
associated with high numbers of post-procedural animal deaths.  It was therefore 
decided to leave the rat with a functioning native kidney to prevent death from acute 
renal failure and to calculate GFR by inulin clearance with ureteric cannulation as 
described in Chapter 2. 
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Rat kidney transplantation became established in the 1960s, and subsequently, several 
studies have reported surgical techniques that make the procedure easier to perform 
(Pahlavan et al., 2006, Schumacher et al., 2003, Spanjol et al., 2011).  2 methods of 
transplantation have been routinely described:   
 
(1) Heterotophic transplantation: End to side anastomosis of the renal artery and 
vein onto the infra-renal abdominal aorta and inferior vena cava respectively, 
with clamps applied superiorly and inferiorly to the incision in the recipient 
vessel.  Ureteric implantation is achieved via ureterovesical anastomosis.  The 
transplanted kidney is left within the peritoneal cavity.  (See Figure 8.1) 
 
 
Figure 8.1: Heterotopic renal transplant, performed by the author during microsurgical training at 
Northwick Park Institute for Medical Research. 
 
(2) Orthotopic transplantation: After left-sided nephrectomy, end-to-end anastomosis 
of the transplanted renal artery and vein onto the native renal vessels is performed.  
The kidney is placed within the native renal bed.  Ureteric anastomosis between the 
transplant and native systems is made in an end-to-end fashion, sometimes over a 
ureteric stent (Herrero F 2004, Pietsch et al., 2004).  
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8.14 PREVIOUS STUDIES OF RENAL TRANSPLANTATION IN RODENTS 
Some studies using MSC therapy have focused investigation upon 
immunomodulation and the ability of MSCs to protect against rejection, while others 
have examined the effects of cellular therapy against IRI +/- rejection.  Reviewing the 
findings of these reports provides insight into the potential of cell-free therapy to 
mitigate injury occurring in the peri-transplant period. 
 
8.15 MSCs AND IMMUNOLOGICAL REJECTION IN KIDNEY 
TRANSPLANT MODELS 
De Martino et al. investigated the immunomodulatory effects of allogeneic MSCs 
after both syngeneic and allogeneic rat kidney transplantation (De Martino et al., 
2010).  MSC therapy was shown to reduce renal tubular damage by reducing 
inflammatory cell infiltrate in both models of transplantation (De Martino et al., 
2010).  This implies that acute cell-mediated rejection is mitigated by MSCs in the 
allogeneic transplantation group, while in syngeneic transplanted animals, enhanced 
immunogenicity as a result of IRI is also ameliorated by MSC treatment.  
 
Franquesa et al. utilized the Fischer to Lewis rat transplant model of chronic allograft 
nephropathy to investigate the effects of BD-MSCs given intravenously 11 weeks 
post transplantation (Franquesa et al., 2012b).  For the first 15 postoperative days, rats 
were treated with cyclosporine A to reduce the incidence of acute rejection.  
Transplanted kidneys were subjected to 150 minutes of cold ischemia, although the 
length of warm ischemia was not reported.  After 24 weeks, MSC therapy was 
associated with a down-regulated inflammatory response with reduced expression of 
inflammatory cytokines and fewer macrophages infiltrating the renal parenchyma.  
Consequently, MSC treated animals were shown to have improved serum creatinine 
levels, superior renal histology and reduced renal fibrosis (Franquesa et al., 2012b).  
 
Using a rat transplant model, Zhang et al. investigated the effects of combined 
cyclosporin A with multiple post-transplant BM-MSC intravenous injections (Zhang 
et al., 2007).  They observed that combined cyclosporin A and BM-MSC therapy 
preserved short-term transplant function better than monotherapy with either 
treatment alone, but ultimately allograft longevity was not superior to any 
combination.  However, as this Wistar into Lewis transplant model utilised minimal 
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renal ischemia and predominantly caused renal dysfunction by acute cell-mediated 
rejection, this finding is unsurprising.  It may be that any initial renal IRI was 
mitigated by MSC therapy, but that ultimately immunological rejection was too 
powerful to be affected by either cyclosporin A or MSC administration. 
 
8.16 MSCs AND PREVENTION OF IRI IN RODENT KIDNEY TRANSPLANT 
MODELS 
Iwal et al investigated the effects of autologous ADRC infusion in a syngeneic rat 
kidney transplant model, which was published around the conclusion of this 
experiment.  Iwal et al concluded that ex vivo intrarenal artery infusion of 1 x 106 
ADRCs was associated with significantly improved renal function after 60 minutes of 
cold and 60 minutes of warm ischemia (Iwai et al., 2014).  Furthermore, it was noted 
that intra-renal artery infusion of ADRCs, although not significantly better at 
protecting renal function and histology than intravenous administration, was not 
associated with complications previously reported with systemic administration (Iwai 
et al., 2014).  
 
Hara et al. investigated the effects of BD-MSCs on renal IRI following 24 hours of 
cold ischemia to study the effects of prolonged cold ischemia on graft 
immunogenicity (Hara et al., 2011).  Using a robust model of acute rat kidney 
rejection, they reported intravenous administration of autologous BD-MSCs to be 
associated with suppression of pro-inflammatory cytokines and down-regulation of 
adhesion molecules and chemokines.  In keeping with previous studies (Zonta et al., 
2010, Schrepfer et al., 2007) they noted that the vast majority of administered cells 
became entrapped within the pulmonary circulation and only a few reached the 
transplanted kidney.  They concluded that BD-MSC administration was able to reduce 
graft immunogenicity following prolonged cold storage, and speculated that this 
effect was due to the inhibition of immune cell migration into the transplanted kidney.  
Furthermore, they concluded that BD-MSC efficacy was likely mediated via a 
paracrine effect (Hara et al., 2011).  Unfortunately, they did not report the period of 
warm ischemia that the transplanted kidney was subjected to.  
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8.17 RATIONALE FOR RAT TRANSPLANT MODEL USED IN THIS 
EXPERIMENT 
Previous experiments in Chapter 5 had indicated prolonged ischemic times are 
necessary to produce a long-standing renal injury - an essential requirement when 
investigating the ability of novel treatments to protect renal function in medium to 
long term.  However, rodents have been shown to lack the artery of Adamkiewicz, a 
branch of the posterior intercostal artery which in man typically arises on the left at 
the level of the 9th – 12th intercostal artery (Schievink et al., 1988).  This vessel is 
necessary to provide collateral spinal blood supply during aortic cross-clamping.  
Lacking this vessel, rodents undergoing prolonged suprarenal aortic cross-clamping 
are reported to suffer high rates of postoperative spinal paralysis due to spinal cord 
ischemia (Taira and Marsala, 1996, Awad et al., 2010).  After discussion with experts 
at Northwick Park Microsurgical Institute, London, it was decided to develop a 
transplant model using an orthotopic transplant model, which would necessitate 
clamping of the renal vessels only.  Syngeneic rats were used as both donors and 
recipients to remove immunological rejection as a confounding factor.  Again, novel 
therapy was administered via the transplant renal artery immediately prior to 
reperfusion to avoid systemic distribution.  Infusion of MSCs via the renal artery has 
previously been shown to be superior to intravenous therapy in a rat transplant model 
(Zonta et al., 2010). 
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8.2 HYPOTHESIS 
(1) Prolonged periods of cold and warm ischemia will result in a predictable 
reduction in long-term function and histology of a renal allograft, transplanted 
between syngeneic rats. 
(2) Administration of therapy, previously shown to mitigate warm renal IRI may 
improve long-term transplant function and histology. 
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8.3 METHODS 
8.31 ANIMAL HOUSING AND HUSBANDRY  
Male Fisher 344 rats, aged 12 - 14 weeks and weighing 225 – 250g were sourced 
from Harlan UK Ltd.  Animals were housed in the JRF, University of Glasgow for at 
least two weeks before surgery to allow the animals to equilibrate with their new 
environment.  Animals were housed and fed as described in Section 2.1.  During 
equilibration before surgery, animals put on weight such that on the day of surgery, 
rats weighing 250 – 320g were used. 
 
8.32 GROUP SELECTION 
 6 animals were randomly assigned to both control and treatment groups.  Donor 
animals were randomly selected from the housed rat population on the day of surgery.  
Transplanted kidneys in control animals were treated with intra-renal artery saline 
vehicle infusion only, 40 minutes prior to graft reperfusion.  Transplanted kidneys in 
treatment group animals were given an intra-renal artery infusion of PF-MVs, given 
exactly 40 minutes prior to transplant reperfusion.  
Post surgery, animals were weighed daily and assessed for signs of distress or illness.  
 
The first 2 successfully transplanted animals, after being subjected to 120 minutes of 
cold ischemia and 120 minutes of warm ischemia, were treated with saline vehicle.  
The next 2 animals were treated with PF-MVs.  Thereafter transplanted animals were 
alternatively treated with saline vehicle or PF-MVs in an attempt to avoid skewed 
outcomes as a result of improved surgical technique. 
 
8.331  KIDNEY TRANSPLANTATION SURGICAL PROCEDURE  
Rodent anaesthesia, positioning during surgery and post-surgical care were conducted 
in standard fashion, as previously described in Sections 2.12 – 2.16. 
 
8.332 Retrieval of Donor Kidney 
Via a long midline incision, the left-sided retroperitoneal structures were exposed by 
mobilising the left colon.  Damp swabs were placed to retract small and large bowel 
and protect the donor kidney.  
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To aid transplantation, it was helpful to have the maximum length of the artery, vein 
and ureter attached to the donor kidney.  Therefore, the full length of the donor left 
renal artery was dissected from the renal hilum to the origin on the abdominal aorta.  
The suprarenal artery was divided with cautery.  Gentle handling with a vascular 
sloop and the direct application of 1% lignocaine prevented spasm of the renal artery.  
The full length of the left renal vein was dissected from the renal hilum to the 
termination of the vein on the inferior vena cava.  The major branches (suprarenal, 
gonadal and lumbar veins) were ligated with 9/0 nylon and divided.  The left ureter 
was dissected free of its attachments from the renal hilum and dissected free distal to 
the crossing of the ureter over the bifurcation of the iliac vessels.  The ureter was then 
transected as distally as possible, and the divided end retracted proximally, out of 
harm's way.  Once this was achieved, the kidney itself was dissected free from the 
renal bed, by sharply incising its fascial attachments.  
 
At this point, the kidney had not been subjected to any ischemia and was attached to 
the donor only by the left renal artery and vein.  (See figure 8.2i) 
A ligature was placed on the renal artery at its origin on the aorta, signifying the start 
of the ischemic period.  (Figure 8.2ii)  An arteriotomy was made, and a cannula was 
placed in the artery.  Using a pre-placed vascular sloop to prevent leakage, the renal 
artery was flushed with ice-cold University of Wisconsin solution (UW), thereby 
flushing the static blood out of the kidney.  (See Figure 8.2iii) 
This typically required a flush of around 4ml of fluid.  The return of this cold fluid to 
the donor circulation, by the left renal vein, universally resulted in donor cardiac 
arrest.  
 
Once the kidney was cooled and adequately flushed, a venotomy was made in the left 
renal vein (8.2iv) and a loop-marking suture placed in the anterior wall.  (8.3v) This 
helped accurate approximation without twisting during transplant anastomosis.  The 
vein was then entirely transected, and the kidney placed in ice-cold UW for 120 
minutes exactly.  The body of the donor rat was discarded. 
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8.333 Recipient Procedure 
The recipient rat was anaesthetized and positioned in standard fashion, again taking 
full sterile procedures.  A midline laparotomy was made, and again the left-sided 
retroperitoneal structures were exposed by mobilising the left colon.  Damp swabs 
were placed to retract the bowel and spleen.  The native left renal artery was 
mobilised along its entire length as described above.  The native left renal vein was 
mobilised up to the origin of the left gonadal vein.  The native left ureter was 
minimally dissected from the left renal hilum.  The kidney's attachments were fully 
excised to mobilise the kidney. 
 
The renal artery clamped at its origin and divided distally to preserve the maximum 
length of the native artery.  The renal vein was clamped distal to the left gonadal vein 
and divided at the renal hilum.  The native ureter was divided as it exited the renal 
hilum, again to preserve the maximum possible length.  The kidney was removed 
from the renal bed and discarded.  The native vessels were flushed with saline in a 
retrograde fashion to eliminate any clots.  (Figure 8.3vi) 
After exactly 120mins of cold ischemia, the transplant kidney was placed in the 
recipient left renal bed (Figure 8.3vii).  This signified the start of the warm ischemic 
period.  The kidney was protected with saline soaked swabs.  
 
Anastomosis of the vessels was begun.  Firstly the native and transplant renal veins 
were anastomosed with 10/0 interrupted nylon sutures in a standard fashion using 16 
stitches.  For this, the two loop-marking sutures helped significantly in ensuring the 
renal vein was sutured in the correct orientation, without twisting or catching the back 
wall.  (Figure 8.3viii)  Venous anastomosis typically took 45 – 50 minutes to 
complete, and attention was then turned to the renal artery.  This was anastomosed as 
described in Section 5.33.  40 minutes prior to reperfusion, the kidney was treated 
with 0.9ml of either saline vehicle or PF-MVs via intra-renal artery infusion, as 
described in Section 5.33.  After exactly 120 minutes of warm ischemia, the vascular 
clamps were removed to re-perfuse the transplanted kidney.  (Figure 8.4x) 
 
Attention was then turned to ureteric anastomosis which was conducted as previously 
described with slight modifications (Herrero F 2004).  Briefly, a 6/0 nylon stent was 
cauterised slightly to blunt each end and placed in native and transplant ureter. (See 
	 215	
Figure 8.4xi).  Over this, the ureter was anastomosed end to end with six equally 
spaced, interrupted 11/0 nylon sutures.  The stent was removed after the final suture 
was placed, but before the final suture being tied. 
 
The renal fascia was tacked over the transplanted kidney with interrupted 10/0 sutures 
to hold it in the renal bed.  The swabs were removed, and the intestines returned to the 
abdomen.  The abdomen was closed with 4/0 continuous vicryl en mass, with un-dyed 
4/0 vicryl to close the skin – as previously described in Section 5.33.  
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Figure 8.2: (i) The retroperitoneal structures in the donor rat are dissected to expose the transplant 
renal artery (TX-LRA) and renal vein (TX-LRV) and the allograft (LK).  The transplant ureter (TX-U) 
is dissected to preserve the maximum length during the transplant process.  The gonadal vessels are 
easily seen.  (LGV)  (ii) A ligature is placed on the renal artery is ligated at its origin on the aorta (A).  
The LK becomes discoloured at this point, signifying the start of the ischemic period.  (iii) Via an 
arteriotomy, a cannula (C) is placed in the TX-LRA and secured with a vascular sloop (S) before the 
allograft is flushed with ice-cold University of Wisconsin solution.  The TX-LRV bulges with UW 
solution and a colour change is seen in the kidney as the blood is expelled.  (iv) The renal artery is 
transected at its origin.  After a ligature is placed at the origin of the TX-LRV, a venotomy is made in 
the anterior wall of the TX-LRV.  
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Figure 8.3: (v) A marking suture is placed in the anterior wall of the TX-LRV before the vein is 
completely transected, and the transplant removed and stored on ice in UW for 120 minutes.  (vi) The 
retroperitoneum of the recipient rat is dissected, preserving the length of the native left renal artery (N-
LRA), native left renal vein (N-LRV) and native left ureter (N-U).  Vascular clamps (VC) are placed 
on the vessels.  The native kidney is removed, leaving the renal bed (RB) free for the transplant.  (vii) 
After exactly 120 minutes on ice, the transplant is placed in the recipient renal bed, and vascular 
anastomosis begins.  (viii) The TX-LRV and N-LRV are placed in frame clamp, approximating the 
anterior vein walls using the marking sutures.  Stay sutures (SS) are placed, and the vein anastomosed 
with interrupted 10/0 nylon.  Yellow background material prevents damage to posterior structures 
during this process.   
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Figure 8.4: (ix) The renal artery and vein are anastomosed in standard fashion as described in Section 
5.33.  (x) The vascular clamps are removed after exactly 120 minutes of warm ischemia, and the 
transplant is reperfused.  (xi) Attention is turned to the ureteric anastomosis.  A 6.0 nylon stent (6/0 
NS) is inserted into both transplant and native ureters to aid suture placement.  It is removed before the 
anastomotic completion.  (xii) The finished transplant before closure of renal fascia to secure the 
kidney in position.   
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8.34 POST-SURGICAL CARE 
This was carried out in standard fashion as described in Section 2.16.  
 
8.35 QUANTIFICATION OF RENAL FUNCTION AND RENAL INJURY 
At day 14 animals underwent inulin clearance studies in order to accurately 
characterise the function of the transplanted kidney, according to the standard 
protocol described in Section 2.2.  Both kidneys were weighed, before being stored in 
10% formalin and RNA later solution for later analysis. 
Formalin preserved kidneys were paraffin embedded and sectioned as described in 
Section 2.3 Histological analysis and immunohistochemistry for P16, P21 and Ki 67 
were carried out as described in Sections 2.3 and 2.4 
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8.4 RESULTS 
8.41 PILOT TRANSPLANTS 
The first 2 animals to undergo transplantation were treated with saline and subjected 
to 120 minutes of cold ischemia, and 90 minutes of warm ischemia.  (See figure 8.5)  
The transplant GFR values obtained from these ‘pilot’ studies appeared broadly 
comparable to GFR values from healthy animals, which suggested a possible lack of 
significant injury after 14 days recovery.  Therefore, the warm ischemia time was 
increased to 120 minutes.  
 
 
 
Figure 8.5:  No significant difference was observed between the native renal function of sham-
operated animals (n=6) and ‘Pilot Study’ transplanted kidneys subjected to 120 minutes of cold and 90 
minutes of warm ischemia (n=2).  Data after 2 weeks recovery post surgery.  
Statistical analysis by unpaired Student's t-test. 
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8.42 POST-PROCEDURE MORTALITY RATES AND TECHNICAL 
COMPLICATIONS 
5 of the first 6 animals to undergo transplantation with 120 minutes of cold and 120 
minutes of warm ischemia did not survive 14 days post procedure.  
 
Of these 5 animals:  
• 1 animal lost >10% of its bodyweight by 7 days, and was culled.  At post mortum, it 
was clear that there was ureteric obstruction of the transplanted kidney, due to dense 
inflammatory adhesions in the surgical field.  
• 1 animal developed a thrombus in the renal vein at kidney reperfusion.  This was not 
technically salvageable without subjecting the animal to >120 minutes warm ischemia 
and so the animal was culled.  
• 1 animal bled from an unligated branch of the renal artery at kidney reperfusion.  
This was not amenable to surgical fixation without subjecting the animal to >120 
minutes of warm ischemia.  The animal was culled.  
• 2 animals were found dead in their cages the following morning, for reasons that 
were not apparent at post mortem. 
 
Following this, 11 further animals were successfully transplanted and survived to 14 
days and were apparently healthy.  
 
8.43 GROUP WEIGHT LOSS COMPARED TO BASELINE WEIGHT 
Animals in both groups lost significant body weight until 10 days post surgery, but 
had recovered body weight by Day 14.  (See Figure 8.6) 
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Fig 8.6: Compared to baseline, animals with both saline and MV-treated kidney transplants exhibited 
significant weight loss on Day 2 (p <0.0001 in both groups).  There remained significant weight loss 
for both groups on Day 4 (p <0.0001 in both groups), Day 7 (p=0.001 and < 0.0001 respectively) and 
day 10 (p=0.0075and 0.001 respectively).  By day 12, the body weight of animals with saline treated 
transplants had returned to baseline (p=0.1213), whilst animals with MV-treated transplants remained 
below their baseline weight (p=0.0443).  By day 14, animals in all groups had put on a mean average of 
4% body weight in comparison to baseline (p =0.0041 and 0.0191 respectively).  
Statistical analysis by unpaired Students t test.  
 
8.44 COMPARISION OF PERCENTAGE WEIGHT LOSS FROM BASELINE 
BETWEEN GROUPS 
There was no significant difference in weight loss from baseline between groups at 
day 2 (p= 0.0876), Day 4 (p=0.2704), Day 7 (p= 0.5494), Day 10 (p=0.9602), Day 12 
(p=0.9442) or Day 14 (p=0.5397).  (See Figure 8.6) 
Statistical analysis by unpaired Students t test.  
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8.45 GLOMERULAR FILTRATION RATE 
There was no significant difference in GFR between transplants treated with saline 
and those treated with PF-MVs. (see Figure 8.7) 
 
 
 
Figure 8.7: Transplant function in saline treated animals was not significantly different to those in 
animals with transplants treated with PF-MVs.  (p = 0.1724)  
Statistical analysis by unpaired Student's t-test. 
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8.46 RENAL HISTOLOGY SCORING 
Epithelial Breaks 
Transplanted kidneys treated with PF-MVs exhibited significantly fewer epithelial 
breaks than transplants treated with saline alone.  (See Figure 8.8) 
 
 
 Figure 8.8: (a) Renal histology shows that transplants treated with PF-MVs exhibit significantly fewer 
epithelial breaks than transplants treated with saline vehicle alone (p=0.0076).  
Statistical analysis by unpaired Student's t-test. 
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Hyaline Cast Formation 
Transplanted kidneys treated with PF-MVs had significantly fewer hyaline casts when 
compared to transplanted kidneys treated with saline alone. (see Figure 8.9) 
 
 
Figure 8.9: Fewer hyaline casts are observed in transplanted kidneys treated with PF-MVs than 
transplanted kidneys treated with saline alone (p= 0.0079). 
Statistical analysis by unpaired Student's t-test. 
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8.5 DISCUSSION 
Although recent improvements in tissue typing and immunosuppression regimes have 
significantly reduced the incidence of post-transplant acute rejection, long-term graft 
survival rates have remained unchanged (Saat et al., 2016).  This probably reflects the 
fact that ECD and DCD renal allografts are increasingly being transplanted into older 
patients, and that ‘marginal’ organs are at increased risk of damage during the 
transplantation process (Ali and Sheerin, 2013).   
 
The common pathology predominantly responsible for long-term allograft loss is 
chronic allograft nephropathy (CAN).  CAN is a multifactorial process that results 
from a combination of injurious processes that begin during the peri-transplant period 
and ultimately lead to late transplant dysfunction and allograft loss (Marcen et al., 
2009, Heemann and Lutz, 2013).  Insults including cold and warm ischemia, 
reperfusion injury, low-grade antibody-mediated rejection together with calcineurin 
toxicity result in severe interstitial fibrosis and tubular atrophy (Marcen, 2009, Grinyo 
et al., 2010).  Evidence suggests that CAN is related to chronic immunological insults, 
but also to uncontrollable factors at the time of transplantation including poor 
allograft quality and IRI that enhances allograft immunogenicity (Timsit et al., 2010).  
 
Unsurprisingly, the complex biological processes that combine to produce acute 
transplant injury are difficult to simulate properly using current rodent models of 
renal transplantation.  Most rodent models of renal transplantation focus upon a single 
pathological process – usually immunological rejection as a result of allogeneic 
transplantation, or a combination of cold and warm ischemia.  In this experiment, it 
was decided to investigate the effects of ECV therapy against prolonged cold and 
warm IRI, as this is reported to be the major insult encountered by ‘marginal’ renal 
allografts.  Allografts were deliberately transplanted between syngeneic rats to 
exclude acute rejection as a confounding factor.  This allowed focused evaluation 
upon the effects of cold storage, warm ischemia and reperfusion injury on allograft 
function and histology, and the ability of ECV therapy to mitigate this.  However, in 
future it would be relatively straightforward to introduce immunological rejection into 
the experiment by transplanting Fischer kidneys into the Lewis rat strain, which is a 
well-recognized rodent model of CAN (White et al., 1969, Shrestha and Haylor, 
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2014).  This would allow the investigation of the effects of stem cell-based therapies 
against prolonged cold and warm ischemia, immunological rejection and 
subsequently against CAN.  In addition, when performing such experiments, it would 
be possible to treated transplanted animals with calcineurin inhibitors, thereby 
investigating the effects of stem cell therapies in a more exact imitation of the clinical 
transplantation process. 
 
The immunomodulatory and anti-inflammatory properties of MSCs have led 
investigators to study their use in animal transplant models, with the aim of reducing 
peri-transplant injury and hopefully lessen the need for long-term immunosuppressive 
medication.  However, cell-free therapy confers some theoretical benefits over 
cellular treatments, and efficacy of cell-free treatment has been demonstrated in some 
different rodent renal IRI models. 
While there are several reports describing the use of cell-based therapies in rodent 
transplant models, there appear to be no studies where an animal renal transplant 
model has been treated with ECV therapy in an attempt to protect allograft function 
against IRI.  Indeed there is only one published study where ECV therapy has been 
given to a rodent kidney transplant model, in an attempt to reduce chronic allograft 
nephropathy (Koch et al., 2015). 
 
The microsurgical challenge of anastomosing the vessels and ureters in rat kidney 
transplantation is known to introduce additional experimental variability when 
compared to results obtained with simple rat renal IRI models (Schumacher et al., 
2003, Pahlavan et al., 2006, Spanjol et al., 2011).  However, transplantation is deemed 
necessary to introduce a period of experimental cold ischemia +/- immunological 
incompatibility, in order to mimic the clinical process of deceased donor renal 
transplantation.  The paucity of studies examining ECV therapy in rodent transplant 
models may highlight a lack of investigator enthusiasm due to the technical 
complexity involved in the procedure itself.  However, it is also possible the lack of 
published data for ECV therapy in this area reflects a lack of therapeutic efficacy that 
is not in the public domain due to publication bias.   
 
The model described here exposed the transplanted kidneys to 120 minutes of cold 
ischemia and 120 minutes of warm ischemia.  This is considered a prolonged 
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ischemic period (Schumacher et al., 2003) and produced a severe, long-standing renal 
injury compared to the split renal function of age and sex matched Fischer rats. 
Initially, ‘pilot’ transplants were performed  (n=2), utilising 120 minutes of cold and 
90 minutes of warm ischemia, but results indicated that transplant function was not 
reliably diminished after 14 days recovery.  The warm ischemia period was therefore 
extended to 120 minutes and a significant decline in transplant function observed.  
 
Increased periods of ischemia during rodent transplantation are reported to cause 
greater variation in renal morphology and function (Pahlavan et al., 2006, 
Schumacher et al., 2003).  Despite this, the variability in GFR and histology results 
obtained here from saline-treated rats subjected to 240 minutes of total ischemia was 
acceptable (mean GFR =0.04815, SD = 0.0394, 95% Confidence Interval = 0.01568 
– 0.08062).  Interestingly, greater variability was observed in the GFR of PF-MV 
treated animals for reasons that are unclear (mean GFR =0.07653, SD =0.03578, 95% 
Confidence Interval =0.03898 – 0.1141).  This may have been the result of 
unrecognised technical complications (e.g. renal artery or ureteric stenosis) or natural 
variability reflecting the prolonged ischemia and the ability of PF-MVs to ameliorate 
this.  Increasing the numbers of animals in both control and experimental groups 
would be a natural next investigative step, as the data indicates the experiment may be 
numerically underpowered to show a significant difference in transplant GFR.  
 
Despite this, PF-MV treated animals exhibited both fewer epithelial breaks and fewer 
hyaline casts when compared to saline treated controls.  This indicates that PF-MVs 
had a beneficial effect on renal morphology, but that this effect did not translate into 
improved GFR at 14 days post-transplant.  Clearly, it is possible that GFR between 
groups could differ significantly at other post-operative time points, although further 
experiments would be required to explore this possibility. 
 
An apparent flaw in this experiment is the lack of molecular data, which may have 
provided an insight into the mechanisms by which PF-MVs produce their effect upon 
renal morphology.  As there is an absence of data regarding the biological action of 
ECVs in transplant models, it is difficult to speculate in what, if any, additional ways 
ECVs may act to counter the cold ischemia and enhanced immunogenicity that result 
from allogeneic transplantation. 
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A single study has thus far reported the use of ECVs in an animal kidney transplant 
model.  Koch et al. harvested MSC-derived ECVs and administered them 
intravenously to an allogeneic rat transplant model of acute rejection on the 1st post 
surgical day (Koch et al., 2015).  Renal IRI was only 30 minutes and no 
immunosuppression was given.  Leucocyte infiltration in treatment and control 
kidneys was significantly different, although this did not appear to affect renal 
function or the production of donor-specific antibodies.  The authors concluded that 
therapy with ECVs was safe but did not seem to confer any functional or histological 
benefit at mitigating acute cell-mediated rejection.  This was unsurprising given the 
fact that cell-mediated rejection is an immunological process that is unlikely to be 
completely nullified by the administration of a single dose of therapy, the efficacy and 
dosing of which had not been demonstrated by the investigators previously.  
Furthermore, timing and route of the dose used in this study were probably sub-
optimal.  As a consequence, it is difficult to draw any firm conclusions regarding the 
potential of ECV therapy in kidney transplantation based on the findings of this study.  
 
At the time of writing, there appear to be no other published reports investigating the 
use of ECV therapy in animal models of renal transplantation.  
Nevertheless, some previous studies have demonstrated the ability of MSCs to 
mitigate damage to renal function and structure in rodent transplant models.  The 
consensus is currently that stem cells act via paracrine mediators in the form of ECVs.  
Furthermore, ECV therapy appears to be equivalent in mechanism and efficacy to 
treatment with the parent stem cell type in a number of studies.  Therefore it is 
possible that if applied to a rodent kidney transplant model, via a common mechanism 
of action, ECVs may have a similar effect to the stem cell type from which they 
derive.  
 
Initially, it was planned to test both PF-MVs and ADRCs in the transplant model.  
However, difficulties in establishing both the technical aspects of the transplant 
procedure and the amount of ischemia required to produce a long-standing insult 
meant that this was not possible.  It is unfortunate that these time constraints did not 
allow the testing of a therapeutic dose (7 x 105) of ADRCs in this rat transplant 
model. 
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Nevertheless, multiple previous studies have shown MSCs to mitigate warm renal IRI 
via anti-inflammatory and anti-oxidative mechanisms (Chen et al., 2011, Feng et al., 
2010b, Sheashaa et al., 2016, Shih et al., 2013, Villanueva et al., 2013).  Furthermore, 
studies in rodent transplant models have shown MSCs to reduce acute cell-mediated 
rejection, mitigate IRI and probably as a long-term consequence of these effects, 
reduce CAN.  Unfortunately, there is a relative shortage of published work exploring 
the effects of ECV therapy in animal kidney transplant models, although the reasons 
for this are unclear.  Increasing the animal numbers in the current experiment and 
furthermore introducing an ADRC treatment group while obtaining molecular data 
from stored tissue samples are obvious next steps that may allow conclusions 
regarding the potential of PF-MVs and ADRCs in this model of renal transplant 
ischemia.  If proved effective, testing these novel therapies in rodent transplant 
models of CAN subjected to similar periods of ischemia may clarify their utility prior 
to testing in porcine models of renal transplantation.  
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CHAPTER 9 
 
GENERAL DISCUSSION 
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9.1 INTRODUCTION 
The experiments presented in this thesis highlight the potential of stem cells and their 
ECVs to reduce the peri-transplantation injury that renal allografts suffer as a result of 
IRI.  Given the increasing use of marginal allografts, which are more prone to IRI, 
such therapies are urgently needed as a reduction in the initial injury may theoretically 
improve allograft function in the long-term.  
 
This is important, as long-term transplant outcomes with marginal kidneys are less 
than satisfactory, although transplantation with such allografts has been shown to be 
preferable to remaining on dialysis.  Nevertheless, renal allografts exhibit a long-term 
decline in function associated with chronic fibrosis that occurs as a result of persisting 
alloreactivity and calcineurin-inhibitor related toxicity.  Strategies to reduce initial 
injury may limit allograft immunogenicity and subsequent calcineurin requirements, 
preserve the number of functioning nephrons and ultimately encourage renal 
regeneration.  
 
Since work on this thesis began, researchers have conducted pilot studies examining 
the safety and feasibility of MSC use for the prevention of peri-transplantation injury.  
No studies reporting the use of ECVs in renal disease have been reported in human 
subjects at the time of writing,  although the use of ECVs to treat graft versus host 
disease has been described (Kordelas et al., 2014).  Perico et al. (Perico et al., 2011) 
were the first to report the use of MSCs in patients undergoing renal transplantation, 
concluding that infusion of autologous MSCs 7 days post-transplant did not improve 
outcomes after one year compared to conventional therapy.  Reinders et al. (Reinders 
et al., 2013) reported that treatment with autologous BD-MSCs in response to acute 
rejection on protocol biopsy was safe, noting reductions in acute rejection and 
interstitial fibrosis 24 weeks post-treatment.  While no conclusions were drawn 
regarding the efficacy of MSC therapy, the treatment appeared safe, and the findings 
were suggestive of systematic immunosuppression (Reinders et al., 2013).  Peng et al. 
(Peng et al., 2013) reported that intra-renal artery infusion of MSCs at the time of 
surgery approximately allowed a 50% reduction in tacrolimus therapy one year after 
transplantation.  
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Unfortunately, while these studies have been suggestive of benefit associated with 
MSC treatment, the small numbers of patients recruited make it difficult to draw firm 
conclusions (Bank et al., 2015).  However, these pilot studies have been conducted 
predominantly using allografts that come from living donors, and the results from 
such allografts are known to be excellent.  This is probably because live donor 
allografts are subjected to a minimal cold and warm ischemic times, and hence peri-
transplantation injury and subsequent enhanced allograft immunogenicity are kept to 
a minimum.  Theoretically, the impact of stem cell-based therapy in this situation is 
likely to be negligible, compared to the application of novel therapies in marginal 
allograft transplantation.  Furthermore, clarification regarding the optimal route of 
administration, numbers of cells per dose and timing of treatment in relation to 
surgery is required to produce the maximum beneficial effect.   
 
The clinical translation of stem cell-based therapies ultimately requires the safety and 
efficacy of treatment to be demonstrated in large animal models of transplantation 
prior to the implementation of widespread clinical trials.  This chapter discusses how 
the progression to large animal work might best be achieved, highlighting 
improvements to the rodent experiments described here and postulating how future 
work might provide information that allows large animal work to be conducted in an 
efficient fashion.   
 
 
9.2 IMPROVEMENTS TO THE RAT MODEL OF RENAL 
ISCHEMIA-REPERFUSION INJURY  
As previously discussed, the rat model described in Chapter 5 addresses some of the 
disadvantages that are associated with conventional rodent models of renal ischemia.  
Nevertheless, there are negative aspects of the novel rat model that principally 
concern the characterization of GFR in terminal studies. 
 
Continuous infusion of an exogenous tracer is regarded as being the most accurate 
method of determining GFR (Huang et al., 2016, Miller et al., 1952).  In U-IRI-N 
models, such as the novel model developed here, individual ureteric cannulation is 
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utilised to allow the individual GFR of each kidney to be characterised.  However, the 
size of rodents makes this technique both time-consuming and technically difficult.   
 
In addition, hypovolemia as a result of insidious bleeding may occur during GFR 
studies using the method described.  Any occult blood loss observed during these 
experiments was universally intra-abdominal, originating from either the incised 
abdominal musculature or from tiny retroperitoneal vessels divided during ureteric 
dissection.  During the dissection necessary to allow the insertion of the ureteric 
cannulas, meticulous hemostasis was routinely performed in an attempt to prevent 
unnecessary blood loss.  Unfortunately, any bleeding after ureteric cannulation was 
not immediately apparent as the intestines were returned to the abdomen post-
cannulation to help maintain the steady core body temperature that is necessary to 
achieve consistent GFR results (Le Clef et al., 2016, Wei and Dong, 2012).  The 
abdomen was also loosely packed with swabs to help prevent unnecessary heat loss.  
Routine inspection of the abdomen was not undertaken after GFR studies begun as 
this risked dislodging the position of the cannulas.  Any bleeding was therefore not 
apparent until the rat’s circulating volume had been reduced sufficiently to reduce 
urine output and thereby artificially producing lower GFR results.  During this thesis, 
four animals were terminated prior to the conclusion of GFR studies, when it became 
apparent that occult intra-abdominal blood loss during the inulin clearance study had 
resulted in reduced urine output and inaccurate GFR results.  These animals were 
excluded from experimental groups, which necessitated the use of an additional 
animal in a repeated procedure.  
 
A second problem with the use of terminal inulin clearance studies is that only a 
single GFR value can be obtained from each animal (Ellery et al., 2015).  Clearly, in 
order to gain GFR values at different times points post surgery, larger numbers of 
animals would be required that if multiple GFR results could be obtained from each 
animal at various time points without sacrificing it. 
 
Therefore, the benefit of ureteric cannulation, namely the characterization of split 
renal function in a U-IRI-N model, needs to be balanced against both the 
inconvenience of excluding animals after technical complications during GFR studies 
and the requirement for large numbers of animals to provide insight into renal 
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function over a prolonged period of time.  The fundamental principles of animal 
research specify that investigators actively seek to reduce the total numbers of 
animals utilised in their experiments, while refining techniques in order to obtain 
more accurate information (2011a).  In keeping with this philosophy, the emergence 
of the 2-compartmental models of inulin clearance have led to the publication of 
methods whereby GFR in conscious rodents can be characterised.  Practically, such 
models are desirable in that repeated GFR measures may be obtained from each 
individual animal at different time points, as the GFR procedure does not necessitate 
the animal to be culled.  Furthermore, the use of conscious animals is beneficial as 
anaesthesia is reported to lower GFR and may be avoided using these techniques (Qi 
et al., 2004, Fusellier et al., 2007).   
 
The fundamental concept upon which all 2-compartmental models rely is the decay of 
exogenous tracer from the plasma and extracellular space following the 
administration of a single intravenous bolus.  The measurement of decay necessitates 
obtaining either a single timed blood sample (Katayama et al., 2010, Katayama et al., 
2011) or multiple, timed blood samples (Sturgeon et al., 1998, Qi et al., 2004).  The 
use of fluorescent or radioactive tracer facilitates the measurement of tracer decay, 
allowing the elimination of tracer by the renal tract to be calculated.   
 
However, 2 compartmental models rely upon mathematical modelling to calculate 
both the initial, rapid redistribution of exogenous tracer from the circulation to the 
extracellular fluid and the subsequent slower elimination of tracer by the renal tract.  
Unfortunately, these less invasive methods of measuring GFR are considered 
inaccurate when compared to the more invasive constant infusion techniques utilised 
in this thesis (Sharmarlouski A, 2014).  However, conventional constant infusion 
techniques make repeated GFR measurements from a single animal impractical. 
 
Happily, a recent report described the continuous monitoring of GFR, by measuring 
the transcutaneous fluorescent decay of FITC – sinistrin in conscious animals 
(Schock-Kusch et al., 2011).  Sinistrin is an inert renal reporter molecule that, like 
inulin, is considered ideal for measurement of GFR.  Recent improvements to this 
method have been reported to give GFR values as accurate as those obtained with 
continuous inulin infusion (Friedemann et al., 2016).  The significant advantage of 
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this method is that there is no requirement for a rodent to be anaesthetized, nor are 
repeated blood samples required.  This allows multiple GFR values to be obtained 
from each animal, enabling the progression of renal function over a long experimental 
time course to be tracked.   
 
However, such transcutaneous monitoring does not measure split renal function, 
which is a necessity in the U-IRI-N model where the GFR of the damaged kidney and 
the response to therapy is of interest.  
 
To make improvements to the novel model described here, this difficulty may be 
overcome in two different ways.  Firstly, it may be possible to safely perform a right-
sided nephrectomy a few days after the initial IRI experiment, as the GFR data 2 
weeks post procedure suggests the function of the left kidney is enough to prevent 
death from uremia.  Surviving animals could have their renal function measured via 
transcutaneous as recently described (Friedemann et al., 2016).  Should mortality 
rates after right-sided nephrectomy prove unacceptably high, it may prove necessary 
to reduce the initial period of left-sided ischemia although the permanent effects on 
renal function as a result of this would need to be clarified.  
 
A second option to measure split GFR, without the requirement for nephrectomy, is to 
use a form of imaging, after the administration of a bolus of contrast medium or 
exogenous tracer.  Recent advances in magnetic resonance imaging (MRI) have 
allowed both renal blood flow and GFR to be measured (Zeng et al., 2015). However, 
such a modality is expensive and consequently may not be practical during ‘screening' 
rodent research.  Ratio-metric determination of GFR by two-photon microscopy has 
been described (Wang et al., 2010).  This technique is minimally invasive and allows 
split renal function to be characterised.  Either of these methods could be employed to 
measure GFR repeatedly in the same animal should right-sided nephrectomy not 
prove feasible.  However, as both imaging modalities require the animal to be 
anaesthetized, transcutaneous measurement of GFR post nephrectomy would be 
preferable.  
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9.3 ORGAN RECRUITMENT OF STEM CELLS AND ECVs POST 
ADMINISTRATION 
In this thesis, no experiments were conducted to investigate the sites to which stem 
cells or ECVs were recruited after infusion directly into the renal artery.  However, 
previous studies using BD-MSCs (Cai et al., 2014) and ADRCs (Iwai et al., 2014) 
administered via the renal artery have shown the vast majority of cells are recruited 
by the kidney and furthermore persist in this location for the next 24 hours.  It 
therefore seems likely that cells administered in the novel rodent model would be 
recruited into the kidney.  This contrasts the findings with cells administered 
intravenously, which were found to localise in the lungs for at least three days (Iwai et 
al., 2014).  
 
At the time of writing, there appear to be no studies that differentially track the fate of 
ECVs in animal models, either given systemically or administered in a local fashion.  
In part, this probably reflects the difficulties in labelling and tracking harvested 
ECVs, and furthermore the difficulty distinguishing between  ‘biologically active' 
ECVs which have become internalised in a cell, or are merely adherent to a cell 
surface (Feng et al., 2010a).  
 
An in-depth discussion as to how this might be achieved is beyond the scope of this 
thesis.  However, in broad terms, the bioluminescent labelling of ECVs has been 
described, using reporters such as firefly luciferase (Sharkey et al., 2016) or  Gaussia 
luciferase (Lai et al., 2015).  This becomes fused to cell membrane domains, and 
consequently is incorporated into ECV membranes during production.  This method 
may be used to track ECV fate in vivo (Lai et al., 2015). 
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9.4 FUTURE EXPERIMENTS WITH ADRC ECVs 
 
A body of convincing evidence has led to the recognition that the beneficial action of 
stem cell therapy in response to renal injury is mediated by ECVs in a paracrine 
fashion (Bi et al., 2007, Bruno et al., 2009b, Bruno and Bussolati, 2013, Gatti et al., 
2011, Zou et al., 2014, Cantaluppi et al., 2012).  One of the constant themes 
throughout this thesis has been that the therapeutic use of stem cells themselves 
should be considered to carry more risk than therapy with ECVs – not least because 
administered cells have the potential for malignant transformation and supra-
therapeutic doses may lead to tissue capillary occlusion.  The use of ECVs has not 
been associated with these problems, and significantly ECV application has been 
shown to have similar efficacy as the use of stem cells themselves (Bruno et al., 
2009b).  
 
Unfortunately, time constraints prevented the isolation of ECVs from the ADRCs in 
this thesis.  However, obtaining a preparation of ECVs from ADRCs using 
centrifugation and examining the effects in the novel rodent model would be an 
interesting next set of experiments.  If the efficacy of this preparation could be 
established, it would be interesting to separate the ECV preparation into its three 
fractions using differential ultracentrifugation protocols previously described 
(McGuinness et al., 2016).  The size of vesicles in each fraction could then be 
determined using either Nanosight analysis (Cantaluppi et al., 2012) and/or 
Nanoparticle tracking analysis (Gardiner et al., 2013) to ensure a ‘clean’ preparation.  
Testing each fraction in the novel model may then identify which of the ECV 
fractions contains the biologically active material that confers beneficial effects.   
 
It is unfortunate that time constraints prevented the completion of IHC and qPCR 
analysis that may have provided further insight into the cellular process by which 
ADRCs and PF-MVs produced their biological effects in severely injured kidneys.  
However, a number of previous studies have indicated that MSCs produce at least 
some of their effects by dampening the inflammatory response to injury (Feng et al., 
2010b, Chen et al., 2011, Shih et al., 2013, Furuichi et al., 2012, Wang et al., 2013b), 
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while PF-MVs are thought to produce their effects through separate pathways that 
encourage cellular regeneration (McGlynn et al., 2013, Stevenson et al., 2011).  
 
This suggests that Pathfinder cells and MSCs produce their effects via different 
biologically active factors.  Evidence suggests that in the case of Pathfinder cells, 
these are contained within microvesicles (McGuinness et al., 2016), while in MSCs 
the identity of the responsible ECV fraction(s) remains unclear. The characterization 
of ECVs from MSCs as described above would allow an investigation into the effects 
of a preparation containing the efficacious ECVs from both Pathfinder cells and 
MSCs. 
Given the likely different mechanism of action of these cell types, it may be that 
combining the active ECV fractions would produce a synergistic effect that resulted 
in initial injury reduction and subsequent regeneration of specialised cell types within 
the damaged kidney.  
 
The ultimate aim of these experiments is to identify any factors contained within 
ECVs that influence cellular processes in a beneficial way.  An in-depth discussion as 
to how this might be achieved is outside the scope of this thesis.  However, in board 
terms, the first step in the process would be to identify the ECV fraction(s) from 
specific cell types that mediate beneficial effects.  One study reported characterising 
the mRNA and miRNA content contained within porcine ADRCs, concluding that 
ECVs were enriched in miRNAs involved in angiogenic and anti-inflammatory 
pathways (Eirin et al., 2014).  However, the use of undifferentiated centrifugation 
resulted in the cargo of all ECV subtypes being reported, and not just the biologically 
active content.  This highlights the importance of investigating the efficacy of 
particular ECV fraction.  From a ‘clean’ preparation of efficacious vesicles, the 
biologically active cargo could be extracted using recognised protocols (Eldh et al., 
2012). Several papers have recently reported different molecular techniques allow the 
cargo of different ECV subtypes to be characterised (Crescitelli et al., 2013, Chevillet 
et al., 2014, Ji et al., 2014).  This may then enable the manufacture of a synthetic 
(cell-free) product for clinical application, the purity of which could be stringently 
tested. 
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9.5 EX VIVO NORMOTHERMIC REPERFUSION AND THE 
POTENTIAL IMPLICATIONS FOR CLINICAL TRANSLATION 
OF STEM CELL THERAPIES 
Several studies have identified the adverse effects of prolonged cold ischemia on 
renal allografts, with the risk of transplant failure at three months reported increasing 
with each additional hour of cold ischemia (Debout et al., 2015).  Compared to 
‘standard criteria’ organs, ECD and DCD kidneys tolerate hypothermia poorly 
(Summers et al., 2013, Kayler et al., 2011), and display high rates of DGF after 
prolonged cold storage (Bilgin et al., 1998).  DGF is itself a poor prognostic indicator 
for long-term allograft outcomes, probably as enhanced allograft immunogenicity 
increases the likelihood of subsequent episodes of rejection (Gill et al., 2016, Wu et 
al., 2015).  
 
As a consequence of the change in donation trends towards marginal kidneys, 
clinicians have recognised the need to move away from the traditional ‘cold storage' 
approach.  Recent research has focused on the development of novel methods of 
organ preservation, with much interest in allograft ex vivo normothermic reperfusion.  
In the context of this thesis, this is important, as this evolving technology may provide 
the opportunity to better investigate stem cell-based therapies and implement them in 
a safer fashion.   
 
Ex vivo normothermic reperfusion of allografts involves the continuous re-circulation 
of a blood-based solution through an extracorporeal organ at body temperature before 
transplantation.  The removal of toxic metabolites and restoration of aerobic 
respiration is thought to ‘resuscitate' organs subjected to periods of warm and cold 
ischemia during retrieval and transportation.  These techniques have gradually been 
adopted in clinical transplantation for other solid organs including the heart (Ardehali 
et al., 2015), lung (Cypel et al., 2011) and liver (Brockmann et al., 2009, Ravikumar 
et al., 2016).  There is growing recognition that normothermic preservation has 
advantages for renal allografts (Hosgood et al., 2015, Kaths et al., 2016b).  The 
perfusion of allografts ex vivo has necessitated the development of isolated perfusion 
systems, which have been adapted from paediatric cardiopulmonary bypass circuits 
(Bagul et al., 2008).  Additionally, leucocyte depleted blood-based perfusion solutions 
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have been developed, which compared to whole blood, reduce the inflammatory 
cascade that occurs during reperfusion, but still allow efficient transfer of oxygen 
(Hosgood and Nicholson, 2011, Harper et al., 2006).   
 
A recent study using porcine kidneys has shown that continuous normothermic 
reperfusion after organ retrieval is associated with superior function compared to 
normothermic reperfusion following a period of static cold storage (Kaths et al., 
2016a).  However, the transportation of organs during continuous reperfusion is likely 
to present dangerous logistical problems, especially as problems with organ perfusion 
in transport could lead to long periods of warm ischemia.  A more practical approach 
would probably involve a period of cold storage during transportation, followed by ex 
vivo normothermic reperfusion just before allograft implantation.  This approach 
theoretically has several advantages as cold storage time is minimised and the 
perfused renal allograft may be macroscopically inspected and its suitability for 
transplantation assessed (Hosgood et al., 2015).  Furthermore, the resistance to renal 
blood flow may be measured, and the restoration of normothermia allows aerobic 
respiration to commence, facilitating the removal of toxins produced under anaerobic 
conditions. 
Recent studies have now demonstrated the benefits of this novel approach in kidney 
transplantation, with the initial clinical pilot study observing a DGF rate of 6% in 
treated ECD allografts, compared to 36% with kidneys treated with traditional static 
cold storage (Nicholson and Hosgood, 2013).  
 
While further discussion regarding the benefits of normothermic kidney perfusion is 
outside the scope of this thesis, it is important to highlight that future efforts to 
improve marginal allograft outcomes are likely to involve this novel technique.  
Happily, the rise of ex vivo normothermic reperfusion creates unique opportunities for 
the development of concomitant strategies to incorporate novel stem cell-based 
treatments into clinical practice.   
 
Firstly, ex vivo perfusion circuits seems to present the ideal opportunity to administer 
intra-renal artery therapy without the potential negative effects of systemic 
distribution.  Novel treatment could easily be administered during allograft 
reperfusion, as the renal artery is readily available.  Such intervention would need to 
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be optimised before use in the clinical setting, however, and experiments using 
discarded porcine kidneys could be conducted to investigate the feasibility of such an 
approach.  This could clarify the optimal dose of stem cell therapy and avoid 
supratherapeutic dosing that could cause blockage of the renal microcirculation.  
Theoretically, it would also be possible to subject porcine kidneys to a prolonged 
period of warm ischemia and, using ex vivo perfusion circuits, to examine the 
response to stem cell-based therapies over 24 hours by measuring GFR via constant 
inulin infusion.  These initial screening experiments could provide useful initial 
information regarding dosing protocols before trialling the efficacy of novel therapies 
in porcine models of kidney transplantation.  Recent work by Kaths et al. has 
described a porcine model in which kidneys are auto transplanted after being 
subjected to 8 hours of static cold storage and a short period of warm ischemia during 
re-implantation (Kaths et al., 2016b, Kaths et al., 2016c).  At day 10, animals 
receiving these kidneys were shown to have elevated serum creatinine and worse 
creatinine clearance versus controls, implying a degree of damage as a result of the 
storage and surgical processes.  This model could be used to study the effect of stem 
cell therapy, administered while the kidney was undergoing ex vivo normothermic 
reperfusion.  However, in order to severely damage the kidney and mimic the use of 
‘marginal’ allografts, it may prove necessary to subject the graft to longer periods of 
warm ischemia than were applied in these studies.  
 
With regard to ex vivo normothermic reperfusion and the parallel use of stem cell-
based therapies, there is one final, important point.  Endothelial membrane stiffening 
in response to rapid reperfusion by whole blood, as occurs in standard clinical 
practice during allograft reperfusion, prevents rapid clearance of the renal 
microcirculation.  This ‘no-reflow’ phenomenon may prevent the adequate 
distribution of any novel cells, administered with therapeutic intent.  However, the 
‘no-flow’ phenomenon is ameliorated by a period of normothermic reperfusion with 
leucocyte depleted blood-based perfusion fluids (Kay et al., 2011).  Therefore, the 
administration of cellular therapy to marginal kidney grafts after a period of 
normothermic reperfusion is thought to be superior to administration immediately 
after hypothermia (Iwai et al., 2014).  It may well be that ex vivo normothermic 
reperfusion enhances the effects of cellular treatments by allowing better penetration 
of therapeutic agents into the allograft. 
	 243	
BIBLIOGRAPHY 
 2010.	SRTR.OPTN	&	SRTR	Annual	Data	report	Am	J	Transplant,	12	(suppl	1):9.	2011a.	Instituate	for	Laboratory	Animal	Research.	Guide	for	the	Care	and	Use	of	Laboratory	Animals.	.	The	National	Academies	Press,	Washington	DC.	.	2011b.	Institute	for	Laboratory	Animal	Research.	Guide	for	the	Care	and	Use	of	Laboratory	Animals.	The	National	Academies	Press,	Washington	DC.	ABBATE,	M.	&	REMUZZI,	G.	1996.	Acceleration	of	recovery	in	acute	renal	failure:	from	cellular	mechanisms	of	tubular	repair	to	innovative	targeted	therapies.	Ren	Fail,	18,	377-88.	ABREU,	S.	C.,	WEISS,	D.	J.	&	ROCCO,	P.	R.	2016.	Extracellular	vesicles	derived	from	mesenchymal	stromal	cells:	a	therapeutic	option	in	respiratory	diseases?	Stem	Cell	Res	Ther,	7,	53.	ADACHI,	T.,	SUGIYAMA,	N.,	GONDAI,	T.,	YAGITA,	H.	&	YOKOYAMA,	T.	2013.	Blockade	of	Death	Ligand	TRAIL	Inhibits	Renal	Ischemia	Reperfusion	Injury.	Acta	Histochem	Cytochem,	46,	161-70.	AGGARWAL,	S.	&	PITTENGER,	M.	F.	2005.	Human	mesenchymal	stem	cells	modulate	allogeneic	immune	cell	responses.	Blood,	105,	1815-22.	AHMADBEIGI,	N.,	SHAFIEE,	A.,	SEYEDJAFARI,	E.,	GHEISARI,	Y.,	VASSEI,	M.,	AMANPOUR,	S.,	AMINI,	S.,	BAGHERIZADEH,	I.	&	SOLEIMANI,	M.	2011.	Early	spontaneous	immortalization	and	loss	of	plasticity	of	rabbit	bone	marrow	mesenchymal	stem	cells.	Cell	Prolif,	44,	67-74.	AKCAY,	A.,	NGUYEN,	Q.	&	EDELSTEIN,	C.	L.	2009.	Mediators	of	inflammation	in	acute	kidney	injury.	Mediators	Inflamm,	2009,	137072.	AKERS,	J.	C.,	GONDA,	D.,	KIM,	R.,	CARTER,	B.	S.	&	CHEN,	C.	C.	2013.	Biogenesis	of	extracellular	vesicles	(EV):	exosomes,	microvesicles,	retrovirus-like	vesicles,	and	apoptotic	bodies.	J	Neurooncol,	113,	1-11.	ALI,	S.	&	SHEERIN,	N.	S.	2013.	Biomarkers	of	acute	injury:	predicting	the	long-term	outcome	after	transplantation.	Kidney	Int,	84,	1072-4.	ALLAM,	R.,	SCHERBAUM,	C.	R.,	DARISIPUDI,	M.	N.,	MULAY,	S.	R.,	HAGELE,	H.,	LICHTNEKERT,	J.,	HAGEMANN,	J.	H.,	RUPANAGUDI,	K.	V.,	RYU,	M.,	SCHWARZENBERGER,	C.,	HOHENSTEIN,	B.,	HUGO,	C.,	UHL,	B.,	REICHEL,	C.	A.,	KROMBACH,	F.,	MONESTIER,	M.,	LIAPIS,	H.,	MORETH,	K.,	SCHAEFER,	L.	&	ANDERS,	H.	J.	2012.	Histones	from	dying	renal	cells	aggravate	kidney	injury	via	TLR2	and	TLR4.	J	Am	Soc	Nephrol,	23,	1375-88.	ANJOS-AFONSO,	F.,	SIAPATI,	E.	K.	&	BONNET,	D.	2004.	In	vivo	contribution	of	murine	mesenchymal	stem	cells	into	multiple	cell-types	under	minimal	damage	conditions.	J	Cell	Sci,	117,	5655-64.	ANTHONY,	D.	F.	&	SHIELS,	P.	G.	2013.	Exploiting	paracrine	mechanisms	of	tissue	regeneration	to	repair	damaged	organs.	Transplant	Res,	2,	10.	APPEL,	D.,	KERSHAW,	D.	B.,	SMEETS,	B.,	YUAN,	G.,	FUSS,	A.,	FRYE,	B.,	ELGER,	M.,	KRIZ,	W.,	FLOEGE,	J.	&	MOELLER,	M.	J.	2009.	Recruitment	of	podocytes	from	glomerular	parietal	epithelial	cells.	J	Am	Soc	Nephrol,	20,	333-43.	ARDEHALI,	A.,	ESMAILIAN,	F.,	DENG,	M.,	SOLTESZ,	E.,	HSICH,	E.,	NAKA,	Y.,	MANCINI,	D.,	CAMACHO,	M.,	ZUCKER,	M.,	LEPRINCE,	P.,	PADERA,	R.,	KOBASHIGAWA,	J.	&	INVESTIGATORS,	P.	I.	T.	2015.	Ex-vivo	perfusion	of	donor	hearts	for	human	heart	transplantation	(PROCEED	II):	a	prospective,	open-label,	multicentre,	randomised	non-inferiority	trial.	
Lancet,	385,	2577-84.	
	 244	
ARSLAN,	F.,	LAI,	R.	C.,	SMEETS,	M.	B.,	AKEROYD,	L.,	CHOO,	A.,	AGUOR,	E.	N.,	TIMMERS,	L.,	VAN	RIJEN,	H.	V.,	DOEVENDANS,	P.	A.,	PASTERKAMP,	G.,	LIM,	S.	K.	&	DE	KLEIJN,	D.	P.	2013.	Mesenchymal	stem	cell-derived	exosomes	increase	ATP	levels,	decrease	oxidative	stress	and	activate	PI3K/Akt	pathway	to	enhance	myocardial	viability	and	prevent	adverse	remodeling	after	myocardial	ischemia/reperfusion	injury.	Stem	Cell	Res,	10,	301-12.	ASANUMA,	H.,	MELDRUM,	D.	R.	&	MELDRUM,	K.	K.	2010.	Therapeutic	applications	of	mesenchymal	stem	cells	to	repair	kidney	injury.	J	Urol,	184,	26-33.	ASCON,	M.,	ASCON,	D.	B.,	LIU,	M.,	CHEADLE,	C.,	SARKAR,	C.,	RACUSEN,	L.,	HASSOUN,	H.	T.	&	RABB,	H.	2009.	Renal	ischemia-reperfusion	leads	to	long	term	infiltration	of	activated	and	effector-memory	T	lymphocytes.	
Kidney	Int,	75,	526-35.	ASHWORTH,	S.	L.	&	MOLITORIS,	B.	A.	1999.	Pathophysiology	and	functional	significance	of	apical	membrane	disruption	during	ischemia.	Curr	Opin	
Nephrol	Hypertens,	8,	449-58.	AUGELLO,	A.,	KURTH,	T.	B.	&	DE	BARI,	C.	2010.	Mesenchymal	stem	cells:	a	perspective	from	in	vitro	cultures	to	in	vivo	migration	and	niches.	Eur	Cell	
Mater,	20,	121-33.	AWAD,	H.,	ANKENY,	D.	P.,	GUAN,	Z.,	WEI,	P.,	MCTIGUE,	D.	M.	&	POPOVICH,	P.	G.	2010.	A	mouse	model	of	ischemic	spinal	cord	injury	with	delayed	paralysis	caused	by	aortic	cross-clamping.	Anesthesiology,	113,	880-91.	BAGUL,	A.,	FROST,	J.	H.	&	DRAGE,	M.	2013.	Stem	cells	and	their	role	in	renal	ischaemia	reperfusion	injury.	Am	J	Nephrol,	37,	16-29.	BAGUL,	A.,	HOSGOOD,	S.	A.,	KAUSHIK,	M.,	KAY,	M.	D.,	WALLER,	H.	L.	&	NICHOLSON,	M.	L.	2008.	Experimental	renal	preservation	by	normothermic	resuscitation	perfusion	with	autologous	blood.	Br	J	Surg,	95,	111-8.	BAKER,	D.	E.,	HARRISON,	N.	J.,	MALTBY,	E.,	SMITH,	K.,	MOORE,	H.	D.,	SHAW,	P.	J.,	HEATH,	P.	R.,	HOLDEN,	H.	&	ANDREWS,	P.	W.	2007.	Adaptation	to	culture	of	human	embryonic	stem	cells	and	oncogenesis	in	vivo.	Nat	Biotechnol,	25,	207-15.	BANAS,	A.,	TERATANI,	T.,	YAMAMOTO,	Y.,	TOKUHARA,	M.,	TAKESHITA,	F.,	OSAKI,	M.,	KAWAMATA,	M.,	KATO,	T.,	OKOCHI,	H.	&	OCHIYA,	T.	2008.	IFATS	collection:	in	vivo	therapeutic	potential	of	human	adipose	tissue	mesenchymal	stem	cells	after	transplantation	into	mice	with	liver	injury.	
Stem	Cells,	26,	2705-12.	BANK,	J.	R.,	RABELINK,	T.	J.,	DE	FIJTER,	J.	W.	&	REINDERS,	M.	E.	2015.	Safety	and	Efficacy	Endpoints	for	Mesenchymal	Stromal	Cell	Therapy	in	Renal	Transplant	Recipients.	J	Immunol	Res,	2015,	391797.	BARBASH,	I.	M.,	CHOURAQUI,	P.,	BARON,	J.,	FEINBERG,	M.	S.,	ETZION,	S.,	TESSONE,	A.,	MILLER,	L.,	GUETTA,	E.,	ZIPORI,	D.,	KEDES,	L.	H.,	KLONER,	R.	A.	&	LEOR,	J.	2003.	Systemic	delivery	of	bone	marrow-derived	mesenchymal	stem	cells	to	the	infarcted	myocardium:	feasibility,	cell	migration,	and	body	distribution.	Circulation,	108,	863-8.	BARBER,	H.	E.	&	BOURNE,	G.	R.	1971.	Determination	of	the	renal	clearance	of	inulin	in	rats:	lowered	values	at	low	urine	flow	rates.	Br	J	Pharmacol,	43,	874-6.	
	 245	
BARRILLEAUX,	B.,	PHINNEY,	D.	G.,	PROCKOP,	D.	J.	&	O'CONNOR,	K.	C.	2006.	Review:	ex	vivo	engineering	of	living	tissues	with	adult	stem	cells.	Tissue	
Eng,	12,	3007-19.	BARTEL,	D.	P.	2004.	MicroRNAs:	genomics,	biogenesis,	mechanism,	and	function.	
Cell,	116,	281-97.	BARTMANN,	C.,	ROHDE,	E.,	SCHALLMOSER,	K.,	PURSTNER,	P.,	LANZER,	G.,	LINKESCH,	W.	&	STRUNK,	D.	2007.	Two	steps	to	functional	mesenchymal	stromal	cells	for	clinical	application.	Transfusion,	47,	1426-35.	BASILE,	D.	P.,	DONOHOE,	D.,	ROETHE,	K.	&	OSBORN,	J.	L.	2001.	Renal	ischemic	injury	results	in	permanent	damage	to	peritubular	capillaries	and	influences	long-term	function.	Am	J	Physiol	Renal	Physiol,	281,	F887-99.	BECKER,	A.	J.,	MC,	C.	E.	&	TILL,	J.	E.	1963.	Cytological	demonstration	of	the	clonal	nature	of	spleen	colonies	derived	from	transplanted	mouse	marrow	cells.	
Nature,	197,	452-4.	BECKER,	G.	J.	&	HEWITSON,	T.	D.	2013.	Animal	models	of	chronic	kidney	disease:	useful	but	not	perfect.	Nephrol	Dial	Transplant,	28,	2432-8.	BEDERSON,	J.	B.,	CONNOLLY,	E.	S.,	JR.,	BATJER,	H.	H.,	DACEY,	R.	G.,	DION,	J.	E.,	DIRINGER,	M.	N.,	DULDNER,	J.	E.,	JR.,	HARBAUGH,	R.	E.,	PATEL,	A.	B.,	ROSENWASSER,	R.	H.	&	AMERICAN	HEART,	A.	2009.	Guidelines	for	the	management	of	aneurysmal	subarachnoid	hemorrhage:	a	statement	for	healthcare	professionals	from	a	special	writing	group	of	the	Stroke	Council,	American	Heart	Association.	Stroke,	40,	994-1025.	BELLOMO,	R.,	FARMER,	M.	&	BOYCE,	N.	1995.	A	prospective	study	of	continuous	venovenous	hemodiafiltration	in	critically	ill	patients	with	acute	renal	failure.	J	Intensive	Care	Med,	10,	187-92.	BERNARDO,	M.	E.,	ZAFFARONI,	N.,	NOVARA,	F.,	COMETA,	A.	M.,	AVANZINI,	M.	A.,	MORETTA,	A.,	MONTAGNA,	D.,	MACCARIO,	R.,	VILLA,	R.,	DAIDONE,	M.	G.,	ZUFFARDI,	O.	&	LOCATELLI,	F.	2007.	Human	bone	marrow	derived	mesenchymal	stem	cells	do	not	undergo	transformation	after	long-term	in	vitro	culture	and	do	not	exhibit	telomere	maintenance	mechanisms.	
Cancer	Res,	67,	9142-9.	BI,	B.,	SCHMITT,	R.,	ISRAILOVA,	M.,	NISHIO,	H.	&	CANTLEY,	L.	G.	2007.	Stromal	cells	protect	against	acute	tubular	injury	via	an	endocrine	effect.	J	Am	Soc	
Nephrol,	18,	2486-96.	BIAN,	S.,	ZHANG,	L.,	DUAN,	L.,	WANG,	X.,	MIN,	Y.	&	YU,	H.	2014.	Extracellular	vesicles	derived	from	human	bone	marrow	mesenchymal	stem	cells	promote	angiogenesis	in	a	rat	myocardial	infarction	model.	J	Mol	Med	
(Berl),	92,	387-97.	BIAN,	S.	Y.,	CUI,	H.,	ZHANG,	X.	N.,	QI,	L.	P.	&	LI,	D.	Y.	2012.	[Mesenchymal	stem	cells	release	membrane	microparticles	in	the	process	of	apoptosis].	
Zhongguo	Shi	Yan	Xue	Ye	Xue	Za	Zhi,	20,	453-7.	BIANCONE,	L.,	BRUNO,	S.,	DEREGIBUS,	M.	C.,	TETTA,	C.	&	CAMUSSI,	G.	2012.	Therapeutic	potential	of	mesenchymal	stem	cell-derived	microvesicles.	
Nephrol	Dial	Transplant,	27,	3037-42.	BIEBACK,	K.	&	BRINKMANN,	I.	2010.	Mesenchymal	stromal	cells	from	human	perinatal	tissues:	From	biology	to	cell	therapy.	World	J	Stem	Cells,	2,	81-92.	
	 246	
BILGIN,	N.,	KARAKAYALI,	H.,	MORAY,	G.,	DEMIRAG,	A.,	ARSLAN,	G.,	AKKOC,	H.	&	TURAN,	M.	1998.	Outcome	of	renal	transplantation	from	elderly	donors.	
Transplant	Proc,	30,	744-6.	BLANPAIN,	C.,	HORSLEY,	V.	&	FUCHS,	E.	2007.	Epithelial	stem	cells:	turning	over	new	leaves.	Cell,	128,	445-58.	BLANPAIN,	C.,	LOWRY,	W.	E.,	GEOGHEGAN,	A.,	POLAK,	L.	&	FUCHS,	E.	2004.	Self-renewal,	multipotency,	and	the	existence	of	two	cell	populations	within	an	epithelial	stem	cell	niche.	Cell,	118,	635-48.	BLUM,	B.	&	BENVENISTY,	N.	2008.	The	tumorigenicity	of	human	embryonic	stem	cells.	Adv	Cancer	Res,	100,	133-58.	BONNER-WEIR,	S.,	TOSCHI,	E.,	INADA,	A.,	REITZ,	P.,	FONSECA,	S.	Y.,	AYE,	T.	&	SHARMA,	A.	2004.	The	pancreatic	ductal	epithelium	serves	as	a	potential	pool	of	progenitor	cells.	Pediatr	Diabetes,	5	Suppl	2,	16-22.	BONVENTRE,	J.	V.	2003.	Dedifferentiation	and	proliferation	of	surviving	epithelial	cells	in	acute	renal	failure.	J	Am	Soc	Nephrol,	14	Suppl	1,	S55-61.	BONVENTRE,	J.	V.	2009.	Microvesicles	from	mesenchymal	stromal	cells	protect	against	acute	kidney	injury.	J	Am	Soc	Nephrol,	20,	927-8.	BONVENTRE,	J.	V.	&	YANG,	L.	2011.	Cellular	pathophysiology	of	ischemic	acute	kidney	injury.	J	Clin	Invest,	121,	4210-21.	BOUMA,	H.	R.,	PLOEG,	R.	J.	&	SCHUURS,	T.	A.	2009.	Signal	transduction	pathways	involved	in	brain	death-induced	renal	injury.	Am	J	Transplant,	9,	989-97.	BRAMMER,	A.,	WEST,	C.	D.	&	ALLEN,	S.	L.	1993.	A	comparison	of	propofol	with	other	injectable	anaesthetics	in	a	rat	model	for	measuring	cardiovascular	parameters.	Lab	Anim,	27,	250-7.	BRAUN,	H.,	SCHMIDT,	B.	M.,	RAISS,	M.,	BAISANTRY,	A.,	MIRCEA-CONSTANTIN,	D.,	WANG,	S.,	GROSS,	M.	L.,	SERRANO,	M.,	SCHMITT,	R.	&	MELK,	A.	2012.	Cellular	senescence	limits	regenerative	capacity	and	allograft	survival.	J	
Am	Soc	Nephrol,	23,	1467-73.	BRIGGS,	J.	A.,	SUN,	J.,	SHEPHERD,	J.,	OVCHINNIKOV,	D.	A.,	CHUNG,	T.	L.,	NAYLER,	S.	P.,	KAO,	L.	P.,	MORROW,	C.	A.,	THAKAR,	N.	Y.,	SOO,	S.	Y.,	PEURA,	T.,	GRIMMOND,	S.	&	WOLVETANG,	E.	J.	2013.	Integration-free	induced	pluripotent	stem	cells	model	genetic	and	neural	developmental	features	of	down	syndrome	etiology.	Stem	Cells,	31,	467-78.	BRIGGS,	J.	D.,	CROMBIE,	A.,	FABRE,	J.,	MAJOR,	E.,	THOROGOOD,	J.	&	VEITCH,	P.	S.	1997.	Organ	donation	in	the	UK:	a	survey	by	a	British	Transplantation	Society	working	party.	Nephrol	Dial	Transplant,	12,	2251-7.	BROCKMANN,	J.,	REDDY,	S.,	COUSSIOS,	C.,	PIGOTT,	D.,	GUIRRIERO,	D.,	HUGHES,	D.,	MOROVAT,	A.,	ROY,	D.,	WINTER,	L.	&	FRIEND,	P.	J.	2009.	Normothermic	perfusion:	a	new	paradigm	for	organ	preservation.	Ann	
Surg,	250,	1-6.	BROOK,	N.	R.,	WALLER,	J.	R.	&	NICHOLSON,	M.	L.	2003.	Nonheart-beating	kidney	donation:	current	practice	and	future	developments.	Kidney	Int,	63,	1516-29.	BRUNO,	S.	&	BUSSOLATI,	B.	2013.	Therapeutic	effects	of	mesenchymal	stem	cells	on	renal	ischemia-reperfusion	injury:	a	matter	of	genetic	transfer?	Stem	
Cell	Res	Ther,	4,	55.	BRUNO,	S.,	BUSSOLATI,	B.,	GRANGE,	C.,	COLLINO,	F.,	DI	CANTOGNO,	L.	V.,	HERRERA,	M.	B.,	BIANCONE,	L.,	TETTA,	C.,	SEGOLONI,	G.	&	CAMUSSI,	G.	
	 247	
2009a.	Isolation	and	characterization	of	resident	mesenchymal	stem	cells	in	human	glomeruli.	Stem	Cells	Dev,	18,	867-80.	BRUNO,	S.	&	CAMUSSI,	G.	2013.	Role	of	mesenchymal	stem	cell-derived	microvesicles	in	tissue	repair.	Pediatr	Nephrol,	28,	2249-54.	BRUNO,	S.,	GRANGE,	C.,	COLLINO,	F.,	DEREGIBUS,	M.	C.,	CANTALUPPI,	V.,	BIANCONE,	L.,	TETTA,	C.	&	CAMUSSI,	G.	2012.	Microvesicles	derived	from	mesenchymal	stem	cells	enhance	survival	in	a	lethal	model	of	acute	kidney	injury.	PLoS	One,	7,	e33115.	BRUNO,	S.,	GRANGE,	C.,	DEREGIBUS,	M.	C.,	CALOGERO,	R.	A.,	SAVIOZZI,	S.,	COLLINO,	F.,	MORANDO,	L.,	BUSCA,	A.,	FALDA,	M.,	BUSSOLATI,	B.,	TETTA,	C.	&	CAMUSSI,	G.	2009b.	Mesenchymal	stem	cell-derived	microvesicles	protect	against	acute	tubular	injury.	J	Am	Soc	Nephrol,	20,	1053-67.	BRUNO,	S.,	PORTA,	S.	&	BUSSOLATI,	B.	2016.	Extracellular	vesicles	in	renal	tissue	damage	and	regeneration.	Eur	J	Pharmacol.	BURGER,	D.,	VINAS,	J.	L.,	AKBARI,	S.,	DEHAK,	H.,	KNOLL,	W.,	GUTSOL,	A.,	CARTER,	A.,	TOUYZ,	R.	M.,	ALLAN,	D.	S.	&	BURNS,	K.	D.	2015.	Human	endothelial	colony-forming	cells	protect	against	acute	kidney	injury:	role	of	exosomes.	Am	J	Pathol,	185,	2309-23.	BURST,	V.	R.,	GILLIS,	M.,	PUTSCH,	F.,	HERZOG,	R.,	FISCHER,	J.	H.,	HEID,	P.,	MULLER-EHMSEN,	J.,	SCHENK,	K.,	FRIES,	J.	W.,	BALDAMUS,	C.	A.	&	BENZING,	T.	2010.	Poor	cell	survival	limits	the	beneficial	impact	of	mesenchymal	stem	cell	transplantation	on	acute	kidney	injury.	Nephron	
Exp	Nephrol,	114,	e107-16.	BURTON,	C.	J.,	COMBE,	C.,	WALLS,	J.	&	HARRIS,	K.	P.	1999.	Secretion	of	chemokines	and	cytokines	by	human	tubular	epithelial	cells	in	response	to	proteins.	Nephrol	Dial	Transplant,	14,	2628-33.	BUSSOLATI,	B.,	TETTA,	C.	&	CAMUSSI,	G.	2008.	Contribution	of	stem	cells	to	kidney	repair.	Am	J	Nephrol,	28,	813-22.	CAI,	J.,	YU,	X.,	XU,	R.,	FANG,	Y.,	QIAN,	X.,	LIU,	S.,	TENG,	J.	&	DING,	X.	2014.	Maximum	efficacy	of	mesenchymal	stem	cells	in	rat	model	of	renal	ischemia-reperfusion	injury:	renal	artery	administration	with	optimal	numbers.	PLoS	One,	9,	e92347.	CAMPISTOL,	J.	M.,	BOLETIS,	I.	N.,	DANTAL,	J.,	DE	FIJTER,	J.	W.,	HERTIG,	A.,	NEUMAYER,	H.	H.,	OYEN,	O.,	PASCUAL,	J.,	POHANKA,	E.,	RUIZ,	J.	C.,	SCOLARI,	M.	P.,	STEFONI,	S.,	SERON,	D.,	SPARACINO,	V.,	ARNS,	W.	&	CHAPMAN,	J.	R.	2009.	Chronic	allograft	nephropathy--a	clinical	syndrome:	early	detection	and	the	potential	role	of	proliferation	signal	inhibitors.	
Clin	Transplant,	23,	769-77.	CAMUSSI,	G.,	DEREGIBUS,	M.	C.,	BRUNO,	S.,	CANTALUPPI,	V.	&	BIANCONE,	L.	2010.	Exosomes/microvesicles	as	a	mechanism	of	cell-to-cell	communication.	Kidney	Int,	78,	838-48.	CAMUSSI,	G.,	DEREGIBUS,	M.	C.,	BRUNO,	S.,	GRANGE,	C.,	FONSATO,	V.	&	TETTA,	C.	2011.	Exosome/microvesicle-mediated	epigenetic	reprogramming	of	cells.	Am	J	Cancer	Res,	1,	98-110.	CAMUSSI,	G.,	DEREGIBUS,	M.	C.	&	CANTALUPPI,	V.	2013.	Role	of	stem-cell-derived	microvesicles	in	the	paracrine	action	of	stem	cells.	Biochem	Soc	
Trans,	41,	283-7.	
	 248	
CANTALUPPI,	V.,	BIANCONE,	L.,	QUERCIA,	A.,	DEREGIBUS,	M.	C.,	SEGOLONI,	G.	&	CAMUSSI,	G.	2013.	Rationale	of	mesenchymal	stem	cell	therapy	in	kidney	injury.	Am	J	Kidney	Dis,	61,	300-9.	CANTALUPPI,	V.,	GATTI,	S.,	MEDICA,	D.,	FIGLIOLINI,	F.,	BRUNO,	S.,	DEREGIBUS,	M.	C.,	SORDI,	A.,	BIANCONE,	L.,	TETTA,	C.	&	CAMUSSI,	G.	2012.	Microvesicles	derived	from	endothelial	progenitor	cells	protect	the	kidney	from	ischemia-reperfusion	injury	by	microRNA-dependent	reprogramming	of	resident	renal	cells.	Kidney	Int,	82,	412-27.	CASIRAGHI,	F.,	PERICO,	N.	&	REMUZZI,	G.	2013a.	Mesenchymal	stromal	cells	to	promote	solid	organ	transplantation	tolerance.	Curr	Opin	Organ	
Transplant,	18,	51-8.	CASIRAGHI,	F.,	REMUZZI,	G.,	ABBATE,	M.	&	PERICO,	N.	2013b.	Multipotent	mesenchymal	stromal	cell	therapy	and	risk	of	malignancies.	Stem	Cell	Rev,	9,	65-79.	CHATTERJEE,	P.	K.	2007.	Novel	pharmacological	approaches	to	the	treatment	of	renal	ischemia-reperfusion	injury:	a	comprehensive	review.	Naunyn	
Schmiedebergs	Arch	Pharmacol,	376,	1-43.	CHATTERJEE,	P.	K.	&	THIEMERMANN,	C.	2003.	Emerging	drugs	for	renal	failure.	
Expert	Opin	Emerg	Drugs,	8,	389-435.	CHAVALITDHAMRONG,	D.,	GILL,	J.,	TAKEMOTO,	S.,	MADHIRA,	B.	R.,	CHO,	Y.	W.,	SHAH,	T.	&	BUNNAPRADIST,	S.	2008.	Patient	and	graft	outcomes	from	deceased	kidney	donors	age	70	years	and	older:	an	analysis	of	the	Organ	Procurement	Transplant	Network/United	Network	of	Organ	Sharing	database.	Transplantation,	85,	1573-9.	CHEN,	Y.	T.,	SUN,	C.	K.,	LIN,	Y.	C.,	CHANG,	L.	T.,	CHEN,	Y.	L.,	TSAI,	T.	H.,	CHUNG,	S.	Y.,	CHUA,	S.,	KAO,	Y.	H.,	YEN,	C.	H.,	SHAO,	P.	L.,	CHANG,	K.	C.,	LEU,	S.	&	YIP,	H.	K.	2011.	Adipose-derived	mesenchymal	stem	cell	protects	kidneys	against	ischemia-reperfusion	injury	through	suppressing	oxidative	stress	and	inflammatory	reaction.	J	Transl	Med,	9,	51.	CHEVILLET,	J.	R.,	KANG,	Q.,	RUF,	I.	K.,	BRIGGS,	H.	A.,	VOJTECH,	L.	N.,	HUGHES,	S.	M.,	CHENG,	H.	H.,	ARROYO,	J.	D.,	MEREDITH,	E.	K.,	GALLICHOTTE,	E.	N.,	POGOSOVA-AGADJANYAN,	E.	L.,	MORRISSEY,	C.,	STIREWALT,	D.	L.,	HLADIK,	F.,	YU,	E.	Y.,	HIGANO,	C.	S.	&	TEWARI,	M.	2014.	Quantitative	and	stoichiometric	analysis	of	the	microRNA	content	of	exosomes.	Proc	Natl	
Acad	Sci	U	S	A,	111,	14888-93.	CHIARI,	P.,	HADOUR,	G.,	MICHEL,	P.,	PIRIOU,	V.,	RODRIGUEZ,	C.,	BUDAT,	C.,	OVIZE,	M.,	JEGADEN,	O.,	LEHOT,	J.	J.	&	FERRERA,	R.	2000.	Biphasic	response	after	brain	death	induction:	prominent	part	of	catecholamines	release	in	this	phenomenon.	J	Heart	Lung	Transplant,	19,	675-82.	CHOUCHANI,	E.	T.,	PELL,	V.	R.,	GAUDE,	E.,	AKSENTIJEVIC,	D.,	SUNDIER,	S.	Y.,	ROBB,	E.	L.,	LOGAN,	A.,	NADTOCHIY,	S.	M.,	ORD,	E.	N.,	SMITH,	A.	C.,	EYASSU,	F.,	SHIRLEY,	R.,	HU,	C.	H.,	DARE,	A.	J.,	JAMES,	A.	M.,	ROGATTI,	S.,	HARTLEY,	R.	C.,	EATON,	S.,	COSTA,	A.	S.,	BROOKES,	P.	S.,	DAVIDSON,	S.	M.,	DUCHEN,	M.	R.,	SAEB-PARSY,	K.,	SHATTOCK,	M.	J.,	ROBINSON,	A.	J.,	WORK,	L.	M.,	FREZZA,	C.,	KRIEG,	T.	&	MURPHY,	M.	P.	2014.	Ischaemic	accumulation	of	succinate	controls	reperfusion	injury	through	mitochondrial	ROS.	Nature,	515,	431-5.	CHOUMERIANOU,	D.	M.,	DIMITRIOU,	H.,	PERDIKOGIANNI,	C.,	MARTIMIANAKI,	G.,	RIMINUCCI,	M.	&	KALMANTI,	M.	2008.	Study	of	oncogenic	transformation	
	 249	
in	ex	vivo	expanded	mesenchymal	cells,	from	paediatric	bone	marrow.	
Cell	Prolif,	41,	909-22.	CLARKE,	D.	J.	&	PAYNE,	A.	P.	1994.	Neuroanatomical	characterization	of	a	new	mutant	rat	with	dopamine	depletion	in	the	substantia	nigra.	Eur	J	
Neurosci,	6,	885-8.	COCUCCI,	E.,	RACCHETTI,	G.	&	MELDOLESI,	J.	2009.	Shedding	microvesicles:	artefacts	no	more.	Trends	Cell	Biol,	19,	43-51.	COLLINO,	F.,	BRUNO,	S.,	INCARNATO,	D.,	DETTORI,	D.,	NERI,	F.,	PROVERO,	P.,	POMATTO,	M.,	OLIVIERO,	S.,	TETTA,	C.,	QUESENBERRY,	P.	J.	&	CAMUSSI,	G.	2015.	AKI	Recovery	Induced	by	Mesenchymal	Stromal	Cell-Derived	Extracellular	Vesicles	Carrying	MicroRNAs.	J	Am	Soc	Nephrol,	26,	2349-60.	COLLINO,	F.,	DEREGIBUS,	M.	C.,	BRUNO,	S.,	STERPONE,	L.,	AGHEMO,	G.,	VILTONO,	L.,	TETTA,	C.	&	CAMUSSI,	G.	2010.	Microvesicles	derived	from	adult	human	bone	marrow	and	tissue	specific	mesenchymal	stem	cells	shuttle	selected	pattern	of	miRNAs.	PLoS	One,	5,	e11803.	COLLINS,	A.	J.,	FOLEY,	R.,	HERZOG,	C.,	CHAVERS,	B.,	GILBERTSON,	D.,	ISHANI,	A.,	KASISKE,	B.,	LIU,	J.,	MAU,	L.	W.,	MCBEAN,	M.,	MURRAY,	A.,	ST	PETER,	W.,	XUE,	J.,	FAN,	Q.,	GUO,	H.,	LI,	Q.,	LI,	S.,	LI,	S.,	PENG,	Y.,	QIU,	Y.,	ROBERTS,	T.,	SKEANS,	M.,	SNYDER,	J.,	SOLID,	C.,	WANG,	C.,	WEINHANDL,	E.,	ZAUN,	D.,	ZHANG,	R.,	ARKO,	C.,	CHEN,	S.	C.,	DALLESKA,	F.,	DANIELS,	F.,	DUNNING,	S.,	EBBEN,	J.,	FRAZIER,	E.,	HANZLIK,	C.,	JOHNSON,	R.,	SHEETS,	D.,	WANG,	X.,	FORREST,	B.,	CONSTANTINI,	E.,	EVERSON,	S.,	EGGERS,	P.	&	AGODOA,	L.	2008.	Excerpts	from	the	United	States	Renal	Data	System	2007	annual	data	report.	Am	J	Kidney	Dis,	51,	S1-320.	COLLINS,	A.	J.,	FOLEY,	R.	N.,	CHAVERS,	B.,	GILBERTSON,	D.,	HERZOG,	C.,	JOHANSEN,	K.,	KASISKE,	B.,	KUTNER,	N.,	LIU,	J.,	ST	PETER,	W.,	GUO,	H.,	GUSTAFSON,	S.,	HEUBNER,	B.,	LAMB,	K.,	LI,	S.,	LI,	S.,	PENG,	Y.,	QIU,	Y.,	ROBERTS,	T.,	SKEANS,	M.,	SNYDER,	J.,	SOLID,	C.,	THOMPSON,	B.,	WANG,	C.,	WEINHANDL,	E.,	ZAUN,	D.,	ARKO,	C.,	CHEN,	S.	C.,	DANIELS,	F.,	EBBEN,	J.,	FRAZIER,	E.,	HANZLIK,	C.,	JOHNSON,	R.,	SHEETS,	D.,	WANG,	X.,	FORREST,	B.,	CONSTANTINI,	E.,	EVERSON,	S.,	EGGERS,	P.	&	AGODOA,	L.	2012.	'United	States	Renal	Data	System	2011	Annual	Data	Report:	Atlas	of	chronic	kidney	disease	&	end-stage	renal	disease	in	the	United	States.	Am	
J	Kidney	Dis,	59,	A7,	e1-420.	CRADDOCK,	G.	N.	1976.	Species	differences	in	response	to	renal	ischemia.	Arch	
Surg,	111,	582-4.	CRAIG,	N.	J.,	DURAN	ALONSO,	M.	B.,	HAWKER,	K.	L.,	SHIELS,	P.,	GLENCORSE,	T.	A.,	CAMPBELL,	J.	M.,	BENNETT,	N.	K.,	CANHAM,	M.,	DONALD,	D.,	GARDINER,	M.,	GILMORE,	D.	P.,	MACDONALD,	R.	J.,	MAITLAND,	K.,	MCCALLION,	A.	S.,	RUSSELL,	D.,	PAYNE,	A.	P.,	SUTCLIFFE,	R.	G.	&	DAVIES,	R.	W.	2001.	A	candidate	gene	for	human	neurodegenerative	disorders:	a	rat	PKC	gamma	mutation	causes	a	Parkinsonian	syndrome.	Nat	Neurosci,	4,	1061-2.	CRESCITELLI,	R.,	LASSER,	C.,	SZABO,	T.	G.,	KITTEL,	A.,	ELDH,	M.,	DIANZANI,	I.,	BUZAS,	E.	I.	&	LOTVALL,	J.	2013.	Distinct	RNA	profiles	in	subpopulations	of	extracellular	vesicles:	apoptotic	bodies,	microvesicles	and	exosomes.	J	
Extracell	Vesicles,	2.	CRISAN,	M.,	YAP,	S.,	CASTEILLA,	L.,	CHEN,	C.	W.,	CORSELLI,	M.,	PARK,	T.	S.,	ANDRIOLO,	G.,	SUN,	B.,	ZHENG,	B.,	ZHANG,	L.,	NOROTTE,	C.,	TENG,	P.	N.,	TRAAS,	J.,	SCHUGAR,	R.,	DEASY,	B.	M.,	BADYLAK,	S.,	BUHRING,	H.	J.,	
	 250	
GIACOBINO,	J.	P.,	LAZZARI,	L.,	HUARD,	J.	&	PEAULT,	B.	2008.	A	perivascular	origin	for	mesenchymal	stem	cells	in	multiple	human	organs.	
Cell	Stem	Cell,	3,	301-13.	CYPEL,	M.,	YEUNG,	J.	C.,	LIU,	M.,	ANRAKU,	M.,	CHEN,	F.,	KAROLAK,	W.,	SATO,	M.,	LARATTA,	J.,	AZAD,	S.,	MADONIK,	M.,	CHOW,	C.	W.,	CHAPARRO,	C.,	HUTCHEON,	M.,	SINGER,	L.	G.,	SLUTSKY,	A.	S.,	YASUFUKU,	K.,	DE	PERROT,	M.,	PIERRE,	A.	F.,	WADDELL,	T.	K.	&	KESHAVJEE,	S.	2011.	Normothermic	ex	vivo	lung	perfusion	in	clinical	lung	transplantation.	N	Engl	J	Med,	364,	1431-40.	DAVANI,	S.,	MARANDIN,	A.,	MERSIN,	N.,	ROYER,	B.,	KANTELIP,	B.,	HERVE,	P.,	ETIEVENT,	J.	P.	&	KANTELIP,	J.	P.	2003.	Mesenchymal	progenitor	cells	differentiate	into	an	endothelial	phenotype,	enhance	vascular	density,	and	improve	heart	function	in	a	rat	cellular	cardiomyoplasty	model.	
Circulation,	108	Suppl	1,	II253-8.	DE	BROE,	M.	E.,	WIEME,	R.	J.,	LOGGHE,	G.	N.	&	ROELS,	F.	1977.	Spontaneous	shedding	of	plasma	membrane	fragments	by	human	cells	in	vivo	and	in	vitro.	Clin	Chim	Acta,	81,	237-45.	DE	LA	FUENTE,	R.,	BERNAD,	A.,	GARCIA-CASTRO,	J.,	MARTIN,	M.	C.	&	CIGUDOSA,	J.	C.	2010.	Retraction:	Spontaneous	human	adult	stem	cell	transformation.	
Cancer	Res,	70,	6682.	DE	MARTINO,	M.,	ZONTA,	S.,	RAMPINO,	T.,	GREGORINI,	M.,	FRASSONI,	F.,	PIOTTI,	G.,	BEDINO,	G.,	COBIANCHI,	L.,	DAL	CANTON,	A.,	DIONIGI,	P.	&	ALESSIANI,	M.	2010.	Mesenchymal	stem	cells	infusion	prevents	acute	cellular	rejection	in	rat	kidney	transplantation.	Transplant	Proc,	42,	1331-5.	DE	ROSA,	S.,	ANTONELLI,	M.	&	RONCO,	C.	2016.	Hypothermia	and	kidney:	a	focus	on	ischaemia-reperfusion	injury.	Nephrol	Dial	Transplant.	DEBOUT,	A.,	FOUCHER,	Y.,	TREBERN-LAUNAY,	K.,	LEGENDRE,	C.,	KREIS,	H.,	MOURAD,	G.,	GARRIGUE,	V.,	MORELON,	E.,	BURON,	F.,	ROSTAING,	L.,	KAMAR,	N.,	KESSLER,	M.,	LADRIERE,	M.,	POIGNAS,	A.,	BLIDI,	A.,	SOULILLOU,	J.	P.,	GIRAL,	M.	&	DANTAN,	E.	2015.	Each	additional	hour	of	cold	ischemia	time	significantly	increases	the	risk	of	graft	failure	and	mortality	following	renal	transplantation.	Kidney	Int,	87,	343-9.	DEHOUX,	J.	P.	&	GIANELLO,	P.	2007.	The	importance	of	large	animal	models	in	transplantation.	Front	Biosci,	12,	4864-80.	DELBRIDGE,	M.	S.,	SHRESTHA,	B.	M.,	RAFTERY,	A.	T.,	EL	NAHAS,	A.	M.	&	HAYLOR,	J.	L.	2007.	The	effect	of	body	temperature	in	a	rat	model	of	renal	ischemia-reperfusion	injury.	Transplant	Proc,	39,	2983-5.	DEREGIBUS,	M.	C.,	CANTALUPPI,	V.,	CALOGERO,	R.,	LO	IACONO,	M.,	TETTA,	C.,	BIANCONE,	L.,	BRUNO,	S.,	BUSSOLATI,	B.	&	CAMUSSI,	G.	2007.	Endothelial	progenitor	cell	derived	microvesicles	activate	an	angiogenic	program	in	endothelial	cells	by	a	horizontal	transfer	of	mRNA.	Blood,	110,	2440-8.	DI	NICOLA,	M.,	CARLO-STELLA,	C.,	MAGNI,	M.,	MILANESI,	M.,	LONGONI,	P.	D.,	MATTEUCCI,	P.,	GRISANTI,	S.	&	GIANNI,	A.	M.	2002.	Human	bone	marrow	stromal	cells	suppress	T-lymphocyte	proliferation	induced	by	cellular	or	nonspecific	mitogenic	stimuli.	Blood,	99,	3838-43.	DIAMANT,	M.,	TUSHUIZEN,	M.	E.,	STURK,	A.	&	NIEUWLAND,	R.	2004.	Cellular	microparticles:	new	players	in	the	field	of	vascular	disease?	Eur	J	Clin	
Invest,	34,	392-401.	
	 251	
DOMINICI,	M.,	LE	BLANC,	K.,	MUELLER,	I.,	SLAPER-CORTENBACH,	I.,	MARINI,	F.,	KRAUSE,	D.,	DEANS,	R.,	KEATING,	A.,	PROCKOP,	D.	&	HORWITZ,	E.	2006.	Minimal	criteria	for	defining	multipotent	mesenchymal	stromal	cells.	The	International	Society	for	Cellular	Therapy	position	statement.	
Cytotherapy,	8,	315-7.	DONOVAN,	P.	J.	&	GEARHART,	J.	2001.	The	end	of	the	beginning	for	pluripotent	stem	cells.	Nature,	414,	92-7.	DOUGLAS-DENTON,	R.,	MORITZ,	K.	M.,	BERTRAM,	J.	F.	&	WINTOUR,	E.	M.	2002.	Compensatory	renal	growth	after	unilateral	nephrectomy	in	the	ovine	fetus.	J	Am	Soc	Nephrol,	13,	406-10.	DOWNEY,	P.,	TOLLEY,	D.	A.,	JOHNSTON,	S.	R.	&	YOUNG,	M.	2001.	Ischemia-reperfusion	injury	after	relief	of	ureteral	obstruction:	an	animal	study.	J	
Endourol,	15,	209-11.	DRAGOVIC,	R.	A.,	GARDINER,	C.,	BROOKS,	A.	S.,	TANNETTA,	D.	S.,	FERGUSON,	D.	J.,	HOLE,	P.,	CARR,	B.,	REDMAN,	C.	W.,	HARRIS,	A.	L.,	DOBSON,	P.	J.,	HARRISON,	P.	&	SARGENT,	I.	L.	2011.	Sizing	and	phenotyping	of	cellular	vesicles	using	Nanoparticle	Tracking	Analysis.	Nanomedicine,	7,	780-8.	DRESSEL,	R.,	SCHINDEHUTTE,	J.,	KUHLMANN,	T.,	ELSNER,	L.,	NOVOTA,	P.,	BAIER,	P.	C.,	SCHILLERT,	A.,	BICKEBOLLER,	H.,	HERRMANN,	T.,	TRENKWALDER,	C.,	PAULUS,	W.	&	MANSOURI,	A.	2008.	The	tumorigenicity	of	mouse	embryonic	stem	cells	and	in	vitro	differentiated	neuronal	cells	is	controlled	by	the	recipients'	immune	response.	PLoS	One,	3,	e2622.	DRUKKER,	M.,	KATCHMAN,	H.,	KATZ,	G.,	EVEN-TOV	FRIEDMAN,	S.,	SHEZEN,	E.,	HORNSTEIN,	E.,	MANDELBOIM,	O.,	REISNER,	Y.	&	BENVENISTY,	N.	2006.	Human	embryonic	stem	cells	and	their	differentiated	derivatives	are	less	susceptible	to	immune	rejection	than	adult	cells.	Stem	Cells,	24,	221-9.	DUFFIELD,	J.	S.,	PARK,	K.	M.,	HSIAO,	L.	L.,	KELLEY,	V.	R.,	SCADDEN,	D.	T.,	ICHIMURA,	T.	&	BONVENTRE,	J.	V.	2005.	Restoration	of	tubular	epithelial	cells	during	repair	of	the	postischemic	kidney	occurs	independently	of	bone	marrow-derived	stem	cells.	J	Clin	Invest,	115,	1743-55.	ECKFELDT,	C.	E.,	MENDENHALL,	E.	M.	&	VERFAILLIE,	C.	M.	2005.	The	molecular	repertoire	of	the	'almighty'	stem	cell.	Nat	Rev	Mol	Cell	Biol,	6,	726-37.	EDWARDS,	R.	G.	&	HOLLANDS,	P.	2007.	Will	stem	cells	in	cord	blood,	amniotic	fluid,	bone	marrow	and	peripheral	blood	soon	be	unnecessary	in	transplantation?	Reprod	Biomed	Online,	14,	396-401.	EIRIN,	A.,	RIESTER,	S.	M.,	ZHU,	X.	Y.,	TANG,	H.,	EVANS,	J.	M.,	O'BRIEN,	D.,	VAN	WIJNEN,	A.	J.	&	LERMAN,	L.	O.	2014.	MicroRNA	and	mRNA	cargo	of	extracellular	vesicles	from	porcine	adipose	tissue-derived	mesenchymal	stem	cells.	Gene,	551,	55-64.	ELDH,	M.,	LOTVALL,	J.,	MALMHALL,	C.	&	EKSTROM,	K.	2012.	Importance	of	RNA	isolation	methods	for	analysis	of	exosomal	RNA:	evaluation	of	different	methods.	Mol	Immunol,	50,	278-86.	ELGER,	M.,	HENTSCHEL,	H.,	LITTERAL,	J.,	WELLNER,	M.,	KIRSCH,	T.,	LUFT,	F.	C.	&	HALLER,	H.	2003.	Nephrogenesis	is	induced	by	partial	nephrectomy	in	the	elasmobranch	Leucoraja	erinacea.	J	Am	Soc	Nephrol,	14,	1506-18.	ELLERY,	S.	J.,	CAI,	X.,	WALKER,	D.	D.,	DICKINSON,	H.	&	KETT,	M.	M.	2015.	Transcutaneous	measurement	of	glomerular	filtration	rate	in	small	rodents:	through	the	skin	for	the	win?	Nephrology	(Carlton),	20,	117-23.	
	 252	
ELTZSCHIG,	H.	K.	&	ECKLE,	T.	2011.	Ischemia	and	reperfusion--from	mechanism	to	translation.	Nat	Med,	17,	1391-401.	ERPICUM,	P.,	DETRY,	O.,	WEEKERS,	L.,	BONVOISIN,	C.,	LECHANTEUR,	C.,	BRIQUET,	A.,	BEGUIN,	Y.,	KRZESINSKI,	J.	M.	&	JOURET,	F.	2014.	Mesenchymal	stromal	cell	therapy	in	conditions	of	renal	ischaemia/reperfusion.	Nephrol	Dial	Transplant,	29,	1487-93.	EVANS,	R.	G.,	GARDINER,	B.	S.,	SMITH,	D.	W.	&	O'CONNOR,	P.	M.	2008.	Intrarenal	oxygenation:	unique	challenges	and	the	biophysical	basis	of	homeostasis.	
Am	J	Physiol	Renal	Physiol,	295,	F1259-70.	FENG,	D.,	ZHAO,	W.	L.,	YE,	Y.	Y.,	BAI,	X.	C.,	LIU,	R.	Q.,	CHANG,	L.	F.,	ZHOU,	Q.	&	SUI,	S.	F.	2010a.	Cellular	internalization	of	exosomes	occurs	through	phagocytosis.	Traffic,	11,	675-87.	FENG,	Z.,	TING,	J.,	ALFONSO,	Z.,	STREM,	B.	M.,	FRASER,	J.	K.,	RUTENBERG,	J.,	KUO,	H.	C.	&	PINKERNELL,	K.	2010b.	Fresh	and	cryopreserved,	uncultured	adipose	tissue-derived	stem	and	regenerative	cells	ameliorate	ischemia-reperfusion-induced	acute	kidney	injury.	Nephrol	Dial	Transplant,	25,	3874-84.	FERRARI,	G.,	CUSELLA-DE	ANGELIS,	G.,	COLETTA,	M.,	PAOLUCCI,	E.,	STORNAIUOLO,	A.,	COSSU,	G.	&	MAVILIO,	F.	1998.	Muscle	regeneration	by	bone	marrow-derived	myogenic	progenitors.	Science,	279,	1528-30.	FIERABRACCI,	A.,	DEL	FATTORE,	A.,	LUCIANO,	R.,	MURACA,	M.,	TETI,	A.	&	MURACA,	M.	2015.	Recent	advances	in	mesenchymal	stem	cell	immunomodulation:	the	role	of	microvesicles.	Cell	Transplant,	24,	133-49.	FINCO,	D.	R.	&	DUNCAN,	J.	R.	1976.	Evaluation	of	blood	urea	nitrogen	and	serum	creatinine	concentrations	as	indicators	of	renal	dysfunction:	a	study	of	111	cases	and	a	review	of	related	literature.	J	Am	Vet	Med	Assoc,	168,	593-601.	FISCHER,	P.	A.,	BOGOLIUK,	C.	B.,	RAMIREZ,	A.	J.,	SANCHEZ,	R.	A.	&	MASNATTA,	L.	D.	2000.	A	new	procedure	for	evaluation	of	renal	function	without	urine	collection	in	rat.	Kidney	Int,	58,	1336-41.	FISCHER,	U.	M.,	HARTING,	M.	T.,	JIMENEZ,	F.,	MONZON-POSADAS,	W.	O.,	XUE,	H.,	SAVITZ,	S.	I.,	LAINE,	G.	A.	&	COX,	C.	S.,	JR.	2009.	Pulmonary	passage	is	a	major	obstacle	for	intravenous	stem	cell	delivery:	the	pulmonary	first-pass	effect.	Stem	Cells	Dev,	18,	683-92.	FLECK,	C.	1999.	Determination	of	the	glomerular	filtration	rate	(GFR):	methodological	problems,	age-dependence,	consequences	of	various	surgical	interventions,	and	the	influence	of	different	drugs	and	toxic	substances.	Physiol	Res,	48,	267-79.	FLECK,	C.	&	BRAUNLICH,	H.	1984.	Kidney	function	after	unilateral	nephrectomy.	
Exp	Pathol,	25,	3-18.	FLYNN,	A.,	BARRY,	F.	&	O'BRIEN,	T.	2007.	UC	blood-derived	mesenchymal	stromal	cells:	an	overview.	Cytotherapy,	9,	717-26.	FORBES,	J.	M.,	HEWITSON,	T.	D.,	BECKER,	G.	J.	&	JONES,	C.	L.	2000.	Ischemic	acute	renal	failure:	long-term	histology	of	cell	and	matrix	changes	in	the	rat.	
Kidney	Int,	57,	2375-85.	FORSYTHE,	J.	L.	2009.	Transplantation,	Saunders.	FOSS,	A.,	HELDAL,	K.,	SCOTT,	H.,	FOSS,	S.,	LEIVESTAD,	T.,	JORGENSEN,	P.	F.,	SCHOLZ,	T.	&	MIDTVEDT,	K.	2009.	Kidneys	from	deceased	donors	more	
	 253	
than	75	years	perform	acceptably	after	transplantation.	Transplantation,	87,	1437-41.	FOX,	J.	M.,	CHAMBERLAIN,	G.,	ASHTON,	B.	A.	&	MIDDLETON,	J.	2007.	Recent	advances	into	the	understanding	of	mesenchymal	stem	cell	trafficking.	Br	
J	Haematol,	137,	491-502.	FRANQUESA,	M.,	HOOGDUIJN,	M.	J.	&	BAAN,	C.	C.	2012a.	The	impact	of	mesenchymal	stem	cell	therapy	in	transplant	rejection	and	tolerance.	Curr	
Opin	Organ	Transplant,	17,	355-61.	FRANQUESA,	M.,	HOOGDUIJN,	M.	J.,	BESTARD,	O.	&	GRINYO,	J.	M.	2012b.	Immunomodulatory	effect	of	mesenchymal	stem	cells	on	B	cells.	Front	
Immunol,	3,	212.	FRANQUESA,	M.,	MENSAH,	F.	K.,	HUIZINGA,	R.,	STRINI,	T.,	BOON,	L.,	LOMBARDO,	E.,	DELAROSA,	O.,	LAMAN,	J.	D.,	GRINYO,	J.	M.,	WEIMAR,	W.,	BETJES,	M.	G.,	BAAN,	C.	C.	&	HOOGDUIJN,	M.	J.	2015.	Human	adipose	tissue-derived	mesenchymal	stem	cells	abrogate	plasmablast	formation	and	induce	regulatory	B	cells	independently	of	T	helper	cells.	Stem	Cells,	33,	880-91.	FREEDMAN,	B.	S.,	BROOKS,	C.	R.,	LAM,	A.	Q.,	FU,	H.,	MORIZANE,	R.,	AGRAWAL,	V.,	SAAD,	A.	F.,	LI,	M.	K.,	HUGHES,	M.	R.,	WERFF,	R.	V.,	PETERS,	D.	T.,	LU,	J.,	BACCEI,	A.,	SIEDLECKI,	A.	M.,	VALERIUS,	M.	T.,	MUSUNURU,	K.,	MCNAGNY,	K.	M.,	STEINMAN,	T.	I.,	ZHOU,	J.,	LEROU,	P.	H.	&	BONVENTRE,	J.	V.	2015.	Modelling	kidney	disease	with	CRISPR-mutant	kidney	organoids	derived	from	human	pluripotent	epiblast	spheroids.	Nat	Commun,	6,	8715.	FREYMAN,	T.,	POLIN,	G.,	OSMAN,	H.,	CRARY,	J.,	LU,	M.,	CHENG,	L.,	PALASIS,	M.	&	WILENSKY,	R.	L.	2006.	A	quantitative,	randomized	study	evaluating	three	methods	of	mesenchymal	stem	cell	delivery	following	myocardial	infarction.	Eur	Heart	J,	27,	1114-22.	FRIEDEMANN,	J.,	HEINRICH,	R.,	SHULHEVICH,	Y.,	RAEDLE,	M.,	WILLIAM-OLSSON,	L.,	PILL,	J.	&	SCHOCK-KUSCH,	D.	2016.	Improved	kinetic	model	for	the	transcutaneous	measurement	of	glomerular	filtration	rate	in	experimental	animals.	Kidney	Int,	90,	1377-1385.	FRIEDENSTEIN,	A.	J.,	CHAILAKHYAN,	R.	K.,	LATSINIK,	N.	V.,	PANASYUK,	A.	F.	&	KEILISS-BOROK,	I.	V.	1974.	Stromal	cells	responsible	for	transferring	the	microenvironment	of	the	hemopoietic	tissues.	Cloning	in	vitro	and	retransplantation	in	vivo.	Transplantation,	17,	331-40.	FRIEDENSTEIN,	A.	J.,	PETRAKOVA,	K.	V.,	KUROLESOVA,	A.	I.	&	FROLOVA,	G.	P.	1968.	Heterotopic	of	bone	marrow.	Analysis	of	precursor	cells	for	osteogenic	and	hematopoietic	tissues.	Transplantation,	6,	230-47.	FROELICH,	K.,	MICKLER,	J.,	STEUSLOFF,	G.,	TECHNAU,	A.,	RAMOS	TIRADO,	M.,	SCHERZED,	A.,	HACKENBERG,	S.,	RADELOFF,	A.,	HAGEN,	R.	&	KLEINSASSER,	N.	2013.	Chromosomal	aberrations	and	deoxyribonucleic	acid	single-strand	breaks	in	adipose-derived	stem	cells	during	long-term	expansion	in	vitro.	Cytotherapy,	15,	767-81.	FURLANI,	D.,	LI,	W.,	PITTERMANN,	E.,	KLOPSCH,	C.,	WANG,	L.,	KNOPP,	A.,	JUNGEBLUTH,	P.,	THEDINGA,	E.,	HAVENSTEIN,	C.,	WESTIEN,	I.,	UGURLUCAN,	M.,	LI,	R.	K.,	MA,	N.	&	STEINHOFF,	G.	2009a.	A	transformed	cell	population	derived	from	cultured	mesenchymal	stem	cells	has	no	functional	effect	after	transplantation	into	the	injured	heart.	Cell	
Transplant,	18,	319-31.	
	 254	
FURLANI,	D.,	UGURLUCAN,	M.,	ONG,	L.,	BIEBACK,	K.,	PITTERMANN,	E.,	WESTIEN,	I.,	WANG,	W.,	YEREBAKAN,	C.,	LI,	W.,	GAEBEL,	R.,	LI,	R.	K.,	VOLLMAR,	B.,	STEINHOFF,	G.	&	MA,	N.	2009b.	Is	the	intravascular	administration	of	mesenchymal	stem	cells	safe?	Mesenchymal	stem	cells	and	intravital	microscopy.	Microvasc	Res,	77,	370-6.	FURUICHI,	K.,	SHINTANI,	H.,	SAKAI,	Y.,	OCHIYA,	T.,	MATSUSHIMA,	K.,	KANEKO,	S.	&	WADA,	T.	2012.	Effects	of	adipose-derived	mesenchymal	cells	on	ischemia-reperfusion	injury	in	kidney.	Clin	Exp	Nephrol,	16,	679-89.	FUSELLIER,	M.,	DESFONTIS,	J.	C.,	MADEC,	S.,	GAUTIER,	F.,	DEBAILLEUL,	M.	&	GOGNY,	M.	2007.	Influence	of	three	anesthetic	protocols	on	glomerular	filtration	rate	in	dogs.	Am	J	Vet	Res,	68,	807-11.	GALLIFORD,	J.	&	GAME,	D.	S.	2009.	Modern	renal	transplantation:	present	challenges	and	future	prospects.	Postgrad	Med	J,	85,	91-101.	GAO,	J.,	DENNIS,	J.	E.,	MUZIC,	R.	F.,	LUNDBERG,	M.	&	CAPLAN,	A.	I.	2001.	The	dynamic	in	vivo	distribution	of	bone	marrow-derived	mesenchymal	stem	cells	after	infusion.	Cells	Tissues	Organs,	169,	12-20.	GARDINER,	C.,	FERREIRA,	Y.	J.,	DRAGOVIC,	R.	A.,	REDMAN,	C.	W.	&	SARGENT,	I.	L.	2013.	Extracellular	vesicle	sizing	and	enumeration	by	nanoparticle	tracking	analysis.	J	Extracell	Vesicles,	2.	GATTI,	S.,	BRUNO,	S.,	DEREGIBUS,	M.	C.,	SORDI,	A.,	CANTALUPPI,	V.,	TETTA,	C.	&	CAMUSSI,	G.	2011.	Microvesicles	derived	from	human	adult	mesenchymal	stem	cells	protect	against	ischaemia-reperfusion-induced	acute	and	chronic	kidney	injury.	Nephrol	Dial	Transplant,	26,	1474-83.	GHEISARI,	Y.,	AHMADBEIGI,	N.,	NADERI,	M.,	NASSIRI,	S.	M.,	NADRI,	S.	&	SOLEIMANI,	M.	2011.	Stem	cell-conditioned	medium	does	not	protect	against	kidney	failure.	Cell	Biol	Int,	35,	209-13.	GIESSING,	M.,	FULLER,	T.	F.,	FRIEDERSDORFF,	F.,	DEGER,	S.,	WILLE,	A.,	NEUMAYER,	H.	H.,	SCHMIDT,	D.,	BUDDE,	K.	&	LIEFELDT,	L.	2009.	Outcomes	of	transplanting	deceased-donor	kidneys	between	elderly	donors	and	recipients.	J	Am	Soc	Nephrol,	20,	37-40.	GILL,	J.,	DONG,	J.,	ROSE,	C.	&	GILL,	J.	S.	2016.	The	risk	of	allograft	failure	and	the	survival	benefit	of	kidney	transplantation	are	complicated	by	delayed	graft	function.	Kidney	Int,	89,	1331-6.	GINGELL-LITTLEJOHN.	2014.	Cellular	Senescence	and	Renal	Transplantation.	Doctor	of	Medicine,	University	of	Glasgow.	GIRAUD,	S.,	FAVREAU,	F.,	CHATAURET,	N.,	THUILLIER,	R.,	MAIGA,	S.	&	HAUET,	T.	2011.	Contribution	of	large	pig	for	renal	ischemia-reperfusion	and	transplantation	studies:	the	preclinical	model.	J	Biomed	Biotechnol,	2011,	532127.	GLENNIE,	S.,	SOEIRO,	I.,	DYSON,	P.	J.,	LAM,	E.	W.	&	DAZZI,	F.	2005.	Bone	marrow	mesenchymal	stem	cells	induce	division	arrest	anergy	of	activated	T	cells.	
Blood,	105,	2821-7.	GNECCHI,	M.,	HE,	H.,	NOISEUX,	N.,	LIANG,	O.	D.,	ZHANG,	L.,	MORELLO,	F.,	MU,	H.,	MELO,	L.	G.,	PRATT,	R.	E.,	INGWALL,	J.	S.	&	DZAU,	V.	J.	2006.	Evidence	supporting	paracrine	hypothesis	for	Akt-modified	mesenchymal	stem	cell-mediated	cardiac	protection	and	functional	improvement.	FASEB	J,	20,	661-9.	GOKAL,	R.	1993.	Quality	of	life	in	patients	undergoing	renal	replacement	therapy.	
Kidney	Int	Suppl,	40,	S23-7.	
	 255	
GOLIGORSKY,	M.	S.	2005.	Whispers	and	shouts	in	the	pathogenesis	of	acute	renal	ischaemia.	Nephrol	Dial	Transplant,	20,	261-6.	GOULD,	S.	J.	&	RAPOSO,	G.	2013.	As	we	wait:	coping	with	an	imperfect	nomenclature	for	extracellular	vesicles.	J	Extracell	Vesicles,	2.	GRAMM,	H.	J.,	MEINHOLD,	H.,	BICKEL,	U.,	ZIMMERMANN,	J.,	VON	HAMMERSTEIN,	B.,	KELLER,	F.,	DENNHARDT,	R.	&	VOIGT,	K.	1992.	Acute	endocrine	failure	after	brain	death?	Transplantation,	54,	851-7.	GREEN,	R.	M.	2007.	Can	we	develop	ethically	universal	embryonic	stem-cell	lines?	Nat	Rev	Genet,	8,	480-5.	GRIGORYEV,	D.	N.,	LIU,	M.,	HASSOUN,	H.	T.,	CHEADLE,	C.,	BARNES,	K.	C.	&	RABB,	H.	2008.	The	local	and	systemic	inflammatory	transcriptome	after	acute	kidney	injury.	J	Am	Soc	Nephrol,	19,	547-58.	GRINYO,	J.	M.,	BESTARD,	O.,	TORRAS,	J.	&	CRUZADO,	J.	M.	2010.	Optimal	immunosuppression	to	prevent	chronic	allograft	dysfunction.	Kidney	Int	
Suppl,	S66-70.	GUELER,	F.,	GWINNER,	W.,	SCHWARZ,	A.	&	HALLER,	H.	2004.	Long-term	effects	of	acute	ischemia	and	reperfusion	injury.	Kidney	Int,	66,	523-7.	GUTIERREZ-ARANDA,	I.,	RAMOS-MEJIA,	V.,	BUENO,	C.,	MUNOZ-LOPEZ,	M.,	REAL,	P.	J.,	MACIA,	A.,	SANCHEZ,	L.,	LIGERO,	G.,	GARCIA-PAREZ,	J.	L.	&	MENENDEZ,	P.	2010.	Human	induced	pluripotent	stem	cells	develop	teratoma	more	efficiently	and	faster	than	human	embryonic	stem	cells	regardless	the	site	of	injection.	Stem	Cells,	28,	1568-70.	GYORGY,	B.,	SZABO,	T.	G.,	PASZTOI,	M.,	PAL,	Z.,	MISJAK,	P.,	ARADI,	B.,	LASZLO,	V.,	PALLINGER,	E.,	PAP,	E.,	KITTEL,	A.,	NAGY,	G.,	FALUS,	A.	&	BUZAS,	E.	I.	2011.	Membrane	vesicles,	current	state-of-the-art:	emerging	role	of	extracellular	vesicles.	Cell	Mol	Life	Sci,	68,	2667-88.	HAMED,	M.	O.,	CHEN,	Y.,	PASEA,	L.,	WATSON,	C.	J.,	TORPEY,	N.,	BRADLEY,	J.	A.,	PETTIGREW,	G.	&	SAEB-PARSY,	K.	2015.	Early	graft	loss	after	kidney	transplantation:	risk	factors	and	consequences.	Am	J	Transplant,	15,	1632-43.	HAN,	C.,	SUN,	X.,	LIU,	L.,	JIANG,	H.,	SHEN,	Y.,	XU,	X.,	LI,	J.,	ZHANG,	G.,	HUANG,	J.,	LIN,	Z.,	XIONG,	N.	&	WANG,	T.	2016.	Exosomes	and	Their	Therapeutic	Potentials	of	Stem	Cells.	Stem	Cells	Int,	2016,	7653489.	HAN,	Z.,	JING,	Y.,	ZHANG,	S.,	LIU,	Y.,	SHI,	Y.	&	WEI,	L.	2012.	The	role	of	immunosuppression	of	mesenchymal	stem	cells	in	tissue	repair	and	tumor	growth.	Cell	Biosci,	2,	8.	HARA,	Y.,	STOLK,	M.,	RINGE,	J.,	DEHNE,	T.,	LADHOFF,	J.,	KOTSCH,	K.,	REUTZEL-SELKE,	A.,	REINKE,	P.,	VOLK,	H.	D.	&	SEIFERT,	M.	2011.	In	vivo	effect	of	bone	marrow-derived	mesenchymal	stem	cells	in	a	rat	kidney	transplantation	model	with	prolonged	cold	ischemia.	Transpl	Int,	24,	1112-23.	HARPER,	S.,	HOSGOOD,	S.,	KAY,	M.	&	NICHOLSON,	M.	2006.	Leucocyte	depletion	improves	renal	function	during	reperfusion	using	an	experimental	isolated	haemoperfused	organ	preservation	system.	Br	J	Surg,	93,	623-9.	HARVEY,	A.	M.	&	MALVIN,	R.	L.	1965.	Comparison	of	creatinine	and	inulin	clearances	in	male	and	female	rats.	Am	J	Physiol,	209,	849-52.	HE,	J.,	WANG,	Y.,	SUN,	S.,	YU,	M.,	WANG,	C.,	PEI,	X.,	ZHU,	B.,	WU,	J.	&	ZHAO,	W.	2012.	Bone	marrow	stem	cells-derived	microvesicles	protect	against	
	 256	
renal	injury	in	the	mouse	remnant	kidney	model.	Nephrology	(Carlton),	17,	493-500.	HEEMANN,	U.	&	LUTZ,	J.	2013.	Pathophysiology	and	treatment	options	of	chronic	renal	allograft	damage.	Nephrol	Dial	Transplant,	28,	2438-46.	HEIJNEN,	H.	F.,	SCHIEL,	A.	E.,	FIJNHEER,	R.,	GEUZE,	H.	J.	&	SIXMA,	J.	J.	1999.	Activated	platelets	release	two	types	of	membrane	vesicles:	microvesicles	by	surface	shedding	and	exosomes	derived	from	exocytosis	of	multivesicular	bodies	and	alpha-granules.	Blood,	94,	3791-9.	HENTZE,	H.,	SOONG,	P.	L.,	WANG,	S.	T.,	PHILLIPS,	B.	W.,	PUTTI,	T.	C.	&	DUNN,	N.	R.	2009.	Teratoma	formation	by	human	embryonic	stem	cells:	evaluation	of	essential	parameters	for	future	safety	studies.	Stem	Cell	Res,	2,	198-210.	HERRERA,	M.	B.,	BUSSOLATI,	B.,	BRUNO,	S.,	FONSATO,	V.,	ROMANAZZI,	G.	M.	&	CAMUSSI,	G.	2004.	Mesenchymal	stem	cells	contribute	to	the	renal	repair	of	acute	tubular	epithelial	injury.	Int	J	Mol	Med,	14,	1035-41.	HERRERA,	M.	B.,	BUSSOLATI,	B.,	BRUNO,	S.,	MORANDO,	L.,	MAURIELLO-ROMANAZZI,	G.,	SANAVIO,	F.,	STAMENKOVIC,	I.,	BIANCONE,	L.	&	CAMUSSI,	G.	2007.	Exogenous	mesenchymal	stem	cells	localize	to	the	kidney	by	means	of	CD44	following	acute	tubular	injury.	Kidney	Int,	72,	430-41.	HERRERA,	M.	B.,	FONSATO,	V.,	GATTI,	S.,	DEREGIBUS,	M.	C.,	SORDI,	A.,	CANTARELLA,	D.,	CALOGERO,	R.,	BUSSOLATI,	B.,	TETTA,	C.	&	CAMUSSI,	G.	2010.	Human	liver	stem	cell-derived	microvesicles	accelerate	hepatic	regeneration	in	hepatectomized	rats.	J	Cell	Mol	Med,	14,	1605-18.	HERRERO	F	,	M.	D.,	ZALDUMBIDE	L,	GARCÍA	E	,	CASANOVA-Q	2004.	A	New	Technique	of	Ureter	Anastomosis	in	Rat	Kidney	Surgery:	The	Temporary	Stent.	Spanish	Journal	of	Surgical	Research,	7,	172	-	174.	HEYMAN	SN,	R.	C.,	ROSEN	S.	2010.	Experimental	ischemia-reperfusion	biases	and	myths	-	the	proximal	vs	distal	hypoxic	tubular	injury	debate	revisited.	.	Kidney	Int,	77,	9	-	16.	HIRSCH,	F.	R.,	VARELLA-GARCIA,	M.,	BUNN,	P.	A.,	JR.,	DI	MARIA,	M.	V.,	VEVE,	R.,	BREMMES,	R.	M.,	BARON,	A.	E.,	ZENG,	C.	&	FRANKLIN,	W.	A.	2003.	Epidermal	growth	factor	receptor	in	non-small-cell	lung	carcinomas:	correlation	between	gene	copy	number	and	protein	expression	and	impact	on	prognosis.	J	Clin	Oncol,	21,	3798-807.	HORBELT,	M.,	LEE,	S.	Y.,	MANG,	H.	E.,	KNIPE,	N.	L.,	SADO,	Y.,	KRIBBEN,	A.	&	SUTTON,	T.	A.	2007.	Acute	and	chronic	microvascular	alterations	in	a	mouse	model	of	ischemic	acute	kidney	injury.	Am	J	Physiol	Renal	Physiol,	293,	F688-95.	HORWITZ,	E.	M.,	GORDON,	P.	L.,	KOO,	W.	K.,	MARX,	J.	C.,	NEEL,	M.	D.,	MCNALL,	R.	Y.,	MUUL,	L.	&	HOFMANN,	T.	2002.	Isolated	allogeneic	bone	marrow-derived	mesenchymal	cells	engraft	and	stimulate	growth	in	children	with	osteogenesis	imperfecta:	Implications	for	cell	therapy	of	bone.	Proc	Natl	
Acad	Sci	U	S	A,	99,	8932-7.	HOSGOOD,	S.	A.	&	NICHOLSON,	M.	L.	2011.	First	in	man	renal	transplantation	after	ex	vivo	normothermic	perfusion.	Transplantation,	92,	735-8.	HOSGOOD,	S.	A.,	VAN	HEURN,	E.	&	NICHOLSON,	M.	L.	2015.	Normothermic	machine	perfusion	of	the	kidney:	better	conditioning	and	repair?	Transpl	
Int,	28,	657-64.	
	 257	
HU,	G.	W.,	LI,	Q.,	NIU,	X.,	HU,	B.,	LIU,	J.,	ZHOU,	S.	M.,	GUO,	S.	C.,	LANG,	H.	L.,	ZHANG,	C.	Q.,	WANG,	Y.	&	DENG,	Z.	F.	2015.	Exosomes	secreted	by	human-induced	pluripotent	stem	cell-derived	mesenchymal	stem	cells	attenuate	limb	ischemia	by	promoting	angiogenesis	in	mice.	Stem	Cell	Res	Ther,	6,	10.	HUANG,	J.,	GRETZ,	N.	&	WEINFURTER,	S.	2016.	Filtration	markers	and	determination	methods	for	the	assessment	of	kidney	function.	Eur	J	
Pharmacol,	790,	92-98.	HUGEL,	B.,	MARTINEZ,	M.	C.,	KUNZELMANN,	C.	&	FREYSSINET,	J.	M.	2005.	Membrane	microparticles:	two	sides	of	the	coin.	Physiology	(Bethesda),	20,	22-7.	HUMPHREYS,	B.	D.	&	BONVENTRE,	J.	V.	2008.	Mesenchymal	stem	cells	in	acute	kidney	injury.	Annu	Rev	Med,	59,	311-25.	HUMPHREYS,	B.	D.,	VALERIUS,	M.	T.,	KOBAYASHI,	A.,	MUGFORD,	J.	W.,	SOEUNG,	S.,	DUFFIELD,	J.	S.,	MCMAHON,	A.	P.	&	BONVENTRE,	J.	V.	2008.	Intrinsic	epithelial	cells	repair	the	kidney	after	injury.	Cell	Stem	Cell,	2,	284-91.	HUYNH,	M.	J.,	VIOLETTE,	P.	D.,	ROWE,	N.	E.,	WEERNINK,	C.,	MACLEAN,	K.,	SENER,	A.	&	LUKE,	P.	P.	2015.	Donation	after	Circulatory	Death	Renal	Allografts--Does	Donor	Age	Greater	than	50	Years	Affect	Recipient	Outcomes?	J	Urol,	194,	1057-61.	IMBERTI,	B.,	MORIGI,	M.,	TOMASONI,	S.,	ROTA,	C.,	CORNA,	D.,	LONGARETTI,	L.,	ROTTOLI,	D.,	VALSECCHI,	F.,	BENIGNI,	A.,	WANG,	J.,	ABBATE,	M.,	ZOJA,	C.	&	REMUZZI,	G.	2007.	Insulin-like	growth	factor-1	sustains	stem	cell	mediated	renal	repair.	J	Am	Soc	Nephrol,	18,	2921-8.	IMBERTI,	B.,	TOMASONI,	S.,	CIAMPI,	O.,	PEZZOTTA,	A.,	DEROSAS,	M.,	XINARIS,	C.,	RIZZO,	P.,	PAPADIMOU,	E.,	NOVELLI,	R.,	BENIGNI,	A.,	REMUZZI,	G.	&	MORIGI,	M.	2015.	Renal	progenitors	derived	from	human	iPSCs	engraft	and	restore	function	in	a	mouse	model	of	acute	kidney	injury.	Sci	Rep,	5,	8826.	ITTRICH,	H.,	LANGE,	C.,	TOGEL,	F.,	ZANDER,	A.	R.,	DAHNKE,	H.,	WESTENFELDER,	C.,	ADAM,	G.	&	NOLTE-ERNSTING,	C.	2007.	In	vivo	magnetic	resonance	imaging	of	iron	oxide-labeled,	arterially-injected	mesenchymal	stem	cells	in	kidneys	of	rats	with	acute	ischemic	kidney	injury:	detection	and	monitoring	at	3T.	J	Magn	Reson	Imaging,	25,	1179-91.	IWAI,	S.,	SAKONJU,	I.,	OKANO,	S.,	TERATANI,	T.,	KASAHARA,	N.,	YOKOTE,	S.,	YOKOO,	T.	&	KOBAYASH,	E.	2014.	Impact	of	ex	vivo	administration	of	mesenchymal	stem	cells	on	the	function	of	kidney	grafts	from	cardiac	death	donors	in	rat.	Transplant	Proc,	46,	1578-84.	JABLONSKI,	P.,	HOWDEN,	B.,	RAE,	D.,	RIGOL,	G.,	BIRRELL,	C.,	MARSHALL,	V.	&	TANGE,	J.	1985.	The	influence	of	the	contralateral	kidney	upon	recovery	from	unilateral	warm	renal	ischemia.	Pathology,	17,	623-7.	JABLONSKI,	P.,	HOWDEN,	B.	O.,	RAE,	D.	A.,	BIRRELL,	C.	S.,	MARSHALL,	V.	C.	&	TANGE,	J.	1983.	An	experimental	model	for	assessment	of	renal	recovery	from	warm	ischemia.	Transplantation,	35,	198-204.	JAGER,	K.	J.,	VAN	DIJK,	P.	C.,	DEKKER,	F.	W.,	STENGEL,	B.,	SIMPSON,	K.,	BRIGGS,	J.	D.	&	COMMITTEE,	E.-E.	R.	2003.	The	epidemic	of	aging	in	renal	replacement	therapy:	an	update	on	elderly	patients	and	their	outcomes.	
Clin	Nephrol,	60,	352-60.	
	 258	
JANG,	H.	R.,	KO,	G.	J.,	WASOWSKA,	B.	A.	&	RABB,	H.	2009.	The	interaction	between	ischemia-reperfusion	and	immune	responses	in	the	kidney.	J	Mol	Med	
(Berl),	87,	859-64.	JI,	H.,	CHEN,	M.,	GREENING,	D.	W.,	HE,	W.,	RAI,	A.,	ZHANG,	W.	&	SIMPSON,	R.	J.	2014.	Deep	sequencing	of	RNA	from	three	different	extracellular	vesicle	(EV)	subtypes	released	from	the	human	LIM1863	colon	cancer	cell	line	uncovers	distinct	miRNA-enrichment	signatures.	PLoS	One,	9,	e110314.	JIANG,	X.	X.,	ZHANG,	Y.,	LIU,	B.,	ZHANG,	S.	X.,	WU,	Y.,	YU,	X.	D.	&	MAO,	N.	2005.	Human	mesenchymal	stem	cells	inhibit	differentiation	and	function	of	monocyte-derived	dendritic	cells.	Blood,	105,	4120-6.	JO,	S.	K.,	YUN,	S.	Y.,	CHANG,	K.	H.,	CHA,	D.	R.,	CHO,	W.	Y.,	KIM,	H.	K.	&	WON,	N.	H.	2001.	alpha-MSH	decreases	apoptosis	in	ischaemic	acute	renal	failure	in	rats:	possible	mechanism	of	this	beneficial	effect.	Nephrol	Dial	Transplant,	16,	1583-91.	JOBIN,	J.	&	BONJOUR,	J.	P.	1985.	Measurement	of	glomerular	filtration	rate	in	conscious	unrestrained	rats	with	inulin	infused	by	implanted	osmotic	pumps.	Am	J	Physiol,	248,	F734-8.	JOHNSON,	R.	J.,	FUGGLE,	S.	V.,	MUMFORD,	L.,	BRADLEY,	J.	A.,	FORSYTHE,	J.	L.,	RUDGE,	C.	J.,	KIDNEY	ADVISORY	GROUP	OF,	N.	H.	S.	B.	&	TRANSPLANT	2010.	A	New	UK	2006	National	Kidney	Allocation	Scheme	for	deceased	heart-beating	donor	kidneys.	Transplantation,	89,	387-94.	JOHNSTONE,	R.	M.,	ADAM,	M.,	HAMMOND,	J.	R.,	ORR,	L.	&	TURBIDE,	C.	1987.	Vesicle	formation	during	reticulocyte	maturation.	Association	of	plasma	membrane	activities	with	released	vesicles	(exosomes).	J	Biol	Chem,	262,	9412-20.	JOOSTEN,	S.	A.,	VAN	KOOTEN,	C.,	SIJPKENS,	Y.	W.,	DE	FIJTER,	J.	W.	&	PAUL,	L.	C.	2004.	The	pathobiology	of	chronic	allograft	nephropathy:	immune-mediated	damage	and	accelerated	aging.	Kidney	Int,	65,	1556-9.	KARNOUB,	A.	E.,	DASH,	A.	B.,	VO,	A.	P.,	SULLIVAN,	A.,	BROOKS,	M.	W.,	BELL,	G.	W.,	RICHARDSON,	A.	L.,	POLYAK,	K.,	TUBO,	R.	&	WEINBERG,	R.	A.	2007.	Mesenchymal	stem	cells	within	tumour	stroma	promote	breast	cancer	metastasis.	Nature,	449,	557-63.	KASSAB,	S.,	HAMDY,	H.,	ABDULGHAFFAR,	T.	&	GRANGER,	J.	P.	2001.	Effects	of	endothelin-A	receptor	antagonism	on	bilateral	renal	function	in	renovascular	hypertensive	rats.	Fundam	Clin	Pharmacol,	15,	379-85.	KATAYAMA,	R.,	WATANABE,	K.,	YAMAGISHI,	N.,	ABE,	S.,	SATOH,	H.	&	FURUHAMA,	K.	2011.	Sequential	measurements	of	glomerular	filtration	rate	in	conscious	rats	by	a	bolus	injection	of	iodixanol	and	a	single	blood	sample.	J	Appl	Toxicol,	31,	360-5.	KATAYAMA,	R.,	YAMAGUCHI,	N.,	YAMASHITA,	T.,	WATANABE,	S.,	SATOH,	H.,	YAMAGISHI,	N.	&	FURUHAMA,	K.	2010.	Calculation	of	glomerular	filtration	rate	in	conscious	rats	by	the	use	of	a	bolus	injection	of	iodixanol	and	a	single	blood	sample.	J	Pharmacol	Toxicol	Methods,	61,	59-64.	KATHS,	J.	M.,	CEN,	J.	Y.,	CHUN,	Y.	M.,	ECHEVERRI,	J.,	LINARES,	I.,	GANESH,	S.,	YIP,	P.,	JOHN,	R.,	BAGLI,	D.,	MUCSI,	I.,	GHANEKAR,	A.,	GRANT,	D.	R.,	ROBINSON,	L.	A.	&	SELZNER,	M.	2016a.	Continuous	Normothermic	Ex	Vivo	Kidney	Perfusion	Is	Superior	to	Brief	Normothermic	Perfusion	Following	Static	Cold	Storage	in	Donation	After	Circulatory	Death	Pig	Kidney	Transplantation.	Am	J	Transplant.	
	 259	
KATHS,	J.	M.,	ECHEVERRI,	J.,	CHUN,	Y.	M.,	CEN,	J.	Y.,	GOLDARACENA,	N.,	LINARES,	I.,	DINGWELL,	L.	S.,	YIP,	P.,	JOHN,	R.,	BAGLI,	D.,	MUCSI,	I.,	GHANEKAR,	A.,	GRANT,	D.,	ROBINSON,	L.	&	SELZNER,	M.	2016b.	Continuous	Normothermic	Ex	Vivo	Kidney	Perfusion	Improves	Graft	Function	in	Donation	after	Circulatory	Death	Pig	Kidney	Transplantation.	
Transplantation.	KATHS,	J.	M.,	ECHEVERRI,	J.,	GOLDARACENA,	N.,	LOUIS,	K.	S.,	CHUN,	Y.	M.,	LINARES,	I.,	WIEBE,	A.,	FOLTYS,	D.	B.,	YIP,	P.	M.,	JOHN,	R.,	MUCSI,	I.,	GHANEKAR,	A.,	BAGLI,	D.	J.,	GRANT,	D.	R.,	ROBINSON,	L.	A.	&	SELZNER,	M.	2016c.	Eight-Hour	Continuous	Normothermic	Ex	Vivo	Kidney	Perfusion	Is	a	Safe	Preservation	Technique	for	Kidney	Transplantation:	A	New	Opportunity	for	the	Storage,	Assessment,	and	Repair	of	Kidney	Grafts.	
Transplantation,	100,	1862-70.	KATO,	N.,	YUZAWA,	Y.,	KOSUGI,	T.,	HOBO,	A.,	SATO,	W.,	MIWA,	Y.,	SAKAMOTO,	K.,	MATSUO,	S.	&	KADOMATSU,	K.	2009.	The	E-selectin	ligand	basigin/CD147	is	responsible	for	neutrophil	recruitment	in	renal	ischemia/reperfusion.	J	
Am	Soc	Nephrol,	20,	1565-76.	KATSUDA,	T.,	KOSAKA,	N.,	TAKESHITA,	F.	&	OCHIYA,	T.	2013.	The	therapeutic	potential	of	mesenchymal	stem	cell-derived	extracellular	vesicles.	
Proteomics,	13,	1637-53.	KAY,	M.	D.,	HOSGOOD,	S.	A.,	HARPER,	S.	J.,	BAGUL,	A.,	WALLER,	H.	L.	&	NICHOLSON,	M.	L.	2011.	Normothermic	versus	hypothermic	ex	vivo	flush	using	a	novel	phosphate-free	preservation	solution	(AQIX)	in	porcine	kidneys.	J	Surg	Res,	171,	275-82.	KAYLER,	L.	K.,	MAGLIOCCA,	J.,	ZENDEJAS,	I.,	SRINIVAS,	T.	R.	&	SCHOLD,	J.	D.	2011.	Impact	of	cold	ischemia	time	on	graft	survival	among	ECD	transplant	recipients:	a	paired	kidney	analysis.	Am	J	Transplant,	11,	2647-56.	KEERTHIKUMAR,	S.,	CHISANGA,	D.,	ARIYARATNE,	D.,	AL	SAFFAR,	H.,	ANAND,	S.,	ZHAO,	K.,	SAMUEL,	M.,	PATHAN,	M.,	JOIS,	M.,	CHILAMKURTI,	N.,	GANGODA,	L.	&	MATHIVANAN,	S.	2016.	ExoCarta:	A	Web-Based	Compendium	of	Exosomal	Cargo.	J	Mol	Biol,	428,	688-92.	KELLERMAN,	P.	S.	1993.	Exogenous	adenosine	triphosphate	(ATP)	preserves	proximal	tubule	microfilament	structure	and	function	in	vivo	in	a	maleic	acid	model	of	ATP	depletion.	J	Clin	Invest,	92,	1940-9.	KERN,	S.,	EICHLER,	H.,	STOEVE,	J.,	KLUTER,	H.	&	BIEBACK,	K.	2006.	Comparative	analysis	of	mesenchymal	stem	cells	from	bone	marrow,	umbilical	cord	blood,	or	adipose	tissue.	Stem	Cells,	24,	1294-301.	KHALIFEH,	T.,	BAULIER,	E.,	LE	PAPE,	S.,	KERFORNE,	T.,	COUDROY,	R.,	MAIGA,	S.,	HAUET,	T.,	PINSARD,	M.	&	FAVREAU,	F.	2015.	Strategies	to	optimize	kidney	recovery	and	preservation	in	transplantation:	specific	aspects	in	pediatric	transplantation.	Pediatr	Nephrol,	30,	1243-54.	KHWAJA,	A.	2012.	KDIGO	clinical	practice	guidelines	for	acute	kidney	injury.	
Nephron	Clin	Pract,	120,	c179-84.	KIM,	J.	&	PADANILAM,	B.	J.	2015.	Renal	denervation	prevents	long-term	sequelae	of	ischemic	renal	injury.	Kidney	Int,	87,	350-8.	KIRK,	A.	D.	2003.	Crossing	the	bridge:	large	animal	models	in	translational	transplantation	research.	Immunol	Rev,	196,	176-96.	
	 260	
KOBAYASHI,	E.,	HISHIKAWA,	S.,	TERATANI,	T.	&	LEFOR,	A.	T.	2012.	The	pig	as	a	model	for	translational	research:	overview	of	porcine	animal	models	at	Jichi	Medical	University.	Transplant	Res,	1,	8.	KOCH,	M.,	LEMKE,	A.	&	LANGE,	C.	2015.	Extracellular	Vesicles	from	MSC	Modulate	the	Immune	Response	to	Renal	Allografts	in	a	MHC	Disparate	Rat	Model.	Stem	Cells	Int,	2015,	486141.	KOFFMAN,	G.	&	GAMBARO,	G.	2003.	Renal	transplantation	from	non-heart-	beating	donors:	a	review	of	the	European	experience.	J	Nephrol,	16,	334-41.	KONTODIMOPOULOS,	N.	&	NIAKAS,	D.	2008.	An	estimate	of	lifelong	costs	and	QALYs	in	renal	replacement	therapy	based	on	patients'	life	expectancy.	
Health	Policy,	86,	85-96.	KOPPELSTAETTER,	C.,	SCHRATZBERGER,	G.,	PERCO,	P.,	HOFER,	J.,	MARK,	W.,	OLLINGER,	R.,	OBERBAUER,	R.,	SCHWARZ,	C.,	MITTERBAUER,	C.,	KAINZ,	A.,	KARKOSZKA,	H.,	WIECEK,	A.,	MAYER,	B.	&	MAYER,	G.	2008.	Markers	of	cellular	senescence	in	zero	hour	biopsies	predict	outcome	in	renal	transplantation.	Aging	Cell,	7,	491-7.	KORDELAS,	L.,	REBMANN,	V.,	LUDWIG,	A.	K.,	RADTKE,	S.,	RUESING,	J.,	DOEPPNER,	T.	R.,	EPPLE,	M.,	HORN,	P.	A.,	BEELEN,	D.	W.	&	GIEBEL,	B.	2014.	MSC-derived	exosomes:	a	novel	tool	to	treat	therapy-refractory	graft-versus-host	disease.	Leukemia,	28,	970-3.	KOSIERADZKI,	M.	&	ROWINSKI,	W.	2008.	Ischemia/reperfusion	injury	in	kidney	transplantation:	mechanisms	and	prevention.	Transplant	Proc,	40,	3279-88.	KRAITCHMAN,	D.	L.,	TATSUMI,	M.,	GILSON,	W.	D.,	ISHIMORI,	T.,	KEDZIOREK,	D.,	WALCZAK,	P.,	SEGARS,	W.	P.,	CHEN,	H.	H.,	FRITZGES,	D.,	IZBUDAK,	I.,	YOUNG,	R.	G.,	MARCELINO,	M.,	PITTENGER,	M.	F.,	SOLAIYAPPAN,	M.,	BOSTON,	R.	C.,	TSUI,	B.	M.,	WAHL,	R.	L.	&	BULTE,	J.	W.	2005.	Dynamic	imaging	of	allogeneic	mesenchymal	stem	cells	trafficking	to	myocardial	infarction.	Circulation,	112,	1451-61.	KRAMPERA,	M.,	GLENNIE,	S.,	DYSON,	J.,	SCOTT,	D.,	LAYLOR,	R.,	SIMPSON,	E.	&	DAZZI,	F.	2003.	Bone	marrow	mesenchymal	stem	cells	inhibit	the	response	of	naive	and	memory	antigen-specific	T	cells	to	their	cognate	peptide.	Blood,	101,	3722-9.	KUEHBACHER,	A.,	URBICH,	C.,	ZEIHER,	A.	M.	&	DIMMELER,	S.	2007.	Role	of	Dicer	and	Drosha	for	endothelial	microRNA	expression	and	angiogenesis.	Circ	
Res,	101,	59-68.	KUNTER,	U.,	RONG,	S.,	BOOR,	P.,	EITNER,	F.,	MULLER-NEWEN,	G.,	DJURIC,	Z.,	VAN	ROEYEN,	C.	R.,	KONIECZNY,	A.,	OSTENDORF,	T.,	VILLA,	L.,	MILOVANCEVA-POPOVSKA,	M.,	KERJASCHKI,	D.	&	FLOEGE,	J.	2007.	Mesenchymal	stem	cells	prevent	progressive	experimental	renal	failure	but	maldifferentiate	into	glomerular	adipocytes.	J	Am	Soc	Nephrol,	18,	1754-64.	KURODA,	T.,	YASUDA,	S.	&	SATO,	Y.	2013.	Tumorigenicity	studies	for	human	pluripotent	stem	cell-derived	products.	Biol	Pharm	Bull,	36,	189-92.	KURODA,	Y.,	KITADA,	M.,	WAKAO,	S.,	NISHIKAWA,	K.,	TANIMURA,	Y.,	MAKINOSHIMA,	H.,	GODA,	M.,	AKASHI,	H.,	INUTSUKA,	A.,	NIWA,	A.,	SHIGEMOTO,	T.,	NABESHIMA,	Y.,	NAKAHATA,	T.,	NABESHIMA,	Y.,	FUJIYOSHI,	Y.	&	DEZAWA,	M.	2010.	Unique	multipotent	cells	in	adult	
	 261	
human	mesenchymal	cell	populations.	Proc	Natl	Acad	Sci	U	S	A,	107,	8639-43.	KWON,	O.,	HONG,	S.	M.	&	RAMESH,	G.	2009.	Diminished	NO	generation	by	injured	endothelium	and	loss	of	macula	densa	nNOS	may	contribute	to	sustained	acute	kidney	injury	after	ischemia-reperfusion.	Am	J	Physiol	Renal	Physiol,	296,	F25-33.	LAI,	C.	P.,	KIM,	E.	Y.,	BADR,	C.	E.,	WEISSLEDER,	R.,	MEMPEL,	T.	R.,	TANNOUS,	B.	A.	&	BREAKEFIELD,	X.	O.	2015.	Visualization	and	tracking	of	tumour	extracellular	vesicle	delivery	and	RNA	translation	using	multiplexed	reporters.	Nat	Commun,	6,	7029.	LAI,	R.	C.,	CHEN,	T.	S.	&	LIM,	S.	K.	2011.	Mesenchymal	stem	cell	exosome:	a	novel	stem	cell-based	therapy	for	cardiovascular	disease.	Regen	Med,	6,	481-92.	LAI,	R.	C.,	TAN,	S.	S.,	TEH,	B.	J.,	SZE,	S.	K.,	ARSLAN,	F.,	DE	KLEIJN,	D.	P.,	CHOO,	A.	&	LIM,	S.	K.	2012.	Proteolytic	Potential	of	the	MSC	Exosome	Proteome:	Implications	for	an	Exosome-Mediated	Delivery	of	Therapeutic	Proteasome.	Int	J	Proteomics,	2012,	971907.	LAI,	R.	C.,	YEO,	R.	W.,	TAN,	K.	H.	&	LIM,	S.	K.	2013.	Exosomes	for	drug	delivery	-	a	novel	application	for	the	mesenchymal	stem	cell.	Biotechnol	Adv,	31,	543-51.	LAMB,	K.	E.,	LODHI,	S.	&	MEIER-KRIESCHE,	H.	U.	2011.	Long-term	renal	allograft	survival	in	the	United	States:	a	critical	reappraisal.	Am	J	Transplant,	11,	450-62.	LAMEIRE,	N.	2005.	The	pathophysiology	of	acute	renal	failure.	Crit	Care	Clin,	21,	197-210.	LAMEIRE,	N.,	VAN	BIESEN,	W.	&	VANHOLDER,	R.	2005.	Acute	renal	failure.	
Lancet,	365,	417-30.	LAMEIRE,	N.,	VAN	BIESEN,	W.,	VANHOLDER,	R.	&	COLARDIJN,	F.	1998.	The	place	of	intermittent	hemodialysis	in	the	treatment	of	acute	renal	failure	in	the	ICU	patient.	Kidney	Int	Suppl,	66,	S110-9.	LAMEIRE,	N.	H.	&	VANHOLDER,	R.	2004.	Pathophysiology	of	ischaemic	acute	renal	failure.	Best	Pract	Res	Clin	Anaesthesiol,	18,	21-36.	LANGE,	C.,	TOGEL,	F.,	ITTRICH,	H.,	CLAYTON,	F.,	NOLTE-ERNSTING,	C.,	ZANDER,	A.	R.	&	WESTENFELDER,	C.	2005.	Administered	mesenchymal	stem	cells	enhance	recovery	from	ischemia/reperfusion-induced	acute	renal	failure	in	rats.	Kidney	Int,	68,	1613-7.	LAUPACIS,	A.,	KEOWN,	P.,	PUS,	N.,	KRUEGER,	H.,	FERGUSON,	B.,	WONG,	C.	&	MUIRHEAD,	N.	1996.	A	study	of	the	quality	of	life	and	cost-utility	of	renal	transplantation.	Kidney	Int,	50,	235-42.	LE	BLANC,	K.	2006.	Mesenchymal	stromal	cells:	Tissue	repair	and	immune	modulation.	Cytotherapy,	8,	559-61.	LE	CLEF,	N.,	VERHULST,	A.,	D'HAESE,	P.	C.	&	VERVAET,	B.	A.	2016.	Unilateral	Renal	Ischemia-Reperfusion	as	a	Robust	Model	for	Acute	to	Chronic	Kidney	Injury	in	Mice.	PLoS	One,	11,	e0152153.	LECH,	M.,	AVILA-FERRUFINO,	A.,	ALLAM,	R.,	SEGERER,	S.,	KHANDOGA,	A.,	KROMBACH,	F.,	GARLANDA,	C.,	MANTOVANI,	A.	&	ANDERS,	H.	J.	2009.	Resident	dendritic	cells	prevent	postischemic	acute	renal	failure	by	help	of	single	Ig	IL-1	receptor-related	protein.	J	Immunol,	183,	4109-18.	LEE,	C.	Y.	&	MANGINO,	M.	J.	2009.	Preservation	methods	for	kidney	and	liver.	
Organogenesis,	5,	105-12.	
	 262	
LEE,	P.	Y.,	CHIEN,	Y.,	CHIOU,	G.	Y.,	LIN,	C.	H.,	CHIOU,	C.	H.	&	TARNG,	D.	C.	2012.	Induced	pluripotent	stem	cells	without	c-Myc	attenuate	acute	kidney	injury	via	downregulating	the	signaling	of	oxidative	stress	and	inflammation	in	ischemia-reperfusion	rats.	Cell	Transplant,	21,	2569-85.	LEE,	R.	H.,	PULIN,	A.	A.,	SEO,	M.	J.,	KOTA,	D.	J.,	YLOSTALO,	J.,	LARSON,	B.	L.,	SEMPRUN-PRIETO,	L.,	DELAFONTAINE,	P.	&	PROCKOP,	D.	J.	2009.	Intravenous	hMSCs	improve	myocardial	infarction	in	mice	because	cells	embolized	in	lung	are	activated	to	secrete	the	anti-inflammatory	protein	TSG-6.	Cell	Stem	Cell,	5,	54-63.	LIEBERTHAL,	W.	&	NIGAM,	S.	K.	2000.	Acute	renal	failure.	II.	Experimental	models	of	acute	renal	failure:	imperfect	but	indispensable.	Am	J	Physiol	
Renal	Physiol,	278,	F1-F12.	LIN,	K.,	MATSUBARA,	Y.,	MASUDA,	Y.,	TOGASHI,	K.,	OHNO,	T.,	TAMURA,	T.,	TOYOSHIMA,	Y.,	SUGIMACHI,	K.,	TOYODA,	M.,	MARC,	H.	&	DOUGLAS,	A.	2008.	Characterization	of	adipose	tissue-derived	cells	isolated	with	the	Celution	system.	Cytotherapy,	10,	417-26.	LIN,	K.	C.,	YIP,	H.	K.,	SHAO,	P.	L.,	WU,	S.	C.,	CHEN,	K.	H.,	CHEN,	Y.	T.,	YANG,	C.	C.,	SUN,	C.	K.,	KAO,	G.	S.,	CHEN,	S.	Y.,	CHAI,	H.	T.,	CHANG,	C.	L.,	CHEN,	C.	H.	&	LEE,	M.	S.	2016.	Combination	of	adipose-derived	mesenchymal	stem	cells	(ADMSC)	and	ADMSC-derived	exosomes	for	protecting	kidney	from	acute	ischemia-reperfusion	injury.	Int	J	Cardiol,	216,	173-85.	LINFERT,	D.,	CHOWDHRY,	T.	&	RABB,	H.	2009.	Lymphocytes	and	ischemia-reperfusion	injury.	Transplant	Rev	(Orlando),	23,	1-10.	LITTLE,	M.	H.	2016.	Growing	Kidney	Tissue	from	Stem	Cells:	How	Far	from	"Party	Trick"	to	Medical	Application?	Cell	Stem	Cell,	18,	695-8.	LITTLE,	M.	H.	&	KAIRATH,	P.	2016.	Regenerative	medicine	in	kidney	disease.	
Kidney	Int,	90,	289-99.	LIU,	K.	D.	&	BRAKEMAN,	P.	R.	2008.	Renal	repair	and	recovery.	Crit	Care	Med,	36,	S187-92.	LORENZ,	J.	N.	&	GRUENSTEIN,	E.	1999.	A	simple,	nonradioactive	method	for	evaluating	single-nephron	filtration	rate	using	FITC-inulin.	Am	J	Physiol,	276,	F172-7.	LOVELL-BADGE,	R.	2001.	The	future	for	stem	cell	research.	Nature,	414,	88-91.	LUNNEY,	J.	K.	2007.	Advances	in	swine	biomedical	model	genomics.	Int	J	Biol	Sci,	3,	179-84.	LYE,	K.	L.,	NORDIN,	N.,	VIDYADARAN,	S.	&	THILAKAVATHY,	K.	2016.	Mesenchymal	stem	cells:	From	stem	cells	to	sarcomas.	Cell	Biol	Int,	40,	610-8.	MAHMOOD,	A.,	LU,	D.,	LU,	M.	&	CHOPP,	M.	2003.	Treatment	of	traumatic	brain	injury	in	adult	rats	with	intravenous	administration	of	human	bone	marrow	stromal	cells.	Neurosurgery,	53,	697-702;	discussion	702-3.	MAITRA,	A.,	ARKING,	D.	E.,	SHIVAPURKAR,	N.,	IKEDA,	M.,	STASTNY,	V.,	KASSAUEI,	K.,	SUI,	G.,	CUTLER,	D.	J.,	LIU,	Y.,	BRIMBLE,	S.	N.,	NOAKSSON,	K.,	HYLLNER,	J.,	SCHULZ,	T.	C.,	ZENG,	X.,	FREED,	W.	J.,	CROOK,	J.,	ABRAHAM,	S.,	COLMAN,	A.,	SARTIPY,	P.,	MATSUI,	S.,	CARPENTER,	M.,	GAZDAR,	A.	F.,	RAO,	M.	&	CHAKRAVARTI,	A.	2005.	Genomic	alterations	in	cultured	human	embryonic	stem	cells.	Nat	Genet,	37,	1099-103.	
	 263	
MALIS,	C.	D.,	CHEUNG,	J.	Y.,	LEAF,	A.	&	BONVENTRE,	J.	V.	1983.	Effects	of	verapamil	in	models	of	ischemic	acute	renal	failure	in	the	rat.	Am	J	Physiol,	245,	F735-42.	MANGE,	K.	C.,	JOFFE,	M.	M.	&	FELDMAN,	H.	I.	2001.	Effect	of	the	use	or	nonuse	of	long-term	dialysis	on	the	subsequent	survival	of	renal	transplants	from	living	donors.	N	Engl	J	Med,	344,	726-31.	MANGI,	A.	A.,	NOISEUX,	N.,	KONG,	D.,	HE,	H.,	REZVANI,	M.,	INGWALL,	J.	S.	&	DZAU,	V.	J.	2003.	Mesenchymal	stem	cells	modified	with	Akt	prevent	remodeling	and	restore	performance	of	infarcted	hearts.	Nat	Med,	9,	1195-201.	MANNELLO,	F.	&	TONTI,	G.	A.	2007.	Concise	review:	no	breakthroughs	for	human	mesenchymal	and	embryonic	stem	cell	culture:	conditioned	medium,	feeder	layer,	or	feeder-free;	medium	with	fetal	calf	serum,	human	serum,	or	enriched	plasma;	serum-free,	serum	replacement	nonconditioned	medium,	or	ad	hoc	formula?	All	that	glitters	is	not	gold!	
Stem	Cells,	25,	1603-9.	MANTOVANI,	A.	2012.	MSCs,	macrophages,	and	cancer:	a	dangerous	menage-a-trois.	Cell	Stem	Cell,	11,	730-2.	MARCEN,	R.	2009.	Immunosuppressive	drugs	in	kidney	transplantation:	impact	on	patient	survival,	and	incidence	of	cardiovascular	disease,	malignancy	and	infection.	Drugs,	69,	2227-43.	MARCEN,	R.,	FERNANDEZ-RODRIGUEZ,	A.,	RODRIGUEZ-MENDIOLA,	N.,	PONTE,	B.,	GALEANO,	C.,	VILLAFRUELA,	J.	J.,	TERUEL,	J.	L.,	BURGOS,	F.	J.	&	ORTUNO,	J.	2009.	Evolution	of	rejection	rates	and	kidney	graft	survival:	a	historical	analysis.	Transplant	Proc,	41,	2357-9.	MARSHALL,	M.	R.,	POLKINGHORNE,	K.	R.,	KERR,	P.	G.,	AGAR,	J.	W.,	HAWLEY,	C.	M.	&	MCDONALD,	S.	P.	2015.	Temporal	Changes	in	Mortality	Risk	by	Dialysis	Modality	in	the	Australian	and	New	Zealand	Dialysis	Population.	Am	J	
Kidney	Dis,	66,	489-98.	MARSHALL	V,	J.	P.,	HOWDEN	B,	LESLIE	E,	RAE	D,	TANGE	J.	1982.	Recovery	of	renal	function	in	the	rat	after	warm	ischaemia:	functional	and	morphological	changes.	Organ	Preservation,	1,	69	-76.	MARTIN	NAVARRO,	J.,	ORTEGA,	M.,	GUTIERREZ,	M.	J.,	GARCIA	MARTIN,	F.,	ALCAZAR,	J.	M.,	MORALES,	J.	M.,	ANDRES,	A.	&	PRAGA,	M.	2009.	Survival	of	patients	older	than	60	years	with	kidneys	transplanted	from	Spanish	expanded	criteria	donors	versus	patients	continued	on	hemodialysis.	
Transplant	Proc,	41,	2376-8.	MASOUD,	M.	S.,	ANWAR,	S.	S.,	AFZAL,	M.	Z.,	MEHMOOD,	A.,	KHAN,	S.	N.	&	RIAZUDDIN,	S.	2012.	Pre-conditioned	mesenchymal	stem	cells	ameliorate	renal	ischemic	injury	in	rats	by	augmented	survival	and	engraftment.	J	
Transl	Med,	10,	243.	MATAS,	A.	J.,	GILLINGHAM,	K.	J.,	PAYNE,	W.	D.	&	NAJARIAN,	J.	S.	1994.	The	impact	of	an	acute	rejection	episode	on	long-term	renal	allograft	survival	(t1/2).	
Transplantation,	57,	857-9.	MATAS,	A.	J.,	SMITH,	J.	M.,	SKEANS,	M.	A.,	LAMB,	K.	E.,	GUSTAFSON,	S.	K.,	SAMANA,	C.	J.,	STEWART,	D.	E.,	SNYDER,	J.	J.,	ISRANI,	A.	K.	&	KASISKE,	B.	L.	2013.	OPTN/SRTR	2011	Annual	Data	Report:	kidney.	Am	J	Transplant,	13	Suppl	1,	11-46.	MATAS,	A.	J.,	SMITH,	J.	M.,	SKEANS,	M.	A.,	THOMPSON,	B.,	GUSTAFSON,	S.	K.,	SCHNITZLER,	M.	A.,	STEWART,	D.	E.,	CHERIKH,	W.	S.,	WAINRIGHT,	J.	L.,	
	 264	
SNYDER,	J.	J.,	ISRANI,	A.	K.	&	KASISKE,	B.	L.	2014.	OPTN/SRTR	2012	Annual	Data	Report:	kidney.	Am	J	Transplant,	14	Suppl	1,	11-44.	MCGLYNN,	L.	M.,	ELLER,	K.,	MACDONALD,	A.	I.,	MACINTYRE,	A.,	RUSSELL,	D.,	KOPPELSTAETTER,	C.,	DAVIES,	R.	W.	&	SHIELS,	P.	G.	2013.	Pathfinder	cells	provide	a	novel	therapeutic	intervention	for	acute	kidney	injury.	
Rejuvenation	Res,	16,	11-20.	MCGLYNN,	L.	M.,	STEVENSON,	K.,	LAMB,	K.,	ZINO,	S.,	BROWN,	M.,	PRINA,	A.,	KINGSMORE,	D.	&	SHIELS,	P.	G.	2009.	Cellular	senescence	in	pretransplant	renal	biopsies	predicts	postoperative	organ	function.	Aging	Cell,	8,	45-51.	MCGUINNESS,	D.,	ANTHONY,	D.	F.,	MOULISOVA,	V.,	MACDONALD,	A.,	MACINTYRE,	A.,	THOMSON,	J.,	NAG,	A.,	DAVIES,	R.	W.	&	SHIELS,	P.	G.	2016.	Microvesicles	but	Not	Exosomes	from	Pathfinder	Cells	Stimulate	Functional	Recovery	of	the	Pancreas	in	a	Mouse	Streptozotocin-Induced	Diabetes	Model.	Rejuvenation	Res.	MEIER-KRIESCHE,	H.	U.	&	KAPLAN,	B.	2002.	Waiting	time	on	dialysis	as	the	strongest	modifiable	risk	factor	for	renal	transplant	outcomes:	a	paired	donor	kidney	analysis.	Transplantation,	74,	1377-81.	MEIER-KRIESCHE,	H.	U.,	OJO,	A.	O.,	PORT,	F.	K.,	ARNDORFER,	J.	A.,	CIBRIK,	D.	M.	&	KAPLAN,	B.	2001.	Survival	improvement	among	patients	with	end-stage	renal	disease:	trends	over	time	for	transplant	recipients	and	wait-listed	patients.	J	Am	Soc	Nephrol,	12,	1293-6.	MEIER-KRIESCHE,	H.	U.,	SCHOLD,	J.	D.,	GASTON,	R.	S.,	WADSTROM,	J.	&	KAPLAN,	B.	2005.	Kidneys	from	deceased	donors:	maximizing	the	value	of	a	scarce	resource.	Am	J	Transplant,	5,	1725-30.	MELK,	A.,	SCHMIDT,	B.	M.,	VONGWIWATANA,	A.,	RAYNER,	D.	C.	&	HALLORAN,	P.	F.	2005.	Increased	expression	of	senescence-associated	cell	cycle	inhibitor	p16INK4a	in	deteriorating	renal	transplants	and	diseased	native	kidney.	Am	J	Transplant,	5,	1375-82.	MELNIKOV,	V.	Y.,	FAUBEL,	S.,	SIEGMUND,	B.,	LUCIA,	M.	S.,	LJUBANOVIC,	D.	&	EDELSTEIN,	C.	L.	2002.	Neutrophil-independent	mechanisms	of	caspase-1-	and	IL-18-mediated	ischemic	acute	tubular	necrosis	in	mice.	J	Clin	
Invest,	110,	1083-91.	MENETON,	P.,	ICHIKAWA,	I.,	INAGAMI,	T.	&	SCHNERMANN,	J.	2000.	Renal	physiology	of	the	mouse.	Am	J	Physiol	Renal	Physiol,	278,	F339-51.	MERION,	R.	M.	2005.	Expanded	criteria	donors	for	kidney	transplantation.	
Transplant	Proc,	37,	3655-7.	METCALFE,	M.	S.,	BUTTERWORTH,	P.	C.,	WHITE,	S.	A.,	SAUNDERS,	R.	N.,	MURPHY,	G.	J.,	TAUB,	N.,	VEITCH,	P.	S.	&	NICHOLSON,	M.	L.	2001a.	A	case-control	comparison	of	the	results	of	renal	transplantation	from	heart-beating	and	non-heart-beating	donors.	Transplantation,	71,	1556-9.	METCALFE,	M.	S.,	WHITE,	S.	A.,	SAUNDERS,	R.	N.,	MURPHY,	G.	J.,	HORSBURGH,	T.,	KNIGHT,	A.	J.	&	NICHOLSON,	M.	L.	2001b.	Long-term	results	of	renal	transplantation	using	organs	from	non-heart-beating	donors.	Transplant	
Proc,	33,	826.	METZGER,	R.	A.,	DELMONICO,	F.	L.,	FENG,	S.,	PORT,	F.	K.,	WYNN,	J.	J.	&	MERION,	R.	M.	2003.	Expanded	criteria	donors	for	kidney	transplantation.	Am	J	
Transplant,	3	Suppl	4,	114-25.	MEYER,	M.	H.,	MEYER,	R.	A.,	JR.,	GRAY,	R.	W.	&	IRWIN,	R.	L.	1985.	Picric	acid	methods	greatly	overestimate	serum	creatinine	in	mice:	more	accurate	
	 265	
results	with	high-performance	liquid	chromatography.	Anal	Biochem,	144,	285-90.	MIAS,	C.,	TROUCHE,	E.,	SEGUELAS,	M.	H.,	CALCAGNO,	F.,	DIGNAT-GEORGE,	F.,	SABATIER,	F.,	PIERCECCHI-MARTI,	M.	D.,	DANIEL,	L.,	BIANCHI,	P.,	CALISE,	D.,	BOURIN,	P.,	PARINI,	A.	&	CUSSAC,	D.	2008.	Ex	vivo	pretreatment	with	melatonin	improves	survival,	proangiogenic/mitogenic	activity,	and	efficiency	of	mesenchymal	stem	cells	injected	into	ischemic	kidney.	Stem	
Cells,	26,	1749-57.	MILLER,	B.	F.,	LEAF,	A.,	MAMBY,	A.	R.	&	MILLER,	Z.	1952.	Validity	of	the	endogenous	creatinine	clearance	as	a	measure	of	glomerular	filtration	rate	in	the	diseased	human	kidney.	J	Clin	Invest,	31,	309-13.	MILWID,	J.	M.,	ICHIMURA,	T.,	LI,	M.,	JIAO,	Y.,	LEE,	J.,	YARMUSH,	J.	S.,	PAREKKADAN,	B.,	TILLES,	A.	W.,	BONVENTRE,	J.	V.	&	YARMUSH,	M.	L.	2012.	Secreted	factors	from	bone	marrow	stromal	cells	upregulate	IL-10	and	reverse	acute	kidney	injury.	Stem	Cells	Int,	2012,	392050.	MINER,	J.	H.	1999.	Renal	basement	membrane	components.	Kidney	Int,	56,	2016-24.	MINOR,	T.,	EFFERZ,	P.,	FOX,	M.,	WOHLSCHLAEGER,	J.	&	LUER,	B.	2013.	Controlled	oxygenated	rewarming	of	cold	stored	liver	grafts	by	thermally	graduated	machine	perfusion	prior	to	reperfusion.	Am	J	Transplant,	13,	1450-60.	MIRONOV,	V.,	VISCONTI,	R.	P.	&	MARKWALD,	R.	R.	2004.	What	is	regenerative	medicine?	Emergence	of	applied	stem	cell	and	developmental	biology.	
Expert	Opin	Biol	Ther,	4,	773-81.	MIURA,	M.,	MIURA,	Y.,	PADILLA-NASH,	H.	M.,	MOLINOLO,	A.	A.,	FU,	B.,	PATEL,	V.,	SEO,	B.	M.,	SONOYAMA,	W.,	ZHENG,	J.	J.,	BAKER,	C.	C.,	CHEN,	W.,	RIED,	T.	&	SHI,	S.	2006.	Accumulated	chromosomal	instability	in	murine	bone	marrow	mesenchymal	stem	cells	leads	to	malignant	transformation.	Stem	
Cells,	24,	1095-103.	MOERS,	C.,	KORNMANN,	N.	S.,	LEUVENINK,	H.	G.	&	PLOEG,	R.	J.	2009.	The	influence	of	deceased	donor	age	and	old-for-old	allocation	on	kidney	transplant	outcome.	Transplantation,	88,	542-52.	MOHSENY,	A.	B.	&	HOGENDOORN,	P.	C.	2011.	Concise	review:	mesenchymal	tumors:	when	stem	cells	go	mad.	Stem	Cells,	29,	397-403.	MOLLURA,	D.	J.,	HARE,	J.	M.	&	RABB,	H.	2003.	Stem-cell	therapy	for	renal	diseases.	Am	J	Kidney	Dis,	42,	891-905.	MONGARDON,	N.,	DYSON,	A.	&	SINGER,	M.	2009.	Is	MOF	an	outcome	parameter	or	a	transient,	adaptive	state	in	critical	illness?	Curr	Opin	Crit	Care,	15,	431-6.	MONSEL,	A.,	ZHU,	Y.	G.,	GENNAI,	S.,	HAO,	Q.,	LIU,	J.	&	LEE,	J.	W.	2014.	Cell-based	therapy	for	acute	organ	injury:	preclinical	evidence	and	ongoing	clinical	trials	using	mesenchymal	stem	cells.	Anesthesiology,	121,	1099-121.	MORESO,	F.	&	HERNANDEZ,	D.	2013.	Has	the	survival	of	the	graft	improved	after	renal	transplantation	in	the	era	of	modern	immunosuppression?	
Nefrologia,	33,	14-26.	MORIGI,	M.,	IMBERTI,	B.,	ZOJA,	C.,	CORNA,	D.,	TOMASONI,	S.,	ABBATE,	M.,	ROTTOLI,	D.,	ANGIOLETTI,	S.,	BENIGNI,	A.,	PERICO,	N.,	ALISON,	M.	&	REMUZZI,	G.	2004.	Mesenchymal	stem	cells	are	renotropic,	helping	to	repair	the	kidney	and	improve	function	in	acute	renal	failure.	J	Am	Soc	
Nephrol,	15,	1794-804.	
	 266	
MORIGI,	M.,	INTRONA,	M.,	IMBERTI,	B.,	CORNA,	D.,	ABBATE,	M.,	ROTA,	C.,	ROTTOLI,	D.,	BENIGNI,	A.,	PERICO,	N.,	ZOJA,	C.,	RAMBALDI,	A.,	REMUZZI,	A.	&	REMUZZI,	G.	2008.	Human	bone	marrow	mesenchymal	stem	cells	accelerate	recovery	of	acute	renal	injury	and	prolong	survival	in	mice.	
Stem	Cells,	26,	2075-82.	MUDRABETTU,	C.,	KUMAR,	V.,	RAKHA,	A.,	YADAV,	A.	K.,	RAMACHANDRAN,	R.,	KANWAR,	D.	B.,	NADA,	R.,	MINZ,	M.,	SAKHUJA,	V.,	MARWAHA,	N.	&	JHA,	V.	2015.	Safety	and	efficacy	of	autologous	mesenchymal	stromal	cells	transplantation	in	patients	undergoing	living	donor	kidney	transplantation:	a	pilot	study.	Nephrology	(Carlton),	20,	25-33.	MUELLER,	T.	F.,	SOLEZ,	K.	&	MAS,	V.	2011.	Assessment	of	kidney	organ	quality	and	prediction	of	outcome	at	time	of	transplantation.	Semin	
Immunopathol,	33,	185-99.	MURALIDHARAN-CHARI,	V.,	CLANCY,	J.	W.,	SEDGWICK,	A.	&	D'SOUZA-SCHOREY,	C.	2010.	Microvesicles:	mediators	of	extracellular	communication	during	cancer	progression.	J	Cell	Sci,	123,	1603-11.	NADASDY,	T.,	LASZIK,	Z.,	BLICK,	K.	E.,	JOHNSON,	L.	D.	&	SILVA,	F.	G.	1994.	Proliferative	activity	of	intrinsic	cell	populations	in	the	normal	human	kidney.	J	Am	Soc	Nephrol,	4,	2032-9.	NAMNUM,	P.,	INSOGNA,	K.,	BAGGISH,	D.	&	HAYSLETT,	J.	P.	1983.	Evidence	for	bidirectional	net	movement	of	creatinine	in	the	rat	kidney.	Am	J	Physiol,	244,	F719-23.	NANKIVELL,	B.	J.	&	KUYPERS,	D.	R.	2011.	Diagnosis	and	prevention	of	chronic	kidney	allograft	loss.	Lancet,	378,	1428-37.	NARVA,	E.,	AUTIO,	R.,	RAHKONEN,	N.,	KONG,	L.,	HARRISON,	N.,	KITSBERG,	D.,	BORGHESE,	L.,	ITSKOVITZ-ELDOR,	J.,	RASOOL,	O.,	DVORAK,	P.,	HOVATTA,	O.,	OTONKOSKI,	T.,	TUURI,	T.,	CUI,	W.,	BRUSTLE,	O.,	BAKER,	D.,	MALTBY,	E.,	MOORE,	H.	D.,	BENVENISTY,	N.,	ANDREWS,	P.	W.,	YLI-HARJA,	O.	&	LAHESMAA,	R.	2010.	High-resolution	DNA	analysis	of	human	embryonic	stem	cell	lines	reveals	culture-induced	copy	number	changes	and	loss	of	heterozygosity.	Nat	Biotechnol,	28,	371-7.	NASH,	K.,	HAFEEZ,	A.	&	HOU,	S.	2002.	Hospital-acquired	renal	insufficiency.	Am	J	
Kidney	Dis,	39,	930-6.	NATHAN,	H.	M.,	CONRAD,	S.	L.,	HELD,	P.	J.,	MCCULLOUGH,	K.	P.,	PIETROSKI,	R.	E.,	SIMINOFF,	L.	A.	&	OJO,	A.	O.	2003.	Organ	donation	in	the	United	States.	Am	
J	Transplant,	3	Suppl	4,	29-40.	NAUTA,	A.	J.,	KRUISSELBRINK,	A.	B.,	LURVINK,	E.,	WILLEMZE,	R.	&	FIBBE,	W.	E.	2006a.	Mesenchymal	stem	cells	inhibit	generation	and	function	of	both	CD34+-derived	and	monocyte-derived	dendritic	cells.	J	Immunol,	177,	2080-7.	NAUTA,	A.	J.,	WESTERHUIS,	G.,	KRUISSELBRINK,	A.	B.,	LURVINK,	E.	G.,	WILLEMZE,	R.	&	FIBBE,	W.	E.	2006b.	Donor-derived	mesenchymal	stem	cells	are	immunogenic	in	an	allogeneic	host	and	stimulate	donor	graft	rejection	in	a	nonmyeloablative	setting.	Blood,	108,	2114-20.	NEMOTO,	T.,	BURNE,	M.	J.,	DANIELS,	F.,	O'DONNELL,	M.	P.,	CROSSON,	J.,	BERENS,	K.,	ISSEKUTZ,	A.,	KASISKE,	B.	L.,	KEANE,	W.	F.	&	RABB,	H.	2001.	Small	molecule	selectin	ligand	inhibition	improves	outcome	in	ischemic	acute	renal	failure.	Kidney	Int,	60,	2205-14.	
	 267	
NEYRINCK,	A.,	VAN	RAEMDONCK,	D.	&	MONBALIU,	D.	2013.	Donation	after	circulatory	death:	current	status.	Curr	Opin	Anaesthesiol,	26,	382-90.	NICHOLSON,	M.	L.	&	HOSGOOD,	S.	A.	2013.	Renal	transplantation	after	ex	vivo	normothermic	perfusion:	the	first	clinical	study.	Am	J	Transplant,	13,	1246-52.	OESEBURG,	H.,	DE	BOER,	R.	A.,	VAN	GILST,	W.	H.	&	VAN	DER	HARST,	P.	2010.	Telomere	biology	in	healthy	aging	and	disease.	Pflugers	Arch,	459,	259-68.	OJO,	A.	O.	2005.	Expanded	criteria	donors:	process	and	outcomes.	Semin	Dial,	18,	463-8.	OJO,	A.	O.,	HANSON,	J.	A.,	MEIER-KRIESCHE,	H.,	OKECHUKWU,	C.	N.,	WOLFE,	R.	A.,	LEICHTMAN,	A.	B.,	AGODOA,	L.	Y.,	KAPLAN,	B.	&	PORT,	F.	K.	2001.	Survival	in	recipients	of	marginal	cadaveric	donor	kidneys	compared	with	other	recipients	and	wait-listed	transplant	candidates.	J	Am	Soc	Nephrol,	12,	589-97.	OLIVER,	J.	A.,	KLINAKIS,	A.,	CHEEMA,	F.	H.,	FRIEDLANDER,	J.,	SAMPOGNA,	R.	V.,	MARTENS,	T.	P.,	LIU,	C.,	EFSTRATIADIS,	A.	&	AL-AWQATI,	Q.	2009.	Proliferation	and	migration	of	label-retaining	cells	of	the	kidney	papilla.	J	
Am	Soc	Nephrol,	20,	2315-27.	ORGANIZATION.,	W.	H.	2013.	Recommendations	for	the	evaluation	of	animal	cell	cultures	as	substrates	for	the	manufacture	of	biological	medicinal	products	and	for	the	characterization	of	cell	banks.	WHO	technical	report	
series,,	No	978,	Annex	3.	ORLIC,	D.,	KAJSTURA,	J.,	CHIMENTI,	S.,	JAKONIUK,	I.,	ANDERSON,	S.	M.,	LI,	B.,	PICKEL,	J.,	MCKAY,	R.,	NADAL-GINARD,	B.,	BODINE,	D.	M.,	LERI,	A.	&	ANVERSA,	P.	2001.	Bone	marrow	cells	regenerate	infarcted	myocardium.	
Nature,	410,	701-5.	ORTIZ,	A.,	SANCHEZ-NINO,	M.	D.,	IZQUIERDO,	M.	C.,	MARTIN-CLEARY,	C.,	GARCIA-BERMEJO,	L.,	MORENO,	J.	A.,	RUIZ-ORTEGA,	M.,	DRAIBE,	J.,	CRUZADO,	J.	M.,	GARCIA-GONZALEZ,	M.	A.,	LOPEZ-NOVOA,	J.	M.,	SOLER,	M.	J.,	SANZ,	A.	B.,	RED	DE	INVESTIGACION,	R.	&	CONSORCIO	MADRILENO	PARA	INVESTIGACION	DEL	FRACASO	RENAL,	A.	2015.	Translational	value	of	animal	models	of	kidney	failure.	Eur	J	Pharmacol,	759,	205-20.	ORTIZ,	L.	A.,	GAMBELLI,	F.,	MCBRIDE,	C.,	GAUPP,	D.,	BADDOO,	M.,	KAMINSKI,	N.	&	PHINNEY,	D.	G.	2003.	Mesenchymal	stem	cell	engraftment	in	lung	is	enhanced	in	response	to	bleomycin	exposure	and	ameliorates	its	fibrotic	effects.	Proc	Natl	Acad	Sci	U	S	A,	100,	8407-11.	PAHLAVAN,	P.	S.,	SMALLEGANGE,	C.,	ADAMS,	M.	A.	&	SCHUMACHER,	M.	2006.	Kidney	transplantation	procedures	in	rats:	assessments,	complications,	and	management.	Microsurgery,	26,	404-11.	PAN,	Q.,	FOURASCHEN,	S.	M.,	DE	RUITER,	P.	E.,	DINJENS,	W.	N.,	KWEKKEBOOM,	J.,	TILANUS,	H.	W.	&	VAN	DER	LAAN,	L.	J.	2014.	Detection	of	spontaneous	tumorigenic	transformation	during	culture	expansion	of	human	mesenchymal	stromal	cells.	Exp	Biol	Med	(Maywood),	239,	105-15.	PASCUAL,	J.,	PEREZ-SAEZ,	M.	J.,	MIR,	M.	&	CRESPO,	M.	2012.	Chronic	renal	allograft	injury:	early	detection,	accurate	diagnosis	and	management.	
Transplant	Rev	(Orlando),	26,	280-90.	PASCUAL,	J.,	ZAMORA,	J.	&	PIRSCH,	J.	D.	2008.	A	systematic	review	of	kidney	transplantation	from	expanded	criteria	donors.	Am	J	Kidney	Dis,	52,	553-86.	
	 268	
PATSCHAN,	D.,	PLOTKIN,	M.	&	GOLIGORSKY,	M.	S.	2006.	Therapeutic	use	of	stem	and	endothelial	progenitor	cells	in	acute	renal	injury:	ca	ira.	Curr	Opin	
Pharmacol,	6,	176-83.	PAYNE,	A.	P.,	CAMPBELL,	J.	M.,	RUSSELL,	D.,	FAVOR,	G.,	SUTCLIFFE,	R.	G.,	BENNETT,	N.	K.,	DAVIES,	R.	W.	&	STONE,	T.	W.	2000.	The	AS/AGU	rat:	a	spontaneous	model	of	disruption	and	degeneration	in	the	nigrostriatal	dopaminergic	system.	J	Anat,	196	(	Pt	4),	629-33.	PENG,	Y.,	KE,	M.,	XU,	L.,	LIU,	L.,	CHEN,	X.,	XIA,	W.,	LI,	X.,	CHEN,	Z.,	MA,	J.,	LIAO,	D.,	LI,	G.,	FANG,	J.,	PAN,	G.	&	XIANG,	A.	P.	2013.	Donor-derived	mesenchymal	stem	cells	combined	with	low-dose	tacrolimus	prevent	acute	rejection	after	renal	transplantation:	a	clinical	pilot	study.	Transplantation,	95,	161-8.	PERERA,	M.	T.	2012.	The	super-rapid	technique	in	Maastricht	category	III	donors:	has	it	developed	enough	for	marginal	liver	grafts	from	donors	after	cardiac	death?	Curr	Opin	Organ	Transplant,	17,	131-6.	PEREZ-RUIZ,	L.,	ROS-LOPEZ,	S.,	CARDUS,	A.,	FERNANDEZ,	E.	&	VALDIVIELSO,	J.	M.	2006.	A	forgotten	method	to	induce	experimental	chronic	renal	failure	in	the	rat	by	ligation	of	the	renal	parenchyma.	Nephron	Exp	Nephrol,	103,	e126-30.	PERICO,	N.,	CASIRAGHI,	F.,	INTRONA,	M.,	GOTTI,	E.,	TODESCHINI,	M.,	CAVINATO,	R.	A.,	CAPELLI,	C.,	RAMBALDI,	A.,	CASSIS,	P.,	RIZZO,	P.,	CORTINOVIS,	M.,	MARASA,	M.,	GOLAY,	J.,	NORIS,	M.	&	REMUZZI,	G.	2011.	Autologous	mesenchymal	stromal	cells	and	kidney	transplantation:	a	pilot	study	of	safety	and	clinical	feasibility.	Clin	J	Am	Soc	Nephrol,	6,	412-22.	PIETSCH,	A.,	NETT,	P.	C.,	SOLLINGER,	H.	W.	&	HULLETT,	D.	A.	2004.	Modified	technique	of	ureteroureterostomy	in	rat	kidney	transplantation.	
Microsurgery,	24,	345-9.	PILEGGI,	A.,	XU,	X.,	TAN,	J.	&	RICORDI,	C.	2013.	Mesenchymal	stromal	(stem)	cells	to	improve	solid	organ	transplant	outcome:	lessons	from	the	initial	clinical	trials.	Curr	Opin	Organ	Transplant,	18,	672-81.	PILZER,	D.,	GASSER,	O.,	MOSKOVICH,	O.,	SCHIFFERLI,	J.	A.	&	FISHELSON,	Z.	2005.	Emission	of	membrane	vesicles:	roles	in	complement	resistance,	immunity	and	cancer.	Springer	Semin	Immunopathol,	27,	375-87.	PIPPIAS,	M.,	STEL,	V.	S.,	ABAD	DIEZ,	J.	M.,	AFENTAKIS,	N.,	HERRERO-CALVO,	J.	A.,	ARIAS,	M.,	TOMILINA,	N.,	BOUZAS	CAAMANO,	E.,	BUTUROVIC-PONIKVAR,	J.,	CALA,	S.,	CASKEY,	F.	J.,	CASTRO	DE	LA	NUEZ,	P.,	CERNEVSKIS,	H.,	COLLART,	F.,	ALONSO	DE	LA	TORRE,	R.,	GARCIA	BAZAGA	MDE,	L.,	DE	MEESTER,	J.,	DIAZ,	J.	M.,	DJUKANOVIC,	L.,	FERRER	ALAMAR,	M.,	FINNE,	P.,	GARNEATA,	L.,	GOLAN,	E.,	GONZALEZ	FERNANDEZ,	R.,	GUTIERREZ	AVILA,	G.,	HEAF,	J.,	HOITSMA,	A.,	KANTARIA,	N.,	KOLESNYK,	M.,	KRAMAR,	R.,	KRAMER,	A.,	LASSALLE,	M.,	LEIVESTAD,	T.,	LOPOT,	F.,	MACARIO,	F.,	MAGAZ,	A.,	MARTIN-ESCOBAR,	E.,	METCALFE,	W.,	NOORDZIJ,	M.,	PALSSON,	R.,	PECHTER,	U.,	PRUTZ,	K.	G.,	RATKOVIC,	M.,	RESIC,	H.,	RUTKOWSKI,	B.,	SANTIUSTE	DE	PABLOS,	C.,	SPUSTOVA,	V.,	SULEYMANLAR,	G.,	VAN	STRALEN,	K.,	THERESKA,	N.,	WANNER,	C.	&	JAGER,	K.	J.	2015.	Renal	replacement	therapy	in	Europe:	a	summary	of	the	2012	ERA-EDTA	Registry	Annual	Report.	Clin	Kidney	J,	8,	248-61.	POMFRET,	E.	A.,	SUNG,	R.	S.,	ALLAN,	J.,	KINKHABWALA,	M.,	MELANCON,	J.	K.	&	ROBERTS,	J.	P.	2008.	Solving	the	organ	shortage	crisis:	the	7th	annual	
	 269	
American	Society	of	Transplant	Surgeons'	State-of-the-Art	Winter	Symposium.	Am	J	Transplant,	8,	745-52.	PONTICELLI,	C.	E.	2015.	The	impact	of	cold	ischemia	time	on	renal	transplant	outcome.	Kidney	Int,	87,	272-5.	PORT,	F.	K.	2003.	Organ	donation	and	transplantation	trends	in	the	United	States,	2001.	Am	J	Transplant,	3	Suppl	4,	7-12.	PORT,	F.	K.,	BRAGG-GRESHAM,	J.	L.,	METZGER,	R.	A.,	DYKSTRA,	D.	M.,	GILLESPIE,	B.	W.,	YOUNG,	E.	W.,	DELMONICO,	F.	L.,	WYNN,	J.	J.,	MERION,	R.	M.,	WOLFE,	R.	A.	&	HELD,	P.	J.	2002.	Donor	characteristics	associated	with	reduced	graft	survival:	an	approach	to	expanding	the	pool	of	kidney	donors.	Transplantation,	74,	1281-6.	PORT,	F.	K.,	WOLFE,	R.	A.,	MAUGER,	E.	A.,	BERLING,	D.	P.	&	JIANG,	K.	1993.	Comparison	of	survival	probabilities	for	dialysis	patients	vs	cadaveric	renal	transplant	recipients.	JAMA,	270,	1339-43.	POTTEN,	C.	S.	&	LOEFFLER,	M.	1990.	Stem	cells:	attributes,	cycles,	spirals,	pitfalls	and	uncertainties.	Lessons	for	and	from	the	crypt.	Development,	110,	1001-20.	POWELL,	J.	T.,	TSAPEPAS,	D.	S.,	MARTIN,	S.	T.,	HARDY,	M.	A.	&	RATNER,	L.	E.	2013.	Managing	renal	transplant	ischemia	reperfusion	injury:	novel	therapies	in	the	pipeline.	Clin	Transplant,	27,	484-91.	PRATSCHKE,	J.,	WILHELM,	M.	J.,	LASKOWSKI,	I.,	KUSAKA,	M.,	PAZ,	D.,	TULLIUS,	S.	G.,	NEUHAUS,	P.,	HANCOCK,	W.	W.	&	TILNEY,	N.	L.	2001.	The	influence	of	donor	brain	death	on	long-term	function	of	renal	allotransplants	in	rats.	
Transplant	Proc,	33,	693-4.	PRESCOTT,	L.	F.	1966.	The	normal	urinary	excretion	rates	of	renal	tubular	cells,	leucocytes	and	red	blood	cells.	Clin	Sci,	31,	425-35.	PRUTHI,	R.,	STEENKAMP,	R.	&	FEEST,	T.	2013.	UK	Renal	Registry	16th	annual	report:	chapter	8	survival	and	cause	of	death	of	UK	adult	patients	on	renal	replacement	therapy	in	2012:	national	and	centre-specific	analyses.	
Nephron	Clin	Pract,	125,	139-69.	QI,	Z.,	WHITT,	I.,	MEHTA,	A.,	JIN,	J.,	ZHAO,	M.,	HARRIS,	R.	C.,	FOGO,	A.	B.	&	BREYER,	M.	D.	2004.	Serial	determination	of	glomerular	filtration	rate	in	conscious	mice	using	FITC-inulin	clearance.	Am	J	Physiol	Renal	Physiol,	286,	F590-6.	QUESENBERRY,	P.	J.,	GOLDBERG,	L.	R.,	ALIOTTA,	J.	M.,	DOONER,	M.	S.,	PEREIRA,	M.	G.,	WEN,	S.	&	CAMUSSI,	G.	2014.	Cellular	phenotype	and	extracellular	vesicles:	basic	and	clinical	considerations.	Stem	Cells	Dev,	23,	1429-36.	RANI,	S.,	RYAN,	A.	E.,	GRIFFIN,	M.	D.	&	RITTER,	T.	2015.	Mesenchymal	Stem	Cell-derived	Extracellular	Vesicles:	Toward	Cell-free	Therapeutic	Applications.	
Mol	Ther,	23,	812-23.	RAO,	M.	S.	&	MALIK,	N.	2012.	Assessing	iPSC	reprogramming	methods	for	their	suitability	in	translational	medicine.	J	Cell	Biochem,	113,	3061-8.	RAO,	P.	S.,	MERION,	R.	M.,	ASHBY,	V.	B.,	PORT,	F.	K.,	WOLFE,	R.	A.	&	KAYLER,	L.	K.	2007.	Renal	transplantation	in	elderly	patients	older	than	70	years	of	age:	results	from	the	Scientific	Registry	of	Transplant	Recipients.	
Transplantation,	83,	1069-74.	RAPOSO,	G.	&	STOORVOGEL,	W.	2013.	Extracellular	vesicles:	exosomes,	microvesicles,	and	friends.	J	Cell	Biol,	200,	373-83.	
	 270	
RATAJCZAK,	J.,	MIEKUS,	K.,	KUCIA,	M.,	ZHANG,	J.,	RECA,	R.,	DVORAK,	P.	&	RATAJCZAK,	M.	Z.	2006a.	Embryonic	stem	cell-derived	microvesicles	reprogram	hematopoietic	progenitors:	evidence	for	horizontal	transfer	of	mRNA	and	protein	delivery.	Leukemia,	20,	847-56.	RATAJCZAK,	J.,	WYSOCZYNSKI,	M.,	HAYEK,	F.,	JANOWSKA-WIECZOREK,	A.	&	RATAJCZAK,	M.	Z.	2006b.	Membrane-derived	microvesicles:	important	and	underappreciated	mediators	of	cell-to-cell	communication.	Leukemia,	20,	1487-95.	RAVIKUMAR,	R.,	JASSEM,	W.,	MERGENTAL,	H.,	HEATON,	N.,	MIRZA,	D.,	PERERA,	M.	T.,	QUAGLIA,	A.,	HOLROYD,	D.,	VOGEL,	T.,	COUSSIOS,	C.	C.	&	FRIEND,	P.	J.	2016.	Liver	Transplantation	After	Ex	Vivo	Normothermic	Machine	Preservation:	A	Phase	1	(First-in-Man)	Clinical	Trial.	Am	J	Transplant,	16,	1779-87.	REINDERS,	M.	E.,	DE	FIJTER,	J.	W.,	ROELOFS,	H.,	BAJEMA,	I.	M.,	DE	VRIES,	D.	K.,	SCHAAPHERDER,	A.	F.,	CLAAS,	F.	H.,	VAN	MIERT,	P.	P.,	ROELEN,	D.	L.,	VAN	KOOTEN,	C.,	FIBBE,	W.	E.	&	RABELINK,	T.	J.	2013.	Autologous	bone	marrow-derived	mesenchymal	stromal	cells	for	the	treatment	of	allograft	rejection	after	renal	transplantation:	results	of	a	phase	I	study.	Stem	Cells	
Transl	Med,	2,	107-11.	REN,	G.,	ZHAO,	X.,	WANG,	Y.,	ZHANG,	X.,	CHEN,	X.,	XU,	C.,	YUAN,	Z.	R.,	ROBERTS,	A.	I.,	ZHANG,	L.,	ZHENG,	B.,	WEN,	T.,	HAN,	Y.,	RABSON,	A.	B.,	TISCHFIELD,	J.	A.,	SHAO,	C.	&	SHI,	Y.	2012.	CCR2-dependent	recruitment	of	macrophages	by	tumor-educated	mesenchymal	stromal	cells	promotes	tumor	development	and	is	mimicked	by	TNFalpha.	Cell	Stem	Cell,	11,	812-24.	REN,	G.,	ZHAO,	X.,	ZHANG,	L.,	ZHANG,	J.,	L'HUILLIER,	A.,	LING,	W.,	ROBERTS,	A.	I.,	LE,	A.	D.,	SHI,	S.,	SHAO,	C.	&	SHI,	Y.	2010.	Inflammatory	cytokine-induced	intercellular	adhesion	molecule-1	and	vascular	cell	adhesion	molecule-1	in	mesenchymal	stem	cells	are	critical	for	immunosuppression.	J	Immunol,	184,	2321-8.	RENKENS,	J.	J.,	ROUFLART,	M.	M.,	CHRISTIAANS,	M.	H.,	VAN	DEN	BERG-LOONEN,	E.	M.,	VAN	HOOFF,	J.	P.	&	VAN	HEURN,	L.	W.	2005.	Outcome	of	nonheart-beating	donor	kidneys	with	prolonged	delayed	graft	function	after	transplantation.	Am	J	Transplant,	5,	2704-9.	REULE,	S.	&	GUPTA,	S.	2011.	Kidney	regeneration	and	resident	stem	cells.	
Organogenesis,	7,	135-9.	RICARDO,	S.	D.,	VAN	GOOR,	H.	&	EDDY,	A.	A.	2008.	Macrophage	diversity	in	renal	injury	and	repair.	J	Clin	Invest,	118,	3522-30.	RICCI,	Z.,	CRUZ,	D.	&	RONCO,	C.	2008.	The	RIFLE	criteria	and	mortality	in	acute	kidney	injury:	A	systematic	review.	Kidney	Int,	73,	538-46.	ROBBINS,	P.	D.	&	MORELLI,	A.	E.	2014.	Regulation	of	immune	responses	by	extracellular	vesicles.	Nat	Rev	Immunol,	14,	195-208.	ROEMELING-VAN	RHIJN,	M.,	REINDERS,	M.	E.,	DE	KLEIN,	A.,	DOUBEN,	H.,	KOREVAAR,	S.	S.,	MENSAH,	F.	K.,	DOR,	F.	J.,	JN,	I.	J.,	BETJES,	M.	G.,	BAAN,	C.	C.,	WEIMAR,	W.	&	HOOGDUIJN,	M.	J.	2012.	Mesenchymal	stem	cells	derived	from	adipose	tissue	are	not	affected	by	renal	disease.	Kidney	Int,	82,	748-58.	ROMAGNANI,	P.	2009.	Toward	the	identification	of	a	"renopoietic	system"?	Stem	
Cells,	27,	2247-53.	
	 271	
RONCONI,	E.,	SAGRINATI,	C.,	ANGELOTTI,	M.	L.,	LAZZERI,	E.,	MAZZINGHI,	B.,	BALLERINI,	L.,	PARENTE,	E.,	BECHERUCCI,	F.,	GACCI,	M.,	CARINI,	M.,	MAGGI,	E.,	SERIO,	M.,	VANNELLI,	G.	B.,	LASAGNI,	L.,	ROMAGNANI,	S.	&	ROMAGNANI,	P.	2009.	Regeneration	of	glomerular	podocytes	by	human	renal	progenitors.	J	Am	Soc	Nephrol,	20,	322-32.	ROSLAND,	G.	V.,	SVENDSEN,	A.,	TORSVIK,	A.,	SOBALA,	E.,	MCCORMACK,	E.,	IMMERVOLL,	H.,	MYSLIWIETZ,	J.,	TONN,	J.	C.,	GOLDBRUNNER,	R.,	LONNING,	P.	E.,	BJERKVIG,	R.	&	SCHICHOR,	C.	2009.	Long-term	cultures	of	bone	marrow-derived	human	mesenchymal	stem	cells	frequently	undergo	spontaneous	malignant	transformation.	Cancer	Res,	69,	5331-9.	ROTHKOTTER,	H.	J.	2009.	Anatomical	particularities	of	the	porcine	immune	system--a	physician's	view.	Dev	Comp	Immunol,	33,	267-72.	ROUFOSSE,	C.	&	COOK,	H.	T.	2008.	Stem	cells	and	renal	regeneration.	Nephron	
Exp	Nephrol,	109,	e39-45.	ROZMYSLOWICZ,	T.,	MAJKA,	M.,	KIJOWSKI,	J.,	MURPHY,	S.	L.,	CONOVER,	D.	O.,	PONCZ,	M.,	RATAJCZAK,	J.,	GAULTON,	G.	N.	&	RATAJCZAK,	M.	Z.	2003.	Platelet-	and	megakaryocyte-derived	microparticles	transfer	CXCR4	receptor	to	CXCR4-null	cells	and	make	them	susceptible	to	infection	by	X4-HIV.	AIDS,	17,	33-42.	RUBIO,	D.,	GARCIA,	S.,	PAZ,	M.	F.,	DE	LA	CUEVA,	T.,	LOPEZ-FERNANDEZ,	L.	A.,	LLOYD,	A.	C.,	GARCIA-CASTRO,	J.	&	BERNAD,	A.	2008.	Molecular	characterization	of	spontaneous	mesenchymal	stem	cell	transformation.	
PLoS	One,	3,	e1398.	RUBIO,	D.,	GARCIA-CASTRO,	J.,	MARTIN,	M.	C.,	DE	LA	FUENTE,	R.,	CIGUDOSA,	J.	C.,	LLOYD,	A.	C.	&	BERNAD,	A.	2005.	Spontaneous	human	adult	stem	cell	transformation.	Cancer	Res,	65,	3035-9.	RUSTER,	B.,	GOTTIG,	S.,	LUDWIG,	R.	J.,	BISTRIAN,	R.,	MULLER,	S.,	SEIFRIED,	E.,	GILLE,	J.	&	HENSCHLER,	R.	2006.	Mesenchymal	stem	cells	display	coordinated	rolling	and	adhesion	behavior	on	endothelial	cells.	Blood,	108,	3938-44.	SAAT,	T.	C.,	VAN	DEN	AKKER,	E.	K.,	JN,	I.	J.,	DOR,	F.	J.	&	DE	BRUIN,	R.	W.	2016.	Improving	the	outcome	of	kidney	transplantation	by	ameliorating	renal	ischemia	reperfusion	injury:	lost	in	translation?	J	Transl	Med,	14,	20.	SACKSTEIN,	R.,	MERZABAN,	J.	S.,	CAIN,	D.	W.,	DAGIA,	N.	M.,	SPENCER,	J.	A.,	LIN,	C.	P.	&	WOHLGEMUTH,	R.	2008.	Ex	vivo	glycan	engineering	of	CD44	programs	human	multipotent	mesenchymal	stromal	cell	trafficking	to	bone.	Nat	Med,	14,	181-7.	SAGRINATI,	C.,	NETTI,	G.	S.,	MAZZINGHI,	B.,	LAZZERI,	E.,	LIOTTA,	F.,	FROSALI,	F.,	RONCONI,	E.,	MEINI,	C.,	GACCI,	M.,	SQUECCO,	R.,	CARINI,	M.,	GESUALDO,	L.,	FRANCINI,	F.,	MAGGI,	E.,	ANNUNZIATO,	F.,	LASAGNI,	L.,	SERIO,	M.,	ROMAGNANI,	S.	&	ROMAGNANI,	P.	2006.	Isolation	and	characterization	of	multipotent	progenitor	cells	from	the	Bowman's	capsule	of	adult	human	kidneys.	J	Am	Soc	Nephrol,	17,	2443-56.	SAIKUMAR,	P.	&	VENKATACHALAM,	M.	A.	2003.	Role	of	apoptosis	in	hypoxic/ischemic	damage	in	the	kidney.	Semin	Nephrol,	23,	511-21.	SALAHUDEEN,	A.	K.	2004.	Cold	ischemic	injury	of	transplanted	kidneys:	new	insights	from	experimental	studies.	Am	J	Physiol	Renal	Physiol,	287,	F181-7.	
	 272	
SANCHEZ-FRUCTUOSO,	A.	I.,	DE	MIGUEL	MARQUES,	M.,	PRATS,	D.	&	BARRIENTOS,	A.	2003.	Non-heart-beating	donors:	experience	from	the	Hospital	Clinico	of	Madrid.	J	Nephrol,	16,	387-92.	SCHENKE-LAYLAND,	K.,	STREM,	B.	M.,	JORDAN,	M.	C.,	DEEMEDIO,	M.	T.,	HEDRICK,	M.	H.,	ROOS,	K.	P.,	FRASER,	J.	K.	&	MACLELLAN,	W.	R.	2009.	Adipose	tissue-derived	cells	improve	cardiac	function	following	myocardial	infarction.	J	Surg	Res,	153,	217-23.	SCHIEVINK,	W.	I.,	LUYENDIJK,	W.	&	LOS,	J.	A.	1988.	Does	the	artery	of	Adamkiewicz	exist	in	the	albino	rat?	J	Anat,	161,	95-101.	SCHNUELLE,	P.,	LORENZ,	D.,	TREDE,	M.	&	VAN	DER	WOUDE,	F.	J.	1998.	Impact	of	renal	cadaveric	transplantation	on	survival	in	end-stage	renal	failure:	evidence	for	reduced	mortality	risk	compared	with	hemodialysis	during	long-term	follow-up.	J	Am	Soc	Nephrol,	9,	2135-41.	SCHOCK-KUSCH,	D.,	SHULHEVICH,	Y.,	XIE,	Q.,	HESSER,	J.,	STSEPANKOU,	D.,	NEUDECKER,	S.,	FRIEDEMANN,	J.,	KOENIG,	S.,	HEINRICH,	R.,	HOECKLIN,	F.,	PILL,	J.	&	GRETZ,	N.	2012.	Online	feedback-controlled	renal	constant	infusion	clearances	in	rats.	Kidney	Int,	82,	314-20.	SCHOCK-KUSCH,	D.,	XIE,	Q.,	SHULHEVICH,	Y.,	HESSER,	J.,	STSEPANKOU,	D.,	SADICK,	M.,	KOENIG,	S.,	HOECKLIN,	F.,	PILL,	J.	&	GRETZ,	N.	2011.	Transcutaneous	assessment	of	renal	function	in	conscious	rats	with	a	device	for	measuring	FITC-sinistrin	disappearance	curves.	Kidney	Int,	79,	1254-8.	SCHOLD,	J.	D.,	KAPLAN,	B.,	BALIGA,	R.	S.	&	MEIER-KRIESCHE,	H.	U.	2005.	The	broad	spectrum	of	quality	in	deceased	donor	kidneys.	Am	J	Transplant,	5,	757-65.	SCHREPFER,	S.,	DEUSE,	T.,	REICHENSPURNER,	H.,	FISCHBEIN,	M.	P.,	ROBBINS,	R.	C.	&	PELLETIER,	M.	P.	2007.	Stem	cell	transplantation:	the	lung	barrier.	
Transplant	Proc,	39,	573-6.	SCHUMACHER,	M.,	VAN	VLIET,	B.	N.	&	FERRARI,	P.	2003.	Kidney	transplantation	in	rats:	an	appraisal	of	surgical	techniques	and	outcome.	Microsurgery,	23,	387-94.	SCHUTGENS,	F.,	VERHAAR,	M.	C.	&	ROOKMAAKER,	M.	B.	2016.	Pluripotent	stem	cell-derived	kidney	organoids:	An	in	vivo-like	in	vitro	technology.	Eur	J	
Pharmacol,	790,	12-20.	SERRANO,	M.,	LEE,	H.,	CHIN,	L.,	CORDON-CARDO,	C.,	BEACH,	D.	&	DEPINHO,	R.	A.	1996.	Role	of	the	INK4a	locus	in	tumor	suppression	and	cell	mortality.	
Cell,	85,	27-37.	SHAKE,	J.	G.,	GRUBER,	P.	J.,	BAUMGARTNER,	W.	A.,	SENECHAL,	G.,	MEYERS,	J.,	REDMOND,	J.	M.,	PITTENGER,	M.	F.	&	MARTIN,	B.	J.	2002.	Mesenchymal	stem	cell	implantation	in	a	swine	myocardial	infarct	model:	engraftment	and	functional	effects.	Ann	Thorac	Surg,	73,	1919-25;	discussion	1926.	SHARKEY,	J.,	SCARFE,	L.,	SANTERAMO,	I.,	GARCIA-FINANA,	M.,	PARK,	B.	K.,	POPTANI,	H.,	WILM,	B.,	TAYLOR,	A.	&	MURRAY,	P.	2016.	Imaging	technologies	for	monitoring	the	safety,	efficacy	and	mechanisms	of	action	of	cell-based	regenerative	medicine	therapies	in	models	of	kidney	disease.	
Eur	J	Pharmacol,	790,	74-82.	SHARMARLOUSKI	A,	S.	Y.,	GERACI	S,	FRIEDEMANN	J,	GRETZ	N,	NEUDECKER	S,	HESSER	J,	STSEPANKOU	D.	2014.	Automatic	artifact	removal	from	GFR	measurements.	Biomed	Signal	Process	Control,	14,	30	-	41.	
	 273	
SHEASHAA,	H.,	LOTFY,	A.,	ELHUSSEINI,	F.,	AZIZ,	A.	A.,	BAIOMY,	A.,	AWAD,	S.,	ALSAYED,	A.,	EL-GILANY,	A.	H.,	SAAD,	M.	A.,	MAHMOUD,	K.,	ZAHRAN,	F.,	SALEM,	D.	A.,	SARHAN,	A.,	GHAFFAR,	H.	A.	&	SOBH,	M.	2016.	Protective	effect	of	adipose-derived	mesenchymal	stem	cells	against	acute	kidney	injury	induced	by	ischemia-reperfusion	in	Sprague-Dawley	rats.	Exp	Ther	
Med,	11,	1573-1580.	SHERIDAN,	A.	M.	&	BONVENTRE,	J.	V.	2000.	Cell	biology	and	molecular	mechanisms	of	injury	in	ischemic	acute	renal	failure.	Curr	Opin	Nephrol	
Hypertens,	9,	427-34.	SHI,	M.,	LI,	J.,	LIAO,	L.,	CHEN,	B.,	LI,	B.,	CHEN,	L.,	JIA,	H.	&	ZHAO,	R.	C.	2007.	Regulation	of	CXCR4	expression	in	human	mesenchymal	stem	cells	by	cytokine	treatment:	role	in	homing	efficiency	in	NOD/SCID	mice.	
Haematologica,	92,	897-904.	SHIH,	Y.	C.,	LEE,	P.	Y.,	CHENG,	H.,	TSAI,	C.	H.,	MA,	H.	&	TARNG,	D.	C.	2013.	Adipose-derived	stem	cells	exhibit	antioxidative	and	antiapoptotic	properties	to	rescue	ischemic	acute	kidney	injury	in	rats.	Plast	Reconstr	
Surg,	132,	940e-51e.	SHRESTHA,	B.	&	HAYLOR,	J.	2014.	Experimental	rat	models	of	chronic	allograft	nephropathy:	a	review.	Int	J	Nephrol	Renovasc	Dis,	7,	315-22.	SIDOROVA,	V.	1978.	The	postnatal	growth	and	restoration	ofinternal	organs	in	
vertebrates.,	PSG	Publishing	Compnay,	Inc.	SIEKEVITZ,	P.	1972.	Biological	membranes:	the	dynamics	of	their	organization.	
Annu	Rev	Physiol,	34,	117-40.	SIMMONS,	M.	N.,	SCHREIBER,	M.	J.	&	GILL,	I.	S.	2008.	Surgical	renal	ischemia:	a	contemporary	overview.	J	Urol,	180,	19-30.	SIMMONS,	R.	G.,	ANDERSON,	C.	R.	&	ABRESS,	L.	K.	1990.	Quality	of	life	and	rehabilitation	differences	among	four	end-stage	renal	disease	therapy	groups.	Scand	J	Urol	Nephrol	Suppl,	131,	7-22.	SINGH,	A.	P.,	JUNEMANN,	A.,	MUTHURAMAN,	A.,	JAGGI,	A.	S.,	SINGH,	N.,	GROVER,	K.	&	DHAWAN,	R.	2012.	Animal	models	of	acute	renal	failure.	Pharmacol	
Rep,	64,	31-44.	SINGH,	R.	P.,	FARNEY,	A.	C.,	ROGERS,	J.,	ZUCKERMAN,	J.,	REEVES-DANIEL,	A.,	HARTMANN,	E.,	ISKANDAR,	S.,	ADAMS,	P.	&	STRATTA,	R.	J.	2011.	Kidney	transplantation	from	donation	after	cardiac	death	donors:	lack	of	impact	of	delayed	graft	function	on	post-transplant	outcomes.	Clin	Transplant,	25,	255-64.	SKRYPNYK,	N.	I.,	HARRIS,	R.	C.	&	DE	CAESTECKER,	M.	P.	2013.	Ischemia-reperfusion	model	of	acute	kidney	injury	and	post	injury	fibrosis	in	mice.	J	
Vis	Exp.	SMOGORZEWSKA,	A.	&	DE	LANGE,	T.	2002.	Different	telomere	damage	signaling	pathways	in	human	and	mouse	cells.	EMBO	J,	21,	4338-48.	SNOEIJS,	M.	G.,	SCHAUBEL,	D.	E.,	HENE,	R.,	HOITSMA,	A.	J.,	IDU,	M.	M.,	IJZERMANS,	J.	N.,	PLOEG,	R.	J.,	RINGERS,	J.,	CHRISTIAANS,	M.	H.,	BUURMAN,	W.	A.	&	VAN	HEURN,	L.	W.	2010a.	Kidneys	from	donors	after	cardiac	death	provide	survival	benefit.	J	Am	Soc	Nephrol,	21,	1015-21.	SNOEIJS,	M.	G.,	WINKENS,	B.,	HEEMSKERK,	M.	B.,	HOITSMA,	A.	J.,	CHRISTIAANS,	M.	H.,	BUURMAN,	W.	A.	&	VAN	HEURN,	L.	W.	2010b.	Kidney	transplantation	from	donors	after	cardiac	death:	a	25-year	experience.	
Transplantation,	90,	1106-12.	
	 274	
SONG,	J.,	CZERNIAK,	S.,	WANG,	T.,	YING,	W.,	CARLONE,	D.	L.,	BREAULT,	D.	T.	&	HUMPHREYS,	B.	D.	2011.	Characterization	and	fate	of	telomerase-expressing	epithelia	during	kidney	repair.	J	Am	Soc	Nephrol,	22,	2256-65.	SPAGGIARI,	G.	M.,	CAPOBIANCO,	A.,	BECCHETTI,	S.,	MINGARI,	M.	C.	&	MORETTA,	L.	2006.	Mesenchymal	stem	cell-natural	killer	cell	interactions:	evidence	that	activated	NK	cells	are	capable	of	killing	MSCs,	whereas	MSCs	can	inhibit	IL-2-induced	NK-cell	proliferation.	Blood,	107,	1484-90.	SPANJOL,	J.,	CELIC,	T.,	JAKLJEVIC,	T.,	IVANCIC,	A.	&	MARKIC,	D.	2011.	Surgical	technique	in	the	rat	model	of	kidney	transplantation.	Coll	Antropol,	35	Suppl	2,	87-90.	SPRADLING,	A.,	DRUMMOND-BARBOSA,	D.	&	KAI,	T.	2001.	Stem	cells	find	their	niche.	Nature,	414,	98-104.	STEVENSON,	K.,	CHEN,	D.,	MACINTYRE,	A.,	MCGLYNN,	L.	M.,	MONTAGUE,	P.,	CHARIF,	R.,	SUBRAMANIAM,	M.,	GEORGE,	W.	D.,	PAYNE,	A.	P.,	DAVIES,	R.	W.,	DORLING,	A.	&	SHIELS,	P.	G.	2011.	Pancreatic-derived	pathfinder	cells	enable	regeneration	of	critically	damaged	adult	pancreatic	tissue	and	completely	reverse	streptozotocin-induced	diabetes.	Rejuvenation	Res,	14,	163-71.	STEVENSON,	K.	S.,	MCGLYNN,	L.,	HODGE,	M.,	MCLINDEN,	H.,	GEORGE,	W.	D.,	DAVIES,	R.	W.	&	SHIELS,	P.	G.	2009.	Isolation,	characterization,	and	differentiation	of	thy1.1-sorted	pancreatic	adult	progenitor	cell	populations.	Stem	Cells	Dev,	18,	1389-98.	STUDENY,	M.,	MARINI,	F.	C.,	CHAMPLIN,	R.	E.,	ZOMPETTA,	C.,	FIDLER,	I.	J.	&	ANDREEFF,	M.	2002.	Bone	marrow-derived	mesenchymal	stem	cells	as	vehicles	for	interferon-beta	delivery	into	tumors.	Cancer	Res,	62,	3603-8.	STURGEON,	C.,	SAM,	A.	D.,	2ND	&	LAW,	W.	R.	1998.	Rapid	determination	of	glomerular	filtration	rate	by	single-bolus	inulin:	a	comparison	of	estimation	analyses.	J	Appl	Physiol	(1985),	84,	2154-62.	SUMMERS,	D.	M.,	JOHNSON,	R.	J.,	ALLEN,	J.,	FUGGLE,	S.	V.,	COLLETT,	D.,	WATSON,	C.	J.	&	BRADLEY,	J.	A.	2010.	Analysis	of	factors	that	affect	outcome	after	transplantation	of	kidneys	donated	after	cardiac	death	in	the	UK:	a	cohort	study.	Lancet,	376,	1303-11.	SUMMERS,	D.	M.,	JOHNSON,	R.	J.,	HUDSON,	A.,	COLLETT,	D.,	WATSON,	C.	J.	&	BRADLEY,	J.	A.	2013.	Effect	of	donor	age	and	cold	storage	time	on	outcome	in	recipients	of	kidneys	donated	after	circulatory	death	in	the	UK:	a	cohort	study.	Lancet,	381,	727-34.	SURANI,	M.	A.	2001.	Reprogramming	of	genome	function	through	epigenetic	inheritance.	Nature,	414,	122-8.	SUTTON,	T.	A.,	FISHER,	C.	J.	&	MOLITORIS,	B.	A.	2002.	Microvascular	endothelial	injury	and	dysfunction	during	ischemic	acute	renal	failure.	Kidney	Int,	62,	1539-49.	TABERA,	S.,	PEREZ-SIMON,	J.	A.,	DIEZ-CAMPELO,	M.,	SANCHEZ-ABARCA,	L.	I.,	BLANCO,	B.,	LOPEZ,	A.,	BENITO,	A.,	OCIO,	E.,	SANCHEZ-GUIJO,	F.	M.,	CANIZO,	C.	&	SAN	MIGUEL,	J.	F.	2008.	The	effect	of	mesenchymal	stem	cells	on	the	viability,	proliferation	and	differentiation	of	B-lymphocytes.	
Haematologica,	93,	1301-9.	TAIRA,	Y.	&	MARSALA,	M.	1996.	Effect	of	proximal	arterial	perfusion	pressure	on	function,	spinal	cord	blood	flow,	and	histopathologic	changes	after	increasing	intervals	of	aortic	occlusion	in	the	rat.	Stroke,	27,	1850-8.	
	 275	
TAKAHASHI,	K.	&	YAMANAKA,	S.	2006.	Induction	of	pluripotent	stem	cells	from	mouse	embryonic	and	adult	fibroblast	cultures	by	defined	factors.	Cell,	126,	663-76.	TAKASATO,	M.,	ER,	P.	X.,	CHIU,	H.	S.	&	LITTLE,	M.	H.	2016a.	Generation	of	kidney	organoids	from	human	pluripotent	stem	cells.	Nat	Protoc,	11,	1681-92.	TAKASATO,	M.,	ER,	P.	X.,	CHIU,	H.	S.,	MAIER,	B.,	BAILLIE,	G.	J.,	FERGUSON,	C.,	PARTON,	R.	G.,	WOLVETANG,	E.	J.,	ROOST,	M.	S.,	LOPES,	S.	M.	&	LITTLE,	M.	H.	2016b.	Kidney	organoids	from	human	iPS	cells	contain	multiple	lineages	and	model	human	nephrogenesis.	Nature,	536,	238.	TAN,	J.,	WU,	W.,	XU,	X.,	LIAO,	L.,	ZHENG,	F.,	MESSINGER,	S.,	SUN,	X.,	CHEN,	J.,	YANG,	S.,	CAI,	J.,	GAO,	X.,	PILEGGI,	A.	&	RICORDI,	C.	2012.	Induction	therapy	with	autologous	mesenchymal	stem	cells	in	living-related	kidney	transplants:	a	randomized	controlled	trial.	JAMA,	307,	1169-77.	TAYLOR,	D.	D.	&	SHAH,	S.	2015.	Methods	of	isolating	extracellular	vesicles	impact	down-stream	analyses	of	their	cargoes.	Methods,	87,	3-10.	TERADA,	N.,	HAMAZAKI,	T.,	OKA,	M.,	HOKI,	M.,	MASTALERZ,	D.	M.,	NAKANO,	Y.,	MEYER,	E.	M.,	MOREL,	L.,	PETERSEN,	B.	E.	&	SCOTT,	E.	W.	2002.	Bone	marrow	cells	adopt	the	phenotype	of	other	cells	by	spontaneous	cell	fusion.	Nature,	416,	542-5.	THERY,	C.,	OSTROWSKI,	M.	&	SEGURA,	E.	2009.	Membrane	vesicles	as	conveyors	of	immune	responses.	Nat	Rev	Immunol,	9,	581-93.	THUILLIER,	R.,	FAVREAU,	F.,	CELHAY,	O.,	MACCHI,	L.,	MILIN,	S.	&	HAUET,	T.	2010.	Thrombin	inhibition	during	kidney	ischemia-reperfusion	reduces	chronic	graft	inflammation	and	tubular	atrophy.	Transplantation,	90,	612-21.	TILL,	J.	E.	&	MC,	C.	E.	1961.	A	direct	measurement	of	the	radiation	sensitivity	of	normal	mouse	bone	marrow	cells.	Radiat	Res,	14,	213-22.	TIMMERS,	L.,	LIM,	S.	K.,	ARSLAN,	F.,	ARMSTRONG,	J.	S.,	HOEFER,	I.	E.,	DOEVENDANS,	P.	A.,	PIEK,	J.	J.,	EL	OAKLEY,	R.	M.,	CHOO,	A.,	LEE,	C.	N.,	PASTERKAMP,	G.	&	DE	KLEIJN,	D.	P.	2007.	Reduction	of	myocardial	infarct	size	by	human	mesenchymal	stem	cell	conditioned	medium.	Stem	
Cell	Res,	1,	129-37.	TIMSIT,	M.	O.,	YUAN,	X.,	FLOERCHINGER,	B.,	GE,	X.	&	TULLIUS,	S.	G.	2010.	Consequences	of	transplant	quality	on	chronic	allograft	nephropathy.	
Kidney	Int	Suppl,	S54-8.	TOGEL,	F.,	HU,	Z.,	WEISS,	K.,	ISAAC,	J.,	LANGE,	C.	&	WESTENFELDER,	C.	2005a.	Administered	mesenchymal	stem	cells	protect	against	ischemic	acute	renal	failure	through	differentiation-independent	mechanisms.	Am	J	
Physiol	Renal	Physiol,	289,	F31-42.	TOGEL,	F.,	ISAAC,	J.,	HU,	Z.,	WEISS,	K.	&	WESTENFELDER,	C.	2005b.	Renal	SDF-1	signals	mobilization	and	homing	of	CXCR4-positive	cells	to	the	kidney	after	ischemic	injury.	Kidney	Int,	67,	1772-84.	TOGEL,	F.,	ISAAC,	J.	&	WESTENFELDER,	C.	2004.	Hematopoietic	stem	cell	mobilization-associated	granulocytosis	severely	worsens	acute	renal	failure.	J	Am	Soc	Nephrol,	15,	1261-7.	TOGEL,	F.,	WEISS,	K.,	YANG,	Y.,	HU,	Z.,	ZHANG,	P.	&	WESTENFELDER,	C.	2007.	Vasculotropic,	paracrine	actions	of	infused	mesenchymal	stem	cells	are	important	to	the	recovery	from	acute	kidney	injury.	Am	J	Physiol	Renal	
Physiol,	292,	F1626-35.	
	 276	
TOGEL,	F.	E.	&	WESTENFELDER,	C.	2012.	Kidney	protection	and	regeneration	following	acute	injury:	progress	through	stem	cell	therapy.	Am	J	Kidney	
Dis,	60,	1012-22.	TOMITA,	S.,	MICKLE,	D.	A.,	WEISEL,	R.	D.,	JIA,	Z.	Q.,	TUMIATI,	L.	C.,	ALLIDINA,	Y.,	LIU,	P.	&	LI,	R.	K.	2002.	Improved	heart	function	with	myogenesis	and	angiogenesis	after	autologous	porcine	bone	marrow	stromal	cell	transplantation.	J	Thorac	Cardiovasc	Surg,	123,	1132-40.	TORSVIK,	A.,	ROSLAND,	G.	V.,	SVENDSEN,	A.,	MOLVEN,	A.,	IMMERVOLL,	H.,	MCCORMACK,	E.,	LONNING,	P.	E.,	PRIMON,	M.,	SOBALA,	E.,	TONN,	J.	C.,	GOLDBRUNNER,	R.,	SCHICHOR,	C.,	MYSLIWIETZ,	J.,	LAH,	T.	T.,	MOTALN,	H.,	KNAPPSKOG,	S.	&	BJERKVIG,	R.	2010.	Spontaneous	malignant	transformation	of	human	mesenchymal	stem	cells	reflects	cross-contamination:	putting	the	research	field	on	track	-	letter.	Cancer	Res,	70,	6393-6.	TOYOHARA,	T.,	MAE,	S.,	SUETA,	S.,	INOUE,	T.,	YAMAGISHI,	Y.,	KAWAMOTO,	T.,	KASAHARA,	T.,	HOSHINA,	A.,	TOYODA,	T.,	TANAKA,	H.,	ARAOKA,	T.,	SATO-OTSUBO,	A.,	TAKAHASHI,	K.,	SATO,	Y.,	YAMAJI,	N.,	OGAWA,	S.,	YAMANAKA,	S.	&	OSAFUNE,	K.	2015.	Cell	Therapy	Using	Human	Induced	Pluripotent	Stem	Cell-Derived	Renal	Progenitors	Ameliorates	Acute	Kidney	Injury	in	Mice.	Stem	Cells	Transl	Med,	4,	980-92.	TRANSPLANT,	N.	B.	A.	2016.	http://www.odt.nhs.uk/pdf/organ_specific_report_kidney_2016.pdf.	TROPPMANN,	C.,	GILLINGHAM,	K.	J.,	BENEDETTI,	E.,	ALMOND,	P.	S.,	GRUESSNER,	R.	W.,	NAJARIAN,	J.	S.	&	MATAS,	A.	J.	1995.	Delayed	graft	function,	acute	rejection,	and	outcome	after	cadaver	renal	transplantation.	The	multivariate	analysis.	Transplantation,	59,	962-8.	TSE,	W.	T.,	PENDLETON,	J.	D.,	BEYER,	W.	M.,	EGALKA,	M.	C.	&	GUINAN,	E.	C.	2003.	Suppression	of	allogeneic	T-cell	proliferation	by	human	marrow	stromal	cells:	implications	in	transplantation.	Transplantation,	75,	389-97.	TSUJI,	Y.,	ARIYOSHI,	A.	&	SAKAMOTO,	K.	1993.	An	experimental	model	for	unilateral	ischaemic	acute	renal	failure	in	dog.	Int	Urol	Nephrol,	25,	83-8.	TUTTLE-NEWHALL,	J.	E.,	KRISHNAN,	S.	M.,	LEVY,	M.	F.,	MCBRIDE,	V.,	ORLOWSKI,	J.	P.	&	SUNG,	R.	S.	2009.	Organ	donation	and	utilization	in	the	United	States:	1998-2007.	Am	J	Transplant,	9,	879-93.	UCCELLI,	A.,	MORETTA,	L.	&	PISTOIA,	V.	2006.	Immunoregulatory	function	of	mesenchymal	stem	cells.	Eur	J	Immunol,	36,	2566-73.	UCCELLI,	A.,	MORETTA,	L.	&	PISTOIA,	V.	2008.	Mesenchymal	stem	cells	in	health	and	disease.	Nat	Rev	Immunol,	8,	726-36.	USAS,	A.,	MACIULAITIS,	J.,	MACIULAITIS,	R.,	JAKUBONIENE,	N.,	MILASIUS,	A.	&	HUARD,	J.	2011.	Skeletal	muscle-derived	stem	cells:	implications	for	cell-mediated	therapies.	Medicina	(Kaunas),	47,	469-79.	VALADI,	H.,	EKSTROM,	K.,	BOSSIOS,	A.,	SJOSTRAND,	M.,	LEE,	J.	J.	&	LOTVALL,	J.	O.	2007.	Exosome-mediated	transfer	of	mRNAs	and	microRNAs	is	a	novel	mechanism	of	genetic	exchange	between	cells.	Nat	Cell	Biol,	9,	654-9.	VAN	MANEN,	J.	G.,	KOREVAAR,	J.	C.,	DEKKER,	F.	W.,	BOESCHOTEN,	E.	W.,	BOSSUYT,	P.	M.,	KREDIET,	R.	T.	&	DIALYSIS,	N.	S.	G.	N.	C.-O.	S.	O.	T.	A.	O.	2002.	How	to	adjust	for	comorbidity	in	survival	studies	in	ESRD	patients:	a	comparison	of	different	indices.	Am	J	Kidney	Dis,	40,	82-9.	
	 277	
VANIKAR,	A.	V.,	TRIVEDI,	H.	L.,	KUMAR,	A.,	GOPAL,	S.	C.	&	KUTE,	V.	B.	2014.	Mesenchymal	stem	cells	and	transplant	tolerance.	Nephrology	(Carlton),	19,	369-74.	VANWIJK,	M.	J.,	VANBAVEL,	E.,	STURK,	A.	&	NIEUWLAND,	R.	2003.	Microparticles	in	cardiovascular	diseases.	Cardiovasc	Res,	59,	277-87.	VEROUX,	M.,	GROSSO,	G.,	CORONA,	D.,	MISTRETTA,	A.,	GIAQUINTA,	A.,	GIUFFRIDA,	G.,	SINAGRA,	N.	&	VEROUX,	P.	2012.	Age	is	an	important	predictor	of	kidney	transplantation	outcome.	Nephrol	Dial	Transplant,	27,	1663-71.	VERSTEILEN,	A.	M.,	BLAAUW,	N.,	DI	MAGGIO,	F.,	GROENEVELD,	A.	B.,	SIPKEMA,	P.,	MUSTERS,	R.	J.	&	TANGELDER,	G.	J.	2011.	rho-Kinase	inhibition	reduces	early	microvascular	leukocyte	accumulation	in	the	rat	kidney	following	ischemia-reperfusion	injury:	roles	of	nitric	oxide	and	blood	flow.	Nephron	
Exp	Nephrol,	118,	e79-86.	VILLANUEVA,	S.,	CARRENO,	J.	E.,	SALAZAR,	L.,	VERGARA,	C.,	STRODTHOFF,	R.,	FAJRE,	F.,	CESPEDES,	C.,	SAEZ,	P.	J.,	IRARRAZABAL,	C.,	BARTOLUCCI,	J.,	FIGUEROA,	F.	&	VIO,	C.	P.	2013.	Human	mesenchymal	stem	cells	derived	from	adipose	tissue	reduce	functional	and	tissue	damage	in	a	rat	model	of	chronic	renal	failure.	Clin	Sci	(Lond),	125,	199-210.	VINAS,	J.	L.,	BURGER,	D.,	ZIMPELMANN,	J.,	HANEEF,	R.,	KNOLL,	W.,	CAMPBELL,	P.,	GUTSOL,	A.,	CARTER,	A.,	ALLAN,	D.	S.	&	BURNS,	K.	D.	2016.	Transfer	of	microRNA-486-5p	from	human	endothelial	colony	forming	cell-derived	exosomes	reduces	ischemic	kidney	injury.	Kidney	Int.	VISHNUBHATLA,	I.	C.,	R;	STEVANATO,	L;	HICKS,	C;	JOHN	SINDEN,	J	2014.	The	Development	of	Stem	Cell-derived	Exosomes	as	a	Cell-free	Regenerative	Medicine.	J	Circ	Biomark,,	3,	10.5772/58597.	VLASSOV,	A.	V.,	MAGDALENO,	S.,	SETTERQUIST,	R.	&	CONRAD,	R.	2012.	Exosomes:	current	knowledge	of	their	composition,	biological	functions,	and	diagnostic	and	therapeutic	potentials.	Biochim	Biophys	Acta,	1820,	940-8.	VULLIET,	P.	R.,	GREELEY,	M.,	HALLORAN,	S.	M.,	MACDONALD,	K.	A.	&	KITTLESON,	M.	D.	2004.	Intra-coronary	arterial	injection	of	mesenchymal	stromal	cells	and	microinfarction	in	dogs.	Lancet,	363,	783-4.	WADEI,	H.	M.,	HECKMAN,	M.	G.,	RAWAL,	B.,	TANER,	C.	B.,	FARAHAT,	W.,	NUR,	L.,	MAI,	M.	L.,	PRENDERGAST,	M.	&	GONWA,	T.	A.	2013.	Comparison	of	kidney	function	between	donation	after	cardiac	death	and	donation	after	brain	death	kidney	transplantation.	Transplantation,	96,	274-81.	WALCZAK,	P.,	ZHANG,	J.,	GILAD,	A.	A.,	KEDZIOREK,	D.	A.,	RUIZ-CABELLO,	J.,	YOUNG,	R.	G.,	PITTENGER,	M.	F.,	VAN	ZIJL,	P.	C.,	HUANG,	J.	&	BULTE,	J.	W.	2008.	Dual-modality	monitoring	of	targeted	intraarterial	delivery	of	mesenchymal	stem	cells	after	transient	ischemia.	Stroke,	39,	1569-74.	WANG,	E.,	SANDOVAL,	R.	M.,	CAMPOS,	S.	B.	&	MOLITORIS,	B.	A.	2010.	Rapid	diagnosis	and	quantification	of	acute	kidney	injury	using	fluorescent	ratio-metric	determination	of	glomerular	filtration	rate	in	the	rat.	Am	J	
Physiol	Renal	Physiol,	299,	F1048-55.	WANG,	H.	J.,	VARNER,	A.,	ABOUSHWAREB,	T.,	ATALA,	A.	&	YOO,	J.	J.	2012.	Ischemia/reperfusion-induced	renal	failure	in	rats	as	a	model	for	evaluating	cell	therapies.	Ren	Fail,	34,	1324-32.	
	 278	
WANG,	Y.,	ZHANG,	Z.,	CHI,	Y.,	ZHANG,	Q.,	XU,	F.,	YANG,	Z.,	MENG,	L.,	YANG,	S.,	YAN,	S.,	MAO,	A.,	ZHANG,	J.,	YANG,	Y.,	WANG,	S.,	CUI,	J.,	LIANG,	L.,	JI,	Y.,	HAN,	Z.	B.,	FANG,	X.	&	HAN,	Z.	C.	2013a.	Long-term	cultured	mesenchymal	stem	cells	frequently	develop	genomic	mutations	but	do	not	undergo	malignant	transformation.	Cell	Death	Dis,	4,	e950.	WANG,	Y.	L.,	LI,	G.,	ZOU,	X.	F.,	CHEN,	X.	B.,	LIU,	T.	&	SHEN,	Z.	Y.	2013b.	Effect	of	autologous	adipose-derived	stem	cells	in	renal	cold	ischemia	and	reperfusion	injury.	Transplant	Proc,	45,	3198-202.	WEBER,	M.,	DINDO,	D.,	DEMARTINES,	N.,	AMBUHL,	P.	M.	&	CLAVIEN,	P.	A.	2002.	Kidney	transplantation	from	donors	without	a	heartbeat.	N	Engl	J	Med,	347,	248-55.	WEI,	Q.	&	DONG,	Z.	2012.	Mouse	model	of	ischemic	acute	kidney	injury:	technical	notes	and	tricks.	Am	J	Physiol	Renal	Physiol,	303,	F1487-94.	WEI,	X.,	YANG,	X.,	HAN,	Z.	P.,	QU,	F.	F.,	SHAO,	L.	&	SHI,	Y.	F.	2013.	Mesenchymal	stem	cells:	a	new	trend	for	cell	therapy.	Acta	Pharmacol	Sin,	34,	747-54.	WHALEN,	H.,	SHIELS,	P.,	LITTLEJOHN,	M.	&	CLANCY,	M.	2016.	A	novel	rodent	model	of	severe	renal	ischemia	reperfusion	injury.	Ren	Fail,	1-8.	WHITE,	E.,	HILDEMANN,	W.	H.	&	MULLEN,	Y.	1969.	Chronic	kidney	allograft	reactions	in	rats.	Transplantation,	8,	602-17.	WHITING,	J.	F.,	ZAVALA,	E.	Y.,	ALEXANDER,	J.	W.	&	FIRST,	M.	R.	1999.	The	cost-effectiveness	of	transplantation	with	expanded	donor	kidneys.	Transplant	
Proc,	31,	1320-1.	WIGHT,	J.	P.,	EDWARDS,	L.,	BRAZIER,	J.,	WALTERS,	S.,	PAYNE,	J.	N.	&	BROWN,	C.	B.	1998.	The	SF36	as	an	outcome	measure	of	services	for	end	stage	renal	failure.	Qual	Health	Care,	7,	209-21.	WISE,	A.	F.	&	RICARDO,	S.	D.	2012.	Mesenchymal	stem	cells	in	kidney	inflammation	and	repair.	Nephrology	(Carlton),	17,	1-10.	WITWER,	K.	W.,	BUZAS,	E.	I.,	BEMIS,	L.	T.,	BORA,	A.,	LASSER,	C.,	LOTVALL,	J.,	NOLTE-'T	HOEN,	E.	N.,	PIPER,	M.	G.,	SIVARAMAN,	S.,	SKOG,	J.,	THERY,	C.,	WAUBEN,	M.	H.	&	HOCHBERG,	F.	2013.	Standardization	of	sample	collection,	isolation	and	analysis	methods	in	extracellular	vesicle	research.	J	Extracell	Vesicles,	2.	WITZGALL,	R.,	BROWN,	D.,	SCHWARZ,	C.	&	BONVENTRE,	J.	V.	1994.	Localization	of	proliferating	cell	nuclear	antigen,	vimentin,	c-Fos,	and	clusterin	in	the	postischemic	kidney.	Evidence	for	a	heterogenous	genetic	response	among	nephron	segments,	and	a	large	pool	of	mitotically	active	and	dedifferentiated	cells.	J	Clin	Invest,	93,	2175-88.	WOLFE,	R.	A.,	ASHBY,	V.	B.,	MILFORD,	E.	L.,	OJO,	A.	O.,	ETTENGER,	R.	E.,	AGODOA,	L.	Y.,	HELD,	P.	J.	&	PORT,	F.	K.	1999.	Comparison	of	mortality	in	all	patients	on	dialysis,	patients	on	dialysis	awaiting	transplantation,	and	recipients	of	a	first	cadaveric	transplant.	N	Engl	J	Med,	341,	1725-30.	WOLFE,	R.	A.,	ROYS,	E.	C.	&	MERION,	R.	M.	2010.	Trends	in	organ	donation	and	transplantation	in	the	United	States,	1999-2008.	Am	J	Transplant,	10,	961-72.	WU,	W.	K.,	FAMURE,	O.,	LI,	Y.	&	KIM,	S.	J.	2015.	Delayed	graft	function	and	the	risk	of	acute	rejection	in	the	modern	era	of	kidney	transplantation.	Kidney	
Int,	88,	851-8.	WYNN,	R.	F.,	HART,	C.	A.,	CORRADI-PERINI,	C.,	O'NEILL,	L.,	EVANS,	C.	A.,	WRAITH,	J.	E.,	FAIRBAIRN,	L.	J.	&	BELLANTUONO,	I.	2004.	A	small	proportion	of	
	 279	
mesenchymal	stem	cells	strongly	expresses	functionally	active	CXCR4	receptor	capable	of	promoting	migration	to	bone	marrow.	Blood,	104,	2643-5.	XIN,	H.,	LI,	Y.,	CUI,	Y.,	YANG,	J.	J.,	ZHANG,	Z.	G.	&	CHOPP,	M.	2013.	Systemic	administration	of	exosomes	released	from	mesenchymal	stromal	cells	promote	functional	recovery	and	neurovascular	plasticity	after	stroke	in	rats.	J	Cereb	Blood	Flow	Metab,	33,	1711-5.	YANG,	L.,	BESSCHETNOVA,	T.	Y.,	BROOKS,	C.	R.,	SHAH,	J.	V.	&	BONVENTRE,	J.	V.	2010.	Epithelial	cell	cycle	arrest	in	G2/M	mediates	kidney	fibrosis	after	injury.	Nat	Med,	16,	535-43,	1p	following	143.	YASUDA,	S.	&	SATO,	Y.	2015.	Tumorigenicity	assessment	of	human	cell-processed	therapeutic	products.	Biologicals,	43,	416-21.	YEO,	R.	W.,	LAI,	R.	C.,	ZHANG,	B.,	TAN,	S.	S.,	YIN,	Y.,	TEH,	B.	J.	&	LIM,	S.	K.	2013.	Mesenchymal	stem	cell:	an	efficient	mass	producer	of	exosomes	for	drug	delivery.	Adv	Drug	Deliv	Rev,	65,	336-41.	YSEBAERT,	D.	K.,	DE	GREEF,	K.	E.,	VERCAUTEREN,	S.	R.,	GHIELLI,	M.,	VERPOOTEN,	G.	A.,	EYSKENS,	E.	J.	&	DE	BROE,	M.	E.	2000.	Identification	and	kinetics	of	leukocytes	after	severe	ischaemia/reperfusion	renal	injury.	Nephrol	Dial	Transplant,	15,	1562-74.	YUAN,	A.,	FARBER,	E.	L.,	RAPOPORT,	A.	L.,	TEJADA,	D.,	DENISKIN,	R.,	AKHMEDOV,	N.	B.	&	FARBER,	D.	B.	2009.	Transfer	of	microRNAs	by	embryonic	stem	cell	microvesicles.	PLoS	One,	4,	e4722.	ZAGER,	R.	A.	1987.	Partial	aortic	ligation:	a	hypoperfusion	model	of	ischemic	acute	renal	failure	and	a	comparison	with	renal	artery	occlusion.	J	Lab	
Clin	Med,	110,	396-405.	ZAGER,	R.	A.	1991.	Adenine	nucleotide	changes	in	kidney,	liver,	and	small	intestine	during	different	forms	of	ischemic	injury.	Circ	Res,	68,	185-96.	ZAGER,	R.	A.,	JOHNSON,	A.	C.,	ANDRESS,	D.	&	BECKER,	K.	2013.	Progressive	endothelin-1	gene	activation	initiates	chronic/end-stage	renal	disease	following	experimental	ischemic/reperfusion	injury.	Kidney	Int,	84,	703-12.	ZAGER,	R.	A.,	JOHNSON,	A.	C.	&	BECKER,	K.	2011.	Acute	unilateral	ischemic	renal	injury	induces	progressive	renal	inflammation,	lipid	accumulation,	histone	modification,	and	"end-stage"	kidney	disease.	Am	J	Physiol	Renal	
Physiol,	301,	F1334-45.	ZELMER,	J.	L.	2007.	The	economic	burden	of	end-stage	renal	disease	in	Canada.	
Kidney	Int,	72,	1122-9.	ZENG,	M.,	CHENG,	Y.	&	ZHAO,	B.	2015.	Measurement	of	single-kidney	glomerular	filtration	function	from	magnetic	resonance	perfusion	renography.	Eur	J	
Radiol,	84,	1419-23.	ZHANG,	W.,	GE,	W.,	LI,	C.,	YOU,	S.,	LIAO,	L.,	HAN,	Q.,	DENG,	W.	&	ZHAO,	R.	C.	2004.	Effects	of	mesenchymal	stem	cells	on	differentiation,	maturation,	and	function	of	human	monocyte-derived	dendritic	cells.	Stem	Cells	Dev,	13,	263-71.	ZHANG,	W.,	QIN,	C.	&	ZHOU,	Z.	M.	2007.	Mesenchymal	stem	cells	modulate	immune	responses	combined	with	cyclosporine	in	a	rat	renal	transplantation	model.	Transplant	Proc,	39,	3404-8.	ZHAO,	J.	J.,	LIU,	J.	L.,	LIU,	L.	&	JIA,	H.	Y.	2014.	Protection	of	mesenchymal	stem	cells	on	acute	kidney	injury.	Mol	Med	Rep,	9,	91-6.	
	 280	
ZHOU,	Y.	F.,	BOSCH-MARCE,	M.,	OKUYAMA,	H.,	KRISHNAMACHARY,	B.,	KIMURA,	H.,	ZHANG,	L.,	HUSO,	D.	L.	&	SEMENZA,	G.	L.	2006.	Spontaneous	transformation	of	cultured	mouse	bone	marrow-derived	stromal	cells.	
Cancer	Res,	66,	10849-54.	ZONTA,	S.,	DE	MARTINO,	M.,	BEDINO,	G.,	PIOTTI,	G.,	RAMPINO,	T.,	GREGORINI,	M.,	FRASSONI,	F.,	DAL	CANTON,	A.,	DIONIGI,	P.	&	ALESSIANI,	M.	2010.	Which	is	the	most	suitable	and	effective	route	of	administration	for	mesenchymal	stem	cell-based	immunomodulation	therapy	in	experimental	kidney	transplantation:	endovenous	or	arterial?	Transplant	
Proc,	42,	1336-40.	ZOU,	X.,	ZHANG,	G.,	CHENG,	Z.,	YIN,	D.,	DU,	T.,	JU,	G.,	MIAO,	S.,	LIU,	G.,	LU,	M.	&	ZHU,	Y.	2014.	Microvesicles	derived	from	human	Wharton's	Jelly	mesenchymal	stromal	cells	ameliorate	renal	ischemia-reperfusion	injury	in	rats	by	suppressing	CX3CL1.	Stem	Cell	Res	Ther,	5,	40.	
 
  
	 281	
APPENDIX 1 
 
 
